

Financial news for JNJ dated on 2020-06-11: Moderna On Track To Start Phase 3 Coronavirus Vaccine Trial In July

Financial news for JNJ dated on 2020-06-11: Shares of several healthcare companies are trading lower in sympathy with the overall market following an increase in coronavirus cases in some US states that have reopened, leading to concerns of a second wave of the virus.

Financial news for JNJ dated on 2020-06-11: It's Not All COVID-19 And The Fed: Lululemon Reports After Close, And Airline Stocks Dive

Financial news for JNJ dated on 2020-06-11: A Peek Into The Markets: US Stock Futures Tumble Ahead Of Jobless Claims Report

Financial news for JNJ dated on 2020-06-11: Johnson & Johnson To Start Coronavirus Vaccine Human Trials Ahead Of Schedule In July

Financial news for JNJ dated on 2020-06-10: J&J Moves Up Human Clinical Trails Of its COVID-19 Vaccine To Start In July, Ahead Of Planned September Start

Financial news for JNJ dated on 2020-06-10: J&J Is In Talks To Begin Phase 3 Coronavirus Vaccine Trial Ahead Of Schedule, Pending Phase 1 Studies Outcome, Regulatory Approval

Financial news for JNJ dated on 2020-06-10: NIH Official Says U.S. Plans 3 Large Studies of Experimental Coronavirus Vaccines From Moderna, AstraZeneca Johnson & Johnson Starting in July, August, September

Financial news for JNJ dated on 2020-06-09: Revlon, Chanel, L'Oreal Are Quietly Removing Talc From Their Products As Cancer Lawsuits Mount: Report

Financial news for JNJ dated on 2020-06-09: Travel Stocks Lose Momentum In Pre-Market After Leading Yesterday's Sharp Rally

Financial news for JNJ dated on 2020-06-08: Navarro: China Is 'Trying To Steal Our Vaccines, As We Speak'

Financial news for JNJ dated on 2020-06-04: Halozyme Announces J&J's Janssen Receives European Marketing Authorization For Subcutaneous DARZALEX Utilizing Halozyme's ENHANZE Technology For The Treatment Of Patients With Multiple Myeloma

Financial news for JNJ dated on 2020-06-04: Ex-FDA Chief On White House's Coronavirus Vaccine Shortlist: 'They Chose Very Novel Platforms'

Financial news for JNJ dated on 2020-06-04: Genmab Reports European Marketing Authorization For Subcutaneous Formulation Of DARZALEX For Treatment Of Patients With Multiple Myeloma

Financial news for JNJ dated on 2020-06-03: Revisiting The Coronavirus Vaccine Race: Updates On The 10 Candidates In Clinics

Financial news for JNJ dated on 2020-06-03: UPDATE: Five Companies Chosen For 'Vaccine Finalist' Are Moderna, Johnson & Johnson, Merck, Pfizer And AstraZeneca

Financial news for JNJ dated on 2020-06-02: Pharma Large And Mid-Caps Race Against COVID-19

Financial news for JNJ dated on 2020-06-02: 4 Blue Chips That Lived Up To Their Title During the Pandemic

Financial news for JNJ dated on 2020-06-02: U.S. Army Planning To Test Vaccines From Moderna, Astrazeneca, Johnson & Johnson And Sanofi; Army Will Test Its Own Vaccine Candidate In Human Trials Later This Summer

Financial news for JNJ dated on 2020-06-01: 4 Sector ETFs To Buy And Sell In June

Financial news for JNJ dated on 2020-05-26: Novavax Begins Phase 1 Clinical Trial Of Its Coronavirus Vaccine

Financial news for JNJ dated on 2020-05-22: US Health Official Says Vaccines From J&J, Sanofi, Merck May Be Added This Summer As They Complete Phase 1 Safety Studies

Financial news for JNJ dated on 2020-05-22: US Says Will Test Experimental Coronavirus Vaccines In 100,000+ People, Health Official Says Oxford Vaccine May Be Tested "Side By Side" With Moderna's Starting In July

Financial news for JNJ dated on 2020-05-20: Johnson & Johnson Pulls Talc-Based Baby Powder From US, Canada As Cancer Claims Kill Demand

Financial news for JNJ dated on 2020-05-19: Johnson & Johnson Consumer Health Will Wind Down Commercialization Of Talc-based Johnson's Baby Powder In The U.S. And Canada In Coming Months

Financial news for JNJ dated on 2020-05-19: In The Midst Of Pandemic, Traders Pin Their Hopes On These Healthcare ETFs

Financial news for JNJ dated on 2020-05-19: Moncef Slaoui To Divest Moderna Stake As He Joins White House Vaccine Accelerator

Financial news for JNJ dated on 2020-05-18: These 6 Coronavirus Vaccine Candidates Are The Likeliest To Succeed, Says Morgan Stanley

Financial news for JNJ dated on 2020-05-18: Janssen Gives an Update on its Phase 1 Study on Teclistamab in patients with Multiple Myeloma

Financial news for JNJ dated on 2020-05-17: Barron's Picks And Pans: Cisco, Gilead, Netflix, Wayfair And More

Financial news for JNJ dated on 2020-05-15: Avicanna Combines Sustainable Cultivation Methods, R&D, and Pharmaceutical Standards to Offer API's with the Aureus Brand

Financial news for JNJ dated on 2020-05-12: Novavax Analysts Say CEPI Funding 'Speaks Volumes' About Coronavirus Vaccine Development

Financial news for JNJ dated on 2020-05-11: Cruise Line Earnings Later This Week Could Provide Insight On Brutal Quarter For Industry

Financial news for JNJ dated on 2020-05-05: Provention Bio's CEO On Identifying Autoimmune Diseases 'Before It's Too Late'

Financial news for JNJ dated on 2020-05-05: What You Should Know About Alexion's \$1.4B Proposed Buyout Of Portola Pharma

Financial news for JNJ dated on 2020-05-05: The Daily Biotech Pulse: Bio-Rad's Coronavirus Test Gets EUA, Beat-And-Raise Quarter From GenMark, Adverum's Positive Gene Therapy Readout

Financial news for JNJ dated on 2020-05-03: Attention Biotech Investors: Mark Your Calendar For These May PDUFA Dates

Financial news for JNJ dated on 2020-05-01: Moderna, Lonza Strike Deal To Manufacture Up To 1 Billion Doses Of Coronavirus Vaccine Candidate Annually

Financial news for JNJ dated on 2020-05-01: The Daily Biotech Pulse: Gilead Slips Despite Forecast-Beating Q1, Moderna Partners With Lonza For Coronavirus Vaccine Production, Lyra Therapeutics IPO

Financial news for JNJ dated on 2020-04-30: Halozyne Highlights Janssen's Receipt Of CHMP Positive Opinion For DARZALEX Subcutaneous Formulation Utilizing Halozyne's ENHANZE Technology For Patients With Multiple Myeloma

Financial news for JNJ dated on 2020-04-30: Johnson & Johnson Announces Committee For Medicinal Products For Human Use Of Ema Has Issued A Positive Opinion Recommending Approval For Darzalex

Financial news for JNJ dated on 2020-04-29: Barclays Maintains Overweight on Johnson & Johnson, Raises Price Target to \$182

Financial news for JNJ dated on 2020-04-29: Morgan Stanley Maintains Overweight on Johnson & Johnson, Raises Price Target to \$170

Financial news for JNJ dated on 2020-04-29: Catalent Signs Agreement With Johnson & Johnson To Be US Manufacturing Partner For Lead Coronavirus Vaccine Candidate

Financial news for JNJ dated on 2020-04-29: Pfizer Says Coronavirus Vaccine Could Be Available By Fall, US Clinical Trials To Begin Next Week

Financial news for JNJ dated on 2020-04-28: UBS Downgrades Johnson & Johnson to Neutral, Lowers Price Target to \$160

Financial news for JNJ dated on 2020-04-28: J&J Says Federal Judge Excludes Certain Plaintiff Expert Testimony from Talc Ovarian Cancer Trials, Deeming Them Not Scientifically Sound

Financial news for JNJ dated on 2020-04-27: U.S. Judge Rules J&J Must Defend Federal Talc Lawsuits

Financial news for JNJ dated on 2020-04-27: Halozyne Announces Janssen Submits NDA In

Japan For Daratumumab Subcutaneous Formulation Utilizing Halozyme's ENHANZE(r) Technology For Patients With Multiple Myeloma

Financial news for JNJ dated on 2020-04-25: Barron's Picks And Pans: Albertsons, Carnival, Harley-Davidson And More

Financial news for JNJ dated on 2020-04-24: J&J's Janssen Pharma Reports Submission Of 2 Applicats Seeking Approval Of SIMPONI ARIA For Treatment Of Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis

Financial news for JNJ dated on 2020-04-24: The Daily Biotech Pulse: FDA Approves Sanofi's Meningococcal Vaccine, Pluristem Secures \$54M In Funding For COVID-19 Treatment, Oric Pharma Prices IPO

Financial news for JNJ dated on 2020-04-24: UPDATE: TRACON Says Is Seeking A Licensing Partner To Develop, Commercialize TRC253 In China

Financial news for JNJ dated on 2020-04-24: TRACON Pharma Reports Retained Global Rights To TRC253 Following Completion Of Phase 1/2 Trial

Financial news for JNJ dated on 2020-04-24: Six Coronavirus Vaccines Under Clinical Trials, WHO Says

Financial news for JNJ dated on 2020-04-23: Inovio CEO Says 'It's Possible' For Coronavirus Vaccine To Be Ready In 12 To 18 Months

Financial news for JNJ dated on 2020-04-23: Stocks That Hit 52-Week Highs On Thursday

Financial news for JNJ dated on 2020-04-23: The Daily Biotech Pulse: FDA Nod For Immunomedics, Lilly's Solid Q1 Beat, Predictive Oncology Restructures Debt

Financial news for JNJ dated on 2020-04-22: Why Johnson & Johnson's Stock Is Trading Higher Today

Financial news for JNJ dated on 2020-04-22: Benzinga's Top Upgrades, Downgrades For April 22, 2020

Financial news for JNJ dated on 2020-04-22: Johnson & Johnson shares are higher after Bank of America upgraded the stock from Neutral to Buy.

Financial news for JNJ dated on 2020-04-22: B of A Securities Upgrades Johnson & Johnson to Buy

Financial news for JNJ dated on 2020-04-22: Oxford University Coronavirus Vaccine Clinical Trial To Start Thursday With \$24.6M Government Funding

Financial news for JNJ dated on 2020-04-21: FDA Says Expanded The Indication Of Ibrutinib (Imbruvica)

Financial news for JNJ dated on 2020-04-20: How The COVID-19 Pandemic Could End

Financial news for JNJ dated on 2020-04-19: The Week Ahead In Biotech (April 19-25): Eli Lilly, Biogen Earnings On Tap, Sanofi Awaits FDA Decision

Financial news for JNJ dated on 2020-04-19: Barron's Picks And Pans: Dropbox, Ford, Johnson & Johnson, Teladoc And More

Financial news for JNJ dated on 2020-04-17: Big Earnings Day As Honeywell, Procter & Gamble, Schlumberger Among Those Reporting

Financial news for JNJ dated on 2020-04-17: Moderna Gets \$483M Federal Funding For Its Coronavirus Vaccine

Financial news for JNJ dated on 2020-04-16: S&P 500 Futures Up 3.2% After Hours; Many Other Stocks Moving Higher With Futures; Investors Reacting Favorably To White Phase Guidelines On Reopening Economy

Financial news for JNJ dated on 2020-04-16: Alibaba, Tesla Among Cramer's Stay-At-Home Stock Ideas

Financial news for JNJ dated on 2020-04-16: Why Johnson & Johnson Inspires Cramer's Bullishness On Disney, Visa, Mastercard

Financial news for JNJ dated on 2020-04-15: Every Member Of Trump's 'Great American Economic Revival' Industry Groups

Financial news for JNJ dated on 2020-04-15: Stifel Maintains Hold on Johnson & Johnson, Raises Price Target to \$155

Financial news for JNJ dated on 2020-04-15: Wells Fargo Maintains Overweight on Johnson & Johnson, Raises Price Target to \$162

Financial news for JNJ dated on 2020-04-15: 10 Biggest Price Target Changes For Wednesday

Financial news for JNJ dated on 2020-04-15: Credit Suisse Reiterates Outperform on Johnson & Johnson, Raises Price Target to \$161

Financial news for JNJ dated on 2020-04-15: Citigroup Maintains Buy on Johnson & Johnson, Raises Price Target to \$165

Financial news for JNJ dated on 2020-04-15: Raymond James Reiterates Outperform on Johnson & Johnson, Raises Price Target to \$157

Financial news for JNJ dated on 2020-04-14: J&J Expects Procedure Volumes In Areas Such As Oncology, General Surgery To Rebound Sooner

Financial news for JNJ dated on 2020-04-14: JPMorgan, Wells Fargo Earnings Lower Than Expected, But Positive Tone Helps Shares

Financial news for JNJ dated on 2020-04-14: J&J CEO Says China Business Starting To Return To Normalcy

Financial news for JNJ dated on 2020-04-14: Tuesday's Market Minute: Earnings Season Begins Again

Financial news for JNJ dated on 2020-04-14: The Daily Biotech Pulse: Amarin Reports Strong Q1 Vascepa Sales, BeiGene Aces Late-Stage Lung Cancer Study, Glaxo, Sanofi Strike COVID-19 Vaccine Partnership

Financial news for JNJ dated on 2020-04-14: Johnson & Johnson shares are trading higher after the company reported better-than-expected Q1 EPS and sales results.

Financial news for JNJ dated on 2020-04-14: Mike Khouw Saw Unusual Options Activity In Johnson & Johnson Ahead Of Earnings

Financial news for JNJ dated on 2020-04-14: Johnson & Johnson: Q1 Earnings Insights

Financial news for JNJ dated on 2020-04-14: ImmunoPrecise Announces Research License Agreement With Janssen

Financial news for JNJ dated on 2020-04-14: Genmab Highlights Q1 Net Sales Of DARZALEX By Johnson And Johnson Were \$937M; Genmab Will Receive Royalties On Sales Under Exclusive Worldwide License

Financial news for JNJ dated on 2020-04-14: Johnson & Johnson Cuts FY20 Adj. EPS Guidance From \$8.95-\$9.10 To \$7.50-\$7.90, Cuts Operational Sales Guidance From \$85.8B-\$86.6B To \$77.5B-\$80.5B; Guidance Includes Impact Of Coronavirus And Related Investments

Financial news for JNJ dated on 2020-04-14: Johnson & Johnson Q1 Adj. EPS \$2.300 Beats \$1.990 Estimate, Sales \$20.691B Beat \$19.440B Estimate

Financial news for JNJ dated on 2020-04-14: Johnson & Johnson Raises Quarterly Dividend From \$0.95 To \$1.01/Share

Financial news for JNJ dated on 2020-04-14: 5 Stocks To Watch For April 14, 2020

Financial news for JNJ dated on 2020-04-14: Earnings Scheduled For April 14, 2020

Financial news for JNJ dated on 2020-04-13: Financials, Healthcare In Eye Of Earnings Hurricane Ahead, With Bank CEOs In Spotlight

Financial news for JNJ dated on 2020-04-13: Monday's Market Minute: OPEC Production Cut To Avoid A Glut

Financial news for JNJ dated on 2020-04-12: The Week Ahead In Biotech: Urogen FDA Decision, Amarin, J&J Earnings And More COVID-19 Updates

Financial news for JNJ dated on 2020-04-10: FTC Closes Investigation of Johnson & Johnson's Proposed Acquisition of TachoSil from Takeda Pharmaceutical; FTC Says JNJ Abandoned Proposed Acquisition

Financial news for JNJ dated on 2020-04-09: Coronavirus Vaccine Developed In Short Time Unlikely To Be Safe, International Vaccine Institute Says

Financial news for JNJ dated on 2020-04-08: SVB Leerink Maintains Outperform on Johnson & Johnson, Lowers Price Target to \$160

Financial news for JNJ dated on 2020-04-08: Materials Stocks See More Interest Amid Hopes for Federal Infrastructure Spending

Financial news for JNJ dated on 2020-04-07: Inovio Pharmaceuticals Begins Phase 1 Human Testing Of Its COVID-19 Vaccine

Financial news for JNJ dated on 2020-04-06: Shares of several healthcare companies are trading higher as markets gain amid optimism that coronavirus cases in several US hotspots may be peaking. A sooner peak could mean a sooner return to economic activity.

Financial news for JNJ dated on 2020-04-06: Cramer Gives His Opinion Alteryx, Johnson & Johnson And More

Financial news for JNJ dated on 2020-04-04: Barron's Picks And Pans: Post-Pandemic Ideas, Safe Dividends And More

Financial news for JNJ dated on 2020-04-03: The Daily Biotech Pulse: Fate Therapeutics Inks Cell Therapy Deal With J&J, Zentalis IPO

Financial news for JNJ dated on 2020-04-03: Global Coronavirus Cases Surge Past 1M, Medical Equipment Remains In Shortage

Financial news for JNJ dated on 2020-04-03: Moderna Coronavirus Vaccine Phase 2 Trials Could Start In Spring, Chairman Says

Financial news for JNJ dated on 2020-04-02: Fate Therapeutics Announces Worldwide Collaboration With Janssen For Novel IPSC-derived Cell-Based Cancer Immunotherapies; Co. To Receive \$50M Upfront And \$50M Equity Investment And Eligible To Receive Up To \$1.8B

Financial news for JNJ dated on 2020-04-02: Wells Fargo Maintains Overweight on Johnson & Johnson, Lowers Price Target to \$150

Financial news for JNJ dated on 2020-04-02: Credit Suisse Compiles List Of Corporations With Most And Least Cash

Financial news for JNJ dated on 2020-04-01: Stifel Maintains Hold on Johnson & Johnson, Lowers Price Target to \$140

Financial news for JNJ dated on 2020-04-01: Shares of several healthcare companies are trading lower amid market weakness as growing coronavirus concerns in the US weigh on equities.

Financial news for JNJ dated on 2020-03-31: The Prize No One Wanted: Dow On Pace For Steepest Q1 Loss Ever As Quarter Finally Ends

Financial news for JNJ dated on 2020-03-31: Johnson & Johnson shares are trading higher on continued strength after the company announced a Coronavirus vaccine candidate. The company anticipates the first batches of the vaccine could be available for emergency use as early as 2021.

Financial news for JNJ dated on 2020-03-30: Afternoon Market Stats in 5 Minutes

Financial news for JNJ dated on 2020-03-30: UPDATE On BZ NOTE For J&J, Abbott Headline: J&J Earlier Suggested Promise For Potential Coronavirus Vaccine Candidate, Sees Phase 1 Human Trials Starting Sept. 2020 With Results From Phase 3 Trials By End Of 2020

Financial news for JNJ dated on 2020-03-30: J&J, Abbott Shares Unaffected Amid Circulation Of Headline From FT Suggesting Co.'s Announce A Potential Coronavirus Vaccine, Rapid Test; BZ NOTE: Reminder J&J Announced Details About An Isolated Coronavirus Candidate At 7 a.m. EDT Mon.

Financial news for JNJ dated on 2020-03-30: COVID-19 Vaccine Updates: J&J Identifies Lead Candidate, IMV Eyes Clinical Testing In Summer, Altimmune Partners With University Of Alabama

Financial news for JNJ dated on 2020-03-30: Johnson & Johnson Gets Boost After Announcing September Trials Of Vaccine Planned

Financial news for JNJ dated on 2020-03-30: Johnson & Johnson shares are trading higher after the company announces a Coronavirus vaccine candidate. The company anticipates the first batches of the vaccine could be available for emergency use as early as 2021.

Financial news for JNJ dated on 2020-03-30: Benzinga Pro's Stock To Watch For Mon., Mar. 30, 2020: Johnson & Johnson (JNJ)

Financial news for JNJ dated on 2020-03-30: UPDATE: Johnson & Johnson Anticipates First Batches Of A Vaccine Could Be Available For Emergency Use Authorization In Early 2021

Financial news for JNJ dated on 2020-03-30: Johnson & Johnson Announces Coronavirus Vaccine Candidate

Financial news for JNJ dated on 2020-03-27: Morgan Stanley Maintains Overweight on Johnson & Johnson, Lowers Price Target to \$160

Financial news for JNJ dated on 2020-03-27: Shares of several healthcare companies are trading lower, selling off from this week's strength. While the US stimulus legislation has boosted economic optimism, demand concerns still exist amid the coronavirus outbreak.

Financial news for JNJ dated on 2020-03-27: Argus Research Reiterates Buy on Johnson & Johnson, Lowers Price Target to \$155

Financial news for JNJ dated on 2020-03-27: Citigroup Maintains Buy on Johnson & Johnson, Lowers Price Target to \$150

Financial news for JNJ dated on 2020-03-26: Shares of several healthcare companies are trading higher following Senate passage of a \$2 trillion economic stimulus package, which has lifted stocks across sectors.

Financial news for JNJ dated on 2020-03-25: EU Antitrust Regulators Open In-depth Investigation Into Johnson & Johnson's Buy Of Takeda's Surgical Patch Product Tachosil; Say Deal May Reduce Potential Competition, Innovation For The Supply Of Dual Haemostatic, Set Aug. 10 Deadline For Decision

Financial news for JNJ dated on 2020-03-24: Shares of several healthcare companies are trading higher as equities gain amid hopes of a US stimulus agreement. Additionally, the coronavirus outbreak has increased demand for certain medical supplies.

Financial news for JNJ dated on 2020-03-24: The Daily Biotech Pulse: Milestone Pharma Flunks Late-Stage Study, CytomX Strikes Cancer Drug Collaboration, BARDA Grant For GenMark's COVID-19 Test

Financial news for JNJ dated on 2020-03-23: Shares of several healthcare companies are trading lower amid market volatility. Sunday's fiscal stimulus bill failed a procedural senate vote while the Fed Monday morning announced further stimulus measures to support liquidity.

Financial news for JNJ dated on 2020-03-23: Stocks That Hit 52-Week Lows On Monday

Financial news for JNJ dated on 2020-03-20: COVID-19: Where It's From And Where We're Going

Financial news for JNJ dated on 2020-03-20: Janssen Announces Health Canada Approval Of Cabenuva, First Long-acting Regimen For Treatment Of HIV; Studies Showed Cabenuva Was As Effective As Continuing Daily, Oral, Antiretroviral Regimens In Maintaining Viral Suppression During 48-week Study

Financial news for JNJ dated on 2020-03-19: The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latest Stage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection

Financial news for JNJ dated on 2020-03-18: J&J's Janssen Submits Ponesimod New Drug Application As Treatment For Adults With Relapsing Multiple Sclerosis

Financial news for JNJ dated on 2020-03-17: 'J&J hopes to start human trials for coronavirus vaccine in November' -CNBC

Financial news for JNJ dated on 2020-03-16: 8 Biotechs With Coronavirus Vaccines In Development

Financial news for JNJ dated on 2020-03-16: Shares of several healthcare companies are trading lower in sympathy with the overall market on continued downward momentum caused by the coronavirus. The virus has had a negative impact on the global economy.

Financial news for JNJ dated on 2020-03-16: J&J Says Sees No Evidence Darunavir Has Effect Against Coronavirus Infection

Financial news for JNJ dated on 2020-03-13: J&J Says Experiencing Increased Consumer-Driven Demand For Products, Particularly Within Our Self Care Portfolio, Including Tylenol; Says It Is Shipping Stock Of Tylenol In A Controlled Manner

Financial news for JNJ dated on 2020-03-13: J&J Reports Collaboration With Beth Israel Deaconess Medical Center To Accelerate Coronavirus Vaccine Development

Financial news for JNJ dated on 2020-03-13: Shares of several healthcare companies are trading higher as the market rebounds following Thursday's selloff. NOTE: Since the coronavirus outbreak the healthcare sector has been extremely volatile.

Financial news for JNJ dated on 2020-03-13: J&J Says Does Not Expect Pharma Supply Interruptions Related To Coronavirus

Financial news for JNJ dated on 2020-03-12: Stocks That Hit 52-Week Lows On Thursday

Financial news for JNJ dated on 2020-03-12: Shares of several healthcare companies are trading lower as equities sell off amid continued global coronavirus concerns. The virus has caused global economic disruption and negatively impacted stocks across sectors.

Financial news for JNJ dated on 2020-03-11: The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment

Financial news for JNJ dated on 2020-03-11: Shares of several healthcare companies are trading lower. Movement appears market related amid selloff in equities. The global coronavirus outbreak has caused volatility in global markets and impacted stocks across sectors.

Financial news for JNJ dated on 2020-03-10: How Close Are Biotechs To Bringing A COVID-19 Treatment To Market?

Financial news for JNJ dated on 2020-03-10: J&J's Janssen Announces FDA Breakthrough Therapy Designation Granted For JNJ-6372 For The Treatment Of Non-Small Cell Lung Cancer

Financial news for JNJ dated on 2020-03-10: Shares of several healthcare companies are trading higher as markets rebound following Monday's selloff. US President Trump on Monday indicated the US may implement payroll tax cuts and other measures to support the economy amid the coronavirus outbreak.

Financial news for JNJ dated on 2020-03-09: 52 Healthcare Stocks Moving In Monday's Pre-Market Session

Financial news for JNJ dated on 2020-03-06: What You Need To Know About Publicly-Traded Psychedelics Companies

Financial news for JNJ dated on 2020-03-06: Credit Suisse Maintains Outperform on Johnson & Johnson, Lowers Price Target to \$159

Financial news for JNJ dated on 2020-03-05: Benzinga's Top Upgrades, Downgrades For March 5, 2020

Financial news for JNJ dated on 2020-03-05: Citigroup Initiates Coverage On Johnson & Johnson with Buy Rating, Announces \$163 Price Target

Financial news for JNJ dated on 2020-03-04: Hearing Citi Initiates Coverage On J&J, Boston Scientific, Zimmer Biomet, Stryker, Medtronic, Insulet With Buy Ratings

Financial news for JNJ dated on 2020-03-04: The Daily Biotech Pulse: Takeda Jumps Into The COVID-19 Fray, Exact Sciences Buys Cancer Diagnostics Companies

Financial news for JNJ dated on 2020-03-04: Shares of several healthcare-related companies are trading higher after Joe Biden secured several key wins in Super Tuesday. Biden's more 'moderate' healthcare policies have been seen as more favorable for the sector.

Financial news for JNJ dated on 2020-03-04: Janssen Submits EMA Application for Ponesimod for Treatment of Adults with Relapsing MS

Financial news for JNJ dated on 2020-03-03: Shares of several healthcare companies are trading lower in sympathy with the overall market. The Fed cut rates to combat the coronavirus outbreak which caused an initial spike but then continued to trade lower.

Financial news for JNJ dated on 2020-03-03: Pfizer Works On Compounds That May Help Stop Coronaviruses

Financial news for JNJ dated on 2020-03-02: How The COVID-19 Outbreak Is Benefiting Biotech Investors

Financial news for JNJ dated on 2020-02-28: Shares of several healthcare companies are trading lower as the global coronavirus spread continues to cause equities across

sectors to sell off amid worsened economic outlook.

Financial news for JNJ dated on 2020-02-25: J&J Issues Press Release To Highlight Launch Of Janssen Pharma's Open Enrollment for Heartline Study With Apple, Will Explore If Heartline Study App On iPhone, Heart Health Features On Apple Watch Can Improve Health Outcomes

Financial news for JNJ dated on 2020-02-21: Some Market Stats In 5 Minutes

Financial news for JNJ dated on 2020-02-18: J&J Shares At Session Highs With Broader Stock Market; Hearing Co.'s Janssen Pharma To Expand Its Existing Partnership With BARDA To Seek Treatment Solutions For Coronavirus

Financial news for JNJ dated on 2020-02-14: 21 States Reject \$18B Offer From Drug Wholesalers To Settle Opioid Litigation

Financial news for JNJ dated on 2020-02-14: The Daily Biotech Pulse: Epizyme's Tazemetostat sNDA Accepted For Priority Review, Eisai To Withdraw Weight Loss Drug, Sol-Gel Prices Offering

Financial news for JNJ dated on 2020-02-12: The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data

Financial news for JNJ dated on 2020-02-11: Johnson & Johnson Announces Collaboration With US Department of Health & Human Services To 'Accelerate Development of a Potential Novel Coronavirus Vaccine'

Financial news for JNJ dated on 2020-02-11: The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology

Financial news for JNJ dated on 2020-02-10: New York Opioid Case A Significant Risk For Pharma Stocks, Says Bearish BofA

Financial news for JNJ dated on 2020-02-10: 3 Leveraged Healthcare ETFs Soaring This Month

Financial news for JNJ dated on 2020-02-07: Johnson & Johnson Hit with \$750M Punitive Damages Verdict for Failing to Warn about Cancer-Causing Asbestos in Talc Products

Financial news for JNJ dated on 2020-02-07: The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns

Financial news for JNJ dated on 2020-02-06: J&J Says Judge Reducing NJ Talc Verdict To \$185M

Financial news for JNJ dated on 2020-02-06: J&J Ordered To Pay \$750M In Punitive Damage Over Talc Case

Financial news for JNJ dated on 2020-02-06: Stocks That Hit 52-Week Highs On Thursday

Financial news for JNJ dated on 2020-02-06: The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs

Financial news for JNJ dated on 2020-02-05: WHO Says There's No Effective Coronavirus Treatment Yet

Financial news for JNJ dated on 2020-02-05: Stocks That Hit 52-Week Highs On Wednesday

Financial news for JNJ dated on 2020-02-05: The Daily Biotech Pulse: Merck Spins Off Slow-Growth Businesses, ZioPharm Announces Offering, PhaseBio Data

Financial news for JNJ dated on 2020-02-04: Stocks That Hit 52-Week Highs On Tuesday

Financial news for JNJ dated on 2020-02-01: Barron's Picks And Pans: Intel, Johnson & Johnson, T-Mobile And More

Financial news for JNJ dated on 2020-01-30: The Daily Biotech Pulse: Sanofi Reports Positive Readout, Tonix Vaccine Candidate Aces Animal Study, Hologix's Weak Guidance

Financial news for JNJ dated on 2020-01-29: Johnson & Johnson Also Says Providing Supplies Of Antiviral Medicines To China For Investigational Use

Financial news for JNJ dated on 2020-01-29: Johnson & Johnson Says Initiating Coronavirus Vaccine Development

Financial news for JNJ dated on 2020-01-29: The Daily Biotech Pulse: Novartis Earnings, Hepion's NASH Candidate Beats Rival Drugs, Annovis Bio To Debut



Financial news for JNJ dated on 2020-01-28: Health Canada Approves New Indication For Invokana To Reduce Risks Associated With Diabetic Kidney Disease In Patients With Type 2 Diabetes

Financial news for JNJ dated on 2020-01-27: Johnson & Johnson Is 'Confident' In Ability To Treat Coronavirus, But Vaccine Could Take Time

Financial news for JNJ dated on 2020-01-27: 10 Biggest Price Target Changes For Monday

Financial news for JNJ dated on 2020-01-27: Health Canada Has Approved Janssen's Stelara For Treatment Of Adult Patients With Moderately To Severely Active Ulcerative Colitis

Financial news for JNJ dated on 2020-01-27: Credit Suisse Maintains Outperform on Johnson & Johnson, Raises Price Target to \$170

Financial news for JNJ dated on 2020-01-23: Janssen Announces European Commission Approves Expanded Use Of Stelara For Treatment Of Paediatric Patients With Moderate To Severe Plaque Psoriasis

Financial news for JNJ dated on 2020-01-23: 10 Biggest Price Target Changes For Thursday

Financial news for JNJ dated on 2020-01-23: Raymond James Maintains Outperform on Johnson & Johnson, Raises Price Target to \$161

Financial news for JNJ dated on 2020-01-22: Mid-Afternoon Market Update: FuelCell Energy Falls On Downbeat Q4 Results; Neurotrope Shares Rise

Financial news for JNJ dated on 2020-01-22: Mid-Day Market Update: Crude Oil Down Over 2%; One Stop Systems Shares Surge

Financial news for JNJ dated on 2020-01-22: Mid-Morning Market Update: Markets Open Higher; Johnson & Johnson Posts Mixed Q4 Results

Financial news for JNJ dated on 2020-01-22: IBM, Netflix Earnings Greeted With Enthusiasm, And Texas Instruments Up Later Today

Financial news for JNJ dated on 2020-01-22: Johnson & Johnson Says Independent Research Continues To Find No Link Between Talc And Cancer

Financial news for JNJ dated on 2020-01-22: Johnson & Johnson Says Off-Patent Drugs Were Able To Retain Business A Little Longer Than Expected In 2019, And Expects It To Continue In 2020

Financial news for JNJ dated on 2020-01-22: Johnson & Johnson Exec Says 2020 Forecast Does Not Assume Any Major Acquisitions Or Other Major Uses Of Cash

Financial news for JNJ dated on 2020-01-22: The Daily Biotech Pulse: Johnson & Johnson Earnings, FDA Nod For Horizon Therapeutics, Slew Of Secondary Offerings

Financial news for JNJ dated on 2020-01-22: Here's How Much Investing \$100 In Johnson & Johnson Stock Back In 2010 Would Be Worth Today

Financial news for JNJ dated on 2020-01-22: Johnson & Johnson Reports Mixed Q4 Earnings

Financial news for JNJ dated on 2020-01-22: A Peek Into The Markets: US Stock Futures Climb Ahead Of Earnings

Financial news for JNJ dated on 2020-01-22: Genmab Highlights 2019 Net DARZALEX Sales By Johnson & Johnson Of \$2.998B

Financial news for JNJ dated on 2020-01-22: Johnson & Johnson Sees FY20 Adj. Operational EPS \$9.00-\$9.15, Operational Sales \$85.8B-\$86.6B

Financial news for JNJ dated on 2020-01-22: Johnson & Johnson Q4 Adj. EPS \$1.88 Beats \$1.87 Estimate, Sales \$20.75B Miss \$20.78B Estimate

Financial news for JNJ dated on 2020-01-22: 8 Stocks To Watch For January 22, 2020

Financial news for JNJ dated on 2020-01-22: Earnings Scheduled For January 22, 2020

Financial news for JNJ dated on 2020-01-21: Johnson & Johnson's Q4 Earnings Outlook

Financial news for JNJ dated on 2020-01-21: Stocks That Hit 52-Week Highs On Tuesday

Financial news for JNJ dated on 2020-01-21: Coronavirus Outbreak, IMF Forecast, Impeachment Trial Weigh On Investor Sentiment

Financial news for JNJ dated on 2020-01-21: 3 ETFs To Consider For The Week Ahead: Big Earnings For Airlines, Chips And Consumers

Financial news for JNJ dated on 2020-01-20: The Week Ahead In Biotech: Focus On Epizyme, Merck Ahead Of PDUFA Dates, J&J To Kickstart Big Pharma Earnings

Financial news for JNJ dated on 2020-01-17: Hearing Johnson & Johnson's Risperdal Verdict Lowered From \$8B to \$6.8B

Financial news for JNJ dated on 2020-01-17: Stocks That Hit 52-Week Highs On Friday

Financial news for JNJ dated on 2020-01-17: Record Run: Stocks Keep Rolling To New Highs as Housing Data, Earnings Look Solid

Financial news for JNJ dated on 2020-01-15: J&N's Janssen Announced Submission Of A Type II Variation Application To European Medicines Agency For Spravato Nasal Spray

Financial news for JNJ dated on 2020-01-10: 'California Gov. Gavin Newsom wants the state to become the first to create its own generic drug label, an attempt to create more competition and bring down prices.' -Axios, From Earlier

Financial news for JNJ dated on 2020-01-09: Wells Fargo Maintains Overweight on Johnson & Johnson, Raises Price Target to \$165

Financial news for JNJ dated on 2020-01-09: Kaleido Biosciences Announces Collaboration With Janssen To Explore Potential For Microbiome Metabolic Therapies To Prevent Childhood-Onset Of Atopic, Immune And Metabolic Conditions By Promoting Healthy Function Of The Gut Microbiome

Financial news for JNJ dated on 2020-01-07: J&J Shares Briefly Turn Positive After U.S. Researchers Find No Clear Talc Link To Ovarian Cancer In Largest Study Yet

Financial news for JNJ dated on 2020-01-07: Investor Movement Index Summary: December 2019

Financial news for JNJ dated on 2020-01-07: Protagonist Therapeutics Achieves Milestone In Janssen Collaboration, Triggering \$5M Payment

Financial news for JNJ dated on 2020-01-06: Johnson & Johnson Reportedly Settles California Talc Case Midtrial

Financial news for JNJ dated on 2020-01-06: 'Johnson & Johnson Settles California Talc Case Midtrial, likely avoiding a huge judgement against them' -Law 360

Financial news for JNJ dated on 2020-01-02: Speaker Of The House Nancy Pelosi Says "Enough is enough. @HouseDemocrats passed the bipartisan #LowerDrugCosts Now Act last year to stop Big Pharma from charging Americans more for our medicines than what they charge for the same drugs overseas."

Financial news for JNJ dated on 2020-01-02: Washington State Sues Johnson & Johnson Over Opioid Epidemic

Financial news for JNJ dated on 2020-01-02: Pulmatrix Shares Soar On Licensing Agreement With Johnson & Johnson

Financial news for JNJ dated on 2020-01-02: Pulmatrix Announces Kinase Inhibitor Licensing Agreement with Lung Cancer Initiative at Johnson & Johnson

Financial news for JNJ dated on 2019-12-26: Provention Bio 8-K Shows Co. Was Informed By J&J's Janssen Pharma It No Longer Intends To Take Up Option To Buy Back Rights For PRV-6527 Compound

Financial news for JNJ dated on 2019-12-22: How The Dow Jones Industrial Average Changed Over The Past Decade

Financial news for JNJ dated on 2019-12-20: Stocks That Hit 52-Week Highs On Friday

Financial news for JNJ dated on 2019-12-20: The Daily Biotech Pulse: Axovant Surges On Gene Therapy Study Results, FDA Approves Merck's Ebola Vaccine, Abeona Announces Offering

Financial news for JNJ dated on 2019-12-20: J&J To Purchase Remaining Stake In Verb Surgical, No Terms Disclosed

Financial news for JNJ dated on 2019-12-19: PreMarket Prep Recap: Earnings Movers, Finding Sellers In Johnson & Johnson

Financial news for JNJ dated on 2019-12-19: Benzinga's Top Upgrades, Downgrades For December 19, 2019

Financial news for JNJ dated on 2019-12-19: Barclays Upgrades Johnson & Johnson to Overweight, Raises Price Target to \$173

Financial news for JNJ dated on 2019-12-17: UPDATE: Morgan Stanley Upgrades Johnson & Johnson To Overweight, Raises Target To \$170 Notes Co's 'defensiveness is down but not out. Legal liabilities appear more than reflected, the pharma segment should accelerate and the business is now more balanced'

Financial news for JNJ dated on 2019-12-17: Benzinga's Top Upgrades, Downgrades For December 17, 2019

Financial news for JNJ dated on 2019-12-17: Benzinga Pro's Top 5 Stocks To Watch For Tues., Dec. 17, 2019: BA, AAPL, BLPH, JNJ, LLY

Financial news for JNJ dated on 2019-12-17: Morgan Stanley Upgrades Johnson & Johnson to Overweight, Announces \$170 Price Target

Financial news for JNJ dated on 2019-12-10: Janssen Announces Results From Phase 3 CANDOR Study; DARZALEX Regimen Showed 'Significant Increase in Progression-Free Survival in Treatment of Patients with Relapsed/Refractory Multiple Myeloma'

Financial news for JNJ dated on 2019-12-10: The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy \$3M In ContraFect Shares

Financial news for JNJ dated on 2019-12-09: Johnson & Johnson Emerging Out Of A Dark Place

Financial news for JNJ dated on 2019-12-09: Janssen and Hitgent to Collaborate on Novel DNA-Encoded Libraries

Financial news for JNJ dated on 2019-12-09: Vaccine Regimen from Janssen and Bavarian Nordic to Support Republic of Rwanda's Preparedness Against Ebola Outbreak

Financial news for JNJ dated on 2019-12-07: Janssen Presents Initial Results for BCMA CAR-T Therapy JNJ-4528 Showing Early, Deep and High Responses in the Treatment of Relapsed or Refractory Multiple Myeloma at ASH 2019

Financial news for JNJ dated on 2019-12-07: The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling

Financial news for JNJ dated on 2019-12-07: XBiotech Announces Agreement to Sell True Human Antibody Bermekimab Targeting IL-1a to Janssen for \$750M in Cash Plus Milestone Payments Up to \$600M

Financial news for JNJ dated on 2019-12-06: Johnson & Johnson Option Alert: Jan 17 \$145 Calls Sweep (2) near the Ask: 3425 @ \$1.44 vs 13950 OI; Earnings 1/21 Before Open [est] Ref=\$141.31

Financial news for JNJ dated on 2019-12-05: Genmab Achieves \$100M Sales Milestone in DARZALEX Collaboration with Janssen

Financial news for JNJ dated on 2019-12-04: Johnson & Johnson Option Alert: Dec 20 \$140 Calls at the Ask: 2650 @ \$1.41 vs 10265 OI; Earnings 1/21 Before Open [est] Ref=\$139.22

Financial news for JNJ dated on 2019-12-04: J&J Shares Tick Lower On Slightly Uptick In Volume Amid Headline FDA Says It Stands By Study Showing Asbestos In J&J's Baby Powder

Financial news for JNJ dated on 2019-12-03: Johnson & Johnson Says Investigation Reaffirmed FDA Finding Of No Asbestos In Baby Powder

Financial news for JNJ dated on 2019-12-02: U.S. Considers Scaling Back IP Protections For Big Drugmakers To Help Win Democratic Support For New Trade Pact With Mexico And Canada

Financial news for JNJ dated on 2019-11-29: Attention Biotech Investors: Mark Your Calendar For These December PDUFA Dates

Financial news for JNJ dated on 2019-11-29: National Business Daily Reports Drugmakers including Johnson & Johnson, Roche, Novartis and Merck have Agreed to Massively Cut the Prices of Some Drugs to Get Included in China's Medical Reimbursement List

Financial news for JNJ dated on 2019-11-27: Health Care ETFs Are Breaking Out, But

## Political Risks Linger In 2020

Financial news for JNJ dated on 2019-11-27: Pharma Companies Shares Tank As Feds Investigate Opioid Crisis

Financial news for JNJ dated on 2019-11-26: McKesson, In Response To Report On Probe Of Opioid Makers, Distributors, Says Information About Co Getting A Subpoena Was Disclosed In Most Recent 10-Q

Financial news for JNJ dated on 2019-11-26: Meg Tirrell On CNBC Says Opioid Investigation Is Not New

Financial news for JNJ dated on 2019-11-26: J&J \$70 Million Award Upheld In Court, May Face Addition Court Hearing For Punitive Damages

Financial news for JNJ dated on 2019-11-26: Shares of opioid-related drugmakers are trading lower on reports federal prosecutors have opened a criminal probe of opioid manufacturers.

Financial news for JNJ dated on 2019-11-26: Brooklyn Federal Prosecutors Open Criminal Probe Of Opioid Manufacturers, Distributors; Mallinckrodt, AmerisourceBergen, Johnson & Johnson and Amneal Say They Have Received Subpoenas

Financial news for JNJ dated on 2019-11-22: Trump Says he Will Release a Plan to Let States Import Prescription Drugs Which are "MUCH CHEAPER"

Financial news for JNJ dated on 2019-11-21: This Dividend ETF Is Having Its Day

Financial news for JNJ dated on 2019-11-20: Benzinga's Top Upgrades, Downgrades For November 20, 2019

Financial news for JNJ dated on 2019-11-20: Cantor Fitzgerald Initiates Coverage On Johnson & Johnson with Overweight Rating, Announces \$160 Price Target

Financial news for JNJ dated on 2019-11-19: Janssen Receives EU Marketing Authorisation For Darzalex In Combination With Lenalidomide And Dexamethasone For Patients With Newly Diagnosed Multiple Myeloma Who Are Transplant Ineligible

Financial news for JNJ dated on 2019-11-17: Barron's Picks And Pans: Medtronic, Tesla, Walmart And More

Financial news for JNJ dated on 2019-11-15: J&J To Appeal Revised Oklahoma Judgment In Opioid Case, Argues Judgment Not Supported By Facts Or The Law

Financial news for JNJ dated on 2019-11-15: Oklahoma Judge Reduces \$572M J&J Owes In Opioid Case To \$465M

Financial news for JNJ dated on 2019-11-15: Shares of several healthcare companies are trading higher after President Trump discussed transparency around pricing & processing in the healthcare industry

Financial news for JNJ dated on 2019-11-14: Johnson & Johnson Ebola Vaccine Begins Rollout in Congo

Financial news for JNJ dated on 2019-11-13: 12 Dow Stocks With At Least 2% Dividend Yields

Financial news for JNJ dated on 2019-11-12: J&J's Actelion Pharmaceuticals Withdraws Regulatory Filings To Extend Indication Of OPSUMIT In CTEPH

Financial news for JNJ dated on 2019-11-09: Janssen Announces New Analysis from Landmark CREDENCE Study Shows the Efficacy and Safety Profiles of INVOKANA are Consistent Across Various Levels of Kidney Function

Financial news for JNJ dated on 2019-11-07: Biotech Stock On The Radar: Alkermes At A Crossroads

Financial news for JNJ dated on 2019-11-07: Johnson & Johnson Announces Submission of European Marketing Authorisation Applications for Janssen's Investigational Ebola Vaccine Regimen

Financial news for JNJ dated on 2019-11-04: Estee Lauder Reports Outstanding First Quarter Results But Cuts Estimates

Financial news for JNJ dated on 2019-10-31: J&J Shares Unaffected As Hearing Co. Has Recalled Surgical Tool After Death Of Patient, Serious Injuries

Financial news for JNJ dated on 2019-10-30: Johnson & Johnson Says Independent Labs Found No Asbestos In Recalled Powder

Financial news for JNJ dated on 2019-10-30: Johnson & Johnson shares are trading higher after the company announced several tests from the same bottle of the company's baby powder that was previously tested by the FDA had no Asbestos.

Financial news for JNJ dated on 2019-10-30: J&J's Janssen Announces Health Canada Approval Of Darzalex In Combination With Lenalidomide And Dexamethasone For Newly Diagnosed Patients With Multiple Myeloma Who Are Transplant Ineligible

Financial news for JNJ dated on 2019-10-30: 13 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for JNJ dated on 2019-10-30: 22 Stocks Moving in Wednesday's Pre-Market Session

Financial news for JNJ dated on 2019-10-30: J&J's Own Expert, Working for FDA, Found Asbestos in Baby Powder

Financial news for JNJ dated on 2019-10-29: 8 Stocks Moving In Tuesday's After-Hours Session

Financial news for JNJ dated on 2019-10-29: Johnson & Johnson shares are trading higher after the company announced several tests from the same bottle of the company's baby powder that was previously tested by the FDA had no Asbestos.

Financial news for JNJ dated on 2019-10-29: Johnson & Johnson Shares Resume Trade

Financial news for JNJ dated on 2019-10-29: UPDATE: Lab Undertook Probe And Determined That Portable Air Conditioner In Use In Auxiliary Room Was Contaminated With Asbestos

Financial news for JNJ dated on 2019-10-29: UPDATE: Additional 48 New Tests Of Samples From Single Lot Of Oct. 18 Recalled J&J Baby Powder Confirm It Does Not Contain Asbestos; Following Recall, Co. Contracted 2 3rd-party Laboratories To Expedite Large Number Of Tests Of Recalled Lot Of Baby Powder

Financial news for JNJ dated on 2019-10-29: Johnson & Johnson Says 15 New Tests From Same Bottle Of Co.'s Baby Powder Previously Tested By FDA Find No Asbestos; Over 60 New Tests Of Recalled Lot Conducted By Two Third Party Laboratories Find No Asbestos

Financial news for JNJ dated on 2019-10-29: Johnson & Johnson Shares Halted, News Pending

Financial news for JNJ dated on 2019-10-25: J&J Says All Product Returned To Company, Whether From Recalled Lot Or Not, Will Be Removed From Marketplace Permanently

Financial news for JNJ dated on 2019-10-25: Target Says Has Removed All J&J Baby Powder 22 oz Bottles From Stores And Website

Financial news for JNJ dated on 2019-10-24: Rite Aid Informed Its Stores To Pull All 22-ounce J&J Baby Powder Bottles On Oct. 18, Immediately After The Recall Was Announced

Financial news for JNJ dated on 2019-10-24: J&J, On CVS Health Removing J&J Baby Powder, Says Co Has Been Informed By CVS It Is A Temporary Removal In Response To The One SKU Of 22 oz Bottles

Financial news for JNJ dated on 2019-10-24: CVS Pulling All 22oz Johnson & Johnson Baby Powder From Shelves Amid Recall

Financial news for JNJ dated on 2019-10-24: Credit Suisse Maintains Outperform on Johnson & Johnson, Raises Price Target to \$163

Financial news for JNJ dated on 2019-10-23: J&J Confirms Deal In Principle To Settle Opioid Litigation As Publicly Announced, Outlined By Committee Of State Attorneys General

Financial news for JNJ dated on 2019-10-23: 'Fast Money Halftime Report' Picks From October 23

Financial news for JNJ dated on 2019-10-23: Biotech Stock On The Radar: Immunomedics' Long Wait For Redemption

Financial news for JNJ dated on 2019-10-23: J&J Medical Devices Unit Auris Health Reports Results From BENEFIT Study Showing Safety, Feasibility Of Monarch Platform

Financial news for JNJ dated on 2019-10-22: Mixed Bag: Better Outlooks From Lockheed, United Technologies, But McDonald's Misses

Financial news for JNJ dated on 2019-10-21: How Much Litigation Risk Is Priced Into Johnson & Johnson?

Financial news for JNJ dated on 2019-10-21: Earnings Roll On With Light Schedule Today But McDonald's, Biogen On Tuesday Calendar

Financial news for JNJ dated on 2019-10-21: J&J's Actelion Pharma Reports Safety, Tolerability Findings From Trial Of Opsumit, Tadalafil Combo Therapy Consistent vs Previous Trials, Was Well Tolerated

Financial news for JNJ dated on 2019-10-21: 4 Pharma Companies Settle Opioid Lawsuits Ahead Of Trial With Ohio Counties; 2,300 Cases Remain

Financial news for JNJ dated on 2019-10-21: 46 Biggest Movers From Friday

Financial news for JNJ dated on 2019-10-20: Barron's Picks And Pans: Boeing, Comcast, Conoco, Emerson And More

Financial news for JNJ dated on 2019-10-19: Benzinga's Bulls And Bears Of The Week: Beyond Meat, Netflix, Johnson & Johnson And More

Financial news for JNJ dated on 2019-10-18: WeTrader Competition: Round Two Wrap-up

Financial news for JNJ dated on 2019-10-18: FDA Alerts Consumers Of Voluntary Recall Of Johnson & Johnson's Baby Powder; Says That Testing Has Found That A Sample For One Lot Of The Product Contains Chrysotile Fibers, A Type Of Asbestos

Financial news for JNJ dated on 2019-10-18: 38 Stocks Moving In Friday's Mid-Day Session

Financial news for JNJ dated on 2019-10-18: From J&J Conference Call To Discuss Powder Recall: Probe Into Asbestos Contamination Of Talc Could Take Up To 30 Days Or More

Financial news for JNJ dated on 2019-10-18: Johnson & Johnson Voluntarily Recalls A Batch Of Baby Powder

Financial news for JNJ dated on 2019-10-18: Johnson & Johnson shares are trading lower after the company recalled 1 lot of baby powder due to trace levels of asbestos.

Financial news for JNJ dated on 2019-10-18: UPDATE: J&J Reports Its Consumer Unit's Recall Of Baby Powder Related To 'test indicating the presence of sub-trace levels of chrysotile asbestos contamination'

Financial news for JNJ dated on 2019-10-18: J&J's Consumer Unit To Voluntarily Recall 1 Lot Of Johnson's Baby Powder

Financial news for JNJ dated on 2019-10-18: The Daily Biotech Pulse: Intuitive Surgical Earnings, Paratek Pulls Out European Application For Antibiotic, Amgen's Evenity In Europe

Financial news for JNJ dated on 2019-10-18: European Medicines Agency Reports Positive Opinion From CHMP For J&J's Combo Treatment In Adults With Treatment-Resistant Major Depressive Disorder

Financial news for JNJ dated on 2019-10-17: J&J's Janssen Presents Four-Year TREMFYA Data Showing Maintained Rates Of Skin Clearance In Adult Patients With Moderate To Severe Plaque Psoriasis

Financial news for JNJ dated on 2019-10-17: Ohio AG Yost Says Multi-State Settlement Requires Johnson & Johnson, Ethicon Inc To Pay About \$117M For 'Deceptive Marketing Of Transvaginal Surgical Mesh Devices'

Financial news for JNJ dated on 2019-10-17: Ohio AG Dave Yost Announces \$117M Multi-State Settlement With Johnson & Johnson

Financial news for JNJ dated on 2019-10-16: PreMarket Prep Recap: Stormy Outlook For Cloud Stocks, Opioid Makers Rally On Settlement Talks

Financial news for JNJ dated on 2019-10-16: Large Option Traders Aren't Buying The Johnson & Johnson Rally

Financial news for JNJ dated on 2019-10-16: Benzinga's Top Upgrades, Downgrades For October 16, 2019

Financial news for JNJ dated on 2019-10-16: Analysts, Investors Like Johnson & Johnson's Improvement, But Lawsuits Loom

Financial news for JNJ dated on 2019-10-16: Opioid Drug Companies Rally On Hopes of Broader Settlement

Financial news for JNJ dated on 2019-10-16: Bank Of America Results Keep Financial Sector Flowing, With Netflix In Focus Later

Financial news for JNJ dated on 2019-10-16: Credit Suisse Maintains Outperform on Johnson & Johnson, Raises Price Target to \$158

Financial news for JNJ dated on 2019-10-16: Wells Fargo Maintains Outperform on Johnson & Johnson, Lowers Price Target to \$155

Financial news for JNJ dated on 2019-10-16: Johnson & Johnson shares are trading higher after it was reported the company has offered \$4 billion to settle opioid claims. Atlantic Equities analysts also upgraded the company's stock from Underweight to Neutral.

Financial news for JNJ dated on 2019-10-16: 17 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for JNJ dated on 2019-10-16: A Peek Into The Markets: US Stock Futures Down; Bank of America Profit Tops Estimates

Financial news for JNJ dated on 2019-10-16: Atlantic Equities Upgrades Johnson & Johnson to Neutral

Financial news for JNJ dated on 2019-10-16: J&J Makes \$4B Offer to Settle Opioid Claims

Financial news for JNJ dated on 2019-10-15: UPDATE: J&J Also In Talks To Contribute Added Money For Opioid Litigation

Financial news for JNJ dated on 2019-10-15: Missouri Appeals Court Overturns Talc Case In Which Jury Had Awarded \$110M To Virginia Woman

Financial news for JNJ dated on 2019-10-15: PreMarket Prep Recap: Impressive Bank Earnings, Aphria Sparks Rally In Marijuana Sector

Financial news for JNJ dated on 2019-10-15: Bank Earnings Quartet Mostly In Tune, Led By Strength At JPMorgan, Citigroup

Financial news for JNJ dated on 2019-10-15: Relmada Shares Hit 4-Year High As Depression Drug Aces Midstage Trial

Financial news for JNJ dated on 2019-10-15: Johnson & Johnson Trades Higher On Q3 Beat-And-Raise, Despite Legal Entanglements

Financial news for JNJ dated on 2019-10-15: 22 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Financial news for JNJ dated on 2019-10-15: The Daily Biotech Pulse: Reata Leaps On Positive Readout, Takeda Divests, FDA Nod For Akorn, J&J Earnings

Financial news for JNJ dated on 2019-10-15: Johnson & Johnson shares are trading higher after the company reported better-than-expected Q3 EPS and sales results. The company also raised its FY19 EPS guidance.

Financial news for JNJ dated on 2019-10-15: A Peek Into The Markets: US Stock Futures Rise Ahead Of Goldman Sachs, Citigroup Earnings

Financial news for JNJ dated on 2019-10-15: Johnson & Johnson Raises FY19 Adj. Operational EPS Guidance From \$8.73-\$8.83 To \$8.84-\$8.89

Financial news for JNJ dated on 2019-10-15: Johnson & Johnson Q3 Adj. EPS \$2.12 Beats \$2 Estimate, Sales \$20.73B Beat \$20.09B Estimate

Financial news for JNJ dated on 2019-10-15: 10 Stocks To Watch For October 15, 2019

Financial news for JNJ dated on 2019-10-15: Earnings Scheduled For October 15, 2019

Financial news for JNJ dated on 2019-10-14: Earnings, Econ Numbers And The Beige Book Pepper The Second Round of The WeTrader Competition

Financial news for JNJ dated on 2019-10-14: Raymond James Maintains Outperform on Johnson & Johnson, Lowers Price Target to \$145

Financial news for JNJ dated on 2019-10-14: Congo to Begin Using J&J Ebola Vaccine in November

Financial news for JNJ dated on 2019-10-13: The Week Ahead In Biotech: FDA Decisions, Johnson & Johnson Among Big Pharma Earnings

Financial news for JNJ dated on 2019-10-12: Barron's Picks And Pans: Apple, Boeing, GE, Kellogg And More

Financial news for JNJ dated on 2019-10-12: Benzinga's Bulls And Bears Of The Week: Apple, Boeing, Facebook, Nike And More

Financial news for JNJ dated on 2019-10-11: Shares of several healthcare companies are trading higher after President Trump made positive remarks on the U.S.-China trade talks as traders grew more optimistic over the possibility of a limited trade deal. Trump is scheduled to meet with Chinese Vice Premier Liu He at the White House today.

Financial news for JNJ dated on 2019-10-11: Benzinga's Top Upgrades, Downgrades For October 11, 2019

Financial news for JNJ dated on 2019-10-11: 28 Healthcare Stocks Moving In Friday's Pre-Market Session

Financial news for JNJ dated on 2019-10-11: The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout

Financial news for JNJ dated on 2019-10-11: Bernstein Upgrades Johnson & Johnson to Outperform

Financial news for JNJ dated on 2019-10-09: Mid-Afternoon Market Update: Dow Rises Over 200 Points; Ocugen Shares Spike Higher

Financial news for JNJ dated on 2019-10-09: Mid-Day Market Update: Crude Oil Up 1%; James River Group Shares Plunge

Financial news for JNJ dated on 2019-10-09: Mid-Morning Market Update: Markets Open Higher; Johnson & Johnson Hit With \$8B Verdict In Risperdal Lawsuit

Financial news for JNJ dated on 2019-10-09: Johnson & Johnson Hit With \$8B Verdict In Risperdal Lawsuit

Financial news for JNJ dated on 2019-10-09: 13 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for JNJ dated on 2019-10-09: Jury Says J&J Must Pay \$8B In Case Over Male Breast Growth Linked To Risperdal

Financial news for JNJ dated on 2019-10-04: The Daily Biotech Pulse: Arbutus Halts Hepatitis B Study, Positive Readout For MEI Pharma's Blood Cancer Drug, Ovid Offering

Financial news for JNJ dated on 2019-10-03: J&J's Janssen Reports FDA Breakthrough Therapy Designation Granted For Niraparib For Treatment Of Metastatic Castration-Resistant Prostate Cancer

Financial news for JNJ dated on 2019-10-02: J&J's Janssen Submits Supplemental New Drug Application To FDA For SPRAVATO CIII Nasal Spray For The Rapid Reduction Of Depressive Symptoms In Adults With Major Depressive Disorder Who Have Active Suicidal Ideation With Intent

Financial news for JNJ dated on 2019-10-02: Sell-Side Positive On Johnson & Johnson's Unexpected Ohio Opioid Settlement

Financial news for JNJ dated on 2019-10-02: Johnson & Johnson shares are trading higher after the company reached a settlement agreement with two Ohio counties ahead of upcoming opioid trial. The company will pay a total of \$20.4 million in relation to the settlement.

Financial news for JNJ dated on 2019-10-02: UPDATE: JNJ To Pay \$5M Of Ohio Counties' Legal Fees And Will Direct \$5.4M To Opioid-Related Charitable Programs

Financial news for JNJ dated on 2019-10-02: The Daily Biotech Pulse: J&J Settles Ohio Opioid Lawsuit, Teligent Explores Options For Certain Assets, Novartis Reports Cosentyx Data

Financial news for JNJ dated on 2019-10-01: Johnson & Johnson Reaches Settlement Agreement with Two Ohio Counties Ahead of Upcoming Opioid Trial; JNJ to Pay \$10M to Cuyahoga and Summit Counties

Financial news for JNJ dated on 2019-09-30: Attention Biotech Investors: Mark Your Calendar For These October PDUFA Dates



Financial news for JNJ dated on 2019-09-30: California Jury Returns \$40M Talc Verdict Against Johnson & Johnson

Financial news for JNJ dated on 2019-09-30: Credit Suisse Reiterates Outperform, \$156 Target On Johnson & Johnson As Firm Notes Co. 'appears to be tracking ahead of our Q3 US Pharma estimates, based on our updated analysis of intra-quarter scrips and IMS-reported sales trends for both July and Aug'

Financial news for JNJ dated on 2019-09-27: The Daily Biotech Pulse: ESMO Conference Gets Underway, J&J's Darzalex Snags Another Approval, Kaleido Biosciences CFO To Leave

Financial news for JNJ dated on 2019-09-26: J&N's Janssen Announces Receives FDA Approval For Of Darzalex (Daratumumab) Combination Regimen For Newly Diagnosed, Transplant-Eligible Patients With Multiple Myeloma

Financial news for JNJ dated on 2019-09-26: The Daily Biotech Pulse: Enanta Aces Midstage NASH Study, Takeda's Ulcerative Colitis Drug Found Superior To AbbVie's, Decision Day For J&J

Financial news for JNJ dated on 2019-09-25: Biotech Stock On The Radar: Anavex, A Neurology-Focused Precision Medicine Company

Financial news for JNJ dated on 2019-09-22: Barron's Picks And Pans: Coca-Cola, McDonald's, Ford, Nike And More

Financial news for JNJ dated on 2019-09-22: The Week Ahead In Biotech: Spotlight On ESMO Conference

Financial news for JNJ dated on 2019-09-20: Shares of several drug companies are trading higher after Senate Majority Leader McConnell suggested a new Democratic drug price reform proposal would be dead on arrival.

Financial news for JNJ dated on 2019-09-20: J&J's Janssen Announced New Real-World Evidence Confirming Xarelto Reduced Risk Of Recurrent Venous Thromboembolism In Patients Who Are Morbidly Obese

Financial news for JNJ dated on 2019-09-18: J&J To Report Q3 Earnings On Tues., Oct 15, 2019 Before Market Open

Financial news for JNJ dated on 2019-09-18: Axsome Shares Flirt With Record High: How Much Upside Is Left?

Financial news for JNJ dated on 2019-09-18: The Daily Biotech Pulse: NewLink Genetics Rallies, Breakthrough Designation For Roche, IGM Biosciences Debuts

Financial news for JNJ dated on 2019-09-16: Purdue Pharma Files For Bankruptcy: What You Need To Know

Financial news for JNJ dated on 2019-09-16: MorphoSys Reports Licensee Janssen R&D Issued Press Release Highlighting Submission Of Supplemental Biologics License Application Seeking Approval Of Tremfya

Financial news for JNJ dated on 2019-09-15: Janssen Pharmaceutical Announces New DARZALEX Data from GRIFFIN Study Show High Response Rate and Depth of Response in Patients with Newly Diagnosed Multiple Myeloma Who are Transplant-Eligible

Financial news for JNJ dated on 2019-09-14: J&J, McKesson Face \$8B Damage Demand in Ohio Opioid Trial

Financial news for JNJ dated on 2019-09-11: J&J Spokesperson Says A New Jersey Jury Has Found Co. Liable For \$37M In Trial Claiming Talc Powder Caused Cancer

Financial news for JNJ dated on 2019-09-11: Johnson & Johnson To Pay \$37.2M To Group Blaming Powder For Cancers

Financial news for JNJ dated on 2019-09-11: Watching J&J Shares Amid Report New Head-To-Head Phase 3 Data For Janssen's Ponesimod Was Superior Compared To Aubagio 14 mg in Adults With Relapsing Multiple Sclerosis

Financial news for JNJ dated on 2019-09-09: J&J Says New Data From Spravato CIII Nasal Spray Phase 3 Studies Showed Rapid Reduction Of Depressive Symptoms In Adult Patients With Major Depressive Disorder

Financial news for JNJ dated on 2019-09-04: European Commission Has Approved Expanded Use Of J&J's Janssen's Ustekinumab For Treatment Of Adults With Moderately To Sever Ulcerative Colitis

Financial news for JNJ dated on 2019-09-03: Cardinal Health, J&J Shares Tick Lower As

Hearing Cos. Must Face Cities Opioid-Conspiracy Claims

Financial news for JNJ dated on 2019-09-02: The Week Ahead In Biotech: Cardiology, Analyst Conferences In The Spotlight

Financial news for JNJ dated on 2019-08-31: Bulls And Bears Of The Week: Altria, Apple, Netflix, Slack And More

Financial news for JNJ dated on 2019-08-29: Citi Turns Bullish On Jabil, Says Customer Risk Concentration 'Played Out'

Financial news for JNJ dated on 2019-08-29: 'Fast Money' Traders Give Their Opinion On Johnson & Johnson And Papa John's

Financial news for JNJ dated on 2019-08-28: Fitch Says Oklahoma's Ruling On J&J May Not Set Standard For Other Companies As Other States Could Employ Legal Approaches Other Than Public Nuisance Law

Financial news for JNJ dated on 2019-08-28: Attention Biotech Investors: Mark Your Calendar For These September PDUFA Dates

Financial news for JNJ dated on 2019-08-28: Arrowhead Collaborator Janssen Begins REEF-1 Phase 2b Combination Study in Patients With Chronic Hepatitis B Infection; Arrowhead Earns \$25M Milestone Payment In Connection With Trial Initiation

Financial news for JNJ dated on 2019-08-27: 46 Stocks Moving In Tuesday's Mid-Day Session

Financial news for JNJ dated on 2019-08-27: Barclays Maintains Equal Weight, \$140 Target On Johnson & Johnson As Firm Believes 'shares are likely to continue to trade at a discount to its sum-of-the-parts valuation due to the litigation overhang'

Financial news for JNJ dated on 2019-08-27: BMO Maintains Outperform On Johnson & Johnson, Maintains \$157 Target As Firm Notes 'We remind investors that litigation is long, lengthy, and difficult to read, and while the amount is less than it could have been, we would expect an extended resolution'

Financial news for JNJ dated on 2019-08-27: Why One Johnson & Johnson Analyst Sees Oklahoma Opioid Ruling As Near-Term Sentiment Positive

Financial news for JNJ dated on 2019-08-27: Raymond James On Johnson & Johnson Also Notes The 'judge ordered J&J to pay ~\$572M for an abatement plan' And 'The state was looking for \$17B from J&J and we believe investor expectations were for ~\$2-3B. J&J ended 2Q19 with ~\$14B in net cash'

Financial news for JNJ dated on 2019-08-27: Raymond James Maintains Outperform On Johnson & Johnson As Firm Notes 'After speaking with management, we remain optimistic in the defense case for J&J when heading to the appellate courts'

Financial news for JNJ dated on 2019-08-27: A Look At Benzinga Pro's Most-Searched Tickers For August 27, 2019

Financial news for JNJ dated on 2019-08-27: Chubb, Salesforce And More 'Fast Money' Picks For August 27

Financial news for JNJ dated on 2019-08-27: Johnson & Johnson shares are trading higher after an Oklahoma Judge finds the company liable in the lawsuit claiming that it helped fuel opioid epidemic, will pay \$572 million in damages. Investors were potentially expecting the company to pay more in fin

Financial news for JNJ dated on 2019-08-27: Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Tuesday., August 27, 2019

Financial news for JNJ dated on 2019-08-27: Neutral Zone: Stocks, Bonds Both Up As Next Moves In Trade War Anxiously Awaited

Financial news for JNJ dated on 2019-08-27: UPDATE: Morgan Stanley On Johnson & Johnson Also Notes 'Given that many investors feared a more substantial judgment against J&J, we expect opioid-exposed specialty pharmaceutical companies to trade higher on Tuesday Aug 27'

Financial news for JNJ dated on 2019-08-27: UPDATE: Morgan Stanley Maintains Equal-Weight On Johnson & Johnson, Maintains \$145 Target As Firm Notes 'we suggested Base case exposure of \$6bn and Bear case exposure of \$16bn and yesterday's judgement does not alter our view'

Financial news for JNJ dated on 2019-08-27: Morgan Stanley Maintains Equal-Weight on Johnson & Johnson, Maintains \$145 Price Target

Financial news for JNJ dated on 2019-08-27: 26 Stocks Moving in Tuesday's Pre-Market Session

Financial news for JNJ dated on 2019-08-27: The Daily Biotech Pulse: Nuvectra Explores Strategic Options, J&J To Contend Opioid Ruling, Sesen Bio Gets New CFO

Financial news for JNJ dated on 2019-08-27: Everyday Health Group Acquires BabyCenter From Johnson & Johnson, Terms Not Disclosed

Financial news for JNJ dated on 2019-08-26: Judge Orders Johnson & Johnson To Pay \$572M In Opioid Case

Financial news for JNJ dated on 2019-08-26: Johnson & Johnson shares are trading higher after an Oklahoma Judge finds the company liable in the lawsuit claiming that it helped fuel opioid epidemic, will pay \$572 million in damages. Investors were potentially expecting the company to pay more in fines.

Financial news for JNJ dated on 2019-08-26: Johnson & Johnson Says It Will Appeal Oklahoma Judge's Ruling In Opioid Case

Financial news for JNJ dated on 2019-08-26: Oklahoma Judge Finds Johnson & Johnson Liable In Lawsuit Claiming Drugmaker Helped Fuel Opioid Epidemic; Co. To Pay \$572M In Damages

Financial news for JNJ dated on 2019-08-26: Johnson & Johnson Shares Now Falling, Reversing From Spike

Financial news for JNJ dated on 2019-08-26: Johnson & Johnson Shares Spike; Oklahoma Judge Preparing To Reveal Decision In Opioid Lawsuit

Financial news for JNJ dated on 2019-08-22: Kohl's, Snap And More 'Fast Money' Picks For August 22

Financial news for JNJ dated on 2019-08-22: The Daily Biotech Pulse: ViiV's Long-Acting HIV Drug Meets Study Goal, Chinese Cheer For FibroGen, Retrophin Flunks Late-Stage Study

Financial news for JNJ dated on 2019-08-21: 'Oklahoma judge to rule on Monday in opioid lawsuit against J&J ' -Reuters

Financial news for JNJ dated on 2019-08-21: 'Trump says his solution to the epidemic of veteran suicides is some new "stimulant" produced by Johnson & Johnson that he's instructed the government to buy in large quantities' -Tweets Aaron Rugar

Financial news for JNJ dated on 2019-08-20: 'It's A Huge Thing': Avicanna Receives Unique Canadian Cannabinoid Research License

Financial news for JNJ dated on 2019-08-13: Shares of several healthcare companies are trading higher with the overall market after the U.S. announced it is excluding and delaying the additional 10% tariff on certain products.

Financial news for JNJ dated on 2019-08-13: Lilly's Psoriasis Drug Found Superior To J&J's Tremfya In Phase 4 Study

Financial news for JNJ dated on 2019-08-12: XOMA Reports J&J's Janssen Has Elected to Accelerate Base Annual License Fee Obligation, Will Make 1-Time \$2.5M Payment To Co.

Financial news for JNJ dated on 2019-07-31: Biotech Stock On The Radar: Veru, A Catalyst-Rich Biopharma

Financial news for JNJ dated on 2019-07-29: In June, FTC Issued Civil Investigative Demand To J&J On Investigation Of Whether Janssen's Remicade Contracting Practices Violate Antitrust Laws

Financial news for JNJ dated on 2019-07-29: Host Of Earnings Loom With Beyond Meat, Apple Among Highlights Ahead Of Fed, Payrolls

Financial news for JNJ dated on 2019-07-28: KBL Merger Corp Acquires Cannabis-Focused Biotech Company

Financial news for JNJ dated on 2019-07-26: The Daily Biotech Pulse: Obseva Gets The Greenlight, Verastem Climbs On Licensing Deal, Merit Medical Earnings Disappoint

Financial news for JNJ dated on 2019-07-23: Social Media Earnings: Facebook And Twitter Prepare To Share

Financial news for JNJ dated on 2019-07-23: With Earnings On Tap, A Stir In This Leveraged Pharmaceuticals ETF

Financial news for JNJ dated on 2019-07-21: Benzinga's Bulls And Bears: Apple, Boeing, Disney, Johnson & Johnson And More

Financial news for JNJ dated on 2019-07-20: The Week Ahead In Biotech: Pharma Earnings Pick Up Pace

Financial news for JNJ dated on 2019-07-19: From Coffee To Cannabis: Colombia's Choice Between Economic Development And 'CannaMercantilism'

Financial news for JNJ dated on 2019-07-19: Intuitive Surgical's Q2 Performance Lauded By Bullish Analysts

Financial news for JNJ dated on 2019-07-19: Halozyme Reports J&J's Janssen Submitted Extension Application To EMA For Subcutaneous Formulation Of DARZALEX Utilizing ENHANZE Technology

Financial news for JNJ dated on 2019-07-19: Janssen Seeks EMA Approval for Novel Subcutaneous Formulation of Darzalex

Financial news for JNJ dated on 2019-07-17: FlexShares Makes A Big Low Vol ETF Splash

Financial news for JNJ dated on 2019-07-17: After Earnings Beat, Wall Street Talks Johnson & Johnson Litigation Risk

Financial news for JNJ dated on 2019-07-17: Raymond James Maintains Outperform on Johnson & Johnson, Lowers Price Target to \$146

Financial news for JNJ dated on 2019-07-16: Mostly Strong Results For Big Banks, And J&J Another Solid Earnings Performer

Financial news for JNJ dated on 2019-07-16: J&J Executive Says Taking A \$190M Charge In The Quarter Related To Talc Litigation For Defense Costs Only

Financial news for JNJ dated on 2019-07-16: From J&J Q2 Earnings Conference Call: Exec Commenting On Oklahoma Opioid Case Says Facts Do Not Align With What State Is Claiming

Financial news for JNJ dated on 2019-07-16: From J&J Q2 Earnings Conference Call: Sees Largest Impact From Generic, Biosimilars In Q3, Has Resumed Distribution Of Its Surgical Staplers To Customers In Jun. Following Recall

Financial news for JNJ dated on 2019-07-16: A Peek Into The Markets: US Stock Futures Edge Lower Ahead Of Citigroup, Wells Fargo Earnings

Financial news for JNJ dated on 2019-07-16: Johnson & Johnson Trades Higher On Q2 Earnings Beat

Financial news for JNJ dated on 2019-07-16: Johnson & Johnson Reaffirms FY19 Adj. EPS Guidance Of \$8.53-\$8.63 vs \$8.60 Est.

Financial news for JNJ dated on 2019-07-16: Johnson & Johnson Raises FY19 Operational Sales Guidance From \$82B-\$82.8B To \$82.4B-\$83.2B; Raises Est. Reported Sales From \$80.4B-\$81.2B To \$80.8B-\$81.6B

Financial news for JNJ dated on 2019-07-16: Johnson & Johnson Q2 Adj. EPS \$2.58 Beats \$2.43 Estimate, Sales \$20.56B Beat \$20.29B Estimate

Financial news for JNJ dated on 2019-07-16: 11 Stocks To Watch For July 16, 2019

Financial news for JNJ dated on 2019-07-16: Earnings Scheduled For July 16, 2019

Financial news for JNJ dated on 2019-07-15: Johnson & Johnson Q2 Earnings Outlook

Financial news for JNJ dated on 2019-07-15: Earnings Season Starts With Beat From Citigroup; Other Banks, Netflix Report Later In Week

Financial news for JNJ dated on 2019-07-13: The Week Ahead In Biotech: Johnson & Johnson Kickstarts Big Pharma Earnings

Financial news for JNJ dated on 2019-07-12: Johnson & Johnson Falls On Report Of Justice Department Probe

Financial news for JNJ dated on 2019-07-12: J&J, In Response To Report About Criminal Probe In Talc Case, Says Implication That There Has Been A New Development In This Matter Is Flatly Wrong

Financial news for JNJ dated on 2019-07-12: Halozyme Therapeutics Reports J&J's Janssen Submitted Biologics License Application To FDA For Subcutaneous Delivery Of DARZALEX For Patients With Multiple Myeloma

Financial news for JNJ dated on 2019-07-12: Johnson & Johnson shares are trading lower following reports of a US criminal probe into the company's denial of asbestos in baby powder.

Financial news for JNJ dated on 2019-07-12: J&J Shares Fall As Hearing Co. Denials Of Asbestos In Baby Powder Have Spurred A US Criminal Probe

Financial news for JNJ dated on 2019-07-12: J&J's Janssen Says Is In the Process Of Submitting Regulatory Applications To Respective Health Authorities Related To Preventive HIV Vaccine

Financial news for JNJ dated on 2019-07-12: Novartis, Amgen Scrap Pivotal Study Of Alzheimer's Prevention Drug

Financial news for JNJ dated on 2019-07-12: Benzinga's Top Upgrades, Downgrades For July 12, 2019

Financial news for JNJ dated on 2019-07-12: Credit Suisse Initiates Coverage On Johnson & Johnson with Outperform Rating, Announces \$156 Price Target

Financial news for JNJ dated on 2019-07-11: Avicanna Gets Conditional Approval To List On Toronto Stock Exchange Senior Board As R&D Issuer

Financial news for JNJ dated on 2019-07-11: 'Johnson & Johnson's stranglehold on the blockbuster drug Remicade' -Recent Axios Article

Financial news for JNJ dated on 2019-07-10: Johnson & Johnson Wins New Trial In Talc Case

Financial news for JNJ dated on 2019-07-10: J&J Says "Pleased With The California Appellate Court's Review" Of The Talc Case; Says Pleased That Court Agreed With Judge Nelson's Finding That Punitive Damages Should Not Have Been Awarded

Financial news for JNJ dated on 2019-07-10: Johnson & Johnson To Get Trial After \$417M Verdict In Talc Case

Financial news for JNJ dated on 2019-07-09: Vaxart Enters Into Research Collaboration With Janssen To Evaluate Oral Universal Influenza Vaccine

Financial news for JNJ dated on 2019-07-08: Johnson & Johnson Janssen Announces Results From Phase 3 Einstein-Jr Study Of Xarelto; Study Met All Pre Specified Endpoints

Financial news for JNJ dated on 2019-06-28: J&J's Janssen Reports Received Positive CHMP Opinion Recommending Expanded Use Of Imbruvica For 2 Indications

Financial news for JNJ dated on 2019-06-26: Morphic Holding IPO: What You Need To Know

Financial news for JNJ dated on 2019-06-24: Minerva Spikes Higher After Novel Insomnia Drug Aces Mid-Stage Trial

Financial news for JNJ dated on 2019-06-19: Fitch Affirms J&J 'AAA' Rating

Financial news for JNJ dated on 2019-06-14: Janssen Reports Top-Line Phase 3 Results For Tremfya In Adults With Active Psoriatic Arthritis

Financial news for JNJ dated on 2019-06-12: UPDATE: Recent Bloomberg Report Indicates J&J And Colgate Ordered To Pay Almost \$10M In Talc Case

Financial news for JNJ dated on 2019-06-12: J&J, Colgate-Palmolive Lose Verdict In Talc-Cancer Case

Financial news for JNJ dated on 2019-06-12: J&J Says Co 'Will Pursue An Appeal Because Johnson's Baby Powder Does Not Contain Asbestos Or Cause Cancer'

Financial news for JNJ dated on 2019-06-12: Hearing Johnson & Johnson And Colgate-Palmolive Have Closed Jury Verdict In Talc Cancer Case

Financial news for JNJ dated on 2019-06-11: Janssen Invokana Incidence Rates Of Adverse Events & Serious Adverse Events Were Numerically Lower For Patients Treated With Invokana Vs Placebo

Financial news for JNJ dated on 2019-06-11: Janssen Invokana Significantly Reduced Major Cardiovascular Events & Kidney Failure In Patients With Type 2 Diabetes & Chronic Kidney Disease In New Credence Analysis

Financial news for JNJ dated on 2019-06-11: The Daily Biotech Pulse: Lilly Reports

Positive Long-Term Efficacy Data For Psoriasis Drug, Provention Bio Offering

Financial news for JNJ dated on 2019-06-04: Shares of several healthcare companies are trading higher with the overall US market. Recent comments out of China and Mexico has renewed trade optimism and lifted economic outlook.

Financial news for JNJ dated on 2019-06-04: 'I believe it is wrong to charge Americans astronomical prices for life-saving drugs developed with taxpayer dollars. You will not find me encouraging pharmaceutical companies to continue ripping off Americans like my Republican colleagues.' -Sen Sanders

Financial news for JNJ dated on 2019-06-04: Obalon Clinches First US Patent For Obesity Treatment Placement System

Financial news for JNJ dated on 2019-06-03: Johnson & Johnson's Janssen Pharmaceutical Highlights Presentation Of Imbruvica Long-Term Data From Two Pivotal Phase 3 Studies At ASCO And EHA Demonstrating Sustained Efficacy And Safety In Patients With Chronic Lymphocytic Leukemia

Financial news for JNJ dated on 2019-05-31: Johnson & Johnson To Pay \$300M In Punitive Damages In Olson Talc Cancer Case

Financial news for JNJ dated on 2019-05-31: UPDATE: J&J Spokesperson Says Talc Trial Had 'Significant Legal And Evidentiary Errors' Which Co. Believes Will Warrant Reversal Amid Appeal

Financial news for JNJ dated on 2019-05-31: UPDATE: J&J Says \$300M Punitive Award In Solson Talc Trial Is On Top Of \$25M Compensatory Damages Awarded Last Week

Financial news for JNJ dated on 2019-05-31: Hearing J&J To Pay \$300M Punitive Award In New York Calc Case

Financial news for JNJ dated on 2019-05-30: Johnson & Johnson Analyst: 3 Takeaways On Opioid Litigation

Financial news for JNJ dated on 2019-05-30: 64 Biggest Movers From Yesterday

Financial news for JNJ dated on 2019-05-29: Obalon Closes Above \$1 Following Questionable Takeover Rumor

Financial news for JNJ dated on 2019-05-29: 42 Stocks Moving In Wednesday's Mid-Day Session

Financial news for JNJ dated on 2019-05-29: Shares of several healthcare companies are trading lower after the US state of Oklahoma filed a multi-billion dollar lawsuit against Johnson & Johnson relating to opioid abuse; Oklahoma settled an opioid lawsuit with Teva Pharmaceuticals earlier this week

Financial news for JNJ dated on 2019-05-29: Johnson & Johnson shares are trading lower after the company's trial in Oklahoma regarding its role in opioid addiction began on Tuesday.

Financial news for JNJ dated on 2019-05-29: Obalon Therapeutics Shares Up 15% Just After Wednesday's Open; Chatter Of Earlier Questionable, Unconfirmed Seeking Alpha Blogpost From Stellar Wealth Mgmt. 'JNJ Makes Bid For OBLN At \$8/Share'

Financial news for JNJ dated on 2019-05-22: FDA Grants Priority Review For J&J's Janssen Pharma's INVOKANA

Financial news for JNJ dated on 2019-05-22: The Daily Biotech Pulse: Tocagen Tumbles, OncoSec Offering, Novartis Asthma Combo Drug Study

Financial news for JNJ dated on 2019-05-21: J&J Shares Indicated Slightly Lower On No Volume Amid Report Co. Said South Carolina Jury Cleared Co. Of Its Liability In Suit Alleging Asbestos In Talc Caused Women's Cancer

Financial news for JNJ dated on 2019-05-21: Johnson & Johnson Issues Statement On May 21 Verdict In New York; Says The Trial Suffered From Significant Legal And Evidentiary Errors; Says It Believes The Errors Will Warrant A Reversal On Appeal

Financial news for JNJ dated on 2019-05-21: J&J Shares Fall Midday Amid Report Co. Lost A \$25M Verdict In New York Over Talc Powder

Financial news for JNJ dated on 2019-05-20: PreMarket Prep Opening NYSE Imbalance Update: GE 215k Shares To Sell; Alibaba 69k To Sell; Pfizer 131k To Sell; Coca-Cola 58k To Sell; J&J 32k To Sell

Financial news for JNJ dated on 2019-05-18: Bulls And Bears Of The Week: Apple, Chevron, FedEx, Uber And More

Financial news for JNJ dated on 2019-05-17: FDA Has Identified Ethicon's Recall Of Circular Staplers As Class I Recall

Financial news for JNJ dated on 2019-05-17: 'FBI targets Johnson & Johnson, Siemens, GE, Philips in Brazil graft case' -Reuters

Financial news for JNJ dated on 2019-05-16: Johnson & Johnson Analysts Laud Accelerating Pharma Business

Financial news for JNJ dated on 2019-05-16: Credit Suisse Maintains Outperform on Johnson & Johnson Common Stock, Raises Price Target to \$156

Financial news for JNJ dated on 2019-05-15: J&J Highlights Will Host Meeting Today With Industry Analysts 'to review the strategy of its Janssen Pharmaceutical Companies to deliver above-market, compound annual growth through 2023'

Financial news for JNJ dated on 2019-05-14: J&J Patent On Zytiga Ruled Invalid By US Appeals Court

Financial news for JNJ dated on 2019-05-13: Minerva Neurosciences Sinks To Lowest Level In A Year On Cloudy Midstage Trial Results For Depression Drug

Financial news for JNJ dated on 2019-05-10: The Daily Biotech Pulse: FibroGen Kidney Disease Trial Disappoints, Medtronic To Buy Titan Spine, Puma's Weak Breast Cancer Drug Sales

Financial news for JNJ dated on 2019-05-09: Drug Prices Will Be Included In TV Ads Under New Trump Admin Rule

Financial news for JNJ dated on 2019-05-07: J&J Shares Unaffected As WHO's Strategic Advisory Group Recommended A Change In Ebola Vaccine Strategy, Has Expanded Eligible Population And Introduced Co.'s Experimental Vaccine

Financial news for JNJ dated on 2019-05-07: J&J Will Pay \$1B To Resolve Pinnacle-Hip Suits

Financial news for JNJ dated on 2019-05-07: Shares of several healthcare companies are trading lower after several companies in the space reported weak earnings with Mylan leading the selloff.

Financial news for JNJ dated on 2019-05-06: PreMarket Prep Opening NYSE Imbalance Update: Alibaba 316k Shares To Sell; Citigroup 67k To Sell; Bank Of America 319k To Sell; JP Morgan 110K To Sell; GE 557k To Sell; Johnson & Johnson 32k To Sell

Financial news for JNJ dated on 2019-05-02: 2 New ETFs For 'Biblically Responsible Investing'

Financial news for JNJ dated on 2019-05-02: Vistagen Shares Fall Under \$1 After Depression Drug Flunks Midstage Trial

Financial news for JNJ dated on 2019-04-30: Attention Biotech Investors: Mark Your Calendar For These May PDUFA Dates

Financial news for JNJ dated on 2019-04-25: J&J Raises Qtr. Dividend From \$0.90 To \$0.95/Share

Financial news for JNJ dated on 2019-04-24: Jim Cramer Gives His Opinion On Barrick Gold, Canopy Growth, EA, Johnson & Johnson And More

Financial news for JNJ dated on 2019-04-23: Shares of several healthcare stocks are trading higher in a potential rebound from last week's selloff. In an upgrade of HCA Healthcare, Raymond James analysts noted the selloff was 'based on legislation that has almost no chance of passing'

Financial news for JNJ dated on 2019-04-23: UroGen Pharma Reports Early-Stage Feasibility Deal With J&J's Janssen, No Terms Disclosed

Financial news for JNJ dated on 2019-04-22: 6 Cannabis Execs On The Strengths Of Their Businesses

Financial news for JNJ dated on 2019-04-22: 3 Options Trading Ideas For The Upcoming Earnings Season

Financial news for JNJ dated on 2019-04-21: The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs

Financial news for JNJ dated on 2019-04-18: Buyer's Remorse? OTC Stock Zoom Technologies Zooms Higher Amid Potential Buyer Confusion

Financial news for JNJ dated on 2019-04-17: Analysts View Johnson & Johnson's Organic Growth Guidance As Conservative

Financial news for JNJ dated on 2019-04-17: BMO Capital Maintains Outperform on Johnson & Johnson, Raises Price Target to \$157

Financial news for JNJ dated on 2019-04-17: Credit Suisse Maintains Outperform on Johnson & Johnson, Raises Price Target to \$152

Financial news for JNJ dated on 2019-04-17: Morgan Stanley Maintains Equal-Weight on Johnson & Johnson, Raises Price Target to \$145

Financial news for JNJ dated on 2019-04-17: Hot, Fresh Earnings On The Menu As Netflix, Morgan Stanley Results In Focus

Financial news for JNJ dated on 2019-04-17: Raymond James Maintains Outperform on Johnson & Johnson, Raises Price Target to \$147

Financial news for JNJ dated on 2019-04-16: FDA Determines Boston Scientific Hasn't Showed Reasonable Assurance Of Safety, Effectiveness For Surgical Meshes

Financial news for JNJ dated on 2019-04-16: Banks On Parade: Bank of America Becomes Latest Big Financial Company To Report

Financial news for JNJ dated on 2019-04-16: J&J Expects To See Largest Impact From Generic And Biosimilar Erosion In 2019

Financial news for JNJ dated on 2019-04-16: J&J Says 800 Sites Now Certified For New Depression Drug SPRAVATO

Financial news for JNJ dated on 2019-04-16: Johnson & Johnson shares are trading higher after the company reported better-than-expected Q1 EPS and revenue results and issued FY19 adjusted EPS guidance above the analyst estimate.

Financial news for JNJ dated on 2019-04-16: The Daily Biotech Pulse: J&J Earnings, FDA Nod For Medicinova, Proteon To Explore Strategic Alternatives

Financial news for JNJ dated on 2019-04-16: A Peek Into The Markets: US Stock Futures Higher Ahead Of Earnings

Financial news for JNJ dated on 2019-04-16: Johnson & Johnson Raises FY19 Adj. EPS Guidance From \$8.65-\$8.80 To \$8.73-\$8.83 vs \$8.58 Est., Raises Sales Guidance From \$81.6B-\$82.4B To \$82.0B-\$82.8B vs \$81.05B Est.

Financial news for JNJ dated on 2019-04-16: Johnson & Johnson Q1 Adj. EPS \$2.1 Beats \$2.08 Estimate, Sales \$20.02B Beat \$19.63B Estimate

Financial news for JNJ dated on 2019-04-16: 10 Stocks To Watch For April 16, 2019

Financial news for JNJ dated on 2019-04-16: Earnings Scheduled For April 16, 2019

Financial news for JNJ dated on 2019-04-15: Earnings Parade Rolls Along As Citigroup, Goldman Sachs Report And SPX Now Tops 2900

Financial news for JNJ dated on 2019-04-12: Granted Accelerated Approval To Johnson & Johnson's Balversa Targeted Therapy For Metastatic Bladder Cancer

Financial news for JNJ dated on 2019-04-12: Nanocap Biotech Tracoon Falls 50% After Shelving Study

Financial news for JNJ dated on 2019-04-11: J&J's Janssen Presents New Data From First Phase 3 Trial Of Single-Tablet Regimen In Rapid Initiation Model Of Care

Financial news for JNJ dated on 2019-04-09: Geron's Blood Cancer Candidate Creates Buying Opportunity, Needham Says In Upgrade

Financial news for JNJ dated on 2019-04-09: PreMarket Prep Opening NYSE Imbalance Update: GE 652k Shares To Sell; ExxonMobil 66k Shares To Sell; BofA 123 To Sell; Citi 52k To Sell; P&G 40k sell; J&J 41k To sell; Pfizer 96k To Sell

Financial news for JNJ dated on 2019-04-08: What's Been Going On With Emerald Bioscience?

Financial news for JNJ dated on 2019-04-08: Immunomedics Reports Promotion Deal In Which Co. Will Provide Detailing Services To J&J's Janssen For Erdafitinib In US

Financial news for JNJ dated on 2019-04-04: Janssen Announces Investigational CAR-T Therapy JNJ-68284528 Granted PRIME Designation by EMA



Financial news for JNJ dated on 2019-03-28: Johnson & Johnson Says TV Ads For Bloodthinner Xarelto To Give \$448 A Month List Price Starting Friday

Financial news for JNJ dated on 2019-03-28: J&J's Janssen Reports FDA Submission Of Supplemental New Drug Application For INVOKANA For Treatment Of Chronic Kidney Disease In Patients With Type 2 Diabetes

Financial news for JNJ dated on 2019-03-27: Plaintiff Lawyer Says Johnson & Johnson Has Settled Three Mesothelioma Talc Cases Brought In State Courts

Financial news for JNJ dated on 2019-03-27: J&J Spokesperson Says Jersey Jury Cleared Co. Of Liability In Mesothelioma Talc Trial

Financial news for JNJ dated on 2019-03-27: 6 Gene Therapy M&A Targets On The Radar

Financial news for JNJ dated on 2019-03-27: Axsome Adds To Strong Gains After FDA Grants Breakthrough Designation For Depression Drug

Financial news for JNJ dated on 2019-03-27: Janssen Seeks Expanded Use of DARZALEX(r)V (daratumumab) Combination Therapy for Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma

Financial news for JNJ dated on 2019-03-26: J&J's Janssen Reports Submission Of Application For Darzalex Combo Therapy

Financial news for JNJ dated on 2019-03-26: Genmab Reports FDA Submission Of Supplemental Biologics License Application For Daratumumab In Combo With Bortezomib, Thalidomide, Dexamethasone, Says J&J Sees Publishing Detailed Data From Phase 3 CASSIOPEIA Study This Year

Financial news for JNJ dated on 2019-03-26: OxyContin Manufacturer Purdue Agrees to Settlement in Oklahoma Lawsuit

Financial news for JNJ dated on 2019-03-25: Raymond James Expects Johnson & Johnson's Growth To Accelerate Into 2020

Financial news for JNJ dated on 2019-03-25: Court Records Show Bayer, J&J Have Settled XARELTO Litigation For \$775M

Financial news for JNJ dated on 2019-03-19: A New Look For The Barron's 400 ETF

Financial news for JNJ dated on 2019-03-15: Actelion Pharmaceuticals-Patients Treated With Opsumit Showed Significant Improvement In Right Ventricular Function, Reduced Pulmonary Vascular Resistance

Financial news for JNJ dated on 2019-03-13: The Daily Biotech Pulse: AEterna Zentaris Explores Options, Verastem Plunges On Weak Copiktra Sales, FDA Nod For Aerie

Financial news for JNJ dated on 2019-03-12: J&J's Janssen Submits Application Seeking Approval Of Darzalex Combo For Patients With Newly-Diagnosed Multiple Myeloma Who Are Transplant Ineligible

Financial news for JNJ dated on 2019-03-12: 'Oklahoma says Johnson & Johnson was the "kingpin" behind the opioid crisis' -Axios

Financial news for JNJ dated on 2019-03-11: Janssen's Phase 3 Study of STELARA Met its Primary and Some Secondary Endpoints

Financial news for JNJ dated on 2019-03-10: The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings, IPOs

Financial news for JNJ dated on 2019-03-07: Another ESG ETF Enters The Fold

Financial news for JNJ dated on 2019-03-07: J&J's Janssen Reports Results Of 2 Phase 3 Studies Which Showed Long-Acting Injectable HIV Treatment Regimen Of Rilpivirine, Cabotegravir Showed Comparable Safety, Efficacy To Daily Oral HIV Therapy

Financial news for JNJ dated on 2019-03-07: Allergan's Depression Drug Letdown Largely Expected: Analysts Focus On Remainder Of Pipeline

Financial news for JNJ dated on 2019-03-07: Daily Biotech Pulse: Allergan's Depression Drug Flunks Late-Stage Trial, Apellis Offering, ShockWave Medical IPO

Financial news for JNJ dated on 2019-03-06: J&J Says Weighted Average Cost Of Spravato Is \$590-\$885/Treatment Session

Financial news for JNJ dated on 2019-03-06: Johnson & Johnson Option Alert: Mar 15 \$142 Calls Sweep (2) near the Ask: 1000 @ \$0.201 vs 260 OI; Earnings 4/16 Before Open

[est] Ref=\$138.94

Financial news for JNJ dated on 2019-03-06: FDA Approves Major Novel Depression Drug For First Time In 3 Decades

Financial news for JNJ dated on 2019-03-06: The Daily Biotech Pulse: Horizon Pharma Under DoJ Radar, FDA Greenlights J&J's Depression Drug, Endologix Reverse Split

Financial news for JNJ dated on 2019-03-05: The Daily Biotech Pulse: Novartis Psoriasis Drug Found Superior, Ascendis Offering, Adamas Earnings

Financial news for JNJ dated on 2019-03-04: Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates

Financial news for JNJ dated on 2019-03-03: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs

Financial news for JNJ dated on 2019-02-26: It Could Be Time For This Pharma ETF

Financial news for JNJ dated on 2019-02-25: Citigroup Maintains Neutral on Johnson & Johnson, Raises Price Target to \$147

Financial news for JNJ dated on 2019-02-21: The Latest From Johnson & Johnson's Asbestos Scandal

Financial news for JNJ dated on 2019-02-21: 'Johnson & Johnson receives federal subpoenas related to baby powder litigation' -Reuters Earlier Reported

Financial news for JNJ dated on 2019-02-21: A Chat With The CEO Behind The Cannabis Company With The 'BOSS' Ticker: 'There Isn't A Single Route To Success'

Financial news for JNJ dated on 2019-02-21: Morphic Therapeutic Reports Integrin R&D Collaboration With J&J's Janssen; Janssen To Pay Co. Undisclosed Upfront Payment, Will Fund Research Activities; Co. Will Receive From Janssen Multiple Preclinical Development, Clinical, Commercial Milestones

Financial news for JNJ dated on 2019-02-19: Supreme Court Rejects Maryland's Bid To Revive A Law Aimed At Preventing Price Gouging By Pharmaceutical Companies, Reuters Reports

Financial news for JNJ dated on 2019-02-15: Pot Stocks, ETFs, Top News And Data From The Cannabis Industry This Week

Financial news for JNJ dated on 2019-02-15: The Week Ahead In Biotech: Conferences, Clinical Trials And Earnings

Financial news for JNJ dated on 2019-02-13: J&J's Talc Supplier Seeks Bankruptcy

Financial news for JNJ dated on 2019-02-13: Penny Stock Auris Medical Spikes On Case Of Mistaken Identity

Financial news for JNJ dated on 2019-02-13: Johnson & Johnson Wins FDA Panel Backing For Nasal Spray Depression Drug; PDUFA Date Awaits

Financial news for JNJ dated on 2019-02-13: Johnson & Johnson To Acquire Auris Health For \$3.4B In Cash, with Additional Contingent Payments Of \$2.5B Upon Certain Milestones

Financial news for JNJ dated on 2019-02-13: The Daily Biotech Pulse: Exelixis Q4 Results, FDA Panel Greenlights J&J's Depression Drug, MacroGenics Prices Offering

Financial news for JNJ dated on 2019-02-12: FDA Panel Votes In Favor Of Johnson & Johnson's Nasal Spray For Treatment-Resistant Depression; Says Benefits Outweigh Risks

Financial news for JNJ dated on 2019-02-12: The Daily Biotech Pulse: NASH Disappointment For Gilead, Xeris To Offer Shares

Financial news for JNJ dated on 2019-02-11: FDA Panel Reviews Johnson & Johnson's Treatment-Resistant Depression Candidate: What To Expect

Financial news for JNJ dated on 2019-02-10: The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials

Financial news for JNJ dated on 2019-02-08: The Daily Biotech Pulse: Big Miss For Seattle Genetics; Hematology Conference Presentations; Gossamer Bio, Harpoon IPOs

Financial news for JNJ dated on 2019-02-06: Drugmakers Offered C\$9.6B in Price Cuts; Freeze of Drug Prices in Response to Proposed Crackdown by Canada Regulator

Financial news for JNJ dated on 2019-02-05: 'Research Announcement: Moody's - Talc-related lawsuits could increase risk to Johnson & Johnson's strong credit profile' -Moody's

Financial news for JNJ dated on 2019-02-05: Johnson & Johnson Talc-related Lawsuits Could Increase Risk To Johnson & Johnson's Strong Credit Profile

Financial news for JNJ dated on 2019-01-31: J&J's Janssen Reports Global Collaboration, License Deal With MeiraGTX To Develop Gene Therapy Programs For Inherited Retinal Diseases

Financial news for JNJ dated on 2019-01-31: Janssen Enters Worldwide Collaboration And License Agreement With Meiragtx To Develop Gene Therapy Programs For Inherited Retinal Diseases

Financial news for JNJ dated on 2019-01-27: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings

Financial news for JNJ dated on 2019-01-23: Geopolitics Aside, How About Those Earnings? Investors Appear To Switch Focus

Financial news for JNJ dated on 2019-01-23: Analysts Stand By Johnson & Johnson Despite Earnings Pullback

Financial news for JNJ dated on 2019-01-23: Johnson & Johnson Said to be Pursuing Acquisition of Auris Health

Financial news for JNJ dated on 2019-01-22: Mid-Afternoon Market Update: Dow Down Over 400 Points; UQM Technologies Shares Spike Higher

Financial news for JNJ dated on 2019-01-22: Mid-Day Market Update: Crude Oil Down Over 3%; Staffing 360 Solutions Shares Jump

Financial news for JNJ dated on 2019-01-22: Wakeup Call: World, China Growth Data Fail To Impress, Pushing Down Global Markets

Financial news for JNJ dated on 2019-01-22: Mid-Morning Market Update: Markets Open Lower; Johnson & Johnson Profit Tops Expectations

Financial news for JNJ dated on 2019-01-22: J&J Executive Says Does Not See Long-run Strategic Impact To Its Consumer Business Related To Talc

Financial news for JNJ dated on 2019-01-22: From J&J Conference Call: CFO Says Co. Plans For Continued Price Decreases On A Net Basis In The Near Future

Financial news for JNJ dated on 2019-01-22: J&J CFO Says Stronger US Dollar Will Likely Result In Negative Impact On Reported Results In 2019

Financial news for JNJ dated on 2019-01-22: A Peek Into The Markets: US Stock Futures Drop Ahead Of Earnings

Financial news for JNJ dated on 2019-01-22: Johnson & Johnson Sees FY19 Adj. EPS \$8.50-\$8.65 vs \$8.61 Est., Sales \$80.4B-\$81.2B vs \$82.68B Est.

Financial news for JNJ dated on 2019-01-22: Johnson & Johnson Q4 Adj. EPS \$1.97 Beats \$1.95 Estimate, Sales \$20.4B Beat \$20.17B Estimate

Financial news for JNJ dated on 2019-01-22: 10 Stocks To Watch For January 22, 2019

Financial news for JNJ dated on 2019-01-22: Earnings Scheduled For January 22, 2019

Financial news for JNJ dated on 2019-01-18: The Daily Biotech Pulse: Regulatory Roadblock For Immunomedics, AdCom Split On Lexicon's Diabetes Drug

Financial news for JNJ dated on 2019-01-17: MediPharm Labs, Pure Global Cannabis, Weekend Unlimited, Plus Products, Trulieve Make Elevator Pitches

Financial news for JNJ dated on 2019-01-17: Johnson & Johnson Announces Research Study With Apple Watch To Help Improve AFib Outcomes Including Stroke Prevention

Financial news for JNJ dated on 2019-01-17: The Daily Biotech Pulse: FDA Panel Backs Amgen's Hypertension Drug, Adamis Allergy Drug Launched In US

Financial news for JNJ dated on 2019-01-16: Johnson & Johnson's Actelion Pharmaceuticals Receives Complete Response Letter From FDA Regarding Its New Drug Application For OPSUMIT; Letter Indicates Additional Data Needed To Evaluate Drug For CTEPH Treatment

Financial news for JNJ dated on 2019-01-16: J&J's Janssen Pharma Says European Commission Approved Erleada For Non-Metastatic Castration-Resistance Prostate Cancer Patients

Financial news for JNJ dated on 2019-01-15: Cannabis Company Avicanna Eyes Canadian IPO

Financial news for JNJ dated on 2019-01-15: Hearing Dealreporter Says JNJ May Be 'Gearing Up' For A Takeover Of Boston Scientific

Financial news for JNJ dated on 2019-01-14: How To Approach Q4 Earnings: The Global Perspective

Financial news for JNJ dated on 2019-01-14: 10 Biggest Price Target Changes For Monday

Financial news for JNJ dated on 2019-01-14: Wells Fargo Maintains Outperform on Johnson & Johnson, Lowers Price Target to \$152

Financial news for JNJ dated on 2019-01-11: J&J Recommends Rejection Of Below-Market "Mini-Tender" Offer By Peer & Peri LLC

Financial news for JNJ dated on 2019-01-11: Johnson & Johnson Raised U.S. Prices On ~Two Dozen Prescription Drugs On Thursday

Financial news for JNJ dated on 2019-01-10: 20 Women Set To Dominate The International Cannabis Space In 2019

Financial news for JNJ dated on 2019-01-07: 'Halftime Report' Picks For January 7: Mastercard, Twilio And More

Financial news for JNJ dated on 2019-01-07: Jon Najarian Sees Big Options Activity In Johnson & Johnson, Nvidia

Financial news for JNJ dated on 2019-01-06: Barron's Picks And Pans: Apple, Exxon, Morgan Stanley And More

Financial news for JNJ dated on 2019-01-04: India Government May Offer More Compensation To J&J Faulty Hip Implant Patients

Financial news for JNJ dated on 2019-01-03: Veracyte shares are trading up after the company announced a strategic collaboration with J&J Innovation for lung cancer detection.

Financial news for JNJ dated on 2019-01-03: UPDATE: Veracyte Reports Will Combine Clinical Study Cohorts Involving 5K+ Patients, Multiple Years Of Clinical Outcome Data

Financial news for JNJ dated on 2019-01-03: Veracyte Reports Strategic Collaboration With J&J Innovation For Lung Cancer Detection

Financial news for JNJ dated on 2019-01-02: Morgan Stanley Maintains Equal-Weight on Johnson & Johnson, Lowers Price Target to \$130

Financial news for JNJ dated on 2018-12-27: Johnson & Johnson Option Alert: Jan 18 \$150 Calls at the Ask: 10000 @ \$0.03 vs 28534 OI; Earnings 1/22 Before Open Ref=\$124.33

Financial news for JNJ dated on 2018-12-23: Barron's Picks And Pans: Unicorns, European Treasures, Health Care Bargains And More

Financial news for JNJ dated on 2018-12-21: The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial

Financial news for JNJ dated on 2018-12-21: Bangladesh To Collect, Test Samples Of Johnson & Johnson Baby Powder

Financial news for JNJ dated on 2018-12-20: J&J's Janssen Reports Submission Of Application For STELARA For Treatment Of Moderately To Severely Active Ulcerative Colitis

Financial news for JNJ dated on 2018-12-20: J&J Says Is In Full Compliance With Current Regulatory Requirements For Manufacturing, Testing Of Its Talc In India

Financial news for JNJ dated on 2018-12-20: Indian Drugs Regulator Orders Johnson & Johnson To Stop Using Raw Material At Two Baby Power Factories In India, Says Co. Can't Produce Baby Powder With Current Raw Materials Until It Is Shown To Be Free Of Asbestos

Financial news for JNJ dated on 2018-12-19: '\$JNJ --that was not an appeal in MO it was a request to overturn to the same judge who first ruled against them. Now it will be appealed to a higher court -CNBC's Jim Cramer Tweets

Financial news for JNJ dated on 2018-12-19: Hearing Morgan Stanley On Johnson & Johnson Baby Powder Verdict Clarifies That Co. Lost Some Post Trials Motions Which Are Customary After Verdict, But Notes Co. Has Been Successful In Other Post Trial Motions.

Financial news for JNJ dated on 2018-12-19: Jury Upholds \$4.69B Verdict In Johnson & Johnson Baby Powder Case

Financial news for JNJ dated on 2018-12-19: J&J Shares Fall ~0.5% Following NY Times Article 'Johnson & Johnson Loses Bid to Overturn a \$4.7 Billion Baby Powder Verdict'

Financial news for JNJ dated on 2018-12-19: J&J Shares Unaffected Midday Amid NY Times Report 'Johnson & Johnson Loses Bid to Overturn a \$4.7 Billion Baby Powder Verdict'

Financial news for JNJ dated on 2018-12-19: J&J To Report Q4 Earnings On Tues., Jan. 22, 2019 Before Market Open

Financial news for JNJ dated on 2018-12-19: J&J Says Indian Authorities Visited Some Of Its Facilities On Wednesday; Says "Unequivocally Stand By The Safety Of Our Products, Are Fully Compliant With Regulatory Standards And Requirements In India"

Financial news for JNJ dated on 2018-12-18: Benzinga Pro's Top 10 Most-Searchd Tickers For Afternoon Of Tues., Dec. 18, 2018

Financial news for JNJ dated on 2018-12-18: Johnson & Johnson And Imerys To Pay More Than \$1.5M In Talc Case

Financial news for JNJ dated on 2018-12-18: Fed Meeting Starts With Market Off To Worst December Start in 38 Years

Financial news for JNJ dated on 2018-12-18: Hearing CNBC's Jim Cramer, On 'Squawk On The Street,' Called J&J 'Absolutely A Buy'

Financial news for JNJ dated on 2018-12-18: Benzinga Pro's Top 10 Most-Searchd Tickers For Morning Of Tues., Dec. 18, 2018

Financial news for JNJ dated on 2018-12-18: Johnson & Johnson CEO Tells Cramer 'Thousands Of Studies' Refute Asbestos Allegations

Financial news for JNJ dated on 2018-12-18: The Daily Biotech Pulse: Puma Aces Late-Stage Trial, Chinese Cheer For FibroGen, J&J \$5B Buyback Plan

Financial news for JNJ dated on 2018-12-17: 'EXCLUSIVE: Johnson & Johnson CEO Alex Gorsky tells CNBC's @JimCramer that "we unequivocally believe that our talc, our baby powder, does not contain asbestos" ' -CNBC

Financial news for JNJ dated on 2018-12-17: J&J Reaffirms FY18 Outlook: Adj. EPS \$8.13-\$8.18 vs \$8.16 Estimate, Sales \$81B-\$81.4B vs \$81.3B Est.

Financial news for JNJ dated on 2018-12-17: Johnson & Johnson Reports \$5B Buyback

Financial news for JNJ dated on 2018-12-17: Johnson & Johnson CEO Alex Gorsky Issues Video Message In Defense Of Co.'s Baby Powder

Financial news for JNJ dated on 2018-12-17: Johnson & Johnson shares are trading lower on continued weakness following Friday reports indicating the company did not disclose prior knowledge of asbestos in its baby powder products; NOTE: Some analysts have are out defending the stock.

Financial news for JNJ dated on 2018-12-17: Benzinga Pro's Top 10 Most-Searchd Tickers For Morning Of Mon., Dec. 17, 2018

Financial news for JNJ dated on 2018-12-17: Johnson & Johnson's Asbestos Woes: Experts Speak Up

Financial news for JNJ dated on 2018-12-17: Hearing Johnson & Johnson CEO Alex Gorsky To Appear On Jim Cramer's 'Mad Money' Tonight

Financial news for JNJ dated on 2018-12-17: BMO On Johnson & Johnson: Firm Thinks The Stock Move Was An Overreaction; Notes The 'last time JNJ finished down more than 10% was on July 19, 2002, declining 16%; it recovered six days later'; Reiterates Outperform, \$154 Target

Financial news for JNJ dated on 2018-12-17: Morgan Stanley On Johnson & Johnson:

Believes 'the stock reaction is not supported by science and may inflate potential legal exposure'; Sees Comparisons To Recent Legal Issues At Bayer (BAYRY) As Flawed; Maintains Overweight, \$153 Target

Financial news for JNJ dated on 2018-12-17: 41 Biggest Movers From Friday

Financial news for JNJ dated on 2018-12-14: Wells Fargo Note Cites Bausch Health Acquiring Shower to Shower Body Powder from J&J; Named as Defendant in 160+ Lawsuits

Financial news for JNJ dated on 2018-12-14: Hearing Wells Fargo Out Negative on Bausch Health Off J&J Reuters Report

Financial news for JNJ dated on 2018-12-14: J&J Issues Statement On Reuters Talc Report: '...article is one-sided, false and inflammatory. Simply put, the Reuters story is an absurd conspiracy theory'

Financial news for JNJ dated on 2018-12-14: Citi Says J&J Has Completely Refuted Premise Of Reuters Article Related To Talc

Financial news for JNJ dated on 2018-12-14: Hearing JP Morgan Now Also Out Giving Defensive Comments On J&J

Financial news for JNJ dated on 2018-12-14: 26 Stocks Moving In Friday's Mid-Day Session

Financial news for JNJ dated on 2018-12-14: Hearing Wells Fargo Analyst Said J&J Shares Appear Oversold Amid Talc Report

Financial news for JNJ dated on 2018-12-14: Johnson & Johnson Falls Following Baby Powder Asbestos Report

Financial news for JNJ dated on 2018-12-14: Hearing Susquehanna Says J&J Has Been Facing Talc Litigation For Years

Financial news for JNJ dated on 2018-12-14: Johnson & Johnson shares are trading lower following reports indicating the company did not disclose prior knowledge of asbestos in its baby powder products.

Financial news for JNJ dated on 2018-12-14: Johnson & Johnson Option Alert: Fri \$145 Puts Sweep (3) near the Ask: 1713 @ \$1.5 vs 2434 OI; Earnings 1/22 Before Open [est] Ref=\$143.711

Financial news for JNJ dated on 2018-12-14: J&J Says 'Thousands of independent tests' Show Talc Is Safe

Financial news for JNJ dated on 2018-12-14: J&J Failed To Tell FDA Of Talc Tests Showing Asbestos From 1970s

Financial news for JNJ dated on 2018-12-14: J&J's Janssen Reports Submitted Supplemental New Drug Application To FDA For XARELTO To Prevent Venous Thromboembolism In Acute Medically Ill Patients

Financial news for JNJ dated on 2018-12-13: J&J Drafted Into A Fight Over Shareholder Suits, Co. Asked SEC To Omit Proposal From 2019 Proxy Statement

Financial news for JNJ dated on 2018-12-12: Hearing JNJ To Pay Average Of \$125K Per Pinnacle-Hip Case

Financial news for JNJ dated on 2018-12-12: Novartis Exec On J&J Call To Discuss TREMFYA Says 'We believe data from ECLIPSE trial...will have limited clinical relevance'

Financial news for JNJ dated on 2018-12-12: BiomX Enters Collaboration With Johnson & Johnson Innovation For Discovery Of Microbiome-Based Biomarkers For IBD

Financial news for JNJ dated on 2018-12-06: The Daily Biotech Pulse: AbbVie Halts Lung Cancer Trial, Oncomed Merges With Mereo, Momenta Offering

Financial news for JNJ dated on 2018-12-04: J&J's Janssen Reports New Phase 3 CASSINI Data Presented On Use Of XARELTO, Composite Primary Endpoint Of VTE Occurrence Did Not Reach Statistical Significance During Full-Study Period

Financial news for JNJ dated on 2018-12-04: J&J's Janssen Reports New Darzalex Phase 3 Study Showed Efficacy, Safety Data On Anti-CD38 Monoclonal Activity In Newly-Diagnosed Transplant Patients, Says Median Progression-Free Survival Has Not Yet been Reached

Financial news for JNJ dated on 2018-12-04: The Daily Biotech Pulse: ASH Presentations Take The Spotlight, Eiger Gets A New CFO

Financial news for JNJ dated on 2018-12-03: Janssen Affiliate Cilag GmbH International Enters Worldwide Collaboration and License Agreement with Argenx for Cancer Immunotherapy Cusatuzumab

Financial news for JNJ dated on 2018-12-02: The Week Ahead In Biotech: ASH Presentations Pick Up Pace, PDUFA Dates, Clinical Trials And IPOs

Financial news for JNJ dated on 2018-11-27: GlaxoSmithKline and J&J's HIV Drug Juluca Received Approval In Japan

Financial news for JNJ dated on 2018-11-26: Stocks Trading Ex Dividend For Mon., Nov. 26, 2018

Financial news for JNJ dated on 2018-11-25: 9 Policy Catalysts For Health Care Investors To Watch Before Year's End

Financial news for JNJ dated on 2018-11-23: Stocks That Will Be Trading Ex Dividend Mon., Nov. 26, 2018

Financial news for JNJ dated on 2018-11-21: A US Appeals Court Has Declined To Block The Sale Of Generic Versions Of J&J's ZYTIGA

Financial news for JNJ dated on 2018-11-21: Stocks Which Set New 52-Week High Yesterday, Tues., Nov. 20, 2018

Financial news for JNJ dated on 2018-11-20: Hearing Appeals Court Says JNJ Can't Prevent Sales Of Generic Zytiga; Says Teva, Mylan Can Enter Market

Financial news for JNJ dated on 2018-11-20: Stocks Which Set New 52-Week High Yesterday, Mon., Nov. 19, 2018

Financial news for JNJ dated on 2018-11-20: The Daily Biotech Pulse: Denali's Positive Results, Novartis' Substance Abuse Therapy Launch, Medtronic Earnings

Financial news for JNJ dated on 2018-11-16: CHMP Says J&J's Janssen Pharma's ERLEADA Receive Positive Opinion For Treatment Of Non-Metastatic Castration Resistant Prostate Cancer

Financial news for JNJ dated on 2018-11-07: Johnson & Johnson Vision Announces Health Canada Has Announced Medical Device License For CUVUE OASYS Contact Lens With Transitions Light Intelligent Technology

Financial news for JNJ dated on 2018-11-05: Fundstrat, Reality Shares Partner On New Multi-Factor ETF

Financial news for JNJ dated on 2018-11-05: Eli Lilly Gets Ready For First Report Post-Elanco IPO

Financial news for JNJ dated on 2018-11-04: Why Apple Will Likely Remain Sole Member Of \$1 Trillion Club For A While

Financial news for JNJ dated on 2018-10-29: These Are The Biggest Stocks Reporting Earnings This Week, And Their Recent Track Records

Financial news for JNJ dated on 2018-10-29: Johnson & Johnson Late Friday Reported A US District Court Ruled Invalidated All Asserted Claims Of Patent For ZYTIGA; Johnson & Johnson Said 'Strongly Disagrees' With Courts Decision

Financial news for JNJ dated on 2018-10-29: TESARO Announces Achievement Of ZEJULA Prostate Cancer Development Milestones By Janssen; Receives \$18M Milestone Payment From Janssen

Financial news for JNJ dated on 2018-10-26: 'A New Way To Treat The Brain': Stanford University Scientists Launch Cannabis Pharma Company

Financial news for JNJ dated on 2018-10-24: Janssen's Stelara Demonstrated Sustained Efficiency In Improving Clinical Remission Rates In Chron's Patients Throughout Three Years; Safety Events Were Not Higher Amongst All Ustekinumab-Treated Patients Entering Long-Term Extension Study vs Placebo

Financial news for JNJ dated on 2018-10-23: '6 kids dead, 12 sick in viral outbreak at New Jersey rehabilitation center' -ABC 7 NY

Financial news for JNJ dated on 2018-10-23: Johnson & Johnson Announces Offer to Acquire Ci:z Holdings Co., for ~ Y=230B

Financial news for JNJ dated on 2018-10-22: Citigroup Maintains Neutral on Johnson & Johnson, Raises Price Target to \$148

Financial news for JNJ dated on 2018-10-19: J&J's Janssen Reports 3-Year TREMFYA Data Showed 'Stably Maintained Rates of Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis'

Financial news for JNJ dated on 2018-10-17: Credit Suisse Maintains Outperform on Johnson & Johnson, Raises Price Target to \$152

Financial news for JNJ dated on 2018-10-17: After Basking In The Glow Of Netflix Results And Tuesday Rally, Pressure Seems Possible

Financial news for JNJ dated on 2018-10-17: Watching Boston Scientific As Traders Circulate Speculation From Dealreporter J&J Could Be Interested In Co.

Financial news for JNJ dated on 2018-10-17: Raymond James Maintains Outperform on Johnson & Johnson, Raises Price Target to \$149

Financial news for JNJ dated on 2018-10-17: A Peek Into The Markets: US Stock Futures Down Ahead Of Fed Minutes

Financial news for JNJ dated on 2018-10-16: Bank Earnings To The Rescue? Market Seeing Some Green After Strong Results

Financial news for JNJ dated on 2018-10-16: J&J CFO On Conference Call Says 'Not Satisfied With The Performance In Medical Devices'

Financial news for JNJ dated on 2018-10-16: The Daily Biotech Pulse: Enzo's Q4 Loss, Sanofi's Positive Trial Results, ImmunoCellular To Delist

Financial news for JNJ dated on 2018-10-16: A Peek Into The Markets: US Stock Futures Rise

Financial news for JNJ dated on 2018-10-16: Johnson & Johnson Raises FY18 Adj. EPS Outlook From \$8.07-\$8.1 To \$8.13-\$8.18 vs \$8.15 Est., Sees FY18 Sales \$81.0B-\$81.4B vs \$81.21B Est.

Financial news for JNJ dated on 2018-10-16: J&J Raises Guidance

Financial news for JNJ dated on 2018-10-16: Johnson & Johnson Q3 EPS \$2.05 Beats \$2.03 Estimate, Sales \$20.348B Beat \$20.03B Estimate

Financial news for JNJ dated on 2018-10-16: 12 Stocks To Watch For October 16, 2018

Financial news for JNJ dated on 2018-10-16: Earnings Scheduled For October 16, 2018

Financial news for JNJ dated on 2018-10-15: Johnson & Johnson Q3 Earnings Preview

Financial news for JNJ dated on 2018-10-15: The Week Ahead: Q3 Earnings Season, Canada Decriminalizes Cannabis

Financial news for JNJ dated on 2018-10-15: As New Week Begins, Markets Still Seem To Be Playing "D" Amid Host of Earnings

Financial news for JNJ dated on 2018-10-14: 4 Major Market Opportunities For The Cannabis Industry

Financial news for JNJ dated on 2018-10-11: FDA Approves Janssen Pharmaceuticals' Xarelto To Reduce Risk Of Major Cardiovascular Events

Financial news for JNJ dated on 2018-10-11: Morgan Stanley Maintains Equal-Weight on Johnson & Johnson, Raises Price Target to \$153

Financial news for JNJ dated on 2018-10-09: FDA Commissioner Scott Gottlieb Issues Statement On 'new efforts to advance the development of generic copies of complex drugs to improve patient access to medicines'

Financial news for JNJ dated on 2018-10-04: Analysts React To Arrowhead's Janssen Collaboration: Downside In Stock May Be 'Misguided'

Financial news for JNJ dated on 2018-10-04: Arrowhead Announces \$3.7B License Agreement With Janssen For Gene-Silencing Drug

Financial news for JNJ dated on 2018-10-04: Arrowhead Pharmaceuticals On Conference Call Says Working On HBV With J&J, Not Going To Create A Competing HBV Product

Financial news for JNJ dated on 2018-10-04: The Daily Biotech Pulse: AtriCure's Guidance, Guardant Health And Kodiak To Debut

Financial news for JNJ dated on 2018-10-04: Jim Cramer Shares His Thoughts On AbbVie,



Clorox, Sirius XM And More

Financial news for JNJ dated on 2018-10-04: Arrowhead Reports \$3.7B License, Collaboration Deal With J&J's Janssen

Financial news for JNJ dated on 2018-10-03: J&J's Janssen Pharmaceuticals Reports Switching To Symtuza Results In Maintained High Virologic Suppression And No Resistance Development Up To 96 Weeks In Virologically Suppressed Adults With HIV-1

Financial news for JNJ dated on 2018-09-30: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for JNJ dated on 2018-09-27: Geron Plunges As Johnson & Johnson Unit Discontinues Blood Cancer Drug Collaboration

Financial news for JNJ dated on 2018-09-27: The Daily Biotech Pulse: Hologic Goes Shopping, Johnson & Johnson Snaps Ties With Geron

Financial news for JNJ dated on 2018-09-27: Geron Reports Discontinuation OF Imetelstat Collaboration With Janssen

Financial news for JNJ dated on 2018-09-26: Geron to Provide an Update on the Imetelstat Collaboration with Janssen on September 27, 2018

Financial news for JNJ dated on 2018-09-24: Hearing Johnson & Johnson California Talcum Powder Case Has Ended In Mistrial, Unconfirmed

Financial news for JNJ dated on 2018-09-23: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for JNJ dated on 2018-09-20: Johnson & Johnson Option Alert: Jun 21 \$160 Calls at the Bid: 500 @ \$2.0 vs 750 OI; Earnings 10/16 Before Open Ref=\$141.87

Financial news for JNJ dated on 2018-09-19: The Daily Biotech Pulse: Johnson & Johnson's Generic Unit Files NDA For Urinary Tract Cancer Drug, GI Therapeutics Prices Offering

Financial news for JNJ dated on 2018-09-16: The Week Ahead In Biotech (Sept. 16-22): Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for JNJ dated on 2018-09-14: Pacira Shares Look Expensive, Stifel Says In Bearish Initiation

Financial news for JNJ dated on 2018-09-13: 'I still believe \$JNJ will drop \$GERN imetelstat. I guess we wait for later this month to see if I'm right or wrong. Nothing today changes my bearish view. If anything, NOT focusing on imetelstat today is a negative.'-Stat's Adam Feuerstein Tweets

Financial news for JNJ dated on 2018-09-13: Stat News' Adam Feuerstein Retweets That Johnson and Johnson Looking At Imetelstat Data Right Now, No Decision Made Yet

Financial news for JNJ dated on 2018-09-13: Johnson and Johnson Holding Investor Conference Call On Its Pharma Business Today

Financial news for JNJ dated on 2018-09-12: J&J's Janssen Reports TREMFYA Improves Long-Term Patient-reported Outcomes In Patients With Moderate To Severe Plaque Psoriasis

Financial news for JNJ dated on 2018-09-11: PreMarket Prep Opening NYSE Imbalance Update: Alibaba 109k Shares To Sell; General Electric 163k To Sell; Taiwan Semiconductor 79k To Sell; AT&T 117K To Buy; Home Depot 15k To Buy; Johnson & Johnson 37k To Sell

Financial news for JNJ dated on 2018-09-10: The Week Ahead: Apple's Special Event, Mobile World Congress, US Inflation Data On Deck

Financial news for JNJ dated on 2018-09-09: The Week Ahead In Biotech: Conferences, Clinical Trial Results, Earnings And IPOs

Financial news for JNJ dated on 2018-09-04: Janssen Submits Esketamine Nasal Spray New Drug Application to U.S. FDA for Treatment-Resistant Depression

Financial news for JNJ dated on 2018-09-02: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings

Financial news for JNJ dated on 2018-08-31: J&J's Janssen Reports European Commission Approval For Darzalex For Treatment Of Newly-Diagnosed Patients With Multiple Myeloma Who Are Transplant Ineligible

Financial news for JNJ dated on 2018-08-27: Sympathy Move: Portola Upgraded After Competitor Reports Sour Data

Financial news for JNJ dated on 2018-08-27: AbbVie's Rare Blood Cancer Drug Combo Snags FDA Approval

Financial news for JNJ dated on 2018-08-27: Stocks Trading Ex Dividend For Mon., Aug. 27, 2018

Financial news for JNJ dated on 2018-08-27: FDA Approves Johnson & Johnson and Abbvie's IMBRUVICA Plus Rituximab As First Chemotherapy-Free Combo Treatment In Adults With Waldenstrom's Macroglobulinemia

Financial news for JNJ dated on 2018-08-24: What's Going On With Geron?

Financial news for JNJ dated on 2018-08-24: Geron Shares Fall Modestly, ~3.7%, As J&J Spokesperson Suggests Recent Job Posting Mentioning Imetelstat Is Not Related To An Expected Decision For A Licensing Deal, And Includes 'Responsibilities For A Variety Of Disease Areas'

Financial news for JNJ dated on 2018-08-24: Hearing J&J Spokesperson Has Issued Response Related To Recent Job Posting: Says Posting Not Related To Expected Decision On Licensing Deal

Financial news for JNJ dated on 2018-08-24: Stocks That Will Be Trading Ex Dividend Mon., Aug. 27, 2018

Financial news for JNJ dated on 2018-08-24: Geron Shares Remain Elevated, Up 28.3% With Some Attributing Upside To Johnson & Johnson Job Posting For a Strategic Pricing Manager For Imbruvica & Imetelstat, Drugs Its Partnered On With AbbVie and Geron, Respectively

Financial news for JNJ dated on 2018-08-24: '\$GERN trading +30% on a JNJ job posting that mentions imetelstat. Yes, it's that ridiculous. Summer Fridays!'-STAT's Adam Feuerstein Tweets

Financial news for JNJ dated on 2018-08-20: 5 Execs Talk Business Models At Cannabis Capital Conference

Financial news for JNJ dated on 2018-08-19: Barron's Picks And Pans: AT&T, Starbucks, State Street, Verizon And More

Financial news for JNJ dated on 2018-08-16: Johnson & Johnson Option Alert: Aug 31 \$132 Calls Sweep (34) near the Ask: 787 @ \$0.961 vs 385 OI; Ref=\$131.58

Financial news for JNJ dated on 2018-08-08: J&J's Janssen Reports Submission Of US, EU Regulatory Applications Seeking Approval For DARZALEX Split-Dosing Regimen

Financial news for JNJ dated on 2018-08-06: Daabon Strikes Deal With Avicanna, Becoming The Largest Agro Company To Enter The Cannabis Industry

Financial news for JNJ dated on 2018-08-01: Price Action In Several Major Healthcare Names Mixed, Stocks Appear Largely Unaffected Following Late-Tues. NY Times Article 'Justice Dept. Investigating Claims That Drug Companies Funded Terrorism in Iraq'

Financial news for JNJ dated on 2018-07-30: Johnson & Johnson Wins a \$227M Defense Contract

Financial news for JNJ dated on 2018-07-26: What It Takes To Be A Dividend King

Financial news for JNJ dated on 2018-07-24: Janssen Presents Switch Data for New HIV-1 Treatment SYMTUZA and Second Study Supporting its Use in a Rapid Initiation Scenario at AIDS 2018

Financial news for JNJ dated on 2018-07-18: Benzinga's Daily Biotech Pulse: Novartis Earnings, J&J's HIV Combo Clears FDA Hurdle, Cara To Offer Shares

Financial news for JNJ dated on 2018-07-17: J&J Reports FDA Approval Of Symtuza For Treatment Of HIV-1 Infection

Financial news for JNJ dated on 2018-07-17: Hearing Johnson & Johnson Nears Sale Of Sylvant To Eusa Pharma

Financial news for JNJ dated on 2018-07-17: Benzinga's Daily Biotech Pulse: Bellicum CFO Resigns, Roche's Trial Meets Endpoints, Avid Bioservices Turns To Black In Q4

Financial news for JNJ dated on 2018-07-17: A Peek Into The Markets: US Stock Futures Edge Lower Ahead Of Goldman Sachs Earnings

Financial news for JNJ dated on 2018-07-17: Johnson & Johnson Sees FY18 Of \$80.5-\$81.3B vs \$81.47B Reflecting An Increase In Expected Operational Growth Of 4.5-5.5%, Sees FY18 Adj. EPS \$8.07-\$8.17 vs \$8.12 Est.

Financial news for JNJ dated on 2018-07-17: Johnson & Johnson Q2 EPS \$2.10 Beats \$2.06 Estimate, Sales \$20.83B Beat \$20.37B Estimate

Financial news for JNJ dated on 2018-07-17: 8 Stocks To Watch For July 17, 2018

Financial news for JNJ dated on 2018-07-17: Earnings Scheduled For July 17, 2018

Financial news for JNJ dated on 2018-07-16: Johnson & Johnson Q2 Earnings Preview

Financial news for JNJ dated on 2018-07-16: The Week Ahead: Netflix Earnings, Comic-Con, 'IPO Thursday' And More

Financial news for JNJ dated on 2018-07-16: J&J's Janssen Pharma Reports Phase 3 CREDENCE Trial Of INVOKANA Stopped Early For Positive Efficacy Findings

Financial news for JNJ dated on 2018-07-16: Upcoming Earnings: Netflix To Report Monday, Subscriber Growth A Focus

Financial news for JNJ dated on 2018-07-16: Earnings Preview: Healthcare Giant Johnson & Johnson Set To Report Tuesday Morning

Financial news for JNJ dated on 2018-07-16: Back To Banks: More Financial Results In Ahead of Powell Testimony Later This Week

Financial news for JNJ dated on 2018-07-16: Round Two Of Bank Earnings Coming Up With Bank of America, Goldman Sachs And Morgan Stanley

Financial news for JNJ dated on 2018-07-16: PreMarket Prep Opening NYSE Imbalance Update: ExxonMobil 55k Shares To Sell; Pfizer 50k To Sell; Merck 26k To Sell; Coca-Cola 54k To Sell; Johnson & Johnson 54k To Sell; Ford 103k To Sell; Kroger 90k To Sell

Financial news for JNJ dated on 2018-07-13: Jury Returns \$4.7B Verdict Against Johnson & Johnson In Asbestos-Laced Talcum Case

Financial news for JNJ dated on 2018-07-13: PreMarket Prep Opening NYSE Imbalance Update: AT&T 167k Shares To Sell; Bank Of America 101k To Buy; JNJ 75k To Sell; Alibaba 55k To Buy

Financial news for JNJ dated on 2018-07-13: The Market In 5 Minutes: AT&T-Time Warner Appeal, Johnson & Johnson Lawsuit, Theresa May And More

Financial news for JNJ dated on 2018-07-13: 24 Stocks Moving In Friday's Mid-Day Session

Financial news for JNJ dated on 2018-07-12: J&J Says Deeply Disappointed in Verdict of St Louis Court, Unfair Process

Financial news for JNJ dated on 2018-07-12: J&J Ordered to Pay \$4.14B in Punitive Damages in Talc Cancer Case

Financial news for JNJ dated on 2018-07-12: Courtroom Video Shows J&J Ordered To Pay \$550M In Compensatory Damages In Missouri Trial Which Claimed Asbestos In Talc Caused Cancer In 22 Women

Financial news for JNJ dated on 2018-07-12: Bank Earnings: JPMorgan, Wells Fargo And Citigroup Are Slated To Report Friday Morning

Financial news for JNJ dated on 2018-07-12: Goldman Sachs Swaps Perrigo, Johnson & Johnson Ratings

Financial news for JNJ dated on 2018-07-12: Benzinga's Top Upgrades, Downgrades For July 12, 2018

Financial news for JNJ dated on 2018-07-12: Goldman Sachs Upgrades Johnson & Johnson to Neutral

Financial news for JNJ dated on 2018-07-11: Benzinga's Daily Biotech Pulse: Pfizer To Defer Price Hikes, Idera-BioCryst Merger Falls Through, ArQule To Offer Shares

Financial news for JNJ dated on 2018-07-10: Johnson & Johnson Option Alert: Aug 17 \$120 Puts Sweep (29) near the Bid: 932 @ \$0.653 vs 3925 OI; Earnings 7/17 Before Open Ref=\$127.295

Financial news for JNJ dated on 2018-07-09: Health Care Sector Outlook: Checking In

## Ahead Of Q2 Earnings Reports

Financial news for JNJ dated on 2018-07-05: A Look At Biotech In 2018 And The Biggest Catalysts Coming Up In The Second Half Of The Year

Financial news for JNJ dated on 2018-07-05: Johnson & Johnson Option Alert: Jul 13 \$125 Calls Sweep (28) near the Ask: 539 @ \$0.693 vs 660 OI; Earnings 7/17 Before Open Ref=\$123.78

Financial news for JNJ dated on 2018-06-29: 'The success of \$XLRN luspatercept is bad for \$GERN and another reason for \$JNJ to sever the imetelstat relationship in Q3.'-STAT's Adam Feuerstein Tweets

Financial news for JNJ dated on 2018-06-27: Benzinga's Top Upgrades, Downgrades For June 27, 2018

Financial news for JNJ dated on 2018-06-27: Bernstein Initiates Coverage On Johnson & Johnson with Market Perform Rating, Announces \$129 Price Target

Financial news for JNJ dated on 2018-06-26: Janssen Pharmaceutical Signs License Agreement With Saladax Biomedical

Financial news for JNJ dated on 2018-06-25: AbbVie Announces sNDA For Ibrutinib Accepted For Review By FDA

Financial news for JNJ dated on 2018-06-19: A Look Back At What's Happened To Each Sector Through The First Half Of 2018 (Part 2)

Financial news for JNJ dated on 2018-06-18: '\$GERN wants \$JNJ to continue a drug development partnership, but new data weaken its case'-STAT's Adam Feuerstein Tweets

Financial news for JNJ dated on 2018-06-18: Johnson & Johnson Announces FDA Approval of iDESIGN Refractive Studio For LASIK Treatment

Financial news for JNJ dated on 2018-06-14: J&J's Janssen Reports XARELTO Associated with Significantly Reduced Hospital Time, Decreased Costs With Low-Risk Pulmonary Embolism

Financial news for JNJ dated on 2018-06-12: Johnson & Johnson Announces Acceptance Of Binding Offer From Platinum Equity To Acquire LifeScan, Inc. For Approximately \$2.1B

Financial news for JNJ dated on 2018-06-11: VIVUS Reports Has Met Closing Conditions For Purchase Of US, Canadian Rights To PANCREAZE Capsules For Treatment Of EPI From J&J's Janssen Pharma For \$135M

Financial news for JNJ dated on 2018-06-07: Benzinga's Daily Biotech Pulse: Johnson & Johnson to Dispose Sterilization Products Business, Mixed Results From Protesostasis' Cystic Fibrosis Study

Financial news for JNJ dated on 2018-06-06: Fortive Reports Binding Offer To Buy Advanced Sterilization Products Business From J&J for ~\$2.7B In Cash

Financial news for JNJ dated on 2018-06-04: J&J Shares Ticker Slightly Higher Over Last Few Mins.; Hearing Jim Cramer Mentioned Stock/Co. Positively On CNBC

Financial news for JNJ dated on 2018-05-31: Janssen Says Phase 3 Study Shows Esketamine Nasal Spray Plus Oral Antidepressant Delayed Time To Relapse In Patients With Treatment-Resistant Depression

Financial news for JNJ dated on 2018-05-30: J&J's Janssen Pharma Earlier Reported Initiation Of Phase 1b/2 Development Program Evaluating JNJ-68284528 Car-T Cells For Treatment Of Multiple Myeloma

Financial news for JNJ dated on 2018-05-29: Stocks That Made New 52-Week Lows Today Include: Patterson Companies, Philip Morris, Coty, and Johnson & Johnson

Financial news for JNJ dated on 2018-05-27: Pot Stocks, ETFs, Top News And Data From The Cannabis Industry This Week

Financial news for JNJ dated on 2018-05-27: Barron's Picks And Pans: Best CEOs, Altice USA, Micron Technology And More

Financial news for JNJ dated on 2018-05-25: Novartis Gets Approval For Remicade Biosimilar In Europe

Financial news for JNJ dated on 2018-05-24: An ETF Play For Quality Stocks At A Fair Price

Financial news for JNJ dated on 2018-05-21: The Week Ahead In Biotech: PDUFA Dates,

IPOs And More

Financial news for JNJ dated on 2018-05-21: Janssen Announces European Commission Approval of JULUCA

Financial news for JNJ dated on 2018-05-19: 12 Dow 30 Companies With Above-Average Salaries

Financial news for JNJ dated on 2018-05-17: How To Get Quality In The Core

Financial news for JNJ dated on 2018-05-17: Jim Cramer Shares His Thoughts On Johnson & Johnson, Nike And More

Financial news for JNJ dated on 2018-05-14: Analyst: Morphosys Is Well-Positioned To Continue Success With Antibody Discovery Platforms

Financial news for JNJ dated on 2018-05-08: Benzinga's Daily Biotech Pulse: Valeant Earnings, Lipocine's FDA Watch, Invivo CFO Departure

Financial news for JNJ dated on 2018-05-08: Jim Cramer Advises His Viewers On Prestige Brands, CVS Health And More

Financial news for JNJ dated on 2018-05-06: Janssen Pharmaceuticals Announces New Phase 3 Data Show Esketamine Nasal Spray Demonstrated Rapid Improvements in Depressive Symptoms in Patients with Treatment-Resistant Depression

Financial news for JNJ dated on 2018-05-03: Stocks That Made New 52-Week Lows Today Include Colgate-Palmolive, Philip Morris, Regeneron, Corning, Hanesbrands, Bed Bath & Beyond, Pepsi, Coca-Cola, Paccar, Johnson & Johnson, Mallinckrodt, CBS, DISH Network, Goodyear Tire, Chubb, Hershey, and AT&T

Financial news for JNJ dated on 2018-05-02: HC2 Reports BeneVir Biopharm To Be Purchased By J&J's Janssen Biotech For Up To \$1.04B

Financial news for JNJ dated on 2018-05-01: Attention Biotech Investors: Mark Your Calendar For These May PDUFA Action Dates

Financial news for JNJ dated on 2018-05-01: VIVUS Acquires PANCREAZE from Janssen for \$135M

Financial news for JNJ dated on 2018-04-26: Johnson & Johnson Raises Qtr. Dividend From \$0.84 To \$0.90/Share

Financial news for JNJ dated on 2018-04-20: Credit Suisse Maintains Outperform on Johnson & Johnson, Lowers Price Target to \$151.00

Financial news for JNJ dated on 2018-04-19: 'An Incredible Signal': 4 Experts Weigh In On Positive FDA Panel Vote For GW Pharma's Epidiolex

Financial news for JNJ dated on 2018-04-18: Big Bank Season Rolls On As Morgan Stanley Easily Beats Expectations

Financial news for JNJ dated on 2018-04-18: Stifel Nicolaus Maintains Hold on Johnson & Johnson, Lowers Price Target to \$135.00

Financial news for JNJ dated on 2018-04-17: A Peek Into The Markets: US Stock Futures Surge, Goldman Sachs Earnings In Focus

Financial news for JNJ dated on 2018-04-17: Johnson & Johnson Reaffirms FY 2018 Adj. EPS Guidance, Raises FY 2018 Sales Guidance From \$80.6B-\$81.4B to \$81.0B-\$81.8B vs \$81.1B Est.

Financial news for JNJ dated on 2018-04-17: Johnson & Johnson Reports Q1 Adj. EPS \$2.06 Beats \$2.01 Est., Sales \$20.0B Beats \$19.4B Est.

Financial news for JNJ dated on 2018-04-17: 12 Stocks To Watch For April 17, 2018

Financial news for JNJ dated on 2018-04-17: Earnings Scheduled For April 17, 2018

Financial news for JNJ dated on 2018-04-16: Bristol-Myers Announces Collaboration With Johnson & Johnson's Janssen to Develop and Commercialize Next-Gen Cardiovascular Therapy

Financial news for JNJ dated on 2018-04-16: Upcoming Earnings: Johnson & Johnson And IBM Are Scheduled To Report This Week

Financial news for JNJ dated on 2018-04-16: The Week Ahead: Netflix Earnings, Big Bank Results, FDA Actions Abound

Financial news for JNJ dated on 2018-04-16: Earnings Parade Continues This Week After Missile Attacks, With Banks, Netflix On Way

Financial news for JNJ dated on 2018-04-16: Netflix Earnings Preview: International Subscriber Growth In Focus

Financial news for JNJ dated on 2018-04-13: Benzinga's Top Analyst Calls From April 13, 2018

Financial news for JNJ dated on 2018-04-13: Next Week's Round Of Bank Earnings Includes Bank Of America, Goldman Sachs And Morgan Stanley

Financial news for JNJ dated on 2018-04-13: Chardan: Assembly Biosciences Hep B Antiviral Data 'Positive,' But Undifferentiated From Competitor Johnson & Johnson

Financial news for JNJ dated on 2018-04-12: Upcoming Earnings: Big Banks JP Morgan, Wells Fargo And Citigroup To Kick Off Q1 Season

Financial news for JNJ dated on 2018-04-12: UPDATE: J&J's Janssen Says Canagliflozin Reduced Urinary Albumin To Creatinine Ratio

Financial news for JNJ dated on 2018-04-12: J&J's Janssen Pharma Says INVOKANA Showed Significant Renal Protective Benefits In Patients with Type-2 Diabetes

Financial news for JNJ dated on 2018-04-11: Courtroom Video Shows J&J, Imerys Subsidiary Ordered To Pay \$80M In Punitive Damages In New Jersey Case Blaming Talc For Mesothelioma

Financial news for JNJ dated on 2018-04-10: FDA Cleared Acuvue Oasys Contact Lenses With Transitions Light Intelligent Tech To Johnson & Johnson

Financial news for JNJ dated on 2018-04-10: Morgan Stanley Maintains Equal-Weight on Johnson & Johnson, Lowers Price Target to \$143.00

Financial news for JNJ dated on 2018-04-06: Pot Stocks, ETFs, Top News And Data From The Cannabis Industry This Week

Financial news for JNJ dated on 2018-04-06: DWS Quantifies Quality In A New ETF

Financial news for JNJ dated on 2018-03-30: Smoking Is Just One Way To Use Marijuana: An Introduction To Vaporizers, Edibles, Oils, Tinctures, Dabs And Other Cannabis Products

Financial news for JNJ dated on 2018-03-23: ICYMI: GameStop, Omeros, Congress Impacts Biotechs

Financial news for JNJ dated on 2018-03-22: Biotech Winners And Losers From Congress' Latest Funding Bill

Financial news for JNJ dated on 2018-03-20: Johnson & Johnson CFO Dominic Caruso to Retire

Financial news for JNJ dated on 2018-03-20: Checking In On The Healthcare Sector Ahead Of Q1 Earnings Season

Financial news for JNJ dated on 2018-03-20: Johnson & Johnson Gets \$2.1B Offer For LifeScan Diabetes Device Unit

Financial news for JNJ dated on 2018-03-20: A Dividend Alternative To Broad Market Exposure

Financial news for JNJ dated on 2018-03-16: Johnson & Johnson Receives Takeover Offer for its LifeScan Business to Platinum Equity for \$2.1B

Financial news for JNJ dated on 2018-03-13: J&J, Macleods in Talks for Licence Deal of Tuberculosis Drug Bedaquiline -Economic Times

Financial news for JNJ dated on 2018-03-11: Janssen Announces INVOKANA Significantly Reduces Risk of Heart Failure-Related Outcomes in Type 2 Diabetes Patients at Risk for or With a History of Cardiovascular Disease

Financial news for JNJ dated on 2018-03-08: Johnson & Johnson and Bayer Announce Judge's Order Sets 1,200 Xarelto Product Liability Lawsuits for Separate Jury Trials

Financial news for JNJ dated on 2018-03-08: Zosano Pharma Is The Latest Low Float Stock To Make A Huge Move

Financial news for JNJ dated on 2018-03-07: Height Casts 65% Odds That Congress Rolls Back Pharma Discounts

Financial news for JNJ dated on 2018-03-06: Analyst: Insulet On Track For Profitability In 2018

Financial news for JNJ dated on 2018-03-01: MedTech's Long-Term Prospects Outweigh Near-Term Risks

Financial news for JNJ dated on 2018-03-01: Jim Cramer Advises His Viewers On Johnson & Johnson, Nokia And More

Financial news for JNJ dated on 2018-02-27: Citigroup Maintains Neutral on Johnson & Johnson, Lowers Price Target to \$146.00

Financial news for JNJ dated on 2018-02-27: Aldeyra Therapeutics Announces Collaborative Agreement with Johnson & Johnson Innovation to Advance Novel Immune-Modulating Drugs for Systemic Inflammatory Diseases

Financial news for JNJ dated on 2018-02-27: Sierra Oncology and Janssen Sign Supply Agreement for Prostate Cancer Study

Financial news for JNJ dated on 2018-02-22: PreMarket Prep Opening NYSE Imbalance Update: Bank Of America 379k Shares To Sell; Johnson & Johnson 25k Shares To Buy; General Electric 66k Shares To Sell; HPQ 49k Shares To Buy

Financial news for JNJ dated on 2018-02-21: Form 4 Filing Late Tuesday Showed Johnson & Johnson Chief Scientific Officer Paulus Stoffels Sold 155.342K Shares at \$129.858

Financial news for JNJ dated on 2018-02-20: Quantifying Quality With An iShares ETF

Financial news for JNJ dated on 2018-02-15: J&J's Janssen Wins Health Canada Approval For New ZYTIGA Indication For Treatment Of Newly-Diagnosed Metastatic Prostate Cancer

Financial news for JNJ dated on 2018-02-14: J&J Shares Unaffected As FDA Says Erleada By Co.'s Janssen Pharma Approved

Financial news for JNJ dated on 2018-02-14: Cramer Looks At The Dow's Biggest Losers

Financial news for JNJ dated on 2018-02-09: Janssen Submits Marketing Authorisation Application to EMA for Apalutamide to Treat Patients with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer

Financial news for JNJ dated on 2018-02-08: 19 Biotech Stocks With Clinical Trial Outcomes In February

Financial news for JNJ dated on 2018-02-08: The Alzheimer's Drug Pipeline: High Failure Rates In Research On An Increasingly Common Disease

Financial news for JNJ dated on 2018-02-07: Theravance Biopharma Reports Entered Global Collaboration With J&J's Janssen For TD-1473 In Inflammatory Intestinal Diseases

Financial news for JNJ dated on 2018-02-05: J&J Shares Fall 3.5%, Quickly Rebound From Lows But Still Down ~2.5% For Session; Traders Circulate Mesothelioma.net Article 'Johnson & Johnson Mesothelioma Trial Likely to Expose Company Documents'

Financial news for JNJ dated on 2018-02-01: Jim Cramer Weighs In On Johnson & Johnson, STMicroelectronics, And More

Financial news for JNJ dated on 2018-01-29: 11 Dividend Growth Stocks To Watch In 2018

Financial news for JNJ dated on 2018-01-29: Protagonist Therapeutics 'Poised For Upside,' Stifel Says

Financial news for JNJ dated on 2018-01-29: PFE, LLY, MRK Write Up 'Scripts For Q4

Financial news for JNJ dated on 2018-01-25: Why GW Pharma's Epidiolex Results Could Shape The Future Of Cannabis-Based Therapeutics

Financial news for JNJ dated on 2018-01-25: J&J No Longer Candidate For Purchase Of Pfizer's Consumer Unit; GlaxoSmithKline, Reckitt Benckiser Working With Banks To Make A Bid

Financial news for JNJ dated on 2018-01-23: Mid-Afternoon Market Update: Crude Oil Up 1.4%; ResMed Shares Rise On Earnings Beat

Financial news for JNJ dated on 2018-01-23: Mid-Day Market Update: Netflix Climbs Following Q4 Results; Insmed Shares Plummet

Financial news for JNJ dated on 2018-01-23: Biotech M&A Off To A Strong Start In 2018: More Deals To Follow?

Financial news for JNJ dated on 2018-01-23: J&J Shares Unaffected Amid Word US Appeals Court Invalidated Co. Patent On Remicade, Ruling Prevents Co. From Challenging Pfizer's '16 Launch Of Cheaper Version Of Remicade

Financial news for JNJ dated on 2018-01-23: Mid-Morning Market Update: Markets Mixed; Johnson & Johnson Beats Q4 Views

Financial news for JNJ dated on 2018-01-23: Johnson & Johnson Shares Down 2.02%; Earlier Co. Reported Q4 Beat, Announced FY18 Guidance, Sees Adj. EPS \$8-\$8.20 vs \$7.87 Est., Sales \$80.6B-\$81.4B vs \$80.7B Est.

Financial news for JNJ dated on 2018-01-23: Johnson & Johnson On Conf. Call Says \$12B Of Overseas Cash Will 'Come Back Immediately'

Financial news for JNJ dated on 2018-01-23: Benzinga Pro's 5 Stocks To Watch Today

Financial news for JNJ dated on 2018-01-23: A Peek Into The Markets: U.S. Stock Futures Mostly Higher Ahead Of Earnings

Financial news for JNJ dated on 2018-01-23: Johnson & Johnson Reports Q4 Adj. EPS \$1.74 vs \$1.72 Est., Sales \$20.20B vs \$20.07B Est.

Financial news for JNJ dated on 2018-01-23: Earnings Scheduled For January 23, 2018

Financial news for JNJ dated on 2018-01-23: 10 Stocks To Watch For January 23, 2018

Financial news for JNJ dated on 2018-01-22: A CURE For The Typical Healthcare Trade

Financial news for JNJ dated on 2018-01-22: The Week Ahead: IPOs, Earnings, And FDA Actions Provide Catalysts

Financial news for JNJ dated on 2018-01-22: Earnings Preview: Johnson & Johnson And Procter & Gamble Take The Stage Tomorrow Morning

Financial news for JNJ dated on 2018-01-22: Upcoming Earnings: Verizon To Report Q4 Results Tomorrow Morning

Financial news for JNJ dated on 2018-01-22: Washington Shutdown Takes Center Stage, But Market Impact Only Slight So Far

Financial news for JNJ dated on 2018-01-19: Will Johnson & Johnson's Pharma Segment Pull Up Its Q4 Earnings?

Financial news for JNJ dated on 2018-01-19: Upcoming Netflix Earnings: Subscriber Growth And Price Hikes In Focus

Financial news for JNJ dated on 2018-01-18: Intel, Johnson & Johnson, UPS: 'Fast Money' Picks For January 18

Financial news for JNJ dated on 2018-01-18: BTG Says Previous Guidance on Zytiga Royalties Is Unchanged, Despite U.S. Administrative Court Decision to Invalidate Patent -Reuters

Financial news for JNJ dated on 2018-01-17: UPDATE: J&J Says 'We believe the '438 patent is valid and will continue to vigorously defend it.'

Financial news for JNJ dated on 2018-01-17: J&J Issues Response Following ZYTIGA IPR: 'strongly disagree...are evaluating our options with respect to a request for rehearing and/or appeal.'

Financial news for JNJ dated on 2018-01-17: UPDATE: Traders Attributing Move Lower In J&J Shares To News From Indonesian Source Suggesting Zytiga Received A Negative IPR Decision

Financial news for JNJ dated on 2018-01-17: J&J Shares Down ~\$2 Over Last Min., Stock Down 0.6% For Session

Financial news for JNJ dated on 2018-01-17: Earnings Preview: IBM to Report on Thursday, Strategic Imperatives in Focus

Financial news for JNJ dated on 2018-01-17: Chinese Bidders Looking at JNJ Diabetes Business in Deal that Could be Valued at \$4B -Reuters

Financial news for JNJ dated on 2018-01-16: Dow Earnings: Analysts Expect Goldman Sachs Revenue Decline



Financial news for JNJ dated on 2018-01-16: Upcoming Earnings: Bank Of America, Goldman Sachs And Morgan Stanley To Report This Week

Financial news for JNJ dated on 2018-01-10: Putting On The Brakes: Rally Takes Breather As Bond Yields Hit 10-Month High

Financial news for JNJ dated on 2018-01-08: 4 Tailwinds Driving Raymond James' Insulet Bull Case

Financial news for JNJ dated on 2018-01-05: The 'Bomb Cyclone' Portfolio: Winners And Losers

Financial news for JNJ dated on 2018-01-02: Benzinga's Top Upgrades, Downgrades For January 2, 2018

Financial news for JNJ dated on 2018-01-02: The Market In 5 Minutes: Oil's Strong Open, Cohen's Comeback, And A Look Back At 2017's Best And Worst Stocks

Financial news for JNJ dated on 2018-01-02: Syros Announces Clinical Supply Agreement with Janssen to Evaluate SY-1425, Its First-in-Class Selective RARa Agonist

Financial news for JNJ dated on 2018-01-02: JP Morgan Downgrades Johnson & Johnson to Neutral

Financial news for JNJ dated on 2017-12-22: The Companies That Led 2017's Biotech Rally

Financial news for JNJ dated on 2017-12-22: Vetr Upgrades Johnson & Johnson As The Stock Tests Resistance

Financial news for JNJ dated on 2017-12-21: J&J's Janssen Says J&J Reaffirmed FY17 Adj. EPS Outlook Of \$7.25-\$7.30 vs \$7.28 Est.

Financial news for JNJ dated on 2017-12-21: J&J's Janssen Reports Global Collaboration, License Deal With Units Of Genscript, Will Make Upfront Payment Of \$350M

Financial news for JNJ dated on 2017-12-21: Earlier Chicago Tribune Report Detailed 5 Illinois Counties Suing Drug Cos. Over Opioid Abuses; Shares Of Cos. Mentioned Seem Largely Unaffected: TEVA +5.3%, ABT -0.33%, JNJ +0.03%, ENDP +0.12%

Financial news for JNJ dated on 2017-12-21: FDA Grants Priority Review For Johnson & Johnson's Janssen NDA For Apalutamide, PDUFA Target Date April 2018

Financial news for JNJ dated on 2017-12-20: 3 Biotech Pipeline Areas To Keep An Eye On In 2018

Financial news for JNJ dated on 2017-12-13: ASH 2017 Highlights: Gilead, Novartis, Juno, Bluebird Bio And More

Financial news for JNJ dated on 2017-12-13: A Trendy New ETF From Pacer

Financial news for JNJ dated on 2017-12-11: 3 Stocks In Focus As Biotech M&A Hopes For 2018 Rise

Financial news for JNJ dated on 2017-12-05: Bayer, Johnson & Johnson Reportedly Ordered By Philadelphia Jury To Pay \$29M In Xarelto Lawsuit

Financial news for JNJ dated on 2017-12-04: REMINDER: Tuesday Is Estimated FDA PDUFA Date For: Johnson & Johnson for Rilpivirine and In Partnership with GlaxoSmithKline For Dolutegravir, and Novo Nordisk for Semaglutide

Financial news for JNJ dated on 2017-12-04: Eli Lilly's Taltz Gets Approval For Label Expansion in US

Financial news for JNJ dated on 2017-12-04: The Week Ahead For December 4: The Biggest Catalysts, Conferences, And Investor Events

Financial news for JNJ dated on 2017-12-01: GlaxoSmithKline Begins Phase III Study On Injection To Prevent HIV

Financial news for JNJ dated on 2017-11-30: Missouri Judge Upholds \$110 Million Talc Verdict Awarded To Virginia Women Who Claims Decades Of Daily Use Of Johnson & Johnson's Talcum Powder Caused Her Ovarian Cancer, Jurisdiction Established By New Evidence In Ovarian Cancer Claim

Financial news for JNJ dated on 2017-11-29: A Lazarus Act For This Pharma ETF

Financial news for JNJ dated on 2017-11-28: Endpoint News Co-Founder John Carroll

Tweets: J&J spokesperson says Telegraph story about axing JLABS in UK is "completely unfounded" asking for a retraction. \$JNJ

Financial news for JNJ dated on 2017-11-22: Stocks Going Ex Dividend The Fifth Week Of November

Financial news for JNJ dated on 2017-11-21: J&J's Janssen Submits FDA Application For Expansion Of Indication For DARZALEX Combo Therapy For Patients With Newly-Diagnosed Multiple Myeloma Who Are Transplant Ineligible

Financial news for JNJ dated on 2017-11-20: Johnson & Johnson's Janssen Gets European Commission Approval to Broaden Marketing Authorization for Zytiga

Financial news for JNJ dated on 2017-11-16: PR Confirms Earlier Johnson & Johnson Legal Headline, Federal Jury Returns \$247 Million Verdict in Defective Hip Implants Case; DePuy Orthopaedics Found Liable For Metal-on-Metal Implant Failures

Financial news for JNJ dated on 2017-11-16: Johnson & Johnson Wins Trial In Lawsuit Claiming Asbestos In Talc Products Caused Cancer

Financial news for JNJ dated on 2017-11-16: Watching J&J Shares Amid Report Jury Has Returned \$247M Verdict Against Co. Unit Depuy Related To Defective Hip Implant Suit

Financial news for JNJ dated on 2017-11-09: Pharma ETFs Down Post Q3 Earnings

Financial news for JNJ dated on 2017-11-06: J&J's Janssen R&D Reports STELARA Showed Positive Results In Treatment Of Systemic Lupus Erythematosus In Phase 2 Trial

Financial news for JNJ dated on 2017-11-04: A Dividend ETF For November And Beyond

Financial news for JNJ dated on 2017-10-31: UPDATE: Halozyme Will Receive \$15M Milestone Payment From J&J's Janssen Following Dosing Of 3rd Patient In Phase 3 Trial

Financial news for JNJ dated on 2017-10-30: How Surgeons Are Responding To TransEnterix's Senhance Following FDA Approval

Financial news for JNJ dated on 2017-10-30: Johnson & Johnson's Janssen Gets FDA Approval for the 10MG Dose of Xarelto

Financial news for JNJ dated on 2017-10-30: Janssen Reports Imbruvica As First Approved Treatment For Chronic Graft-Versus-Host Disease Granted By Health Canada Priority Review

Financial news for JNJ dated on 2017-10-27: REMINDER: Johnson & Johnson Has PDUFA Date Expected For XARELTO Oct. 28

Financial news for JNJ dated on 2017-10-25: Vetr Upgrades Johnson & Johnson Following Post-Earnings Dip

Financial news for JNJ dated on 2017-10-25: J&J's Janssen Reports Darunavir-Based Single Tablet Regimen Showed Effective Viral Suppression In HIV-1 Patients

Financial news for JNJ dated on 2017-10-24: This Week's Most And Least Crowded Trades

Financial news for JNJ dated on 2017-10-23: 5 Biggest Price Target Changes For Monday

Financial news for JNJ dated on 2017-10-23: The Week Ahead: Earnings Season Starts In Earnest

Financial news for JNJ dated on 2017-10-23: This Factor ETF Could Be Ready To Shine

Financial news for JNJ dated on 2017-10-20: J&J's Janssen Reports Received 2 FDA Approvals For SIMPONI ARIA For Treatment Of Adults with Active Psoriatic Arthritis, Active Ankylosing Spondylitis

Financial news for JNJ dated on 2017-10-19: White House 'Shenanigans' Represent A Buying Opportunity: Cramer

Financial news for JNJ dated on 2017-10-19: Johnson & Johnson to Acquire Software Company Surgical Process Institute, Terms Not Disclosed

Financial news for JNJ dated on 2017-10-18: Benzinga's Option Alert Recap From October 18

Financial news for JNJ dated on 2017-10-18: Cramer Breaks Down 3 Cheap Stocks That Crushed Earnings

Financial news for JNJ dated on 2017-10-18: 5 Biggest Price Target Changes For Wednesday

Financial news for JNJ dated on 2017-10-18: J&J Option Alert: Jan, 2019 \$140 Puts Sweep (27) at the Bid: 658 @ \$9.504 vs 301 OI; Ref=\$140.23

Financial news for JNJ dated on 2017-10-18: Pre-Market Imbalance Update: IBM 219K Shares To Buy, Alibaba 133K To Buy, Coca-Cola 131K To Sell, Twitter 88K To Sell, Square 79K To Buy, AT&T 73K To Buy, Pfizer 71K To Sell, Ford 67K To Sell, J&J 55K To Sell

Financial news for JNJ dated on 2017-10-17: Johnson & Johnson Makes New All-Time High By A Wide Margin

Financial news for JNJ dated on 2017-10-17: Hearing Court Papers Show Missouri Appeals Court Has Overturned \$72M Verdict Against J&J Related To Talc Case

Financial news for JNJ dated on 2017-10-17: Can The Dow Pass Another Milestone? Financials Feed Frenzy, But Might It Be Enough?

Financial news for JNJ dated on 2017-10-17: A Peek Into The Markets: U.S. Stock Futures Flat; Goldman Sachs Earnings In Focus

Financial news for JNJ dated on 2017-10-17: Johnson & Johnson Discontinues its Study of Talacotuzumab in Patients with Acute Myeloid Leukemia

Financial news for JNJ dated on 2017-10-17: Johnson & Johnson Says it Will Not Pursue Approvals of Sirukumab for Rheumatoid Arthritis

Financial news for JNJ dated on 2017-10-17: Johnson & Johnson Sees FY 2017 EPS \$7.25-\$7.30 from \$7.12-\$7.22, Sales \$76.1B-\$76.5B from \$75.8B-\$76.1B

Financial news for JNJ dated on 2017-10-17: Johnson & Johnson Raises Guidance

Financial news for JNJ dated on 2017-10-17: Johnson & Johnson Q3 EPS \$1.90 vs \$1.80 Est., Sales \$19.7B vs \$19.3B Est.

Financial news for JNJ dated on 2017-10-17: 10 Stocks To Watch For October 17, 2017

Financial news for JNJ dated on 2017-10-17: Earnings Scheduled For October 17, 2017

Financial news for JNJ dated on 2017-10-16: 10 Most/Least Crowded Trades Of Week Ended Oct. 13

Financial news for JNJ dated on 2017-10-16: Cerveau Technologies Reports Research Collaboration With Janssen Pharmaceuticals For Use Of [F-18]MK-6240

Financial news for JNJ dated on 2017-10-16: The Week Ahead: Earnings, Earnings, And More Earnings

Financial news for JNJ dated on 2017-10-16: 5 Biggest Price Target Changes For Monday

Financial news for JNJ dated on 2017-10-13: Pharma Stock Roundup: Pfizer Mulls Options For Consumer Healthcare, Eli Lilly's Pipeline Setback

Financial news for JNJ dated on 2017-10-13: REMINDER: Johnson & Johnson Has PDUFA Date For Stelara Over the Weekend, Oct. 15th

Financial news for JNJ dated on 2017-10-13: JNJ And IBM Report Q3 Earnings Early Next Week: What Might Be In Store?

Financial news for JNJ dated on 2017-10-13: Janssen-Cilag Intl. CHMP Issues Positive Opinion On Zytiga To Include Earlier Stage Prostate Patients

Financial news for JNJ dated on 2017-10-12: Pre-Market Imbalance Update: Verizon 60K Shares To Sell, J&J 42K To Sell

Financial news for JNJ dated on 2017-10-11: 10 Of The Most Crowded Trades, And 10 Of The Least Crowded

Financial news for JNJ dated on 2017-10-11: Why Jefferies Upgraded Johnson & Johnson

Financial news for JNJ dated on 2017-10-11: J&J's Janssen Earlier Reported Submission Of NDA For ARN-509 To Treat Men With Non-Metastatic Castration-Resistant Prostate Cancer

Financial news for JNJ dated on 2017-10-11: Benzinga's Top Upgrades, Downgrades For October 11, 2017

Financial news for JNJ dated on 2017-10-11: The Market In 5 Minutes: Alibaba's Expansion, Uber's Warning

Financial news for JNJ dated on 2017-10-11: A Peek Into The Markets: U.S. Stock Futures Edge Lower Ahead Of Fed Minutes

Financial news for JNJ dated on 2017-10-11: Jefferies Upgrades Johnson & Johnson to Buy

Financial news for JNJ dated on 2017-10-11: Jefferies Upgrades J&J to Buy from Hold; Raises PT to \$157 from \$145

Financial news for JNJ dated on 2017-10-09: Benzinga's Top Upgrades, Downgrades For October 9, 2017

Financial news for JNJ dated on 2017-10-09: Wells Fargo Upgrades Johnson & Johnson to Outperform

Financial news for JNJ dated on 2017-10-06: Heaps Of Healthy Health Care ETFs

Financial news for JNJ dated on 2017-10-05: J&J Diabetes Care Cos., Animas, Announces Intention To Discontinue Manufacturing, Sale Of Vibe, OneTouch Ping Insulin Pumps, Close Operations, Exit Insulin Pump Business

Financial news for JNJ dated on 2017-10-02: Morgan Stanley Catches Flack For Colgate-Palmolive Upgrade

Financial news for JNJ dated on 2017-10-02: J&J's Janssen Reports Submission Of sNDA Seeking New Indication For INVOKANA To Reduce Risk Of Major Adverse Cardiovascular Events Based On Landmark CANVAS Program

Financial news for JNJ dated on 2017-10-02: Janssen Submits sNDA To FDA Seeking New Indication For INVOKANA To Reduce Risk Of Major Adverse Cardiovascular Events Based On Landmark Canvas Programs

Financial news for JNJ dated on 2017-09-28: Attention Biotech Investors, Here's Your PDUFA Primer For October

Financial news for JNJ dated on 2017-09-28: A.I. Summit in San Francisco Concludes Today, Attendees Include Morgan Stanley, Johnson & Johnson, Bank of America, IBM, Nvidia, Microsoft, Amazon and Footlocker

Financial news for JNJ dated on 2017-09-28: Jim Cramer Weighs In On Johnson & Johnson, Ford And More

Financial news for JNJ dated on 2017-09-27: FTC Says It Requires Divestiture Of 5 Medical Device Product Lines As Condition Of Integra Acquiring Johnson & Johnson's Codman Neuro Division

Financial news for JNJ dated on 2017-09-26: Bloomberg Earlier Reported Apple, Samsung, Roche Holding Will Participate In FDA Pilot Program For Digital Health Software

Financial news for JNJ dated on 2017-09-23: Cramer's Guide To Profit From Market Rotations

Financial news for JNJ dated on 2017-09-21: A Venerable Vanguard Dividend ETF

Financial news for JNJ dated on 2017-09-20: Johnson & Johnson Downgraded On Hefty Valuation Compared To Peers

Financial news for JNJ dated on 2017-09-20: Goldman Sachs Downgrades Johnson & Johnson to Sell

Financial news for JNJ dated on 2017-09-20: Johnson & Johnson Shares Down 1.64% Premarket

Financial news for JNJ dated on 2017-09-19: UPDATE: NY AG Schneiderman Served Subpoenas To Endo Int'l, J&J's Janssen Pharma, Teva, Allergan

Financial news for JNJ dated on 2017-09-15: Janssen's Guselkumab Drug for the Treatment of Plaque Psoriasis Recommended by the EU Medicines Agency for Approval

Financial news for JNJ dated on 2017-09-14: Johnson & Johnson's Janssen Announces Submission of sNDA To FDA For Zytiga

Financial news for JNJ dated on 2017-09-12: A Hidden Gem Among Dividend ETFs

Financial news for JNJ dated on 2017-09-12: Wall Street's M&A Chatter From September 11: Western Digital-Toshiba, Pilgrim's Pride-Moy Park, Gigamon And More

Financial news for JNJ dated on 2017-09-11: Your Easy Guide To Credit Suisse's New Top Stocks List

Financial news for JNJ dated on 2017-09-11: Janssen Terminates Worldwide Collaboration for Hepatitis C With Achillion Pharmaceuticals

Financial news for JNJ dated on 2017-09-09: What Pharmaceuticals Spend On Lobbying To Influence Trump

Financial news for JNJ dated on 2017-09-07: New Mexico Said To Be Suing Johnson & Johnson, Endo, Teva, Allergan & Others Over Their Role In Opioid Drug Epidemic

Financial news for JNJ dated on 2017-09-07: This Drug, An Alternative To Marijuana And Ketamine, Could Treat Suicidal Depression And PTSD

Financial news for JNJ dated on 2017-09-01: Attention Biotech Investors: September Ushers In Another Slew Of PDUFA Catalysts

Financial news for JNJ dated on 2017-08-31: MacroGenics Reports Termination Of Duvortuxizumab Collab., License Deal With J&J's Janssen

Financial news for JNJ dated on 2017-08-31: Johnson & Johnson Management Meetings Leave UBS Reiterating Stock As A Top Pick

Financial news for JNJ dated on 2017-08-24: Protagonist Therapeutics Announces Receipt Of \$50M Upfront Payment From JNJ's Jansse License Deal For PTG-200

Financial news for JNJ dated on 2017-08-24: Playing The US Pharma Space: Buy Portola, Hold Corvus, Sell Teva

Financial news for JNJ dated on 2017-08-23: Explaining A 'Crowded Trade,' And The Top 10 Cramped Plays Right Now

Financial news for JNJ dated on 2017-08-22: Pre-Market Imbalance Update: Sprint 223K Shares To Buy, Square 139K To Buy, GE 90K To Buy, Snap 54K To Buy, Coca-Cola 53K Shares To Sell, Alibaba 53K To Buy, J&J 49K To Sell

Financial news for JNJ dated on 2017-08-22: Jury Awards Woman \$417 Million On Allegation Johnson & Johnson Talcum Powder Gave Her Cancer

Financial news for JNJ dated on 2017-08-21: Premarket Prep Host Dennis Dick Tweets: Notable opening imbalances: \$SNAP +354K, \$GE -262K, \$PFE -122K, \$JNJ -92K, \$BABA +81K

Financial news for JNJ dated on 2017-08-16: Meg Tirrell Tweets: \$JNJ says president's more recent comments "changed our decision to participate in the White House Manufacturing Advisory Council"

Financial news for JNJ dated on 2017-08-09: Genmab CEO Says It's Moving Forward 'Aggressively' Together With Janssen On Subcutaneous Formulation Of daratumumab

Financial news for JNJ dated on 2017-08-07: Every Generation Has Its Drug: How People Are Dealing With Opioids, The New (Old) Thing

Financial news for JNJ dated on 2017-08-07: Wall Street's M&A Chatter From August 4-7: Acadia Pharma, United Technologies-Rockwell Collins, United Therapeutics

Financial news for JNJ dated on 2017-08-02: Hearing FDA Panel Has Said Safety Profile Of J&J's Sirukumab Not Adequate To Support Approval

Financial news for JNJ dated on 2017-08-01: Key FDA Events To Watch Out For In August 2017

Financial news for JNJ dated on 2017-08-01: August PDUFA Dates: Biotech Investors Stay Tuned To A Month Of Plenty

Financial news for JNJ dated on 2017-07-31: Johnson & Johnson Granted Orphan Drug Designation for Bedaquiline

Financial news for JNJ dated on 2017-07-27: On, Wisconsin: University Wins Half Billion In iPhone Patent Suit, Another Sign Schools Are Research Cash Cows

Financial news for JNJ dated on 2017-07-27: Samsung, Amazon -- Everyone Is Getting Into Pharmaceuticals

Financial news for JNJ dated on 2017-07-27: Wall Street's M&A Chatter From July 26: Biomarin, Sigma Designs, Colgate-Palmolive, Markel-State National

Financial news for JNJ dated on 2017-07-25: Meet Avicanna, The First Marijuana Company To Be Accepted Into Johnson & Johnson Innovation, JLABS @ Toronto

Financial news for JNJ dated on 2017-07-25: 4 Benefits ETF Investing May Add To Your Portfolio

Financial news for JNJ dated on 2017-07-24: 2 Ways To Trade This Week's Healthcare Earnings

Financial news for JNJ dated on 2017-07-24: JNJ Announces Encouraging First-In-Human Clinical Data For Investigational HIV Preventive Vaccine

Financial news for JNJ dated on 2017-07-22: 6 Months In, Trump Has Filled Only 27 Out Of More Than 200 Envoy Posts, Mostly With Cronies

Financial news for JNJ dated on 2017-07-22: Dow 30 Earnings Score Card From The Past Week: IBM, Visa, Goldman And More

Financial news for JNJ dated on 2017-07-21: Johnson & Johnson Shares Might Break Lower Before They Break Out

Financial news for JNJ dated on 2017-07-21: Atlantic Equities Downgrades Johnson & Johnson to Underweight

Financial news for JNJ dated on 2017-07-21: BTIG Research Downgrades Johnson & Johnson to Sell

Financial news for JNJ dated on 2017-07-20: Johnson & Johnson Shares Strong Since Actelion Acquisition, But Potential For Upside Remains

Financial news for JNJ dated on 2017-07-20: The Market In 5 Minutes

Financial news for JNJ dated on 2017-07-20: Credit Suisse Reinstates Outperform on Johnson & Johnson, Announces \$148.00 Price Target

Financial news for JNJ dated on 2017-07-19: Caution Still The Watchword But Stocks Hit Record Highs As Earnings Mostly Strong

Financial news for JNJ dated on 2017-07-18: Finding A Way: Banks Beat Expectations Despite Struggles As Earnings Go Into High Gear

Financial news for JNJ dated on 2017-07-18: A Peek Into The Markets: U.S. Stock Futures Mostly Flat Ahead Of Goldman Sachs Earnings

Financial news for JNJ dated on 2017-07-18: Johnson & Johnson Sees FY 2017 EPS \$7.12-\$7.22 from \$7.00-\$7.15 vs \$7.10 Est., See Sales \$75.8B-\$76.1B from \$75.4B-\$76.1B vs \$75.7B Est.

Financial news for JNJ dated on 2017-07-18: Johnson & Johnson Raises FY 2017 Guidance

Financial news for JNJ dated on 2017-07-18: Johnson & Johnson Q2 EPS \$1.83 vs \$1.80 Est, Sales \$18.84B vs \$18.95B Est

Financial news for JNJ dated on 2017-07-18: 10 Stocks To Watch For July 18, 2017

Financial news for JNJ dated on 2017-07-18: Earnings Scheduled For July 18, 2017

Financial news for JNJ dated on 2017-07-17: Earnings Roundup: JNJ, IBM, And LMT Report Q2 Results Tomorrow

Financial news for JNJ dated on 2017-07-17: Earnings Preview: Financial Giants BAC, GS, And MS Report Q2 Results This Week

Financial news for JNJ dated on 2017-07-17: 4 Sell-Ranked Drug Stocks To Avoid Ahead Of Q2 Earnings

Financial news for JNJ dated on 2017-07-14: FDA's 60-Day Extension For Medical Device Defects Not Likely Obstructive To Public Health

Financial news for JNJ dated on 2017-07-13: J&J Announces FDA Approval For Janssen's Plaque Psoriasis Treatment TREMFYA

Financial news for JNJ dated on 2017-07-12: J&J To Commence Pharma Q2 Earnings Season: What's Up?

Financial news for JNJ dated on 2017-07-10: The Royalty-Amassing Strategy Of Royalty Pharma

Financial news for JNJ dated on 2017-07-08: The Japanese Government's Pension Fund Made A Cool \$70 Billion Last Year

Financial news for JNJ dated on 2017-07-06: Focusing On An Alternative To S&P 500 ETFs

Financial news for JNJ dated on 2017-07-06: Pre-Market Imbalance Update: Sprint 84K Shares To Buy, GE 80K Shares To Sell, Twitter 41K To Sell, Coca-Cola 37K To Sell, P&G 35K To Buy, Citi 28K To Buy, BofA 26K To Buy, Wells Fargo 25K To Buy, J&J 22K To Sell

Financial news for JNJ dated on 2017-07-05: 5 Biggest Price Target Changes For Wednesday

Financial news for JNJ dated on 2017-06-28: Janssen Says FDA Accepted For Priority Review A SNDA For Xarelto

Financial news for JNJ dated on 2017-06-26: Attention To Details: Neos' ADHD Portfolio

Financial news for JNJ dated on 2017-06-23: A New ETF For Low Vol ETFs

Financial news for JNJ dated on 2017-06-23: Benzinga PMP Host Dennis Dick Tweets: A few large imbalances this morning: \$GE +825K, \$JNJ -157K, \$F -118K, \$BAC +110K, \$WFC +66K, \$JPM +61K

Financial news for JNJ dated on 2017-06-22: If Colgate's Looking To Sell Itself, Would Berkshire Be Looking To Buy?

Financial news for JNJ dated on 2017-06-22: Wall Street's M&A Chatter From June 21: Staples-Sycamore Partners, Diageo-Casamigos, Bristol-Myers, Acadia Pharma

Financial news for JNJ dated on 2017-06-21: Non-Horrible Bosses: Meet The Best CEOs Of 2017

Financial news for JNJ dated on 2017-06-16: FDA Reports Approval Of J&J's Janssen's Darzalex In Combo With Pomalidomide, Dexamethasone For Patients With Multiple Myeloma

Financial news for JNJ dated on 2017-06-16: JNJ Completes Acquisition of Actelion

Financial news for JNJ dated on 2017-06-14: Johnson & Johnson's Janssen Present Phase 3 Data On Sirukumab, Says Long-Term Efficacy Is 'Encouraging'

Financial news for JNJ dated on 2017-06-14: Cramer: 3M's Stock Quietly Hit All-Time Highs Thanks To Weak US Dollar

Financial news for JNJ dated on 2017-06-12: UPDATE: Tesaro Says Janssen Anticipates Re-opening Enrollment for Galahad Trial Soon -8-K

Financial news for JNJ dated on 2017-06-12: Tesaro Says on June Janssen Updated Clinicaltrials.gov Website to Reflect Janssen had Placed Temporary Enrollment Hold in Galahad Trial; Says Galahad Trial Not on Clinical Hold, Temporary Enrollment Hold Not Due to Safety Concerns

Financial news for JNJ dated on 2017-06-12: Janssen and TESARO GALAHAD Trial Puts Patient Enrollment on Temporary Hold

Financial news for JNJ dated on 2017-06-09: Johnson & Johnson, Tesaro Niraparib Trial Enrollment Suspension Not Related To Safety

Financial news for JNJ dated on 2017-06-09: Tesaro Volatile After Johnson & Johnson Suspends Enrollment In Prostate Cancer Trial

Financial news for JNJ dated on 2017-06-09: JNJ Spokesperson Says, 'Our team put a temporarily hold on enrollment so we could assess the enrolled currently patients against the protocol criteria. We need to make sure we don't over-enroll some patient types and under-enroll others.'

Financial news for JNJ dated on 2017-06-09: Johnson & Johnson Spokesperson Tells Benzinga TESARO's Niraparib Study Enrollment Is, 'on temporary hold and we anticipate re-opening enrollment soon. The hold is not related to safety.'

Financial news for JNJ dated on 2017-06-09: Johnson & Johnson Acquisition of Actelion is Approved by the EU

Financial news for JNJ dated on 2017-06-04: Barron's Picks And Pans: AT&T, Express Scripts, Accenture And More

Financial news for JNJ dated on 2017-06-03: Trial Results Show Johnson & Johnson's Zytiga Lowers Death Risk by 38% in Newly Diagnosed Advanced Prostate Cancer #ASCO2017

Financial news for JNJ dated on 2017-06-01: States Are Firing Back At Opioid Drug Producers

Financial news for JNJ dated on 2017-05-31: Shares Of Johnsons & Johnson, Teva Pharma, Endo Int'l, And Allergan All Higher Today Despite News State Of Ohio Has Sued These Companies For Alleged Role In Opioid Epidemic

Financial news for JNJ dated on 2017-05-30: Protagonist Therapeutics Spikes to High of \$14.85 Following Announcement of Worldwide Agreement with Janssen

Financial news for JNJ dated on 2017-05-30: Tracking The Busy June PDUFA Calendar

Financial news for JNJ dated on 2017-05-30: Protagonist Therapeutics Enters into Worldwide Agreement with Janssen to Co-Develop and Commercialize PTG-200, Protagonist to Gets \$50M Upfront Payment

Financial news for JNJ dated on 2017-05-18: 3 Most Likely Suitors For Colgate-Palmolive, In Jefferies' View

Financial news for JNJ dated on 2017-05-17: Pre-Market Imbalance Update: GE 179K Shares to Sell, Twitter 167K to Sell, General Mills 114K to Sell, J&J 47K to Sell, Morgan Stanley 36K to Sell

Financial news for JNJ dated on 2017-05-17: Johnson & Johnson Holding Pharmaceutical Business Review Today

Financial news for JNJ dated on 2017-05-17: Johnson & Johnson Says Expecting to Launch or File for Regulatory Approval for 10 New Products from 2017 to 2021 and 50 Line Extensions of Existing Products

Financial news for JNJ dated on 2017-05-15: Johnson & Johnson's Sales Slump Has Played Itself Out, Could Reaccelerate This Year

Financial news for JNJ dated on 2017-05-15: Benzinga's Top Upgrades, Downgrades For May 15, 2017

Financial news for JNJ dated on 2017-05-15: JP Morgan Upgrades Johnson & Johnson to Overweight

Financial news for JNJ dated on 2017-05-12: Top Picks For The Rest Of 2017, Courtesy Of UBS

Financial news for JNJ dated on 2017-05-03: Apple Is The World's Biggest Dividend Payer

Financial news for JNJ dated on 2017-05-03: Exclusive: Capricor CEO Talks Exondys Competition

Financial news for JNJ dated on 2017-04-30: Weed Vs. Opioids: Nontraditional And Traditional Biotech Take On Wall Street, But Who's Winning?

Financial news for JNJ dated on 2017-04-27: Johnson & Johnson Increases Qtr. Dividend From \$0.80/Share To \$0.84/Share

Financial news for JNJ dated on 2017-04-27: Companies Holding Shareholder Meetings Today Include: Akorn, AstraZeneca, HCA Holdings, Johnson & Johnson, & Lockheed Martin

Financial news for JNJ dated on 2017-04-27: Janssen Holding Announces 92.51% of Actelion Shares Tendered

Financial news for JNJ dated on 2017-04-24: Earnings: Caterpillar, Lockheed Martin, and Eli Lilly Report Tomorrow

Financial news for JNJ dated on 2017-04-24: How Family Office Manager Julio Gonzalez Is Helping Keep Jobs In The U.S. Using Tax Engineering

Financial news for JNJ dated on 2017-04-24: Jim Cramer Gives His Opinion On Johnson & Johnson And PPG Industries

Financial news for JNJ dated on 2017-04-20: What Would A \$5.8 Billion NIH Cut Look Like? Devastation

Financial news for JNJ dated on 2017-04-20: The Lucky Beneficiaries Of Tax Day

Financial news for JNJ dated on 2017-04-18: JMP Calls Alteryx A Compelling Investment, Sees 23% Upside

Financial news for JNJ dated on 2017-04-18: Johnson & Johnson Pummeled After Mixed Q1 Report

Financial news for JNJ dated on 2017-04-18: Meg Tirrell Tweets: \$JNJ says it's seeing



higher discounting on drugs for favorable coverage; increased rx assistance, discounts hit Q1 results by \$200m per JPM

Financial news for JNJ dated on 2017-04-18: A Peek Into The Markets: U.S. Stock Futures Mostly Lower Ahead Of Earnings

Financial news for JNJ dated on 2017-04-18: Johnson & Johnson Sees FY 2017 EPS \$7.00 to \$7.15 vs \$7.05 Est

Financial news for JNJ dated on 2017-04-18: Johnson & Johnson Q1 EPS \$1.83 vs \$1.77 Est, Sales \$17.8B vs \$18.0B Est

Financial news for JNJ dated on 2017-04-18: 10 Stocks To Watch For April 18, 2017

Financial news for JNJ dated on 2017-04-18: Earnings Scheduled For April 18, 2017

Financial news for JNJ dated on 2017-04-17: Earnings: Another Financial Roundup With BAC, GS, and MS

Financial news for JNJ dated on 2017-04-17: Johnson & Johnson's Janssen Data From 2 Phase 3 Studies Supported New Approval Darzalex In Canada

Financial news for JNJ dated on 2017-04-14: United Airlines Should Learn From How These 6 Companies Handled PR Disasters

Financial news for JNJ dated on 2017-04-12: Healthcare Sector Earnings: Making A Comeback In Q1 2017?

Financial news for JNJ dated on 2017-04-10: From Conf Call: Geron Says Jansen has Right to Terminate Agreement at Any Time for Any Reason

Financial news for JNJ dated on 2017-04-10: Adam Feuerstein Tweets: \$JNJ reluctance to commit to imetelstat, disclosed in last sentence of \$GERN PR, is most important point.

Financial news for JNJ dated on 2017-04-05: There Is Value To Be Had With The Right Healthcare ETFs

Financial news for JNJ dated on 2017-04-01: 50 Advertisers Boycott YouTube Advertising, And It Won't Mean More Than A 1% Dip In Google's Top Line

Financial news for JNJ dated on 2017-03-31: Pre-Market Imbalance Update: AT&T 90K Shares to Buy, Salesforce 70K to Sell, BofA 64K to Buy, CVS 64K to Sell, Twitter 42K to Sell, J&J 38K to Sell, Walmart 25K to Sell

Financial news for JNJ dated on 2017-03-31: JNJ Subsidiary Janssen Declares Tender Offer for Actelion Successful

Financial news for JNJ dated on 2017-03-27: Here's Every Major Corporation That's Pulled Ads From YouTube

Financial news for JNJ dated on 2017-03-27: Watch These 5 Huge Put Purchases In Monday Trade

Financial news for JNJ dated on 2017-03-24: Benzinga's Option Alert Recap From March 24

Financial news for JNJ dated on 2017-03-24: Option Alert: JNJ May \$120 Put; 2800 @ Bid @\$0.90; Ref=\$125.79

Financial news for JNJ dated on 2017-03-24: YouTube's Ad Controversy Not Going Away Yet; Will It Prove To Be Temporary?

Financial news for JNJ dated on 2017-03-24: Johnson & Johnson Unit Mentor Spokeswoman Tells Benzinga, 'We fully support the FDA's efforts to gather additional data and study BIA-ALCL in patients with breast implants,' Will Continue To Work To Understand Associated Risks And Causes

Financial news for JNJ dated on 2017-03-24: American Express, Johnson & Johnson, Square, Vale: Fast Money Picks For March 24

Financial news for JNJ dated on 2017-03-22: Allergan Continues Educational Strategy Amid FDA's Report Linking Breast Implants To Rare Cancer

Financial news for JNJ dated on 2017-03-22: Premarket Prep Host Dennis Dick Tweets: \$BAC -1.2M, \$C -179K, \$MS -82K, \$WFC -48K, \$NKE -113K, \$BABA -67K, \$TWTR -51K, \$JNJ -84K, \$GE -163K, \$F +344K

Financial news for JNJ dated on 2017-03-21: FDA Links Breast Implants To A Rare Form

Of Cancer

Financial news for JNJ dated on 2017-03-21: Watch For Weakness In Sientra, Johnson & Johnson, and Allergan NBC News Reports That FDA Says Breast Implants Can Cause A Rare Form Of Cancer That May Have Killed At Least 9 People

Financial news for JNJ dated on 2017-03-16: That Was Fast: Healthcare ETF Races To New Highs

Financial news for JNJ dated on 2017-03-14: Barclays Global Healthcare Conference Begins Today; Presenters Include Johnson & Johnson, Alnylam, Axovant, Paraxel, Gilead, bluebird bio, Envision Healthcare, & Tenet Healthcare

Financial news for JNJ dated on 2017-03-10: How The Ultra-Wealthy Are Helping Advance Health And Life Sciences

Financial news for JNJ dated on 2017-03-10: Jim Cramer Advises His Viewers On Johnson & Johnson, Corecivic, Urban Outfitters And Realty Income

Financial news for JNJ dated on 2017-03-08: Fast Money Picks For March 8

Financial news for JNJ dated on 2017-03-07: Concerns From Valeant's 10-K: \$8 Billion Of Asset Sales Is Now A Mirage

Financial news for JNJ dated on 2017-03-06: Benzinga Premarket Prep Host Dennis Dick Tweets: Notable opening imbalances: \$XRX +467K, \$BAC -353K, \$PFE -133K, \$CRM -129K, \$PEP -89K, \$JNJ -72K, \$PG -50K

Financial news for JNJ dated on 2017-03-03: J&J's Janssen Reports Results from Second Phase 3 Study of Guselkumab vs Humira for Treatment of Moderate-to-Severe Plaque Psoriasis Show Significant Efficacy, Superiority

Financial news for JNJ dated on 2017-02-27: Johnson & Johnson In 10-K Filing Says Janssen Pharma Subsidiary Received Civil Investigative Demand From DoJ Related To Allegations Concerning Sales & Marketing Practices Of Olysio

Financial news for JNJ dated on 2017-02-27: J&J Reports Expected Charge Of \$2B-\$2.4B Related To Medical Devices Unit Restructuring

Financial news for JNJ dated on 2017-02-27: Johnson & Johnson Received Subpoena From Massachusetts Seeking Records Related To Payments To Any 501(C)(3) Charitable Organizations That Provide Assistance To Medicare Patients

Financial news for JNJ dated on 2017-02-27: How Trump's Tax Policy Could Affect Large Companies Like Apple

Financial news for JNJ dated on 2017-02-26: Dan Nathan's Bearish Johnson & Johnson Trade

Financial news for JNJ dated on 2017-02-23: Hearing Johnson and Johnson Searching For Medical Device Partnerships At RBC Conf.

Financial news for JNJ dated on 2017-02-23: RBC Capital Markets Healthcare Conference Concludes Today; Presenters Include Spark Therapeutics, Johnson & Johnson, HCA Holdings, Ocular Therapeutix, Valeant & Agile Therapeutics

Financial news for JNJ dated on 2017-02-22: 10 Companies With The Best Corporate Reputations

Financial news for JNJ dated on 2017-02-21: Icahn Takes Bristol-Myers Stake With M&A In Mind; Who Could Be The Acquirer?

Financial news for JNJ dated on 2017-02-17: Exclusive: Following Up Akebia, Johnson & Johnson's Research And License Agreement

Financial news for JNJ dated on 2017-02-17: J&J Medical Devices' Ethicon Reports Deal to Buy Torax Medical, No Terms Disclosed

Financial news for JNJ dated on 2017-02-17: Wall Street's M&A Chatter From February 16

Financial news for JNJ dated on 2017-02-16: Swiss Takeover Commission Says J&J Offer for Actelion Meets Legal Requirements

Financial news for JNJ dated on 2017-02-16: J&J Publishes Prospectus for Actelion Tender Offer

Financial news for JNJ dated on 2017-02-15: A Peek Into The Markets: U.S. Stock Futures Mostly Higher Ahead Of Economic Data, Yellen Speech

Financial news for JNJ dated on 2017-02-15: Integra Acquires Codman Neurosurgery Business From Johnson & Johnson for \$1.045B Cash

Financial news for JNJ dated on 2017-02-14: ACADIA Shares Up \$0.80 Over Last Min as Hearing Dealreporter Suggesting J&J Could Approach Co.

Financial news for JNJ dated on 2017-02-06: Johnson & Johnson's Janssen Pharmaceuticals Enters Agreement To Give Investigational New Drug File For Stresscopin To Renova Therapeutics

Financial news for JNJ dated on 2017-01-31: Donald Trump Calls Johnson & Johnson A 'Good Company'

Financial news for JNJ dated on 2017-01-27: A CEO Who's Who Of Trump's Manufacturing Council

Financial news for JNJ dated on 2017-01-26: Missouri Supreme Court Denies Request To Delay Johnson & Johnson Talc-Product Cancer Allegation Trials

Financial news for JNJ dated on 2017-01-26: Benzinga's Top Upgrades, Downgrades For January 26, 2017

Financial news for JNJ dated on 2017-01-26: The Market In 5 Minutes: Earnings, Trump And Dow20k

Financial news for JNJ dated on 2017-01-26: A Peek Into The Markets: U.S. Stock Futures Up Ahead Of Earnings

Financial news for JNJ dated on 2017-01-26: Wells Fargo Downgrades Johnson & Johnson To Market Perform

Financial news for JNJ dated on 2017-01-26: JNJ to Acquire Actelion for \$280/Share in Cash; Actelion to Spin Out Drug Discovery Operations and Early-Stage Clinical Development Assets

Financial news for JNJ dated on 2017-01-25: Dow 10K's Hottest Stocks: Where Are They Now?

Financial news for JNJ dated on 2017-01-25: Trump Helps Send Markets To New Highs With Keystone Pipeline Order

Financial news for JNJ dated on 2017-01-24: Q4 Earnings Thus Far A Reality Check For The Trump Rally?

Financial news for JNJ dated on 2017-01-24: Q4 2016 Real-Time Call Brief

Financial news for JNJ dated on 2017-01-24: Johnson & Johnson Takes A Hit After Mixed Q4 Report

Financial news for JNJ dated on 2017-01-24: Stocks Could Remain Range-Bound Until Trump Policy Details Become Clearer

Financial news for JNJ dated on 2017-01-24: Johnson and Johnson Says To Expect 10 New Product Launches By 2019 With \$1B In Sales Potential

Financial news for JNJ dated on 2017-01-24: The Market In 5 Minutes: Alibaba Beats, Verizon Disappoints

Financial news for JNJ dated on 2017-01-24: A Peek Into The Markets: U.S. Stock Futures Flat Ahead Of Earnings Reports

Financial news for JNJ dated on 2017-01-24: Johnson & Johnson Says Evaluating Strategic Options for Diabetes Care Companies

Financial news for JNJ dated on 2017-01-24: Johnson & Johnson Sees FY EPS \$6.93 to \$7.08 vs \$7.11 Est

Financial news for JNJ dated on 2017-01-24: Johnson & Johnson Q4 EPS \$1.58 vs \$1.56 Est, Revenue \$18.1B vs \$18.3B Est

Financial news for JNJ dated on 2017-01-24: 12 Stocks You Should Be Watching Today

Financial news for JNJ dated on 2017-01-24: Earnings Scheduled For January 24, 2017

Financial news for JNJ dated on 2017-01-23: J&J Chair, CEO, Alex Gorsky, Offers Statement Following Manufacturer Meeting with Trump

Financial news for JNJ dated on 2017-01-23: Earnings: Last Call for Yahoo? Johnson &

Johnson, Alibaba Also Release This Week

Financial news for JNJ dated on 2017-01-23: ReutersBiz Tweets: BREAKING: Executives from Whirlpool, Under Armour, Tesla, Lockheed Martin, Johnson & Johnson and more attend Trump meeting on manufacturing

Financial news for JNJ dated on 2017-01-23: Execs from Tesla, J&J, Lockheed, Under Armour, Whirlpool Attend Trump Meeting with Key US Manufacturers

Financial news for JNJ dated on 2017-01-23: Dow Earnings: High Hopes For Chevron, Johnson & Johnson

Financial news for JNJ dated on 2017-01-23: Health Canada Wants Warning Stickers on Prescription Painkillers -Reuters

Financial news for JNJ dated on 2017-01-20: Inauguration Day: Trump Speech In Focus As New President Prepares To Take Office

Financial news for JNJ dated on 2017-01-20: Johnson and Johnson Unit Ethicon Acquires Megadyne Medical Products, Terms Not Disclosed

Financial news for JNJ dated on 2017-01-17: Does Luxottica Now Have A Monopoly On The Eyeglass Space?

Financial news for JNJ dated on 2017-01-17: Quality Dividends On The Cheap With This ETF

Financial news for JNJ dated on 2017-01-12: Johnson & Johnson Deal With Actelion Said To Be Valued At \$250-\$260/Share

Financial news for JNJ dated on 2017-01-11: J&J and Actelion Said TO Reach Tentative Agreement On Price

Financial news for JNJ dated on 2017-01-10: The Fentanyl Abuse Epidemic

Financial news for JNJ dated on 2017-01-09: JP Morgan Healthcare Conf. Begins Today; Presenters Include Insulet, Teladoc, Incyte, Johnson & Johnson, Acadia Healthcare, & Teva Pharmaceuticals

Financial news for JNJ dated on 2017-01-06: J&J, Actelion Discuss Deal with Swiss Takeover Board -Tages-Anzeiger

Financial news for JNJ dated on 2017-01-05: Execs Giving CES Keynote Speeches Could Create Volatility For Shareholders

Financial news for JNJ dated on 2016-12-30: A Peek Into The Markets: U.S. Stock Futures Rise On Final Trading Day Of 2016

Financial news for JNJ dated on 2016-12-30: Wall Street's M&A Chatter From December 29

Financial news for JNJ dated on 2016-12-29: Hearing J&J is Negotiating Placing Actelion's R&D Assets Into a Separate Co.

Financial news for JNJ dated on 2016-12-28: UPDATE: Achillion Receives \$15M Milestone Payment from J&J's Janssen Research & Development

Financial news for JNJ dated on 2016-12-28: Achillion Reports Clinical Milestone for Advancement of JNJ-4178 in Phase 2B Development for Chronic HPV

Financial news for JNJ dated on 2016-12-22: The Market In 5 Minutes: GDP, Jobless Claims And Micron

Financial news for JNJ dated on 2016-12-22: Wall Street's M&A Chatter From December 21

Financial news for JNJ dated on 2016-12-21: Johnson & Johnson Confirms Exclusive Negotiations With Actelion In Press Release

Financial news for JNJ dated on 2016-12-21: Actelion and Johnson & Johnson Enter Into Exclusive Discussion

Financial news for JNJ dated on 2016-12-20: J&J's Janssen Announces Submission of Two FDA Applications for Approval of SIMPONI ARIA for Treatment of Active Psoriatic Arthritis, Active Ankylosing Spondylitis

Financial news for JNJ dated on 2016-12-19: Janssen Sciences Ireland UC Announces Positive Results From First Phase III Studies of Investigational Two-Drug HIV Treatment Regimen

Financial news for JNJ dated on 2016-12-19: Jefferies' 2017 Global Pharma Outlook

Financial news for JNJ dated on 2016-12-16: Janssen Submits Application Seeking FDA Approval Of Stelara For Treatment Of Adolescents With Moderate-To-Severe Plaque Psoriasis

Financial news for JNJ dated on 2016-12-15: Wall Street's M&A Chatter From December 14

Financial news for JNJ dated on 2016-12-15: Watch These 7 Huge Call Purchases In Thursday Trade

Financial news for JNJ dated on 2016-12-14: Who Else Might Johnson & Johnson Seek To Acquire With Actelion Now Out Of Its Crosshairs?

Financial news for JNJ dated on 2016-12-14: Option Alert: JNJ Dec16 119 Calls Sweep: 1482 @ ASK \$0.12: 1482 traded vs 230 OI: Earnings 1/24 Before Open \$116.87 Ref

Financial news for JNJ dated on 2016-12-14: The Market In 5 Minutes: All Eyes On The Fed

Financial news for JNJ dated on 2016-12-14: Wall Street's M&A Chatter From December 13

Financial news for JNJ dated on 2016-12-13: Actelion Confirms J&J has Withdrawn from Discussions With Actelion; Says Engaged in Discussions with Another Party

Financial news for JNJ dated on 2016-12-13: JNJ Confirms it Ended Discussions with Actelion

Financial news for JNJ dated on 2016-12-12: Vetr Calls For A Hold On Johnson & Johnson Amid Sector Competition

Financial news for JNJ dated on 2016-12-12: Barron's Picks And Pans: Goodyear, Johnson & Johnson And More

Financial news for JNJ dated on 2016-12-07: Facebook, Google Make Glassdoor's List Of Top 50 Places To Work

Financial news for JNJ dated on 2016-12-07: Pfizer, J&J, Other Big Pharma Names Dip Lower Just After the Open

Financial news for JNJ dated on 2016-12-06: Karyopharm Therapeutics' Top Execs Talk Recent Results In Multiple Myeloma And Acute Myeloid Leukemia

Financial news for JNJ dated on 2016-12-06: The Market In 5 Minutes: Lower Oil Prices, Higher Apple Watch Sales

Financial news for JNJ dated on 2016-12-06: Actelion Large Shareholder Would Back Johnson & Johnson Acquisition Takeover for 246 SFR or Higher, According to Reuters

Financial news for JNJ dated on 2016-12-05: Sanofi Said To Explore Actelion Counterbid To Johnson & Johnson

Financial news for JNJ dated on 2016-12-02: Johnson & Johnson Shares Trading Down 0.3% Pre-Market on \$1B Verdict On Faulty Pinnacle Hip Implants From Its DePuy Orthopedics Unit

Financial news for JNJ dated on 2016-11-30: Achillion Says Dosing of Phase 2B Study Initiated by Janssen

Financial news for JNJ dated on 2016-11-29: Barclays Downgrades 5 Biopharma Stocks, Upgrades Pfizer And Alexion

Financial news for JNJ dated on 2016-11-29: J&J Said To Raise Actelion Takeover Offer As Talks Advance

Financial news for JNJ dated on 2016-11-29: 7 Biggest Price Target Changes For Tuesday

Financial news for JNJ dated on 2016-11-29: Benzinga's Top Downgrades

Financial news for JNJ dated on 2016-11-29: Jim Cramer Shares His Thoughts On Johnson & Johnson, Anheuser Busch And Starbucks

Financial news for JNJ dated on 2016-11-29: Barclays Downgrades Johnson & Johnson to Equal-Weight

Financial news for JNJ dated on 2016-11-28: Financial Times Reporting, 'Actelion weighs complicated deal to combine with part of J&J'

Financial news for JNJ dated on 2016-11-28: The Market In 5 Minutes: Castro, Trump And Oil In Focus

Financial news for JNJ dated on 2016-11-28: Wall Street's M&A Chatter From November 25-27

Financial news for JNJ dated on 2016-11-25: Johnson & Johnson Press Release Confirms Prelim Discussions With Actelion Pharma Regarding To Potential Acquisition

Financial news for JNJ dated on 2016-11-25: Actelion Issues Press Release Confirming Co. Has Been Approached by J&J Related to Possible Transaction

Financial news for JNJ dated on 2016-11-25: The Market In 5 Minutes: Black Friday Closes Shortened Trading Week

Financial news for JNJ dated on 2016-11-25: Johnson & Johnson Said to Approach Actelion Regarding Potential Takeover -Bloomberg

Financial news for JNJ dated on 2016-11-22: Technical Alert - Johnson & Johnson Lower For Third Day In A Row

Financial news for JNJ dated on 2016-11-22: Johnson & Johnson Opens Slightly Lower; JNJ's Janssen Reported FDA Approval Of DARZALEX Yesterday

Financial news for JNJ dated on 2016-11-17: Janssen Submits Application To FDA Seeking guselkumab Approval For Treatment Of Plaque Psoriasis

Financial news for JNJ dated on 2016-11-15: UPDATE: Janssen Reports Safety Observations Through 24 Weeks For guselkumab Show 36% of Patients Experienced Adverse Events vs. 32.7% Of Placebo

Financial news for JNJ dated on 2016-11-15: Janssen Reports guselkumab Phase 2 Results In Psoriatic Arthritis Follow Positive Phase 3 Study In Plaque Psoriasis, 2 Serious Adverse Events Were Reported, Safety Observations

Financial news for JNJ dated on 2016-11-14: 13F from Paulson & Co. Shows New Stakes in eBay, HP Enterprises, Infoblox, Carmike, Increased Stake in Facebook, Boston Scientific, Reduced Stake in J&J, Liquidated Stakes in EMC, B/E Aerospace

Financial news for JNJ dated on 2016-11-14: Johnson And Johnson New Phase 3 Data Shows Simponi Aria Significantly Improved Signs & Symptoms In Patients With Ankylosing Spondylitis

Financial news for JNJ dated on 2016-11-11: 9 Of The Most Successful Veterans Turned CEOs

Financial news for JNJ dated on 2016-11-10: Janssen Reports Clinical Trial Partnership And Supply Agreement With Amgen To Evaluate daratumumab In Combination With carfilzomib

Financial news for JNJ dated on 2016-11-09: UPDATE: Bayer Says Statements Published in Handelsblatt are Misleading -Reuters

Financial news for JNJ dated on 2016-11-09: Handelsblatt Reports Test Equipment Used in Pivotal Trial of Bayer's Xarelto was Defective

Financial news for JNJ dated on 2016-11-04: In Latest Johnson & Johnson 10-Q, Company Reported A Patient Death In Janssen's IMBark and IMerge With Adverse Events Associated With Geron's imetelstat

Financial news for JNJ dated on 2016-10-31: Are The Drugs Working? Pfizer Updates Financials And Disease Therapy Performances

Financial news for JNJ dated on 2016-10-28: Can You Guess This Chart?

Financial news for JNJ dated on 2016-10-28: Jury Awards \$70M in Johnson & Johnson Cancer Suit

Financial news for JNJ dated on 2016-10-24: Goldman Says These 25 Healthcare Stocks Are Immune To The Election

Financial news for JNJ dated on 2016-10-19: Fed Speakers And Beige Book, Bank Earnings, Rising Crude Take Center Stage

Financial news for JNJ dated on 2016-10-19: Johnson & Johnson's Robust Pipeline Supports Its Above-Average Valuation

Financial news for JNJ dated on 2016-10-18: Technical Alert: Johnson & Johnson Craters After Q3 Report

Financial news for JNJ dated on 2016-10-18: Earnings Roll On, With Goldman, Netflix Results Giving Market A Lift

Financial news for JNJ dated on 2016-10-18: The Market In 5 Minutes: Netflix Dominates, Goldman Sachs Keeps Banks Flowing

Financial news for JNJ dated on 2016-10-18: A Peek Into The Markets: U.S. Stock Futures Surge; Goldman Sachs Earnings In Focus

Financial news for JNJ dated on 2016-10-18: Johnson & Johnson Delivers Another Earnings Beat

Financial news for JNJ dated on 2016-10-18: Johnson & Johnson Sees FY EPS \$6.68 to \$6.73 vs \$6.69 est, Revenue \$71.5B to \$72.2B vs \$72.2B est

Financial news for JNJ dated on 2016-10-18: Johnson & Johnson Q3 EPS \$1.68 vs \$1.65 est, Revenue \$17.8B vs \$17.7B est

Financial news for JNJ dated on 2016-10-18: 10 Stocks To Watch For October 18, 2016

Financial news for JNJ dated on 2016-10-18: Earnings Scheduled For October 18, 2016

Financial news for JNJ dated on 2016-10-17: Technical Alert: Johnson & Johnson Finds Support

Financial news for JNJ dated on 2016-10-17: Earnings: Who's At Bat Next? Netflix, IBM, And More.

Financial news for JNJ dated on 2016-10-17: Plenty To Chew On As Heart Of Earnings Season Approaches; Fed Speakers On Prowl

Financial news for JNJ dated on 2016-10-11: Kevin Kelly's Johnson & Johnson Trade

Financial news for JNJ dated on 2016-10-11: Can You Guess This Chart?

Financial news for JNJ dated on 2016-10-04: J&J Warns Diabetic Patients that Insulin Pump is Vulnerable to Hacking -Reuters

Financial news for JNJ dated on 2016-09-28: Here's Everything You Need To Know About Blue Chip Stocks

Financial news for JNJ dated on 2016-09-26: vTv Therapeutics Shares Initiated With Buy Rating, \$13 Target

Financial news for JNJ dated on 2016-09-26: J&J's Janssen Reports FDA Approval of STELARA for Treatment of Adults With Moderately To Severely Active Crohn's Disease

Financial news for JNJ dated on 2016-09-26: First Trust Gets Smart With New Sector ETFs

Financial news for JNJ dated on 2016-09-22: The Market In 5 Minutes: No Interest Rate Hike...Yet

Financial news for JNJ dated on 2016-09-22: Can You Guess This Chart?

Financial news for JNJ dated on 2016-09-21: Shares of Johnson & Johnson Volatile, Traders Attribute Action To Negative Comments From Favus Research

Financial news for JNJ dated on 2016-09-19: Credit Suisse Can Clearly See Why Johnson & Johnson Acquired Abbott's Optics Division

Financial news for JNJ dated on 2016-09-16: Alere Shares Up ~\$0.60 Over Last Few Mins as Traders Seemingly Responding to J&J, Abbott Deal

Financial news for JNJ dated on 2016-09-16: UPDATE: Abbott Labs Says Net Impact Of J&J Transaction Will Not Effect Abbott's Targeted EPS In 2017

Financial news for JNJ dated on 2016-09-16: Johnson & Johnson To Acquire Abbott Medical Optics For \$4.325B Cash

Financial news for JNJ dated on 2016-09-16: Hearing Johnson & Johnson Nearing Deal To Buy Abbott's Eye-Surgery Equipment Unit

Financial news for JNJ dated on 2016-09-16: BZ NOTE: J&J Shares Appear Rangebound Over the Last Hour, Trading Between \$118.40 and \$118.60

Financial news for JNJ dated on 2016-09-16: J&J Shares Up ~\$0.13 Over Last Min; Upside Attributing to Unconfirmed Chatter of Bill Ackman Stake

Financial news for JNJ dated on 2016-09-16: J&J's Janssen Says Following Positive CHMP Opinion on Ustekinumab, Final Decision from EC Expected Later in '16

Financial news for JNJ dated on 2016-09-15: The Market In 5 Minutes: Apple Helps Lead Stocks Higher

Financial news for JNJ dated on 2016-09-15: Can You Guess This Chart?

Financial news for JNJ dated on 2016-09-12: J&J Reports WHO Will Review Co.'s Ebola Vaccine Regiment for EUAL

Financial news for JNJ dated on 2016-09-12: Geron +13.64% @\$3.25 Following Update on Imetelstat

Financial news for JNJ dated on 2016-09-11: Reads For The Weed-Kend: Marijuana Roadside Testing, Pregnancy And Depression

Financial news for JNJ dated on 2016-09-09: Achillion Pharma Reports 100% SVR Reported in Janssen's Phase 2a Trial Evaluating Triple Combination of Odalasvir, AL-335, and Simeprevir for Genotype 1 Treatment-Naive HCV

Financial news for JNJ dated on 2016-09-08: How Does Amazon's Meteoric Rise Compare To Those Of Its Mega-Cap Peers?

Financial news for JNJ dated on 2016-09-08: Another Election Year View On Healthcare ETFs

Financial news for JNJ dated on 2016-09-06: FDA Orders Stores To Cleanse Their Shelves Of Ineffective Hand Soaps

Financial news for JNJ dated on 2016-09-06: Out With The Old, In With The New: State Agencies Seem To Prefer Marijuana Over Opioids

Financial news for JNJ dated on 2016-09-01: Johnson & Johnson Gets Patent For Ortho Regenerate Technologies

Financial news for JNJ dated on 2016-08-31: Pre-Market Prep Host Dennis Dick Tweets Notable Opening Imbalance: Notable opening imbalances: \$BAC +1.1M, \$ABX -234K, \$GE -56K, \$JNJ +35K, \$VEEV +40K, \$F -90K, \$MS -40K, \$C +35K

Financial news for JNJ dated on 2016-08-24: Option Alert: JNJ Fri 8/26 119 Puts (Wkly): 2000 @ ASK \$0.55: 2398 traded vs 1999 OI: Earnings 10/11 \$118.80 Ref

Financial news for JNJ dated on 2016-08-24: Write A Prescription For More Pharma M&A With This ETF

Financial news for JNJ dated on 2016-08-23: Janssen Submit European Application To Expand Darzalex Use - Reuters

Financial news for JNJ dated on 2016-08-22: Goldman Sachs Talks Pfizer's Acquisition Deal Of Medivation

Financial news for JNJ dated on 2016-08-19: Geron Shares Seen Range-Bound On Lack Of Major Data Until Late 2017

Financial news for JNJ dated on 2016-08-18: 10 Notable Stocks Trading Ex-Dividend Friday, August 19

Financial news for JNJ dated on 2016-08-18: Deutsche Takes A Look At Johnson & Johnson's Patent Woes

Financial news for JNJ dated on 2016-08-18: Recent Patent Ruling A Positive For Pfizer

Financial news for JNJ dated on 2016-08-17: Johnson & Johnson Reaffirms Sales Guidance For FY16 Of 3-4%, Not Including Possibility Of A Biosimilar Launch On Or After Oct. 3th 2016

Financial news for JNJ dated on 2016-08-17: Johnson & Johnson Says Janssen Continuing Appeal Process In Proceedings Related To '471 Patent Before USPTO

Financial news for JNJ dated on 2016-08-17: JNJ Spikes to High of \$121.19 on Volume

Financial news for JNJ dated on 2016-08-16: J&J's Janssen R&D Unit Says Esketamine Receives Breakthrough Therapy Designation from FDA Related to Major Depressive



Disorder with Imminent Risk for Suicide

Financial news for JNJ dated on 2016-08-11: Biogen Cancels Out Of Citigroup Conference Following Weeks Of Rumors

Financial news for JNJ dated on 2016-08-08: Canada's Plan To Fight Opioid Addiction Might Hurt Its Weakest Patients

Financial news for JNJ dated on 2016-08-08: Biogen Shares Unaffected Amid Dealreporter Report Suggesting Pfizer, J&J Could Also Be Looking at Co.

Financial news for JNJ dated on 2016-08-05: Deutsche Downgrades Ligand As Risk/Reward Becomes Challenging

Financial news for JNJ dated on 2016-08-05: Another Jobs Report Bonanza: Big July Job Gains Lend Support To Stock Market

Financial news for JNJ dated on 2016-07-25: 3 Things The Market Is Focused On This Week

Financial news for JNJ dated on 2016-07-22: Johnson & Johnson Subsidiary Acclarent To Pay \$18M To Settle False Claims Act Allegations

Financial news for JNJ dated on 2016-07-21: Opioid Addiction: What To Do When A Loved One Is Hooked, According To Science

Financial news for JNJ dated on 2016-07-20: Argus Boosts Price Target On Johnson & Johnson Following Strong Quarter

Financial news for JNJ dated on 2016-07-20: Option Alert: JNJ Sep16 130 Calls: 2500 @ ASK \$0.41: 2556 traded vs 1057 OI: \$125.51 Ref

Financial news for JNJ dated on 2016-07-20: 7 Biggest Price Target Changes For Wednesday

Financial news for JNJ dated on 2016-07-20: The Market In 5 Minutes: Microsoft Beat, Disney Downgrade And Donald Trump

Financial news for JNJ dated on 2016-07-20: Benzinga's Top Upgrades

Financial news for JNJ dated on 2016-07-20: Argus Research Upgrades Johnson & Johnson to Buy, Raises PT to \$145.00

Financial news for JNJ dated on 2016-07-19: Earnings: HAL's Tie to Oil Prices Could Set Stage for Quarterly Loss

Financial news for JNJ dated on 2016-07-19: Stocks Hitting 52-Week Highs

Financial news for JNJ dated on 2016-07-19: The Market In 5 Minutes: Netflix Earnings Disappoint, Goldman Sachs Has Big Beat

Financial news for JNJ dated on 2016-07-19: 12 Stocks Moving In Tuesday's Pre-Market Session

Financial news for JNJ dated on 2016-07-19: A Peek Into The Markets: U.S. Stock Futures Down Ahead Of Earnings

Financial news for JNJ dated on 2016-07-19: Investors Cheer Johnson & Johnson's Q2 Results

Financial news for JNJ dated on 2016-07-19: Ionis Pharma Reports Licensing of First Oral Antisense Drug Acting Locally in GT Tract to J&J's Janssen

Financial news for JNJ dated on 2016-07-19: Johnson & Johnson Q2 EPS \$1.74 vs \$1.68 est, Revenue \$18.5B vs \$18.0B est

Financial news for JNJ dated on 2016-07-19: Keep an Eye on These 12 Stocks for July 19, 2016

Financial news for JNJ dated on 2016-07-19: Earnings Scheduled For July 19, 2016

Financial news for JNJ dated on 2016-07-18: Johnson & Johnson Dividend Offers 2.6% Yield

Financial news for JNJ dated on 2016-07-18: Can NFLX Grow its Subscriber Base?

Financial news for JNJ dated on 2016-07-18: Bank Earnings Keep Coming In New Week, But Economic Data Flow to Slow

Financial news for JNJ dated on 2016-07-18: The Market In 5 Minutes: Earnings Season Is Upon Us

Financial news for JNJ dated on 2016-07-18: A Shark Of An ETF In The Dividend ETF Tank

Financial news for JNJ dated on 2016-07-17: Benzinga's Weekend M&A Chatter

Financial news for JNJ dated on 2016-07-14: Amazon Moves Cloud Service Focus From Startups Like Lyft To Big Enterprises Like Netflix And Capital One

Financial news for JNJ dated on 2016-07-14: Amazon's Cloud Services Could Add \$1 Billion To Revenue, Says Pacific Crest

Financial news for JNJ dated on 2016-07-11: UPDATE: CI:Z Will Receive Two Board Members From Johnson & Johnson

Financial news for JNJ dated on 2016-07-11: UPDATE: A Johnson & Johnson Subsidiary Will Buy A 19.9% Stake In CI:Z, Becoming 2nd Largest Shareholder

Financial news for JNJ dated on 2016-07-11: Johnson & Johnson To Buy 20% Stake In Japanese Cosmetics Maker

Financial news for JNJ dated on 2016-07-08: Barclays Morning Research Summary: Commodities, Comcast And Healthcare In Focus

Financial news for JNJ dated on 2016-07-07: Achillion Shares Rally Following JMP's Upgrade To Market Outperform

Financial news for JNJ dated on 2016-07-06: Be Aware Of These Key Technical Levels As You Trade Today

Financial news for JNJ dated on 2016-07-06: Johnson & Johnson Subsidiary DePuy Orthopaedics Says Patients Suffering From Company's Pinnacle Metal-on-Metal Hip Implants Will Be Heard In September

Financial news for JNJ dated on 2016-06-27: No Tears In Johnson & Johnson

Financial news for JNJ dated on 2016-06-27: Invega Trinza Approved By Health Canada For Schizophrenia

Financial news for JNJ dated on 2016-06-24: Baird Says Buy Cooper Companies At Current Levels

Financial news for JNJ dated on 2016-06-23: Gilead Sciences Get European Commission Grant For Marketing Authorization Of Its Single Tablet Regimen Odefsey

Financial news for JNJ dated on 2016-06-23: European Commission Grants Marketing Authorization for Gilead's Single Tablet Regimen Odefsey for the Treatment of HIV

Financial news for JNJ dated on 2016-06-22: Technology Forces Advertisers To Get Creative

Financial news for JNJ dated on 2016-06-22: S&P 500 Index Futures Trading Higher

Financial news for JNJ dated on 2016-06-22: A Peek Into The Markets: U.S. Stock Futures Edge Higher Ahead Of Yellen Speech

Financial news for JNJ dated on 2016-06-22: Johnson & Johnson Names Joseph Wolk As VP Of Investor Relations In Place Of Louise Mehrotra

Financial news for JNJ dated on 2016-06-16: Arbutus Biopharma Taken Off Of Chardan's Sell List

Financial news for JNJ dated on 2016-06-14: 5 Pharmaceutical Price Target Raises From Jefferies

Financial news for JNJ dated on 2016-06-14: February 27 Earnings Update

Financial news for JNJ dated on 2016-06-11: Janssen Announces EPREX Demonstrates Effectiveness as Treatment for Anaemia in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes at EHA

Financial news for JNJ dated on 2016-06-10: Johnson & Johnson's Janssen R&D Reports Phase 3 POLLUX Trial Shows daratumumab Achieved 63% Reduction In Risk Of Disease Progression or Death Compared To lenalidomide and dexamethasone Alone

Financial news for JNJ dated on 2016-06-09: S&P 500 Index Futures Trading Lower

Financial news for JNJ dated on 2016-06-06: 4 Key Takeaways From ASCO

Financial news for JNJ dated on 2016-06-06: Johnson & Johnson Continues Winning Streak, Makes Another New All-Time High

Financial news for JNJ dated on 2016-06-06: S&P 500 Index Futures Trading Higher

Financial news for JNJ dated on 2016-06-06: Amyris +22% Premarket @ \$0.65; Co Announced Collaboration With J&J on Biosynthetic Drug Discovery

Financial news for JNJ dated on 2016-06-02: S&P 500 Index Futures Trading Lower In Choppy Session

Financial news for JNJ dated on 2016-06-02: The Market In 5 Minutes: Draghi, iPhones And Warriors

Financial news for JNJ dated on 2016-06-02: Johnson & Johnson Announces Acquisition of Vogue International for \$3.3B Cash

Financial news for JNJ dated on 2016-06-01: Janssen Pharmaceutica NV Idylla Ebola Virus Triage Test Granted Emergency Use Authorization by FDA -Reuters

Financial news for JNJ dated on 2016-05-20: The Market In 5 Minutes: National Send A Nude Day?

Financial news for JNJ dated on 2016-05-20: Benzinga's Top Initiations

Financial news for JNJ dated on 2016-05-20: Standpoint Research Initiates Coverage on Johnson & Johnson at Sell

Financial news for JNJ dated on 2016-05-19: One Analyst's Top 5 Takeaways From Johnson & Johnson's Analyst Day

Financial news for JNJ dated on 2016-05-19: 5 Reasons Arrowhead Pharma Is A Hepatitis B Leader

Financial news for JNJ dated on 2016-05-17: Johnson & Johnson Aligns With HP To Create Personalized Healthcare Solutions

Financial news for JNJ dated on 2016-05-17: Johnson & Johnson, HP Partner On 3D Printing Technologies To Reduce Costs and Improve Healthcare

Financial news for JNJ dated on 2016-05-16: An ETF That Takes Investors To Dividend Growth

Financial news for JNJ dated on 2016-05-13: Benzinga's Top Downgrades

Financial news for JNJ dated on 2016-05-13: What To Expect This 13F Season (And Which Hedge Funds To Watch)

Financial news for JNJ dated on 2016-05-13: BTIG Downgrades Johnson & Johnson, Admits Buy Thesis 'Had Some Hits & Misses'

Financial news for JNJ dated on 2016-05-12: BTIG Research Downgrades Johnson & Johnson to Neutral

Financial news for JNJ dated on 2016-05-11: Jefferies Updates Price Targets In Global Pharma, Sees 'Rich Catalyst Environment' Ahead

Financial news for JNJ dated on 2016-05-11: The Market In 5 Minutes: Don't Stop Me Now

Financial news for JNJ dated on 2016-05-10: A Trusted Dividend ETF

Financial news for JNJ dated on 2016-05-10: J&J's Janssen Pharma Unit Reports Received CID in Mar. Related to Contractual Relationships with Pharmacy Benefit Managers

Financial news for JNJ dated on 2016-05-05: S&P 500 Index Futures Turn Lower

Financial news for JNJ dated on 2016-05-03: Johnson & Johnson Loses Another Court Case Over Claims Its Talcum Powder Causes Cancer

Financial news for JNJ dated on 2016-05-02: GeoInvesting Says Anavex Life Sciences' Stock Has A Book Value Of Just \$0.36

Financial news for JNJ dated on 2016-04-29: JPMorgan Doesn't See A Competing Bid For St. Jude Medical, Downgrades To Neutral

Financial news for JNJ dated on 2016-04-28: Johnson & Johnson Boosts Dividend By 6.7%

Financial news for JNJ dated on 2016-04-28: Biotech Boom May Continue Through Earnings Season

Financial news for JNJ dated on 2016-04-28: Johnson & Johnson Raises Dividend 6.7% from \$0.75 to \$0.80

Financial news for JNJ dated on 2016-04-27: 3 Put Spread Strategies For The Next Week: McDonald's, Johnson & Johnson And Nvidia

Financial news for JNJ dated on 2016-04-27: What's Weighing on Markets? AAPL, Tech Stocks

Financial news for JNJ dated on 2016-04-26: Johnson & Johnson Consumer Inc. to Acquire NeoStrata Company, Inc., Terms Not Disclosed

Financial news for JNJ dated on 2016-04-25: The Heart Of Major Pharma Q1 Earnings Season: Eli Lilly, AbbVie, Bristol-Myers

Financial news for JNJ dated on 2016-04-22: Cramer: What To Know About Perrigo

Financial news for JNJ dated on 2016-04-20: Johnson & Johnson Makes New All-Time High

Financial news for JNJ dated on 2016-04-20: Argus Research Maintains Buy on Johnson & Johnson, Raises PT to \$130.00

Financial news for JNJ dated on 2016-04-20: Buy Bank Of America, Sell JPMorgan: Fast Money Picks For April 20

Financial news for JNJ dated on 2016-04-20: Goldman Sachs Maintains Neutral on Johnson & Johnson, Raises PT to \$114.00

Financial news for JNJ dated on 2016-04-20: Barclays Maintains Overweight on Johnson & Johnson, Raises PT to \$120.00

Financial news for JNJ dated on 2016-04-19: All Eyes on Markets: They're Reaching for Fresh Highs

Financial news for JNJ dated on 2016-04-19: Johnson & Johnson Q1 Adjusted EPS Tops Estimations, Boosts Full Year Outlook

Financial news for JNJ dated on 2016-04-19: Johnson & Johnson Sees FY 2016 EPS \$6.53 to \$6.68 vs \$6.54 est, Revenue \$71.2B to \$71.9B vs \$71.6B est

Financial news for JNJ dated on 2016-04-19: Johnson & Johnson Q1 EPS \$1.68 vs \$1.65 est, Revenue \$17.5B vs \$17.5B est

Financial news for JNJ dated on 2016-04-19: Disney, Twitter And More Fast Money Picks For April 19

Financial news for JNJ dated on 2016-04-19: Keep an Eye on These 10 Stocks for April 19, 2016

Financial news for JNJ dated on 2016-04-19: Earnings Scheduled For April 19, 2016

Financial news for JNJ dated on 2016-04-18: Cost Efficiency And Quality With This Dividend ETF

Financial news for JNJ dated on 2016-04-18: Flextronics Hires John Carlson As President For Flex Medical Solutions

Financial news for JNJ dated on 2016-04-18: Earnings: IBM, NFLX, GS and JNJ Join the Earnings Parade

Financial news for JNJ dated on 2016-04-15: Notable Imbalances Before Friday's Open: Telecom Pair Trade, Health Care Stocks In Focus

Financial news for JNJ dated on 2016-04-14: Johnson & Johnson Approaches All-Time High

Financial news for JNJ dated on 2016-04-06: New Tax Inversions Rules: Threats To Healthcare ETFs?

Financial news for JNJ dated on 2016-04-06: PPH May Be Home To Hedge Fund Hotels, But This ETF Can Endure

Financial news for JNJ dated on 2016-04-06: SocGen Picks New Favorites In Big Pharma

Financial news for JNJ dated on 2016-04-06: 3 Options Trades Goldman Is Watching With Catalysts Coming

Financial news for JNJ dated on 2016-04-06: Societe Generale Initiates Coverage on Johnson & Johnson at Hold

Financial news for JNJ dated on 2016-04-06: Pfizer Receives FDA Approval For Cheaper Version Of Johnson & Johnson's Top Drug Remicade

Financial news for JNJ dated on 2016-04-06: Goldman Offers 3 Options Trades For Upcoming Catalyst In AMG, JNJ, LPLA

Financial news for JNJ dated on 2016-04-06: Johnson & Johnson Launches New Global Public Health Strategy

Financial news for JNJ dated on 2016-04-05: FDA Approved Inflectra (Infliximab-Dyyb) For Multiple Indications; Shares of JNJ Maker of Remicade, Sell off on News

Financial news for JNJ dated on 2016-04-05: Inflectra, Biosimilar To Johnson and Johnson's Remicade, Approved By FDA; Shares Fell To \$107.37 After Hours Before Trading Up Back At \$108.7/Share

Financial news for JNJ dated on 2016-04-05: S&P 500 Index Futures Trading Lower

Financial news for JNJ dated on 2016-04-04: Genmab Announces Patent Infringement Suit Against Co., Janssen in US Related to DARZALEX

Financial news for JNJ dated on 2016-04-04: MorphoSys Sues Janssen Biotech and Genmab for Patent Infringement

Financial news for JNJ dated on 2016-04-04: Make A House Call With A Familiar Healthcare ETF

Financial news for JNJ dated on 2016-04-01: EU Medicines Agency Recommends Approval of JNJ & Genmab A/S's Daratumumab

Financial news for JNJ dated on 2016-03-31: CORRECTION: Janssen Announces Discontinuation Of Fulranumab Phase 3 Development Program In Osteoarthritis Pain

Financial news for JNJ dated on 2016-03-31: Janssen Announces Discontinuation Of Fulranumab Phase 3 Development Program In Osteoarthritis Pain

Financial news for JNJ dated on 2016-03-23: Johnson & Johnson Approaches All-Time High

Financial news for JNJ dated on 2016-03-21: UPDATE: Janssen Research & Development LLC Signs Clinical Trial Collaboration With Roche Group Member 'Genentech'

Financial news for JNJ dated on 2016-03-21: Janssen Announces Initiation Of 2 Studies Evaluating Daratumumab & Atezolizumab In Multiple Myeloma & Solid Tumor

Financial news for JNJ dated on 2016-03-18: Johnson & Johnson Phase 3 Data Shows Treatment W/ Stelara Induced Clinical Response And Clinical Remission

Financial news for JNJ dated on 2016-03-17: J&J Unit Says to Appeal Jury Verdicts in Ultamet Metal-on-Metal Hip Trial -DJ

Financial news for JNJ dated on 2016-03-17: Dallas Jury Awards Nearly \$500 Million Against J&J Unit in Bellwether Hip Implant Trial

Financial news for JNJ dated on 2016-03-17: Option Alert: JNJ Mar16 106 Puts Sweep: 1000 @ ASK \$0.18: 1525 traded vs 2546 OI: Earnings 4/19 Before Open \$106.78 Ref

Financial news for JNJ dated on 2016-03-14: Benzinga's Top Upgrades

Financial news for JNJ dated on 2016-03-14: Goldman Upgrades Johnson & Johnson, Removes From America's Sell List

Financial news for JNJ dated on 2016-03-14: Goldman Sachs Says J&J Conglomerate Structure Has Caused Shareholder Value To Be Trapped, Goldman Continues To Advocate For A Break-Up Of Co To Maximize Value

Financial news for JNJ dated on 2016-03-14: Goldman Sachs Upgrades Johnson & Johnson to Neutral, Raises PT to \$112.00

Financial news for JNJ dated on 2016-03-08: The Market In 5 Minutes: Tuesday, March 8, 2016

Financial news for JNJ dated on 2016-03-08: Sum-Of-The-Parts Analysis Suggests J&J

Stock Price Of \$124

Financial news for JNJ dated on 2016-03-07: The Other Sector ETF Player

Financial news for JNJ dated on 2016-03-03: A Winning Dividend ETF Idea For March

Financial news for JNJ dated on 2016-03-02: P&G Reports Divestiture of Hipoglos Brand to J&J Consumer, No Terms Disclosed

Financial news for JNJ dated on 2016-03-02: Galapagos Shares -\$0.58 Premarket @ \$43.37; Co Announced Transparency Notification from JNJ on Tuesday

Financial news for JNJ dated on 2016-02-29: Watch Pharma Names Following FDA Issuance Of New Mandatory Clinical Study For Bayer's 'Essure', Requires Product Labeling, Including Box Warnings And Patient Decision Checklist

Financial news for JNJ dated on 2016-02-27: Cramer Says He Likes Bargain Stores: It's All About Value

Financial news for JNJ dated on 2016-02-26: Option Alert: JNJ Fri 3/4 106 Calls (Wkly): 4000 @ ASK \$0.86: 4024 traded vs 862 OI: Earnings 4/12 \$105.78 Ref

Financial news for JNJ dated on 2016-02-25: Love This Low Volatility Dividend ETF

Financial news for JNJ dated on 2016-02-22: J&J Selling 2.5M Galapagos Shares-BBG

Financial news for JNJ dated on 2016-02-22: Should Johnson & Johnson Break Up?

Financial news for JNJ dated on 2016-02-22: Morgan Stanley Says Johnson & Johnson Could Possibly Operate Better If Broken Up, Cautions Breakup Unlikely To Resonate With Investors

Financial news for JNJ dated on 2016-02-18: New Dividend ETF Proves To Be A Worthy Hideout

Financial news for JNJ dated on 2016-02-18: S&P 500 Index Futures Treading Water

Financial news for JNJ dated on 2016-02-17: Everything You Might Have Missed This 13F Season: Part 2

Financial news for JNJ dated on 2016-02-13: The Stocks That Moved The S&P, Dow And Nasdaq Yesterday

Financial news for JNJ dated on 2016-02-10: The Generic Drug Battle

Financial news for JNJ dated on 2016-02-09: FDA Panel Has Backed Approval of Celltrion's Biosimilar Version of J&J's Remicade

Financial news for JNJ dated on 2016-02-09: Icahn, Gilead, GE Lead Top Insider Trades Of The Week

Financial news for JNJ dated on 2016-02-08: How To Invest In An Aging World With The 'Live Long & Prosper' ETF

Financial news for JNJ dated on 2016-02-08: S&P 500 Index Futures Sharply Lower

Financial news for JNJ dated on 2016-02-05: A Checkup On A Big Healthcare ETF

Financial news for JNJ dated on 2016-02-04: How To Build A Defensive Portfolio

Financial news for JNJ dated on 2016-02-01: Bull Market, Bear Market Or Just A Trading Range?

Financial news for JNJ dated on 2016-02-01: Warm Up With This Low Volatility ETF

Financial news for JNJ dated on 2016-01-28: Benzinga's M&A Chatter for Thursday January 28, 2015

Financial news for JNJ dated on 2016-01-28: 7 Biotech Traders Pick Their Favorite Stocks For 2016

Financial news for JNJ dated on 2016-01-28: Large Johnson & Johnson Shareholder Just Revealed 8 Major Concerns

Financial news for JNJ dated on 2016-01-28: Stocks To Play In A Zika Virus Pandemic

Financial news for JNJ dated on 2016-01-28: TRXC Bidding War Ramping Up According To Report, JNJ/GOOGL Both Focused On TRXC According To MoneyMorning Report

Financial news for JNJ dated on 2016-01-28: Hearing Unconfirmed Market Chatter of Potential JNJ Deal to Acquire GlaxoSmithKline

Financial news for JNJ dated on 2016-01-28: Artisan Partners Urges J&J to Adopt New, Publicly-Disclosed Financial Targets for Medical Devices, Consumer Businesses

Financial news for JNJ dated on 2016-01-28: UPDATE: Artisan Partners Global Value's Daniel O'Keefe Sends Letter to J&J Board

Financial news for JNJ dated on 2016-01-28: Artisan Partners Global Value's Daniel O'Keefe Sends Letter to J&J Board

Financial news for JNJ dated on 2016-01-27: UPDATE: FT Article Citing A Source Speculates On Turnaround Catalyst For JNJ's Recent Poor Performance

Financial news for JNJ dated on 2016-01-27: Johnson & Johnson Shares Steadily Gain Over Past 20 Min, Reports Shareholders Pushing Activists For 'shake up'

Financial news for JNJ dated on 2016-01-27: Johnson & Johnson Continues To Rally

Financial news for JNJ dated on 2016-01-27: S&P 500 Index Futures Lower

Financial news for JNJ dated on 2016-01-26: Earnings Recap For January 26

Financial news for JNJ dated on 2016-01-26: S&P 500 Index Futures Sharply Higher

Financial news for JNJ dated on 2016-01-26: No Shortage of Stock Drivers: Oil Swivels, Fed Meets, Apple Reports

Financial news for JNJ dated on 2016-01-26: Johnson and Johnson Sees FY EPS \$6.43 to \$6.58 vs \$6.38 est, Revenue \$70.8B to \$71.5B vs \$71.9B est

Financial news for JNJ dated on 2016-01-26: Johnson and Johnson Q4 EPS \$1.44 vs \$1.42 est, Revenue \$17.8B vs \$17.9B est

Financial news for JNJ dated on 2016-01-26: 7 Stocks You Should Be Watching Today

Financial news for JNJ dated on 2016-01-26: Earnings Scheduled For January 26, 2016

Financial news for JNJ dated on 2016-01-25: JNJ Kicks Off Health Care Earnings--What About Deals, Buybacks?

Financial news for JNJ dated on 2016-01-25: US Big Pharma: What To Watch For In Q4 Results

Financial news for JNJ dated on 2016-01-19: Johnson & Johnson Details \$1 Billion Cost Saving Initiative For Its Medical Devices Segment, Will 'Deliver More Value To Customers'

Financial news for JNJ dated on 2016-01-19: Najarian Brothers See Unusual Activity In Johnson & Johnson And Cisco Systems, Inc.

Financial news for JNJ dated on 2016-01-19: Johnson & Johnson Restructures Medical Devices Unit, Sees Nearly \$1 Billion In Annual Cost Savings

Financial news for JNJ dated on 2016-01-19: UPDATE: J&J Reaffirms FY15 Adj. EPS Outlook of \$6.15-\$6.20 vs \$6.18 Est., Sales \$70B-\$71B vs \$70.1B Est.

Financial news for JNJ dated on 2016-01-19: UPDATE: J&J Restructuring Related to Medical Devices Unit; Consumer Medical Devices, Vision Care, Diabetes Care Units Will Not Be Impacted by Restructuring

Financial news for JNJ dated on 2016-01-19: J&J Shares Indicated ~\$1.25 Higher; Co. Announced Restructuring with Projected, Annualized Pre-Tax Cost Savings \$800M-\$1B, Sees \$2B-\$2.4B Charge; Affirms FY15 Outlook

Financial news for JNJ dated on 2016-01-15: Dividend Aristocrats ETF Joins The \$1 Billion Club

Financial news for JNJ dated on 2016-01-15: Write A Prescription For This Healthcare ETF

Financial news for JNJ dated on 2016-01-14: 11 Different Ways To Play The Bear Market (From 11 Traders)

Financial news for JNJ dated on 2016-01-14: How Will Dividend Stocks Perform This Year?

Financial news for JNJ dated on 2016-01-13: J&J's Janssen Reports Health Canada Has

Approved Stelara for Treatment of Chronic Moderate-to-Severe Plaque Psoriasis in Adolescents

Financial news for JNJ dated on 2016-01-11: Chemdiv Achieves Development Milestone In Drug Recovery Collaboration With Janssen

Financial news for JNJ dated on 2016-01-08: For This Low Vol ETF, It's Not All About Sector Selection

Financial news for JNJ dated on 2016-01-08: Sino Biopharmaceutical Says Chia Tai-Tianqing Pharmaceutical Entered Into Exclusive License Agreement With Janssen Pharmaceuticals Under Johnson & Johnson -Reuters

Financial news for JNJ dated on 2016-01-07: Johnson and Johnson Along With Janssen Agree To Develop and Commercialize HBV Treatments With Chia Tai

Financial news for JNJ dated on 2016-01-06: Apple Is The Second Cheapest Mega-Cap On A Free Cash Flow Basis

Financial news for JNJ dated on 2016-01-02: The Two Best Sector SPDR ETFs For January

Financial news for JNJ dated on 2015-12-30: A Sound ETF Idea For 2016

Financial news for JNJ dated on 2015-12-23: Hearing Kentucky Attorney General Announcing Settlement Related to Purdue Pharma, J&J's Janssen Case Related to Oxycontin, Risperdal

Financial news for JNJ dated on 2015-12-23: Not All Of Clinton's Policies Are Bad For Pharmaceuticals

Financial news for JNJ dated on 2015-12-23: Peering Through The Fog To Find The Best Sectors Into Year End

Financial news for JNJ dated on 2015-12-22: Intrexon To Partner With Johnson & Johnson For Type 2 Diabetes Innovative Therapies

Financial news for JNJ dated on 2015-12-21: Medivir Announces Development of AL-704 Terminated by Janssen Following Completion of Phase I Clinical Studies

Financial news for JNJ dated on 2015-12-20: Dan Nathan Reduces Risk On His Utilities SPDR (ETF) Trade

Financial news for JNJ dated on 2015-12-19: Credit Suisse Offers 2016 U.S. Large-Cap Pharma Outlook

Financial news for JNJ dated on 2015-12-18: Atlantic Equities Initiates Coverage on Johnson & Johnson at Neutral, Announces \$95.00 PT

Financial news for JNJ dated on 2015-12-16: Janney Lists Top 'Bond Surrogate Stocks' By Sector, Identified By Beta, Dividend Yield, And Forward P/E

Financial news for JNJ dated on 2015-12-10: J&J Reports Formation of Verb Surgical

Financial news for JNJ dated on 2015-12-08: J&J's Janssen Issues Release Showing IMBRUVICA RESONATE-2 Data Demonstrated Significant Improvements in Progression-Free, Overall Survival vs Chlorambucil

Financial news for JNJ dated on 2015-12-07: S&P 500 Index Futures Under Pressure

Financial news for JNJ dated on 2015-12-07: Carter Worth And Mike Khouw's Johnson & Johnson Trade

Financial news for JNJ dated on 2015-12-01: Barclays' Biopharmaceuticals Blueprint For 2016

Financial news for JNJ dated on 2015-12-01: Benzinga's Top Upgrades

Financial news for JNJ dated on 2015-12-01: J&J's 'Steady Cash Flow Is Key,' Barclays Upgrades To Overweight

Financial news for JNJ dated on 2015-12-01: US Stock Futures Signal Higher Start On Wall Street

Financial news for JNJ dated on 2015-12-01: Barclays Upgrades Johnson & Johnson to Overweight, Raises PT to \$115.00

Financial news for JNJ dated on 2015-11-21: A Look At Investment Firms' Favorite Stocks In Q3



Financial news for JNJ dated on 2015-11-16: 8 Value Stocks For Investors Worried About Risk

Financial news for JNJ dated on 2015-11-09: Hanmi Pharmaceuticals Signs an Exclusive License Agreement with Janssen to Develop Treatment for Diabetes, Obesity

Financial news for JNJ dated on 2015-11-06: Goldman's First ETF Is Off To A Stellar Start

Financial news for JNJ dated on 2015-11-04: Johnson & Johnson to Acquire Novira Therapeutics; Financial Terms Not Dislcosed

Financial news for JNJ dated on 2015-11-04: S&P 500 Index Futures Unchanged

Financial news for JNJ dated on 2015-10-29: Johnson & Johnson Moves Up

Financial news for JNJ dated on 2015-10-29: Aduro Biotech Announces Received Up-Front \$30M Milestone Payment from J&J's Janssen for Acceptance of IND App for ADU-214 in Lung Cancer

Financial news for JNJ dated on 2015-10-25: Genmab Announces \$3M Milestone Payment in DuoBody Platform Collaboration with Janssen

Financial news for JNJ dated on 2015-10-21: Some New Multi-Factor ETFs Look Appealing

Financial news for JNJ dated on 2015-10-19: Counting On Quality With ETFs

Financial news for JNJ dated on 2015-10-19: J&J's Janssen Reports R&D Segment Showed UNITI-2 Study Meet Primary Endpoint, Major Secondary Endpoints Showed Clinical Remission Significantly Higher Than Placebo

Financial news for JNJ dated on 2015-10-19: Hearing J&J's Stelara for Crohn's Disease Showed Clinical Response, Statistically Higher Remission for Candidate Than Placebo

Financial news for JNJ dated on 2015-10-16: Achillion Announces Janssen Initiated Phase 2a Study to Evaluate Combination of AL-335, ACH-3102, and Simeprevir for Treatment of Genotype 1 Chronic HCV

Financial news for JNJ dated on 2015-10-14: J&J's Janssen Reports Collaboration Deal with Novera for Acceleration of Development of Promising Small Molecule Drug Candidates for Hematological Cancers

Financial news for JNJ dated on 2015-10-14: enGene Announces Strategic Collaboration With Johnson & Johnson Innovation To Develop Novel Gene Delivery Products For Inflammatory Bowel Disease

Financial news for JNJ dated on 2015-10-13: Mid-Afternoon Market Update: Ryder System Declines On Lowered Forecast; NewBridge Bancorp Shares Spike Higher

Financial news for JNJ dated on 2015-10-13: Johnson & Johnson Sales Fall: What The Street Is Saying Now

Financial news for JNJ dated on 2015-10-13: Mid-Day Market Update: Wausau Paper Jumps On Acquisition News; AIXTRON Shares Slide

Financial news for JNJ dated on 2015-10-13: Mid-Morning Market Update: Markets Down; Johnson & Johnson Posts Mixed Q3 Results

Financial news for JNJ dated on 2015-10-13: Johnson & Johnson Posts Upbeat Q3 Earnings, But Sales Drop

Financial news for JNJ dated on 2015-10-13: Johnson & Johnson Reports Q3 Adj Eps \$1.49 Vs Est \$1.45

Financial news for JNJ dated on 2015-10-13: J&J Raises FY15 EPS to \$6.15-\$6.20 vs \$6.16 Est.

Financial news for JNJ dated on 2015-10-13: US Stock Futures Down; JPMorgan Earnings In Focus

Financial news for JNJ dated on 2015-10-13: JNJ Announces \$10B Share Buyback Program

Financial news for JNJ dated on 2015-10-13: J&J Announces \$10B Buyback Plan

Financial news for JNJ dated on 2015-10-13: 7 Stocks You Should Be Watching Today

Financial news for JNJ dated on 2015-10-13: Earnings Scheduled For October 13, 2015

Financial news for JNJ dated on 2015-10-12: Johnson & Johnson Is First Of Big Pharma

Earnings Reports: Will Price Debate Dominate?

Financial news for JNJ dated on 2015-10-09: Johnson & Johnson Announces Start of Safety and Immunogenicity Clinical Trial of Ebola Vaccine Regimen in Sierra Leone

Financial news for JNJ dated on 2015-10-07: Benzinga's M&A Chatter for Wednesday October 7, 2015

Financial news for JNJ dated on 2015-10-06: Singapore Ministry of Health Convenes Independent Review Committee on Report of Cluster of 22 Acute Cases of Hepatitis C Among Kidney Patients -Reuters

Financial news for JNJ dated on 2015-10-05: Earnings Outlook: Is Street Already Positioned For Same Story Of Global Woes, Oil Stain?

Financial news for JNJ dated on 2015-10-05: Energy Weakness Skews Earnings View -- Can The Rest Of Corporate America Deliver?

Financial news for JNJ dated on 2015-10-05: Genmab Reaches \$3M Milestone Payment in DuoBody Platform Collaboration with Janssen

Financial news for JNJ dated on 2015-09-29: Benzinga's Top Upgrades

Financial news for JNJ dated on 2015-09-29: Johnson & Johnson Collaborates With UBIVAC To Develop And Test A Oral Cancer Vaccine To be Tested In Preclinical Trials

Financial news for JNJ dated on 2015-09-29: Johnson & Johnson Seen As 'Safe Haven' By These Experts

Financial news for JNJ dated on 2015-09-29: Deutsche Bank Upgrades Johnson & Johnson to Buy

Financial news for JNJ dated on 2015-09-28: Patients To Benefit From Latest Tech Trends

Financial news for JNJ dated on 2015-09-25: J&J's Consumer Unit Reports Closing of Divestiture of SPLENDIA Brand

Financial news for JNJ dated on 2015-09-25: 5 U.S. Stocks Likely To Hike Their Dividends

Financial news for JNJ dated on 2015-09-25: Genmab Announces CHMP Grants Accelerated Assessment for Daratumumab for Double Refractory Multiple Myeloma

Financial news for JNJ dated on 2015-09-22: UBS Initiates Coverage on Johnson & Johnson at Buy

Financial news for JNJ dated on 2015-09-18: Make The World A Better Place With...Stock Picks?

Financial news for JNJ dated on 2015-09-18: Bearish On Bucks? Try This ETF

Financial news for JNJ dated on 2015-09-09: S&P 500 Index Futures Trading Higher

Financial news for JNJ dated on 2015-09-08: MKM Partners Would Sell These Healthcare Stocks On Weaker Relative Trends

Financial news for JNJ dated on 2015-09-02: S&P 500 Index Retreats From Highs

Financial news for JNJ dated on 2015-09-01: It's Not Shopping, It's Market Research: Talking Investing Trends With TD Ameritrade's Nicole Sherrod

Financial news for JNJ dated on 2015-08-25: Benzinga's M&A Chatter for Tuesday, August 25, 2015

Financial news for JNJ dated on 2015-08-25: Heartland Food Products Group Reports Definitive Deal to Buy J&J Consumer's Splenda Brand, No Terms Disclosed

Financial news for JNJ dated on 2015-08-25: Heartland Food Products to Acquire Splenda Brand From Johnson & Johnson Consumer Inc.

Financial news for JNJ dated on 2015-08-24: Fast Money Traders Give Their Opinion On What To Buy In This Sell-Off

Financial news for JNJ dated on 2015-08-19: 13F Recap: The Most Popular (And Unpopular) Stocks Of Q2

Financial news for JNJ dated on 2015-08-18: S&P 500 Index Futures Trading Lower

Financial news for JNJ dated on 2015-08-13: When Size Matters, Consider These ETFs

Financial news for JNJ dated on 2015-08-12: Johnson & Johnson Cashes Out Of Aquinox Pharmaceuticals' Parabolic Rally

Financial news for JNJ dated on 2015-08-12: Johnson & Johnson Sells 1,514,821 Shares Of Aquinox Pharmaceuticals @\$22.41/Share -Form 4

Financial news for JNJ dated on 2015-08-10: Here's Which IT Stocks Benefit From Healthcare M&A

Financial news for JNJ dated on 2015-08-09: 20 Dividend Growth Stocks To Buy Today For Your Retirement Portfolio

Financial news for JNJ dated on 2015-08-04: 5 U.S. Mega Caps With Less Than 0.1% Insider Ownership

Financial news for JNJ dated on 2015-08-03: Achillion Announces Janssen Initiated Phase I Study to Evaluate Effect of Simeprevir and Odalasvir on AL-335 Pharmacokinetics

Financial news for JNJ dated on 2015-07-29: S&P 500 Index Futures Trading Higher

Financial news for JNJ dated on 2015-07-28: ETFs For The Next Pharma Takeover Candidates

Financial news for JNJ dated on 2015-07-14: Johnson & Johnson Q2 Earnings Top Expectations

Financial news for JNJ dated on 2015-07-14: UPDATE: Johnson & Johnson 2Q Medical Devices Sales \$6.36B, Cardiovascular Sales \$544M, Orthopaedics Sales \$2.33B

Financial news for JNJ dated on 2015-07-14: J&J Raises FY15 Adj. EPS \$6.10-\$6.20 vs \$6.14 Est.

Financial news for JNJ dated on 2015-07-14: Johnson & Johnson Reports Q2 EPS \$1.71 vs. Est. \$1.67, Rev. \$17.8B vs. Est. \$17.57B

Financial news for JNJ dated on 2015-07-14: Earning & Economic Calendar for Tuesday July 14, 2015

Financial news for JNJ dated on 2015-07-14: Earnings Scheduled For July 14, 2015

Financial news for JNJ dated on 2015-07-14: 7 Stocks You Should Be Watching Today

Financial news for JNJ dated on 2015-07-13: From JPMorgan To Johnson & Johnson, Options Activity Surrounds This Week's Earnings

Financial news for JNJ dated on 2015-07-13: Can Johnson & Johnson Deliver Its Best Quarter Ever Despite FX Headwinds?

Financial news for JNJ dated on 2015-07-10: Strong Dollar? Not So Good For Johnson & Johnson Earnings

Financial news for JNJ dated on 2015-07-07: TD Ameritrade Clients Are Buying Apple, Twitter; Selling Facebook, AOL

Financial news for JNJ dated on 2015-07-07: J&J Reports 15.6% Passive Stake In Achillion Pharmaceuticals as of July 1, 2015

Financial news for JNJ dated on 2015-06-26: S&P 500 Index Futures Trading Higher

Financial news for JNJ dated on 2015-06-19: A 'Gay Friendly' Portfolio Includes Apple, Microsoft & Disney...And It Beats The Market

Financial news for JNJ dated on 2015-06-15: S&P 500 Index Futures Trading Lower In Volatile Session

Financial news for JNJ dated on 2015-06-11: S&P 500 Index Futures Trading Higher

Financial news for JNJ dated on 2015-06-09: Analyst: Cardinal Health Buying Spree To Boost FY17 EPS

Financial news for JNJ dated on 2015-06-08: This Technology Could Disrupt U.S. Pharma Stocks, Credit Suisse Says

Financial news for JNJ dated on 2015-06-08: S&P 500 Index Futures Trading Lower In Choppy Session

Financial news for JNJ dated on 2015-06-05: S&P 500 Index Futures Trading Lower In Volatile Session

Financial news for JNJ dated on 2015-06-04: JMP Securities Boosts Halozyme Price Target On 'Long-Term Value'

Financial news for JNJ dated on 2015-06-01: J&J's Janssen R&D LLC Reported Data from Phase 3 Multicenter Study SAR3007: Showed Significant Improvement in PFS with Trabectedin vs. Dacarbazine

Financial news for JNJ dated on 2015-05-31: Healthcare, Yen And Oil ETFs To Watch This Week

Financial news for JNJ dated on 2015-05-30: Phase III HELIOS Study Results Show IMBRUVICA Combination Therapy Significantly Increased Progression-Free Survival in Previously-Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients

Financial news for JNJ dated on 2015-05-29: 1 Positive, 1 Negative For Johnson & Johnson Stock

Financial news for JNJ dated on 2015-05-28: J&J Reports Acceptance of Binding Offer from Cordis

Financial news for JNJ dated on 2015-05-27: UPDATE: J&J Removed the Device from the Market Last Year

Financial news for JNJ dated on 2015-05-27: FBI Said to Be Investigating JNJ Surgical Device Tied to Cancer in Women -DJ

Financial news for JNJ dated on 2015-05-22: S&P 500 Index Futures Trading Lower In Quiet Session

Financial news for JNJ dated on 2015-05-22: CHMP Gave Six Recommendations on Extensions of Therapeutic Indication for: Janssen's Simponi and Stelara, Pharmacoclics' Imbruvica, Eisai's Fycompa, BioMarin's Kuvan, Novo's Xultophy

Financial news for JNJ dated on 2015-05-21: S&P 500 Index Futures Trading Higher

Financial news for JNJ dated on 2015-05-21: Raymond James: Johnson & Johnson Has 'Innovation'

Financial news for JNJ dated on 2015-05-21: What Does The Johnson & Johnson/Achillion Deal Mean For HCV Competitors?

Financial news for JNJ dated on 2015-05-21: The Most Popular Stocks Held By 4 Different Generations Of Investors

Financial news for JNJ dated on 2015-05-20: Novo Sells License On Autoimmune Disease To Janssen

Financial news for JNJ dated on 2015-05-20: Morning Market Losers

Financial news for JNJ dated on 2015-05-20: JMP Says Stepping To The Sidelines On Achillion

Financial news for JNJ dated on 2015-05-20: Benzinga's Top #PreMarket Losers

Financial news for JNJ dated on 2015-05-20: J&J Announces Pharma Unit Will Continue Driving Above-Industry Growth with Plans to File More than 10 New Products by '19

Financial news for JNJ dated on 2015-05-20: Achillion Pharmaceuticals Shares Fall ~2% Premarket Following Announcement of Hep C Collaboration With Janssen

Financial news for JNJ dated on 2015-05-19: UPDATE: Achillion, Janssen Deal Includes \$225M Investment for ~18.4M Newly Issued, Unregistered Shares of Achillion at \$12.25/Share

Financial news for JNJ dated on 2015-05-19: UPDATE: Achillion, Janssen Collab Includes Up to \$1.1B in Potential Development, Regulatory, Sales Milestone Payments, Separate Equity Investment

Financial news for JNJ dated on 2015-05-19: Achillion Announces Collaboration for Hep C with J&J's Janssen Pharma

Financial news for JNJ dated on 2015-05-19: From Achillion Events Page: Posts Link for Co., Janssen Discussion for HCV Collab Webcast

Financial news for JNJ dated on 2015-05-19: J&J's Janssen Pharma Reports FDA Approval of INVEGA TRINZA for Treatment of Schizophrenia

Financial news for JNJ dated on 2015-05-18: J&J's Janssen Reports Data Demonstrates Adults with Type 2 Diabetes Achieved Blood Glucose Treatment Goals with Use of INVOKANA

Financial news for JNJ dated on 2015-05-15: The FDA's Authority Challenged By Mallinckrodt

Financial news for JNJ dated on 2015-05-15: These Charts Explain Why Johnson & Johnson Should Be Approached Tactically

Financial news for JNJ dated on 2015-05-15: Morgan Stanley Has 'Cautious Optimism' On Johnson & Johnson

Financial news for JNJ dated on 2015-05-14: What Current Buyback Levels Mean For The Bull Market

Financial news for JNJ dated on 2015-05-12: Bavarian Nordic Announces Presentation of Preliminary Phase 1 Results for Ebola Prime-Boost Vaccine Regimen of MVA-BN Filo and Janssen's AdVac

Financial news for JNJ dated on 2015-05-12: IPO Outlook: Galapagos Offers New Hope For CF And RA Sufferers

Financial news for JNJ dated on 2015-05-12: Bavarian Nordic Receives EUR50M Loan from the European Investment Bank to Help Co Develop Ebola Vaccine -Reuters

Financial news for JNJ dated on 2015-05-11: J&J's Janssen Pharma Announces FDA Issued CRL to sNDA for Expanded Labe on INVEGA SUSTENNA

Financial news for JNJ dated on 2015-05-11: Traders, Here's What You're Doing Wrong (And How To Fix It)

Financial news for JNJ dated on 2015-05-11: 9 Hot (Or Not) IPOs Scheduled To Debut This Week

Financial news for JNJ dated on 2015-05-07: Countdown To The Best Public Reputations Company

Financial news for JNJ dated on 2015-05-07: Johnson & Johnson, NYU School of Medicine Partner to Evaluate Compassionate Use of Investigational Medicines

Financial news for JNJ dated on 2015-05-05: Credit Suisse: We Prefer Pfizer, Bristol Over Pharma Peers

Financial news for JNJ dated on 2015-04-29: J&J Announces Further PTO Action Realted to REMICADE: Office Maintained Rejection of Patent, Patent '471 Remains Valid

Financial news for JNJ dated on 2015-04-23: Technician Breaks Down Johnson & Johnson

Financial news for JNJ dated on 2015-04-23: J&J Raises Qtr. Dividend from \$0.70 to \$0.75/Share

Financial news for JNJ dated on 2015-04-23: J&J's Janssen Reports SVR12 Rates with Twelve Weeks of Treatment with All-Oral, Once-Daily Regimen of Simeprevir Plus Sofosbuvir

Financial news for JNJ dated on 2015-04-15: Bank Of America Sees Big Divestitures Upcoming For Johnson & Johnson

Financial news for JNJ dated on 2015-04-15: Morgan Stanley Shares What Johnson & Johnson Investors Should Focus On Now

Financial news for JNJ dated on 2015-04-15: What Specific Role Will Apple Play In IBM's Watson Health Cloud Alliance?

Financial news for JNJ dated on 2015-04-15: J&J's Janssen Highlights Study Published in JCP Showing Long-Acting INVEGA SUSTENNA Effective Six Months Longer Than Other Oral Antipsychotics

Financial news for JNJ dated on 2015-04-14: Why Johnson & Johnson's Strong Pharmaceutical Business Is A Concern

Financial news for JNJ dated on 2015-04-14: The Big Health Data Orgy Happening In The Cloud

Financial news for JNJ dated on 2015-04-14: US Stock Futures Down Ahead Of Business Inventories Data

Financial news for JNJ dated on 2015-04-14: From J&J Earnings Conference Call: Expecting FY15 Constant Currency Sales \$75B-\$76B vs \$74B Est.

Financial news for JNJ dated on 2015-04-14: Johnson & Johnson Posts Upbeat Q1 Earnings, But Lowers FY15 Forecast

Financial news for JNJ dated on 2015-04-14: UPDATE: J&J Cuts FY EPS Outlook from \$6.12-\$6.27 Previously to \$6.04-\$6.19 vs \$6.16 Est.

Financial news for JNJ dated on 2015-04-14: Johnson & Johnson Cuts Outlook

Financial news for JNJ dated on 2015-04-14: Johnson & Johnson Reports Q1 EPS \$1.56 Vs Est \$1.54, Sales \$17.37B Vs Est \$17.31B

Financial news for JNJ dated on 2015-04-14: Earnings Scheduled For April 14, 2015

Financial news for JNJ dated on 2015-04-14: 7 Stocks You Should Be Watching Today

Financial news for JNJ dated on 2015-04-13: Stock Investors Dig In For Bank Earnings, Ready For Next SPX Test

Financial news for JNJ dated on 2015-04-13: Ichor Medical Systems Announces Entering Into Product Development Collaboration, Global License Deal with J&J's Janssen Pharma

Financial news for JNJ dated on 2015-04-13: MorphoSys AG to Receive Milestone Payment for Guselkumab Program in Psoriatic Arthritis

Financial news for JNJ dated on 2015-04-12: 13 Stocks To Watch As Earnings Season Ramps Up

Financial news for JNJ dated on 2015-04-07: Sector ETFs And Earnings

Financial news for JNJ dated on 2015-04-06: JPMorgan Cut Its Johnson & Johnson Forecast Before Earnings, But Why?

Financial news for JNJ dated on 2015-04-02: Janssen Pharmaceuticals, Inc. Finalizes Divestiture of U.S. License Rights to NUCYNTA(r) (tapentadol), NUCYNTA(r) ER (tapentadol) extended-release tablets and NUCYNTA(r) (tapentadol) Oral Solution to Depomed, Inc For \$1.05B

Financial news for JNJ dated on 2015-04-02: Hearing Unconfirmed Market Chatter JNJ to Spinoff Pharma Business from Medical Device Business

Financial news for JNJ dated on 2015-03-30: J&J's Janssen Announces FDA Approval for Label Update for ZYTIGA to Include Statistically Significant Overall Survival Results in Chemotherapy-Naive Men with Metastatic Castration-Resistant Prostate Cancer

Financial news for JNJ dated on 2015-03-27: Johnson & Johnson Teams With Google On Surgery Robot Development

Financial news for JNJ dated on 2015-03-27: Watch Shares of Intuitive Surgical Here as Bloomberg Reporting J&J In a Deal with Google Related to Surgical Robotics, Terms Not Disclosed

Financial news for JNJ dated on 2015-03-24: J&J, Bausch & Lomb Accused Of Price Fixing, Antitrust Suit Claims Contact Lens Makers Set Minimum Resale Prices

Financial news for JNJ dated on 2015-03-19: Benzinga's M&A Chatter for Thursday March 19, 2015

Financial news for JNJ dated on 2015-03-19: J&J Announces Janssen Purchase of XO1 Limited

Financial news for JNJ dated on 2015-03-19: Janssen Acquires XO1 Limited; Terms Not Disclosed

Financial news for JNJ dated on 2015-03-18: FDA Panel to Discuss Development of Ebola Vaccines in May -Reuters

Financial news for JNJ dated on 2015-03-16: PREVIEW: Pharmacyclics Shares to Resume Trading at 3:30 PM ET

Financial news for JNJ dated on 2015-03-16: UPDATE: Independent Data Monitoring Committee Unanimously Recommends Unblinding of IMBRUVICA

Financial news for JNJ dated on 2015-03-16: Johnson and Johnson's Janssen Unit Loses Appeal For \$11M Topamax Verdict

Financial news for JNJ dated on 2015-03-10: Lifetime Income Payments Or Lump Sum: How

To Decide?

Financial news for JNJ dated on 2015-03-10: J&J's McNeil Consumer Healthcare Unit Announces Deal for Resolution of US DoJ Probe: Will Pay \$25M Settlement, Enter Plea for Single Misdemeanor Violation

Financial news for JNJ dated on 2015-03-10: McNeil Consumer Healthcare Resolves U.S. DOJ Investigation; To Pay Settlement of \$25M

Financial news for JNJ dated on 2015-03-05: J&J Ordered To Pay \$5.7M For Incontinence Implant

Financial news for JNJ dated on 2015-03-05: Johnson & Johnson's Ethicon Unit Ordered to Pay \$5.6M from Trial ver Transvaginal Mesh Injuries -Reuters

Financial news for JNJ dated on 2015-03-04: Benzinga's M&A Chatter for Wednesday March 4, 2015

Financial news for JNJ dated on 2015-03-04: Report: Pharmacyclics Inc. To Be Acquired By Johnson & Johnson

Financial news for JNJ dated on 2015-03-04: UPDATE: J&J's Purchase of Pharmacyclics May Be Announced as Soon as Thursday

Financial news for JNJ dated on 2015-03-04: Hearing J&J Has Agreed to Purchase Pharmacyclics

Financial news for JNJ dated on 2015-03-04: Fast Money Halftime Report Final Trade From March 4

Financial news for JNJ dated on 2015-03-04: Hearing FT Reporting J&J Near Deal to Purchase Pharmacyclics

Financial news for JNJ dated on 2015-03-02: Benzinga's M&A Chatter for Monday March 2, 2015

Financial news for JNJ dated on 2015-03-02: 'Merger Monday' Lives Up To Name: From NXP Semiconductors To eBay, There's At Least \$20 Billon In Total Deals

Financial news for JNJ dated on 2015-03-02: UPDATE: Johnson & Johnson Announces Binding Offer from Cardinal Health to Acquire Cordis

Financial news for JNJ dated on 2015-03-02: Johnson & Johnson Announces Binding Offer from Cardinal Health to Acquire Cordis

Financial news for JNJ dated on 2015-02-27: WHO Says Independent Advisory Body to Decide No Earlier than August on Recommendation of Widespread Ebola Vaccinations

Financial news for JNJ dated on 2015-02-26: J&J Announces Formation of New Health and Wellness Platform Aimed at Transforming Health Care Delivery, Improve the Patient Experience

Financial news for JNJ dated on 2015-02-25: Benzinga's M&A Chatter for Wednesday February 25, 2015

Financial news for JNJ dated on 2015-02-25: Deutsche Bank On Pharmacyclics: 'We Do Not See Much Upside'

Financial news for JNJ dated on 2015-02-25: Bloomberg Reporting JNJ Loses Bid To Get South Carolina Risperdal Verdict Tossed

Financial news for JNJ dated on 2015-02-25: Ontario Institute for Cancer Research Extends Collaboration With Janssen on Developing Clinical Trials for Prostate Cancer

Financial news for JNJ dated on 2015-02-24: Johnson & Johnson To Pay \$2.5M For Failing to Properly Warn About Risperdal Risks

Financial news for JNJ dated on 2015-02-23: JNJ Shares Spike Higher After-Hours

Financial news for JNJ dated on 2015-02-23: 3 Companies That Could Be Negatively Impacted By Johnson & Johnson Sale Of Cordis

Financial news for JNJ dated on 2015-02-23: Morgan Stanley Analyst Sees Higher Net For Cardinal Health In Johnson & Johnson Deal

Financial news for JNJ dated on 2015-02-23: J&J Has Agreed to Pay Additional \$420M Related to Deal in ASR Hip Settlement Case

Financial news for JNJ dated on 2015-02-23: Cardnial Health Potential Buyer for J&J's

Cordis Unit -Bloomberg

Financial news for JNJ dated on 2015-02-20: Jefferies Names AbbVie As Top Pharmaceutical Pick, Offers Alternative Choices

Financial news for JNJ dated on 2015-02-20: 10 Stocks Institutional Investors Loved Last Quarter

Financial news for JNJ dated on 2015-02-20: Sterne Agee To Investors: Caution! Boston Scientific Priced To Perfection

Financial news for JNJ dated on 2015-02-18: Boston Scientific Closes Up 12%

Financial news for JNJ dated on 2015-02-18: Boston Scientific Soars 11% After Settling Dispute With Johnson & Johnson

Financial news for JNJ dated on 2015-02-18: Mid-Day Market Update: Angie's List Jumps On Upbeat Earnings; MedAssets Shares Tumble

Financial news for JNJ dated on 2015-02-18: Sterne Agree Weighs In On Boston Scientific-Johnson & Johnson Litigation Settlement

Financial news for JNJ dated on 2015-02-18: Stocks Hitting 52-Week Highs

Financial news for JNJ dated on 2015-02-18: Morning Market Gainers

Financial news for JNJ dated on 2015-02-18: Benzinga's Top #PreMarket Gainers

Financial news for JNJ dated on 2015-02-17: Fast Money Halftime Report Final Trade From February 17

Financial news for JNJ dated on 2015-02-17: Boston Scientific Shares Rise 12% After-Hours on JNJ Settlement News

Financial news for JNJ dated on 2015-02-17: Boston Scientific Reports Deal with J&J for Resolution of Guidant Litigation, Will Make \$600M in Payments, Sees Pretax Charge \$600M

Financial news for JNJ dated on 2015-02-16: 8 Stocks Going Ex-Dividend This Week (And 1 Trading Idea)

Financial news for JNJ dated on 2015-02-13: American Firms In China Feel Anti-Foreign Sentiment Rising In The Wake Of Qualcomm Settlement

Financial news for JNJ dated on 2015-02-13: Bill Ackman Thinks Valeant Is 'Incredibly Disciplined,' And Says He'd Own McDonald's If 3G Capital Was In Charge

Financial news for JNJ dated on 2015-02-13: Johnson & Johnson Faces Pressure From U.S. Patent Office

Financial news for JNJ dated on 2015-02-13: ITC to Acquire JNJ's Savlon, Shower to Shower Brands -Business Standard

Financial news for JNJ dated on 2015-02-12: J&J Announces PTO Action Related to REMICADE: Co. Has 60 Days To Respond

Financial news for JNJ dated on 2015-02-12: Johnson & Johnson Under Selling Pressure

Financial news for JNJ dated on 2015-02-12: J&J Shares Plunge Below \$100 Level Few Mins Ahead of Bloomberg Headline Suggesting Co.'s Remicade Patent Claims Have Been Given Final Patent Office Rejection

Financial news for JNJ dated on 2015-02-12: JNJ Shares Selling Off

Financial news for JNJ dated on 2015-02-10: Hearing Unconfirmed Market Chatter JNJ has Hired Goldman Sachs to Explore Breakup into 3 Cos

Financial news for JNJ dated on 2015-02-06: J&J Reports 15.1% Passive Stake in Aquinox Pharmaceuticals as of December 31

Financial news for JNJ dated on 2015-02-03: U.S. FDA Grants Priority Review for YONDELIS

Financial news for JNJ dated on 2015-02-03: J&J Sarcoma Drug Yondelis Gets FDA Priority Review

Financial news for JNJ dated on 2015-01-29: ETF Spotlight: Dividend Aristocrat Index

Financial news for JNJ dated on 2015-01-29: #Premarket Prep Technical Update -



Johnson & Johnson Lower

Financial news for JNJ dated on 2015-01-23: WHO's Aylward Says Running Out of Cash Needed to Fight Ebola; Needs \$260M; 4-5 Months Best Case for Virus to Stop -Reuters

Financial news for JNJ dated on 2015-01-22: Morgan Stanley Analyst Sees FY15 'Trough' For Johnson & Johnson Pharma Growth

Financial news for JNJ dated on 2015-01-21: Why Minerva Neurosciences Is Trading Higher

Financial news for JNJ dated on 2015-01-21: ECB Easing Could Strengthen Headwinds For U.S. Firms

Financial news for JNJ dated on 2015-01-21: UN's David Nabarro Cites Need for \$1B to Fight Ebola -Reuters

Financial news for JNJ dated on 2015-01-21: Morgan Stanley Sees Balance Sheet & Pipeline As More Critical For Johnson & Johnson

Financial news for JNJ dated on 2015-01-20: CNBC's Stock Pops & Drops From January 20

Financial news for JNJ dated on 2015-01-20: 4 Companies Capturing Social Media Attention On Tuesday Morning

Financial news for JNJ dated on 2015-01-20: Morning Market Losers

Financial news for JNJ dated on 2015-01-20: From Conf Call: J&J CFO Says Expects Better Growth Outlook for Medical Devices, Consumer Products for 2015 vs 2014

Financial news for JNJ dated on 2015-01-20: UPDATE: Johnson & Johnson Posts Upbeat Q4 Earnings

Financial news for JNJ dated on 2015-01-20: Benzinga's Top #PreMarket Losers

Financial news for JNJ dated on 2015-01-20: Earning & Economic Calendar for Tuesday January 20, 2015

Financial news for JNJ dated on 2015-01-20: Woman Who Worked with Ebola Patients Taken off United Airlines Flight Monday in Newark, After Showing Ebola Signs; Being Tested at Hackensack University Medical Center

Financial news for JNJ dated on 2015-01-20: Earnings Scheduled For January 20, 2015

Financial news for JNJ dated on 2015-01-20: 7 Stocks You Should Be Watching Today

Financial news for JNJ dated on 2015-01-16: Mid-Afternoon Market Update: Precision Castparts Slides After Weak Q3 Outlook; Schlumberger Shares Spike Higher

Financial news for JNJ dated on 2015-01-16: NIH Director Says Study of Experimental Ebola Drug ZMapp Could Start Next Month in West Africa -DJ

Financial news for JNJ dated on 2015-01-16: Mid-Day Market Update: U.S. Stocks Rise; SunTrust Shares Surge On Upbeat Earnings

Financial news for JNJ dated on 2015-01-16: Benzinga's Volume Movers

Financial news for JNJ dated on 2015-01-16: Knuckman On Johnson & Johnson And Ford: Surprise Movers?

Financial news for JNJ dated on 2015-01-16: Stocks Hitting 52-Week Highs

Financial news for JNJ dated on 2015-01-16: Morning Market Gainers

Financial news for JNJ dated on 2015-01-16: Depomed Surges 8% Following NUCYNTA Acquisition From Janssen Pharmaceuticals

Financial news for JNJ dated on 2015-01-16: Benzinga's Top #PreMarket Gainers

Financial news for JNJ dated on 2015-01-16: US Stock Futures Slip Ahead Of Goldman Sachs Earnings

Financial news for JNJ dated on 2015-01-16: UPDATE: J&J Announces Formation of Ebola Vaccine Development Consortia; IMI to Award Consortia Grants Totaling EUR100M+

Financial news for JNJ dated on 2015-01-16: Johnson & Johnson Announces Formation Of Ebola Vaccine Development Consortia

Financial news for JNJ dated on 2015-01-15: A Pair Trade With Eli Lilly And Johnson &

Johnson? Goldman Just Explained Why It's A Solid Idea

Financial news for JNJ dated on 2015-01-15: Depomed To Acquire Rights To NUCYNTA Franchise For \$1.05 Billion

Financial news for JNJ dated on 2015-01-15: DepoMed Shares Resume Trading, Now Up 15%

Financial news for JNJ dated on 2015-01-15: PREVIEW: Depomed to Resume Trading at 4:30 PM ET

Financial news for JNJ dated on 2015-01-15: #Premarket Prep Technical Update - Johnson & Johnson Lower

Financial news for JNJ dated on 2015-01-15: Goldman Sachs Downgrades Johnson & Johnson to Sell, Maintains \$97.00 PT

Financial news for JNJ dated on 2015-01-13: Wall Street's Wheelings And Dealings

Financial news for JNJ dated on 2015-01-13: J&J's Janssen, Johnson & Johnson Innovation Report License Deal with Vedanta Related to Microbiome Pharma Candidate for Inflammatory Bowel Disease

Financial news for JNJ dated on 2015-01-12: Bloomberg Reporting Johnson & Johnson, AC Immune Enter Alzheimer's Disease Vaccines Pact

Financial news for JNJ dated on 2015-01-12: JNJ CEO 'Intends \$1B In Operational Savings Over Next 3 Years'

Financial news for JNJ dated on 2015-01-12: Johnson & Johnson Webcast Presentation Begins

Financial news for JNJ dated on 2015-01-09: What Investors Should Expect From Portola Pharmaceutical's Upcoming Data Readouts

Financial news for JNJ dated on 2015-01-08: #Premarket Prep Technical Update - Johnson & Johnson Higher

Financial news for JNJ dated on 2015-01-07: 3 Sectors That Could Survive A Correction

Financial news for JNJ dated on 2015-01-06: Healthcare Sector Survives Europe's Slide

Financial news for JNJ dated on 2015-01-06: J&J Reports Commencement of Phase 1 Trial of Ebola Virus Vaccine Regimen

Financial news for JNJ dated on 2015-01-06: Johnson & Johnson Announces Commencement of Phase 1 Clinical Trial of Ebola Vaccine Regimen

Financial news for JNJ dated on 2015-01-05: Isis Pharmaceuticals Shares Rise 4.5% Premarket Following Announcement of Deal with JNJ

Financial news for JNJ dated on 2015-01-05: Isis Pharmaceuticals Announces Collaboration With Janssen on RNA-Targeted Therapeutics for Autoimmune Diseases in the GI Tract

Financial news for JNJ dated on 2014-12-29: Gilead Reports Amended Deals with J&J's Janssen to Develop PREZISTA-Based Single-Tablet Regimen for Treatment of People Living with HIV

Financial news for JNJ dated on 2014-12-26: #Premarket Prep Technical Update - Johnson & Johnson Higher

Financial news for JNJ dated on 2014-12-24: #Premarket Prep Technical Update - Johnson & Johnson Higher

Financial news for JNJ dated on 2014-12-22: MacroGenics Enters Collaboration, License Agreement with Janssen to Develop MGD011 for Multiple B-Cell Malignancies, MacroGenics to Receive \$50M Upfront License Fee, \$75M Equity Investment by JNJ

Financial news for JNJ dated on 2014-12-17: Analysts See No Sweeter Deal For Volcano

Financial news for JNJ dated on 2014-12-16: UPDATE: Geron Says Initial Payment of \$35M Due

Financial news for JNJ dated on 2014-12-16: Geron Reports Early HSR Clearance for Global Strategic Collaboration with J&J's Janssen

Financial news for JNJ dated on 2014-12-12: Janssen Research Announces Presentation Of Data At SABCS From The Phase 3 EPO-ANE-3010 Study

Financial news for JNJ dated on 2014-12-11: Market Mixed Amid Plan To Spend \$300 Million On Ebola Vaccines

Financial news for JNJ dated on 2014-12-10: #Premarket Prep Technical Update - Johnson & Johnson Lower

Financial news for JNJ dated on 2014-12-09: #Premarket Prep Technical Update - Johnson & Johnson Lower

Financial news for JNJ dated on 2014-12-09: J&J's Janssen Reports IMBRUVICA 'Shows Sustained Progression-Free Survival in Patients with High-Risk Chronic Lymphocytic Leukemia with Genetic Mutation'

Financial news for JNJ dated on 2014-12-05: New ETF For Environmentalists

Financial news for JNJ dated on 2014-12-04: Markets Marginally Lower Ahead Of Friday's Jobs Report

Financial news for JNJ dated on 2014-12-03: Markets Inch Higher Following Encouraging Beige Book Commentary

Financial news for JNJ dated on 2014-12-03: Report: Johnson & Johnson May Put Splenda On Block

Financial news for JNJ dated on 2014-12-03: Reuters Reports Johnson & Johnson Hired Goldman Sachs to Explore Sale of Splenda, According to Sources

Financial news for JNJ dated on 2014-12-02: Top 4 Stocks In The Drug Manufacturers-Major Industry With The Highest Operating Margin

Financial news for JNJ dated on 2014-12-01: S&P 500 Stocks With Most Active Options Today: PWR, XEL, NSC, BSX, LLTC, JNJ

Financial news for JNJ dated on 2014-11-24: CORRECTION: FDA Says JNJ's Hysterectomy Device Shouldn't Be Used By Most Women

Financial news for JNJ dated on 2014-11-24: FDA Says JNJ's Hysterectomy Device Shouldn't Be Used By Most Women

Financial news for JNJ dated on 2014-11-20: Riding The Bull Market With These 2 Momentum ETFs

Financial news for JNJ dated on 2014-11-19: J&J's Janssen Reports Submission of NDA for Three-Mo. Paliperidone Palmitate to Treat Schizophrenia

Financial news for JNJ dated on 2014-11-12: What Johnson & Johnson's 'Chart Watchers' Need To Know

Financial news for JNJ dated on 2014-11-10: Jim Cramer Weighs In On Johnson & Johnson And Toyota Motor

Financial news for JNJ dated on 2014-11-10: #PreMarket Primer: Monday, November 10: Nuclear Talks Enter Second Day

Financial news for JNJ dated on 2014-11-10: Johnson & Johnson CEO Says Seeks Acquisitions in China -WSJ

Financial news for JNJ dated on 2014-11-07: #Premarket Prep Technical Update - Johnson & Johnson Lower

Financial news for JNJ dated on 2014-11-07: #Premarket Prep Technical Update - Facebook Trading Higher

Financial news for JNJ dated on 2014-11-07: Reuters Reports Group of Scientists Proposes US Health Officials Find Ebola Treatment in Survivor's Antibodies -Reuters

Financial news for JNJ dated on 2014-11-05: #Premarket Prep Technical Update - Johnson & Johnson Makes New All Time High And Retreats

Financial news for JNJ dated on 2014-11-05: Which Mega-Caps Aren't Paying Taxes?

Financial news for JNJ dated on 2014-10-30: Ebola Vaccine Contenders

Financial news for JNJ dated on 2014-10-28: UPDATE: GTCR Announces Devicor Medical Products to be Acquired by Danaher Corporation's Leica Biosystems,

Financial news for JNJ dated on 2014-10-25: WHO Says Ebola Death Toll Rises to 4,922 from 10,141 Cases in Eight Countries Through October 23

Financial news for JNJ dated on 2014-10-24: Report Mali's First Ebola Case, A 2-Year Old Girl has Died, According to Health Official -Reuters

Financial news for JNJ dated on 2014-10-24: Ebola Related Stocks Move Off Lows on Report of Potential New Ebola Case in Houston, TX

Financial news for JNJ dated on 2014-10-24: CDC Spokesperson Says a Number of Options for Returnees from Africa are on the Table; Changes to Policy Likely

Financial news for JNJ dated on 2014-10-24: NIH Says Did Not Administer Experimental Drugs to Nina Pham While She Was in Maryland Hospital

Financial news for JNJ dated on 2014-10-24: Dallas Nurse Nina Pham Declared Virus Free, Being Discharged -DJ

Financial news for JNJ dated on 2014-10-24: UPDATE: WHO Expects First Data on Efficacy of Ebola Vaccines By April 2015

Financial news for JNJ dated on 2014-10-24: WHO Says at Least Five More Experimental Ebola Vaccines Scheduled to Begin Clinical Trials Soon; Says 100K Doses of Vaccine Should be Ready in H1 2015 -Reuters

Financial news for JNJ dated on 2014-10-23: Procter & Gamble Co Shares Lower Following Management Change

Financial news for JNJ dated on 2014-10-23: Genmab to Receive \$10M Milestone Payment for Daratumumab Collaboration With Janssen

Financial news for JNJ dated on 2014-10-22: Drug ETFs Attractive Buys On Pullback

Financial news for JNJ dated on 2014-10-22: Markets Reverse Early Morning Gains Following Canadian Shooting

Financial news for JNJ dated on 2014-10-22: #PreMarket Primer: Wednesday, October 22: Johnson & Johnson Develops Ebola Vaccine

Financial news for JNJ dated on 2014-10-22: Johnson & Johnson Commits Up to \$200M to Speed Ebola Vaccine Development

Financial news for JNJ dated on 2014-10-20: J&J's Janssen Announces IMBRUVICA sNDA Submitted to FDA for Waldenstrom's Macroglobulinemia

Financial news for JNJ dated on 2014-10-19: Benzinga Weekly Preview: Earnings Season Is In Full Swing

Financial news for JNJ dated on 2014-10-17: Sometimes You Need To Close Your Eyes And Buy

Financial news for JNJ dated on 2014-10-16: #PreMarket Primer: Thursday, October 16: This Year's Spending Season Could Be Muted

Financial news for JNJ dated on 2014-10-15: Barclays: Johnson & Johnson's Q3 Could Be 'High Water Mark'

Financial news for JNJ dated on 2014-10-15: UPDATE: Bank Of America Reiterates On Johnson & Johnson On Likely EPS Headwinds

Financial news for JNJ dated on 2014-10-14: Markets Unable To Hold On To Gains As Oil Continues To Plunge

Financial news for JNJ dated on 2014-10-14: Johnson & Johnson Conference Call Highlights

Financial news for JNJ dated on 2014-10-14: #Premarket Prep Technical Update - Johnson & Johnson Trading Lower

Financial news for JNJ dated on 2014-10-14: Deutsche Bank Says Gilead Sciences Stock Reaction Is Overdone

Financial news for JNJ dated on 2014-10-14: Deutsche Bank Just Out with Mid-Day Defense on Gilead, 'weakness on Irish tax, JNJ comments is overdone'

Financial news for JNJ dated on 2014-10-14: UPDATE: Johnson & Johnson Posts Better-Than-Expected Q3 Earnings, Lifts Full-Year Forecast

Financial news for JNJ dated on 2014-10-14: From J&J Earnings Conference Call: Expecting FY14 Operating Sales Growth (on a Constant Currency Basis) 5.5-6.5%

Financial news for JNJ dated on 2014-10-14: J&J Worldwide Pharama Sales Growth YoY

Financial news for JNJ dated on 2014-10-14: Johnson & Johnson 3Q Orthopaedics Sales \$2.34B

Financial news for JNJ dated on 2014-10-14: Johnson & Johnson 3Q RisperdalConsta Sales \$284M

Financial news for JNJ dated on 2014-10-14: Johnson & Johnson 3Q Worldwide Pharmaceutical Sales \$8.31B

Financial news for JNJ dated on 2014-10-14: Johnson & Johnson 3Q Worldwide Consumer Sales \$3.59B

Financial news for JNJ dated on 2014-10-14: Johnson & Johnson Sees FY2014 EPS \$5.92-5.97 vs \$5.93 Est

Financial news for JNJ dated on 2014-10-14: Johnson & Johnson Reports Q3 EPS of \$1.50 vs \$1.43 Est; Revenue of \$18.47B vs \$18.36B Est. Raising Guidance

Financial news for JNJ dated on 2014-10-14: Earnings Scheduled For October 14, 2014

Financial news for JNJ dated on 2014-10-14: Stocks To Watch For October 14, 2014

Financial news for JNJ dated on 2014-10-13: J&J's Alios BioPharma Reports Presented Positive Results of Anti-RSV Nucleoside Analog AL-8176

Financial news for JNJ dated on 2014-10-13: Bristol-Myers, Pharmacyclics, Janssen Report Clinical Collaboration of Evaluate OPDIVO, IMBRUVICA in NHL

Financial news for JNJ dated on 2014-10-13: Bavarian Nordic's Shares Rise 8% in Copenhagen on CEO Comments its MVA Technology Can be Used to Improve Ebola Vaccines from JNJ, GSK, Create Biodefense Business

Financial news for JNJ dated on 2014-10-12: Earnings Expectations For The Week Of October 13: The Crunch Is On

Financial news for JNJ dated on 2014-10-10: Janssen Presents Data from Hepatitis C in European, Israeli Patients at Viral Hepatitis Congress

Financial news for JNJ dated on 2014-10-09: #Premarket Prep Technical Update - Johnson & Johnson Trading Sharply Lower

Financial news for JNJ dated on 2014-10-08: Strike While the Iron is Hot: Stryker (SYK)

Financial news for JNJ dated on 2014-10-08: #PreMarket Primer: Wednesday, October 8: IMF Cuts Global Growth Prospects, Puts A Damper On Wall Street

Financial news for JNJ dated on 2014-10-03: #PreMarket Primer: Friday, October 3: JP Morgan Suffers Largest Cyberattack Against A Financial Institution

Financial news for JNJ dated on 2014-10-02: Markets Little Changed Ahead Of Friday's Jobs Report

Financial news for JNJ dated on 2014-10-02: Benzinga's Top Initiations

Financial news for JNJ dated on 2014-10-02: Guggenheim Securities Initiates Johnson & Johnson At Neutral

Financial news for JNJ dated on 2014-10-02: Guggenheim Securities Initiates Coverage on Johnson & Johnson at Neutral, Announces \$115.00 PT

Financial news for JNJ dated on 2014-10-01: Johnson & Johnson Falls On Bernstein Downgrade

Financial news for JNJ dated on 2014-10-01: Benzinga's Top Downgrades

Financial news for JNJ dated on 2014-10-01: Bernstein Downgrades Johnson & Johnson To Market Perform, Shares Drop

Financial news for JNJ dated on 2014-10-01: Bernstein Downgrades Johnson & Johnson to Market Perform

Financial news for JNJ dated on 2014-09-30: Achillion Pharmaceuticals, Inc. Less Attractive Amid Johnson & Johnson/Alios BioPharma Deal

Financial news for JNJ dated on 2014-09-30: J&J Announces Deal to Buy Alios Biopharma for ~\$1.75B in Cash

Financial news for JNJ dated on 2014-09-29: #Premarket Prep Technical Update - Johnson & Johnson Trading Lower

Financial news for JNJ dated on 2014-09-29: J&J's Janssen Says ZYTIGA Plus Prednisone Shows Statistically Significant Overall Survival in Men with Advanced Prostate Cancer Prior to Chemotherapy

Financial news for JNJ dated on 2014-09-25: #PreMarket Primer: Thursday, September 25: US Airstrikes Do Little To Stem ISIS Advances

Financial news for JNJ dated on 2014-09-24: J&J's Janssen Reports Research Demonstrated Association Between CONNECT Injection Centers, Increased Adherence to Healthcare Provider-Ordered Janssen Long-Acting Treatment for Schizophrenia

Financial news for JNJ dated on 2014-09-24: #Premarket Prep Technical Update - Johnson & Johnson Approaches All Time High

Financial news for JNJ dated on 2014-09-19: #Premarket Prep Technical Update - Johnson & Johnson Makes New All-Time High

Financial news for JNJ dated on 2014-09-19: Stocks Hitting 52-Week Highs

Financial news for JNJ dated on 2014-09-17: New Active ETF for All Risk Environments

Financial news for JNJ dated on 2014-09-16: #Premarket Prep Technical Update - Johnson & Johnson Trading Higher

Financial news for JNJ dated on 2014-09-14: 3 Companies Investing In Stem Cell Research

Financial news for JNJ dated on 2014-09-08: Janssen, J&J Innovation Announce Establishment of Research Collaboration with University of Toronto

Financial news for JNJ dated on 2014-09-05: Jury Finds J&J's Incontinence Sling Caused Woman's Injuries, Co. Ordered to Pay \$3.25M - Bloomberg

Financial news for JNJ dated on 2014-09-05: WHO Says Available Supply of Ebola Drugs Will Be Used in the Field

Financial news for JNJ dated on 2014-09-05: WHO Says Two Promising Ebola Vaccines Identified; Safety Results from Clinical Trials May be Available in Nov 2015, Paving Way for Use

Financial news for JNJ dated on 2014-09-04: Johnson & Johnson Metal Hip Might Lead To Poisoning, Facing 6,000+ Suits

Financial news for JNJ dated on 2014-09-04: US Stock Futures Gain; ADP, Jobless Claims Data In Focus

Financial news for JNJ dated on 2014-09-04: Johnson & Johnson to Fast-Track Development of Ebola Vaccine

Financial news for JNJ dated on 2014-09-02: Morgan Stanley Sees Johnson & Johnson Taking Rx Estimates Higher

Financial news for JNJ dated on 2014-08-29: Bank Of America Remains Optimistic On Johnson & Johnson

Financial news for JNJ dated on 2014-08-29: Morgan Stanley Sees More Focused Device Strategy Continue For Johnson & Johnson

Financial news for JNJ dated on 2014-08-28: WSJ Reporting J&J Looking for Buyers for Cordis Unit, Deal Could Be for Up to \$2B

Financial news for JNJ dated on 2014-08-25: The 4 Companies Teaming Up For A New Tool To Fight Cancer

Financial news for JNJ dated on 2014-08-25: VIVUS Announces Purchase of Topiramate-Related Patents from J&J's Janssen Pharma, Will Dismiss Suit Against VIVUS

Financial news for JNJ dated on 2014-08-22: #PreMarket Primer: Friday, August 22: Draghi, Yellen Set To Speak At Jackson Hole

Financial news for JNJ dated on 2014-08-21: Illumina Announces Strategic Partnerships with AstraZeneca, Janssen, Sanofi

Financial news for JNJ dated on 2014-08-15: #Premarket Prep Technical Update - Johnson & Johnson Trading Lower

Financial news for JNJ dated on 2014-08-12: Earnings Season Is The Right Prescription For Health Care ETFs

Financial news for JNJ dated on 2014-08-11: Genmab Announces Janssen to Start New Phase III Study of Daratumumab in Front Line Multiple Myeloma

Financial news for JNJ dated on 2014-08-07: 3 Companies That Should Benefit From The New Initiative In Africa

Financial news for JNJ dated on 2014-08-07: #PreMarket Primer: Thursday, August 7: Russia Set To Release A List Of Banned Goods

Financial news for JNJ dated on 2014-08-06: #Premarket Prep Technical Update - Johnson & Johnson Trading Higher

Financial news for JNJ dated on 2014-08-01: Unique 3D Startups And The Public Companies That Should Buy Them

Financial news for JNJ dated on 2014-07-31: #Premarket Prep Technical Update - Johnson & Johnson Trading Lower

Financial news for JNJ dated on 2014-07-29: IBM Announces Alex Gorsky, CEO of Johnson & Johnson Joining Board, Peter Voser Will Also Join Board

Financial news for JNJ dated on 2014-07-28: FDA Expands Approved Use, Labeling of Imbruvica For Chronic Lymphocytic Leukemia

Financial news for JNJ dated on 2014-07-28: Phase 2 COSMOS Study Results Published in The Lancet Demonstrate Efficacy and Safety of Janssen's Once-Daily Simeprevir in All Oral 12-Week Combination with Sofosbuvir for Genotype 1 Chronic Hepatitis C

Financial news for JNJ dated on 2014-07-25: EU Medicines Agency Recommends Johnson & Johnson, Pharmacoclytics Leukaemia Drug Ibrutinib

Financial news for JNJ dated on 2014-07-24: YTD Biggest Buyback Companies Trailing S&P In Stock Appreciation

Financial news for JNJ dated on 2014-07-24: Organovo Up 19% #PreMarket; In Research Pact With Johnson & Johnson Unit

Financial news for JNJ dated on 2014-07-24: Organovo Holdings Enters Agreement With Janssen R&D To Evaluate Use of 3D Bio-Printed Tissue In Drug Discovery Setting

Financial news for JNJ dated on 2014-07-22: The 10 Most-Respected Corporate Brands

Financial news for JNJ dated on 2014-07-22: Stocks To Watch For July 22, 2014

Financial news for JNJ dated on 2014-07-21: J&J Announces \$5B Buyback Plan

Financial news for JNJ dated on 2014-07-18: Why Has Wall Street Punished Johnson & Johnson For Its Earnings Beat?

Financial news for JNJ dated on 2014-07-18: #PreMarket Primer: Friday, July 18: Tension Between Russia And The West At An All Time High

Financial news for JNJ dated on 2014-07-17: #Premarket Prep Technical Update - Johnson & Johnson Trading Lower

Financial news for JNJ dated on 2014-07-17: Alzheimer's Rates Falling, But Pharma's Search For A Cure Yields No Results

Financial news for JNJ dated on 2014-07-17: Shares of Minerva Neurosciences Moving Higher Following 13G Filing from J&J Showing 18% Stake in Co.

Financial news for JNJ dated on 2014-07-16: Earnings Continue Driving Markets Higher

Financial news for JNJ dated on 2014-07-16: Which Matters More: Janet Yellen Or Earnings & Economic Data?

Financial news for JNJ dated on 2014-07-16: Morgan Stanley Sees Meaningful '15 Headwind For Johnson & Johnson

Financial news for JNJ dated on 2014-07-16: #PreMarket Primer: Wednesday, July 16: Yellen Hints At Sooner Than Expected Rate Hike

Financial news for JNJ dated on 2014-07-15: Markets Mixed, NASDAQ Lower As Yellen Suggests Valuations Are Stretched

Financial news for JNJ dated on 2014-07-15: Goldman Sachs, JPMorgan Chase Report

Strong Earnings; Retail Numbers Fall Below Estimates

Financial news for JNJ dated on 2014-07-15: U.S. Stocks Sink; JPMorgan Shares Surge On Upbeat Earnings

Financial news for JNJ dated on 2014-07-15: Markets Rise; Goldman Sachs Profit Beats Estimates

Financial news for JNJ dated on 2014-07-15: From J&J Call: Sees Sales \$74.50B-75.30B vs \$74.91B Est

Financial news for JNJ dated on 2014-07-15: Johnson & Johnson, Goldman Sachs Pushing These ETFs Upward

Financial news for JNJ dated on 2014-07-15: UPDATE: Johnson & Johnson Posts Upbeat Q2 Earnings, Lifts Outlook

Financial news for JNJ dated on 2014-07-15: UPDATE: Johnson & Johnson Raises FY2014 EPS Guidance from \$5.80-5.90 to \$5.85-5.92 vs \$5.90 Est

Financial news for JNJ dated on 2014-07-15: Johnson & Johnson Reports Q2 EPS of \$1.66 vs \$1.54 Est; Revenue of \$19.50B vs \$18.86B Est; Raises Outlook

Financial news for JNJ dated on 2014-07-15: US Stock Futures Mostly Higher Ahead Of Goldman Sachs Earnings

Financial news for JNJ dated on 2014-07-15: #PreMarket Primer: Tuesday, July 15: Citigroup Settles Mortgage Probe

Financial news for JNJ dated on 2014-07-15: Earnings Scheduled For July 15, 2014

Financial news for JNJ dated on 2014-07-15: Stocks To Watch For July 15, 2014

Financial news for JNJ dated on 2014-07-14: Dow Sets New Intraday High; Citigroup Impresses With Earnings

Financial news for JNJ dated on 2014-07-14: J&J's Janssen Pharma Announces Seeking Expanded Label for Once-Monthly INVEGA Sustenna

Financial news for JNJ dated on 2014-07-14: Earnings Expectations For The Week Of July 14: Big Banks, Tech Giants And More

Financial news for JNJ dated on 2014-07-11: Benzinga Weekly Preview: Earnings Season Kicks Into High Gear

Financial news for JNJ dated on 2014-07-11: #Premarket Prep Technical Update - Johnson & Johnson Trading Lower

Financial news for JNJ dated on 2014-07-10: J.P. Morgan: Johnson & Johnson's Drug Segment May Beat Q2 Street Views

Financial news for JNJ dated on 2014-07-07: #Premarket Prep Technical Update - Johnson & Johnson Makes New All-Time High

Financial news for JNJ dated on 2014-07-07: Genmab Announces Has Reached \$25M Milestone in Daratumumab Deal with J&J's Janssen

Financial news for JNJ dated on 2014-07-03: #Premarket Prep Technical Update - Johnson & Johnson Finds Resistance

Financial news for JNJ dated on 2014-07-02: J&J Settles with State of Oregon, First State Deal Related to Co.'s Hip Implants - Bloomberg

Financial news for JNJ dated on 2014-07-02: Markets Little Changed Ahead Of 4th Of July Break

Financial news for JNJ dated on 2014-07-02: Barclays Downgrades Pharmaceutical Sector

Financial news for JNJ dated on 2014-07-01: AbbVie Has Lost US Court Bid to Revive Patent Case Against J&J - Bloomberg

Financial news for JNJ dated on 2014-06-30: Markets Little Changed As The Quarter Comes To An End

Financial news for JNJ dated on 2014-06-30: Johnson & Johnson Completes Divestiture Of Ortho-Clinical Diagnostics To The Carlyle Group For \$4B

Financial news for JNJ dated on 2014-06-27: Johnson and Johnson Submits Marketing Application for Velcade in Europe



Financial news for JNJ dated on 2014-06-23: #Premarket Prep Technical Update - Johnson & Johnson Trading Lower

Financial news for JNJ dated on 2014-06-20: #Premarket Prep Technical Update - Johnson & Johnson Makes New All-Time High

Financial news for JNJ dated on 2014-06-19: #Premarket Prep Technical Update - Johnson & Johnson Trading Higher

Financial news for JNJ dated on 2014-06-18: Advances In HIV, Hep C Treatments Could Spark Renewed Interest In Biotech Stocks

Financial news for JNJ dated on 2014-06-18: J&J's Janssen Announces License Deal with Vertex to Develop Novel Treatment for Influenza A

Financial news for JNJ dated on 2014-06-16: J&J Offers New Long-Term Data Showing INVOKANA Reduces Blood Glucose, Also Demonstrates Reductions in Secondary Endpoints

Financial news for JNJ dated on 2014-06-12: #Premarket Prep Technical Update - Johnson & Johnson Trading Lower

Financial news for JNJ dated on 2014-06-12: UPDATE: Viiv Healthcare Collaborates With Janssen to Investigate Single-Tablet Regimen for Maintenance Treatment Of HIV-1

Financial news for JNJ dated on 2014-06-12: Janssen Collaborates With Viiv Healthcare to Develop Two-Drug Single Tablet Regimen for Maintenance Treatment HIV

Financial news for JNJ dated on 2014-06-11: Takeover Whispers Add To Achillion Pharmaceuticals' Momentum

Financial news for JNJ dated on 2014-06-11: #Premarket Prep Technical Update - Johnson & Johnson Trading Lower

Financial news for JNJ dated on 2014-06-10: #Premarket Prep Technical Update - Johnson & Johnson Makes New All-Time High

Financial news for JNJ dated on 2014-06-09: Hearing Leering Says JNJ, AbbVie, Bristol-Myers Squibb Could Target Achillion Pharmaceuticals

Financial news for JNJ dated on 2014-06-09: Medical Device Companies' Future Remains Bright, Albeit Slow Penetration

Financial news for JNJ dated on 2014-06-06: #Premarket Prep Technical Update - Johnson & Johnson Trading Lower

Financial news for JNJ dated on 2014-06-05: #Premarket Prep Technical Update - Johnson & Johnson Makes New All-Time High

Financial news for JNJ dated on 2014-06-05: Hearing Unconfirmed Market Chatter Circulating in Chat Rooms of Potential JNJ Interest in Isoray

Financial news for JNJ dated on 2014-06-04: #Premarket Prep Technical Update - Johnson & Johnson Makes New All-Time High

Financial news for JNJ dated on 2014-06-04: ASCO Meeting Day 2: 'Promising' Results From JNJ's Imbruvica & Targeted Therapy

Financial news for JNJ dated on 2014-06-03: #Premarket Prep Technical Update - Johnson & Johnson Makes New All-Time High

Financial news for JNJ dated on 2014-06-02: UPDATE: Jim Cramer Says JNJ Should Spinoff their Medical Device Business and Merge it with Smith & Nephew

Financial news for JNJ dated on 2014-06-02: Jim Cramer Says JNJ Could be a Potential Suitor for Smith & Nephew

Financial news for JNJ dated on 2014-06-02: Is This Time Really Going To Be Different? A True Look at Current Financial Asset Valuations (PG, WMT, JNJ)

Financial news for JNJ dated on 2014-06-02: #Premarket Prep Technical Update - Johnson & Johnson Trading Higher

Financial news for JNJ dated on 2014-06-02: J&J's Janssen Announces Data on Ibrutinib RESONATE(TM) Showed Significant Improvements in Progression-Free Survival, Overall Survival in Patients with CLL, SLL

Financial news for JNJ dated on 2014-06-02: UPDATE: Pharmacyclics Shares Rise 9% on Positive IMBRUVICA Data Presented at ASCO

Financial news for JNJ dated on 2014-05-31: Pharmacyclics, JNJ Announce IMBRUVICA Shows Durable, Long-Term Responses for Patients with CLL

Financial news for JNJ dated on 2014-05-28: #PreMarket Primer: Wednesday, May 28: Poroshenko Moves To End Pro-Russian Rebellion

Financial news for JNJ dated on 2014-05-23: Morgan Stanley Sees Three Debate-Worthy Topics For Johnson & Johnson

Financial news for JNJ dated on 2014-05-22: J&J's Medical Devices & Diagnostics Announces Expansion with Innovative Products, Customer-Focused Solutions

Financial news for JNJ dated on 2014-05-20: UPDATE: Actavis Shows Co. J&J's Janssen Have Amended Supply Deal for Generic Concerta

Financial news for JNJ dated on 2014-05-20: Form 8-K from Actavis Shows Co. J&J's Janssen Have Amended Supply Deal for Generic Concerta

Financial news for JNJ dated on 2014-05-20: Dissecting Dividend Growth ETFs

Financial news for JNJ dated on 2014-05-19: J&J's Janssen Announces Withdraws Application in EU for Approval of IV-Administered SIMPONI

Financial news for JNJ dated on 2014-05-14: R&D Tax Credit Passed In The House, Faces Challenges Ahead

Financial news for JNJ dated on 2014-05-12: Google Celebrates Dorothy Hodgkin & Her Contributions To Chemistry

Financial news for JNJ dated on 2014-05-11: Benzinga's Weekend M&A Chatter

Financial news for JNJ dated on 2014-05-09: Sanofi Rumored Not to Be Interested in Allergan, J&J Said to Demur on Co.'s Breast Implant Business - Bloomberg

Financial news for JNJ dated on 2014-05-09: JNJ's Ortho Caps Gmbh Gets Favorable Decision In Patent Dispute in Federal Patent Court In Germany -Reuters

Financial news for JNJ dated on 2014-05-07: UPDATE: J&J's Janssen Submits sNDA for Olysio

Financial news for JNJ dated on 2014-05-07: J&J's Janssen Submits sNDA for Olysio

Financial news for JNJ dated on 2014-05-05: Market Wrap For May 5: Dow Erases Triple-Digit Loss, All Three Major Indices Positive

Financial news for JNJ dated on 2014-05-05: 5 Top Dow Stocks With The Most Upside Potential

Financial news for JNJ dated on 2014-05-05: #Premarket Technical Update - Johnson & Johnson Trading Higher

Financial news for JNJ dated on 2014-04-29: Benzinga's M&A Chatter for Tuesday April 29, 2014

Financial news for JNJ dated on 2014-04-29: UPDATE: JNJ, Sanofi Spokespersons Decline Comment on Rumored Contact from Allergan

Financial news for JNJ dated on 2014-04-29: Allergan Could Explore Sale to Sanofi, J&J Instead of Valeant - Bloomberg

Financial news for JNJ dated on 2014-04-29: J&J Reports New Collaboration with Stop TB Partnership's Global Drug Facility to Enhance Access to Anti-TB Compound

Financial news for JNJ dated on 2014-04-28: 3 Mega Cap ETFs For Your Portfolio (MGC, OEF, XLG, AAPL, MSFT)

Financial news for JNJ dated on 2014-04-25: Form 8-K from J&J Includes Proxy Materials for Annual Shareholder Meeting

Financial news for JNJ dated on 2014-04-24: J&J Raises Qtr. Dividend from \$0.66 to \$0.70/Share

Financial news for JNJ dated on 2014-04-23: FDA Approves J&J's Janssen's Sylvant for Rare Castleman's Disease

Financial news for JNJ dated on 2014-04-21: Johnson & Johnson Crosses Above \$100

Financial news for JNJ dated on 2014-04-17: #PreMarket Primer: Thursday, April 17:

## Violence In Ukraine Could Deter Thursday's Negotiations

Financial news for JNJ dated on 2014-04-16: Market Wrap For April 16: Markets Hold On To Gains On Positive Yellen Comments And Economic Data

Financial news for JNJ dated on 2014-04-16: Mylan Launches First Generic ORTHO EVRA Patch

Financial news for JNJ dated on 2014-04-16: UPDATE: Bank of America Reiterates on Johnson & Johnson Following Strong Q1 Performance

Financial news for JNJ dated on 2014-04-16: UPDATE: Deutsche Bank Reiterates on Johnson & Johnson as Defensive Stock

Financial news for JNJ dated on 2014-04-16: Credit Suisse Maintains Underperform on Johnson & Johnson, Raises PT to \$100.00

Financial news for JNJ dated on 2014-04-16: Bank of America Maintains Neutral on Johnson & Johnson, Raises PO to \$106.00

Financial news for JNJ dated on 2014-04-16: #PreMarket Primer: Wednesday, April 16: Chinese GDP Slows, But Surpasses Expectations

Financial news for JNJ dated on 2014-04-15: Market Wrap For April 15: Who Doesn't Love A Turnaround?

Financial news for JNJ dated on 2014-04-15: Mid-Afternoon Market Update: Markets Trade in Highly Volatile Session as Talk of a Pull-Back is Widespread

Financial news for JNJ dated on 2014-04-15: #Premarket Prep Technical Update - Johnson & Johnson Trading Sharply Higher

Financial news for JNJ dated on 2014-04-15: Mid-Day Market Update: US Stocks Turn Red; Pep Boys Shares Drop After Q4 Results

Financial news for JNJ dated on 2014-04-15: The Market Is Not Acting Right

Financial news for JNJ dated on 2014-04-15: Mid-Morning Market Update: Markets Gain; Johnson & Johnson Profit Beats Street View

Financial news for JNJ dated on 2014-04-15: UPDATE: Johnson & Johnson Shares Rise 2.5% Premarket on Earnings Beat, Raised Guidance

Financial news for JNJ dated on 2014-04-15: UPDATE: Johnson & Johnson Posts Upbeat Q1 Earnings, Lifts FY14 Outlook

Financial news for JNJ dated on 2014-04-15: Johnson & Johnson Q1 Xarel Sales \$319M, Risperdal \$310M, Velcade \$408M, Remicade \$1.61B

Financial news for JNJ dated on 2014-04-15: Johnson & Johnson Raises FY2014 EPS Guidance to \$5.80-5.90

Financial news for JNJ dated on 2014-04-15: Johnson & Johnson Reports Q1 EPS of \$1.54 vs \$1.48 Est; Revenue of \$18.12B vs \$18.0B Est

Financial news for JNJ dated on 2014-04-15: ETF Outlook for Tuesday, April 15, 2014 (EWH, FCG, PSP, HDV)

Financial news for JNJ dated on 2014-04-15: #PreMarket Primer: Tuesday, April 15: Hopes For Diplomacy In Ukraine Help Settle Markets

Financial news for JNJ dated on 2014-04-15: Earning, Economic and IPO Calendar for Tuesday April 15, 2014

Financial news for JNJ dated on 2014-04-15: Earnings Scheduled For April 15, 2014

Financial news for JNJ dated on 2014-04-15: Stocks To Watch For April 15, 2014

Financial news for JNJ dated on 2014-04-14: Jefferies Downgrades Johnson & Johnson to Hold, Maintains \$105.00 PT

Financial news for JNJ dated on 2014-04-14: #PreMarket Primer: Monday, April 14: Military Action In Ukraine Looking More Likely

Financial news for JNJ dated on 2014-04-14: Earnings Expectations For The Week Of April 14: Coca-Cola, Goldman Sachs, Google And More

Financial news for JNJ dated on 2014-04-11: Benzinga Weekly Preview: Short, But Action Packed Week Ahead

Financial news for JNJ dated on 2014-04-11: Top 40 Upcoming Earnings Releases

Financial news for JNJ dated on 2014-04-10: #PreMarket Primer: Thursday, April 10: Job Creation Will Be China's Main Focus

Financial news for JNJ dated on 2014-04-09: #PreMarket Primer: Wednesday, April 9: John Kerry Accuses Russia Of Stirring Trouble In Ukraine

Financial news for JNJ dated on 2014-04-08: Pharmacyclics Says sNDA for Imbruvica Submitted to US FDA

Financial news for JNJ dated on 2014-04-07: Is The Market Still Playing Defense?

Financial news for JNJ dated on 2014-04-01: J&J's Janssen Submits NDA for Fixed-Dose Combo Tablet of Darunavir with Cobicistat to FDA

Financial news for JNJ dated on 2014-03-31: Benzinga's M&A Chatter for Monday March 31, 2014

Financial news for JNJ dated on 2014-03-31: Market Wrap For March 31: Stocks Rally As Yellen Confirms Support For Economy

Financial news for JNJ dated on 2014-03-31: Stocks Hitting 52-Week Highs

Financial news for JNJ dated on 2014-03-31: UPDATE: J&J Announces Acceptance of Binding Offer from Carlyle Group to Buy Ortho-Clinical Diagnostics for ~\$4B

Financial news for JNJ dated on 2014-03-31: J&J Announces Acceptance of Binding Offer from Carlyle Group to Buy Ortho-Clinical Diagnostics for ~\$4B

Financial news for JNJ dated on 2014-03-28: FDA Okays Janssen's Topamax for Migraine Prevention in Adolescents

Financial news for JNJ dated on 2014-03-27: Fitch Affirms AAA Rating on J&J; Outlook Stable

Financial news for JNJ dated on 2014-03-27: ETFs Shrugging Off The Selling (DHS, SMH, IGF, INTC)

Financial news for JNJ dated on 2014-03-25: Stocks Hitting 52-Week Highs

Financial news for JNJ dated on 2014-03-24: Google Honors Activist Dorothy Height & Her Contributions

Financial news for JNJ dated on 2014-03-20: AP Reporting J&J \$1.2B Judgement Overturned by Arkansas Supreme Court

Financial news for JNJ dated on 2014-03-20: J&J's Janssen Investigational Treatment for Schizophrenia Shows Positive Efficacy, Delays Relapse

Financial news for JNJ dated on 2014-03-13: Slap The Floor: Market Playing Defense

Financial news for JNJ dated on 2014-03-10: JNJ's Janssen Receives Positive Recommendation On Stelara From SMC

Financial news for JNJ dated on 2014-03-10: Reckitt Benckiser to Acquire K-Y Brand from McNeil PPC; Terms Not Disclosed

Financial news for JNJ dated on 2014-03-05: Cramer Recommends J&J For Best Big Pharma Pipeline Play

Financial news for JNJ dated on 2014-03-04: J&J Says New Data on XEPLION Significantly Delays Time to Relapse

Financial news for JNJ dated on 2014-02-28: What Companies Stand To Benefit From The 86th Academy Awards?

Financial news for JNJ dated on 2014-02-26: J&J Files Automatic Mixed Securities Shelf

Financial news for JNJ dated on 2014-02-25: J&J's Biosense Webster Receives FDA Approval for First Catheter Ablation Therapy

Financial news for JNJ dated on 2014-02-21: J&J's Cordis Receives CE Mark for Renlane Renal Deneration System

Financial news for JNJ dated on 2014-02-21: EMA Issues New Compassionate-Use Programme

Financial news for JNJ dated on 2014-02-20: Pharma ETFs On The Move Again (IHE, PJP, PPH, ACT, FRX)

Financial news for JNJ dated on 2014-02-19: Jefferies: 3D Printers Are About To Burst Across Many Fields

Financial news for JNJ dated on 2014-02-18: Bloomberg Reporting J&J Has Persuaded Judge to Throw Out Suit Related to Vaginal-Mesh Sling

Financial news for JNJ dated on 2014-02-14: Market Wrap For February 14: Markets End The Week Positive

Financial news for JNJ dated on 2014-02-12: UPDATE: Pharmacyclics Announces Will Receive \$60M Milestone Payment Related to J&J's Imbruvica Deal

Financial news for JNJ dated on 2014-02-12: Shares of Pharmacyclics On the Move Higher Following FDA Okay for Imbruvica

Financial news for JNJ dated on 2014-02-12: FDA Issues Okay for JanssenMD's Imbruvica for Chronic Lymphocytic Leukemia

Financial news for JNJ dated on 2014-02-12: An Investor's Guide to Hot In Vitro Diagnostics Market

Financial news for JNJ dated on 2014-02-06: Three Steps to Overcoming Losses in a Declining Market

Financial news for JNJ dated on 2014-02-05: Bloomberg Reporting Judge in J&J Vaginal-Mesh Case Found Co. Improperly Destroyed Documents

Financial news for JNJ dated on 2014-01-30: Market Wrap For January 30: Markets Focus on Good News

Financial news for JNJ dated on 2014-01-27: Bloomberg Reporting J&J Escapes \$482M Verdict Following Rejection of Patent Appeal

Financial news for JNJ dated on 2014-01-27: #PreMarket Primer: Monday, January 27: Markets Open The Week On Edge

Financial news for JNJ dated on 2014-01-24: Is It Time To Worry Again?

Financial news for JNJ dated on 2014-01-24: J&J's Flubendazole Wins FDA Orphan Drug Designation

Financial news for JNJ dated on 2014-01-23: Court Rules in Favor of Covidien in Ethicon Patent Infringement Lawsuit

Financial news for JNJ dated on 2014-01-22: Morgan Stanley Maintains on Johnson & Johnson as 2014 Looks Promising

Financial news for JNJ dated on 2014-01-22: J&J's Janssen Announces Health Canada Approval for Stelara

Financial news for JNJ dated on 2014-01-22: #PreMarket Primer: Wednesday, January 22: Syrian Peace Talks Kick Off Surrounded By Doubt

Financial news for JNJ dated on 2014-01-21: Market Wrap For January 21: Dow Hit by Earnings; S&P And Nasdaq End The Day Positive

Financial news for JNJ dated on 2014-01-21: Johnson & Johnson Earnings Recap: Beats Estimates By Four Cents

Financial news for JNJ dated on 2014-01-21: Johnson & Johnson Shares Lower After Earnings

Financial news for JNJ dated on 2014-01-21: UPDATE: Johnson & Johnson Posts Higher Q4 Earnings

Financial news for JNJ dated on 2014-01-21: Johnson & Johnson Sees FY2014 Sales \$73.50B-74.30B vs \$73.90B Est

Financial news for JNJ dated on 2014-01-21: Johnson & Johnson Sees FY2014 EPS \$5.75-5.85 vs \$5.85 Est

Financial news for JNJ dated on 2014-01-21: Johnson & Johnson Reports Q4 EPS of \$1.24 vs \$1.20 Est; Revenue of \$18.40B vs \$17.95B Est

Financial news for JNJ dated on 2014-01-21: #PreMarket Primer: Tuesday, January 21:

China's Central Bank Adds Record Amount Of Cash To Markets

Financial news for JNJ dated on 2014-01-21: Earnings Scheduled For January 21, 2014

Financial news for JNJ dated on 2014-01-21: Stocks To Watch For January 21, 2014

Financial news for JNJ dated on 2014-01-20: Economic Outlook For The Week of January 20: How To Trade With Binary Options

Financial news for JNJ dated on 2014-01-19: Earnings Expectations For The Week Of January 20: Microsoft, McDonald's, Netflix And More

Financial news for JNJ dated on 2014-01-18: Benzinga Weekly Preview: Earnings Season Continues

Financial news for JNJ dated on 2014-01-16: J&J's Janssen Confirms FDA Panel Votes Against Approval of XARELTO for Use in Patients with ACS

Financial news for JNJ dated on 2014-01-16: FDA Advisory Panel Votes 10-0 J&J/Bayer's Xarelto Should NOT Be Approved

Financial news for JNJ dated on 2014-01-16: J&J Announces Binding Offer from Carlyle Group to Buy Ortho-Clinical Diagnostics Unit for \$4.15B

Financial news for JNJ dated on 2014-01-15: UPDATE: J&J Could Sell Ortho Unit to Carlyle for \$4B

Financial news for JNJ dated on 2014-01-15: Bloomberg Reporting J&J Could Announce Deal with Carlyle as Soon as Tomorrow (Thursday)

Financial news for JNJ dated on 2014-01-15: WSJ Reporting Carlyle Paying \$4-4.2B for J&J's Blood-Testing Unit

Financial news for JNJ dated on 2014-01-15: Carlyle Paying \$4B-\$4.2B for J&J Blood-Testing Unit, According to Sources -DJ

Financial news for JNJ dated on 2014-01-14: Market Wrap For January 14: Markets Rebound On Earnings Season Kickoff

Financial news for JNJ dated on 2014-01-13: Reuters Reporting Carlyle Ready to \$3.7B in Financing for Bid for J&J Unit

Financial news for JNJ dated on 2014-01-13: Market Consolidates Ahead Of Major Earnings Reports

Financial news for JNJ dated on 2014-01-10: Barclays Downgrades Johnson & Johnson to Equalweight, Maintains \$99.00 PT

Financial news for JNJ dated on 2014-01-09: Market Wrap For January 9: All Eyes on Tomorrow's Job Report

Financial news for JNJ dated on 2014-01-09: Jefferies Upgrades Johnson & Johnson to Buy, Raises PT to \$108.00

Financial news for JNJ dated on 2014-01-08: Procter & Gamble vs. Johnson & Johnson: Which is the Better Bet?

Financial news for JNJ dated on 2014-01-08: Johnson & Johnson: Off To A Good Start In 2014

Financial news for JNJ dated on 2014-01-07: Market Wrap For January 7: Markets Reverse 3-Day Slump

Financial news for JNJ dated on 2014-01-07: UPDATE: RBC Capital Markets Upgrades Johnson & Johnson

Financial news for JNJ dated on 2014-01-07: J&J Says IDMC Recommends Early Stopping of Pharmacocyclics' Phase 3 Study

Financial news for JNJ dated on 2014-01-07: RBC Capital Upgrades Johnson & Johnson to Outperform, Raises PT to \$104.00

Financial news for JNJ dated on 2013-12-27: Stocks to Watch for December 27, 2013

Financial news for JNJ dated on 2013-12-23: Hearing Carlyle Group Favorite to Acquire Johnson & Johnson's Clinical Diagnostics Unit -Sources

Financial news for JNJ dated on 2013-12-20: EMA Issues Positive Opinion on Bedaquiline

Financial news for JNJ dated on 2013-12-19: GlaxoSmithKline Rocked By China Bribery Scandal

Financial news for JNJ dated on 2013-12-19: Orion Signs License Pact with Janssen Pharma for Alzheimer's Treatment, Will Receive Upfront Payment of \$31M

Financial news for JNJ dated on 2013-12-18: Which Companies Hoarded The Most Cash In 2013?

Financial news for JNJ dated on 2013-12-17: UPDATE: EMA Says Will Discuss Voluntary Withdrawal of Janssen's Doribax, Risk-Benefit Balance of ARIAD's Iclusig

Financial news for JNJ dated on 2013-12-12: FDA Issues Complete Response Letter for Canagliflozin/Metformin Fixed-Dose Combination Therapy for Type 2 Diabetes

Financial news for JNJ dated on 2013-12-12: Johnson & Johnson Shares Under Pressure For Second Day in a Row

Financial news for JNJ dated on 2013-12-09: Myriad Genetics Announces Collaboration With Janssen

Financial news for JNJ dated on 2013-12-04: FDA Announces \$1.25M Settlement with J&J's Advanced Sterilization Products, Execs

Financial news for JNJ dated on 2013-12-02: J&J Files for Two-Part Note Offering via BofA, Goldman, JP Morgan

Financial news for JNJ dated on 2013-11-27: J&J Says May Pay \$1B in Medical Costs Related to Hip Settlement

Financial news for JNJ dated on 2013-11-25: Benzinga's M&A Chatter for Monday November 25, 2013

Financial news for JNJ dated on 2013-11-22: Form 8-K from Vertex Pharma Shows J&J's Janssen Will Make \$152M Payment Related to Incivo Sales Royalties During Q4

Financial news for JNJ dated on 2013-11-21: Reuters Reporting J&J Has Chosen Two Possible Bidders for its Diagnostics Unit Sale

Financial news for JNJ dated on 2013-11-21: Hearing Carlyle Group, Danaher, Blackstone Group in Final Stage of Negotiations for J&J's Diagnostics Unit, According to Sources

Financial news for JNJ dated on 2013-11-20: Market Wrap For November 20: Inflation Data Points To "No" Tapering, Fed Meeting Notes Points To "Yes" Tapering

Financial news for JNJ dated on 2013-11-20: J&J's Janssen Says Galexos Approved by Canada Priority Review

Financial news for JNJ dated on 2013-11-20: Vertex Sells INCIVO Product Royalty Rights to Janssen Pharmaceutica for \$152M

Financial news for JNJ dated on 2013-11-19: Bloomberg Reporting J&J Will Pay \$2.47B to Settle First Round of Hip Suits

Financial news for JNJ dated on 2013-11-19: WSJ Breaking News Tweets: 'Johnson & Johnson has agreed to pay at least \$2.5 billion to settle hip lawsuits.'

Financial news for JNJ dated on 2013-11-18: Top Four Overlooked Stocks for Income-Seeking Investors

Financial news for JNJ dated on 2013-11-15: Bloomberg Reporting J&J Said Set to Announce ASR Hip-Implant Settlement on Nov. 19th

Financial news for JNJ dated on 2013-11-14: #PreMarket Primer: Thursday, November 14: Markets Primed For Yellen's Big Day

Financial news for JNJ dated on 2013-11-13: Pharmacyclics Resumes Trading

Financial news for JNJ dated on 2013-11-13: UPDATE: Pharmacyclics Will Hold 1PM Call to Discuss FDA Approval of IMBRUVICA

Financial news for JNJ dated on 2013-11-13: Pharmacyclics, J&J's Janssen Now Confirming FDA Approval of IMBRUVICA

Financial news for JNJ dated on 2013-11-13: Pharmacyclics Halted News Pending

Financial news for JNJ dated on 2013-11-13: FDA Approves Ibrutinib for MCL

Financial news for JNJ dated on 2013-11-13: October Job Numbers a Tale of Two Economies

Financial news for JNJ dated on 2013-11-12: Bloomberg Reporting J&J Said to Reach \$4B Deal to Settle Hip-Implant Suits

Financial news for JNJ dated on 2013-11-11: Johnson & Johnson, Amazon at Odds Over 3rd Party Sales

Financial news for JNJ dated on 2013-11-11: Why Did Institutions Sell 29 Million Apple Shares?

Financial news for JNJ dated on 2013-11-08: Market Wrap For November 8: Markets Erase Thursday's Losses; Dow Companies Dominate Headlines

Financial news for JNJ dated on 2013-11-08: Johnson & Jonhson Unit Could Fetch Over \$4 Billion in Sale

Financial news for JNJ dated on 2013-11-05: #PreMarket Primer: Tuesday, November 5: Fed Speakers Calm Taper Nerves

Financial news for JNJ dated on 2013-11-04: J&J, Gilead Report HCV Combo Shows 93% SVR12 Rate Prior Null Responders, Says Medivir Showed No Benefit from Ribavirin, 12-Week Regimen Similar to 24

Financial news for JNJ dated on 2013-11-04: J&J Said to Pay More Than \$2.2 Billion in Risperdal Accord

Financial news for JNJ dated on 2013-11-04: US DoJ Says J&J Will Pay \$2.2B+ Related to Drug Cases, Co. Has Admitted to Promoting Risperdal for Non-Schizophrenic Uses

Financial news for JNJ dated on 2013-11-04: Bloomberg Reporting J&J's Settlement Related to Risperdal Said to Be Announced Today

Financial news for JNJ dated on 2013-11-04: DJ Reporting J&J to Pay \$2B to Settle Marketing Probes

Financial news for JNJ dated on 2013-10-30: J&J's Janssen Must Pay \$4.02M Related to Topamax Seizure Case

Financial news for JNJ dated on 2013-10-30: First Trial Related to J&J's Janssen Product Topamax Seizure Drug Goes to Jury Today

Financial news for JNJ dated on 2013-10-29: #PreMarket Primer: Tuesday, October 29: Fed Meeting Likely Uneventful

Financial news for JNJ dated on 2013-10-28: Think Silver: Top Stocks Catering to Seniors

Financial news for JNJ dated on 2013-10-28: J&J's Janssen Reports Nearly 70% on Simponi Aria at Two Years Had ACR 20 Response

Financial news for JNJ dated on 2013-10-16: Market Primer: Wednesday, October 16: Markets Wobble On Debt Deal Setback

Financial news for JNJ dated on 2013-10-15: Market Wrap For Tuesday, October 15: Earnings Reports And White House Progress Send Markets Down

Financial news for JNJ dated on 2013-10-15: PreMarket Info Recap for October 15, 2013: Earnings Kick Off Tuesday

Financial news for JNJ dated on 2013-10-15: UPDATE: Johnson & Johnson Posts Higher Q3 Profit

Financial news for JNJ dated on 2013-10-15: Benzinga's Top Pre-Market Gainers

Financial news for JNJ dated on 2013-10-15: UPDATE: J&J Reported Q3 Remicade Sales \$1.69B, Zytiga Sales \$464M, Prezista \$410M, Velcade \$404M, Stelara \$370M, Risperdal Consta \$326M

Financial news for JNJ dated on 2013-10-15: Johnson & Johnson Raises FY2013 EPS Guidance from \$5.40-5.47 to \$5.44-5.49 vs \$5.46 Est

Financial news for JNJ dated on 2013-10-15: Johnson & Johnson Reports Q3 EPS of \$1.36 vs \$1.32 Est; Revenue of \$17.60B vs \$17.42B Est; Raises Outlook

Financial news for JNJ dated on 2013-10-15: ETF Outlook for October 15, 2013 (IHE, ITB, EWZ, SMH)



Financial news for JNJ dated on 2013-10-15: Market Primer: Tuesday, October 15: Tuesday Could Be 'Deal Day'

Financial news for JNJ dated on 2013-10-15: Earnings Scheduled For October 15, 2013

Financial news for JNJ dated on 2013-10-15: Stocks To Watch For October 15, 2013

Financial news for JNJ dated on 2013-10-13: Earnings Expectations For The Week Of October 14: Financials, Tech and Consumer Goods

Financial news for JNJ dated on 2013-10-11: Benzinga Weekly Preview: Earnings Season Gets Into Full Swing

Financial news for JNJ dated on 2013-10-11: UPDATE: Goldman Sachs Upgrades Johnson & Johnson Based on Solid Pharma Business

Financial news for JNJ dated on 2013-10-11: Benzinga's Top Upgrades

Financial news for JNJ dated on 2013-10-11: US Stock Futures Up; J.P. Morgan Earnings In Focus

Financial news for JNJ dated on 2013-10-11: Goldman Sachs Upgrades Johnson & Johnson to Neutral, Raises PT to \$95.00

Financial news for JNJ dated on 2013-10-08: J&J's Janssen Buys Investigational NS5A Inhibitor from Glaxo

Financial news for JNJ dated on 2013-10-07: Playing Momentum With ETFs (PDP, PIE, MTUM)

Financial news for JNJ dated on 2013-10-01: J&J Says Boehringer Doxil Dispute May Cause Year-Long Shortage

Financial news for JNJ dated on 2013-09-26: Form 8-K from Endocyte Shows Janssen Pharma Informed Co. of Estimated Doxil Supply Interruption, Sees Sufficient Doxil Supply to Support Patients on Trials

Financial news for JNJ dated on 2013-09-25: BioMarin, Celgene Lead Trend in Biotech Short Interest (BRMN, CELG, REGN)

Financial news for JNJ dated on 2013-09-19: Write A Prescription For Health Care ETFs

Financial news for JNJ dated on 2013-09-18: Johnson and Johnson near Major Resistance Level

Financial news for JNJ dated on 2013-09-14: Alexion, Pharmacyclics Buck Trend in Biotech Short Interest (ALXN, CELG, PCYC)

Financial news for JNJ dated on 2013-09-12: Some New ETFs Off To Impressive Starts

Financial news for JNJ dated on 2013-09-07: Duke Energy, VIVUS And Others Insiders Have Been Buying

Financial news for JNJ dated on 2013-09-06: AP Reporting J&J Has Recalled 200K Bottles of Infant Motrin

Financial news for JNJ dated on 2013-09-06: DJ Reporting J&J Rumored to Hold Talks to Sell Diagnostics Unit

Financial news for JNJ dated on 2013-08-30: Plenty Of ETFs With Favorable Risk Traits

Financial news for JNJ dated on 2013-08-27: Short Interest In Celgene, Onyx Continues To Shrink (CELG, ONXX, VRTX)

Financial news for JNJ dated on 2013-08-20: Hearing Symbols Impacted by Options Issues: IBKR, IVZ, JLL, JNJ, JNPR, JOE, JOY, JPM, JWN, K, KBR, KEY

Financial news for JNJ dated on 2013-08-19: J&J Closes Purchase of Aragon Pharma

Financial news for JNJ dated on 2013-08-17: Nordstrom Joins UBS List Of Top Dividend Payers

Financial news for JNJ dated on 2013-08-15: Has Johnson & Johnson Peaked? Time to Book Profits?

Financial news for JNJ dated on 2013-08-15: UPDATE: Berkshire Hathaway Shows Increased Stakes In American Express, ConocoPhillips, Costco, Davita Healthcare, Deere, DirecTV, GE, GM, GlaxoSmithKline, J&J, Liberty Media, M&T Bank

Financial news for JNJ dated on 2013-08-14: How Much Does It Cost To Develop A New Drug?

Financial news for JNJ dated on 2013-08-12: Royalty Pharma Partners with Aisling Capital and Clarus Ventures in Recent Ibrutinib Royalty Purchase

Financial news for JNJ dated on 2013-08-07: Johnson and Johnson Wins Appeal Over Rembrandt's Contact Lens Patent, Court Says JNJ Did Not Infringe On Patent

Financial news for JNJ dated on 2013-08-06: Buyback ETF Defies Logic

Financial news for JNJ dated on 2013-08-05: Biotechnology Stock Wins

Financial news for JNJ dated on 2013-08-05: Deferred Tax Assets and Liabilities

Financial news for JNJ dated on 2013-08-05: Is Procter & Gamble a Strategic Bet?

Financial news for JNJ dated on 2013-08-02: S&P: Heaping Praise For Some Health Care ETFs

Financial news for JNJ dated on 2013-08-02: Three Soaring, But Overlooked Health Care ETFs

Financial news for JNJ dated on 2013-07-30: SLIDESHOW: 8 Stocks to Benefit From a Repatriation Deal In Congress

Financial news for JNJ dated on 2013-07-26: FDA Issues Warning on J&J's Nizoral Tablets, Says Could Cause Severe Liver Injuries, Could Have Harmful Interactions with Medications

Financial news for JNJ dated on 2013-07-19: Rookie ETF Offers Exposure to Rising EM Dividends

Financial news for JNJ dated on 2013-07-17: J&J Agrees to Pay \$22.9M to Settle Case Over Drug Recalls

Financial news for JNJ dated on 2013-07-17: UPDATE: Citigroup Raises PT on Johnson & Johnson Following Good 2Q Results

Financial news for JNJ dated on 2013-07-17: UPDATE: Deutsche Bank Downgrades Johnson & Johnson on Valuation

Financial news for JNJ dated on 2013-07-17: Benzinga's Top Downgrades

Financial news for JNJ dated on 2013-07-17: A Peek Into The Market Before The Trading Starts

Financial news for JNJ dated on 2013-07-17: Deutsche Bank Downgrades Johnson & Johnson to Hold, Raises PT to \$93.00

Financial news for JNJ dated on 2013-07-17: Benzinga Market Primer: Wednesday, July 17: Bernanke Is Back

Financial news for JNJ dated on 2013-07-16: Eli Lilly Tries Again with Alzheimer's Drug as the Race for a Cure Continues (LLY)

Financial news for JNJ dated on 2013-07-16: UPDATE: Johnson & Johnson Posts Upbeat Q2 Profit

Financial news for JNJ dated on 2013-07-16: UPDATE: Johnson and Johnson Q2 EPS Includes Gain On Sale of Elan Stake, Saw Negative Currency Impact of 0.9%

Financial news for JNJ dated on 2013-07-16: Johnson & Johnson Raises FY2013 EPS Guidance from \$5.35-5.45 to \$5.40-5.47 vs \$5.42 Est

Financial news for JNJ dated on 2013-07-16: Johnson & Johnson Reports Q2 EPS of \$1.48 vs \$1.39 Est; Revenue of \$17.90B vs \$17.71B Est; Raising Guidance

Financial news for JNJ dated on 2013-07-16: Benzinga Market Primer: Tuesday, July 16: Futures Flat Ahead of Earnings

Financial news for JNJ dated on 2013-07-16: US Stock Futures Edge Higher; Goldman Sachs Earnings, CPI In Focus

Financial news for JNJ dated on 2013-07-16: Earnings Scheduled For July 16, 2013

Financial news for JNJ dated on 2013-07-16: Stocks To Watch For July 16, 2013

Financial news for JNJ dated on 2013-07-15: Health Care ETFs Looking Healthy Ahead of Earnings

Financial news for JNJ dated on 2013-07-14: Earnings Expectations for the Week of July 15

Financial news for JNJ dated on 2013-07-14: A Look Ahead: This Week's ETFs to Watch

Financial news for JNJ dated on 2013-07-12: Weekly Preview: Earnings Back With A Bang

Financial news for JNJ dated on 2013-07-12: UPDATE: Jefferies Raises PT on Johnson & Johnson on Challenges Ahead

Financial news for JNJ dated on 2013-07-12: Jefferies Maintains Hold on Johnson & Johnson, Raises PT to \$92.00

Financial news for JNJ dated on 2013-07-07: Earnings Expectations for the Week of July 8 (AA, JPM, WFC)

Financial news for JNJ dated on 2013-07-05: 5 Healthcare Stocks With The Highest Revenue

Financial news for JNJ dated on 2013-07-01: ETFs For an Onyx Takeover Battle

Financial news for JNJ dated on 2013-06-30: Barron's Recap: World's Most Respected Companies

Financial news for JNJ dated on 2013-06-26: Short Interest in Biogen Idec and Vertex Shrinks (BIIB, CELG, VRTX)

Financial news for JNJ dated on 2013-06-26: Abbott Wins Appeal in Heart Stent Dispute with J&J, Pfizer

Financial news for JNJ dated on 2013-06-21: Rising 10-Year Yields Could Crush Popular Dividend ETFs

Financial news for JNJ dated on 2013-06-18: One Simple Measure for Investing in a Volatile Market

Financial news for JNJ dated on 2013-06-17: Benzinga's M&A Chatter for Monday June 17, 2013

Financial news for JNJ dated on 2013-06-17: Market Wrap for Monday, June 17: Stocks Jump to Start Trading Week; Dow Rallies Triple Digits

Financial news for JNJ dated on 2013-06-17: Siemens to Create Companion Diagnostic Test for In-Development Janssen Heart Failure Drug

Financial news for JNJ dated on 2013-06-17: UPDATE: Johnson & Johnson Announces Definitive Agreement To Acquire Aragon Pharma For \$650M; Includes Contingent for Possible Additional Payments of up to \$350M

Financial news for JNJ dated on 2013-06-17: J&J Announces Definitive Deal to Buy Aragon Pharma, to Make \$650M Upfront Payment

Financial news for JNJ dated on 2013-06-13: Bloomberg Reporting a J&J Spokesperson Has Said the Company Sold 25.4M Elan Shares Today, This Would Be Nearly Entire Stake

Financial news for JNJ dated on 2013-06-12: J&J's Janssen Issues Research Study Results for Simponi in Active RA

Financial news for JNJ dated on 2013-06-07: UPDATE: Jefferies Lowers PT on Johnson & Johnson Following Global Pharma Review

Financial news for JNJ dated on 2013-06-07: Jefferies Maintains Hold on Johnson & Johnson, Lowers PT to \$91.00

Financial news for JNJ dated on 2013-06-05: J&J Innovation Announces Opening of California Innovation Center, Janssen, Second Genome Announce Deal on Microbiome Drug Discovery

Financial news for JNJ dated on 2013-06-04: With Bond Yields So Low, Reluctant Investors Are Now Making the Move into These Stocks

Financial news for JNJ dated on 2013-06-02: CVR Energy, Warner Chilcott and Other Top Performers in May

Financial news for JNJ dated on 2013-05-28: Valeant Pharmaceuticals to Buy Bausch & Lomb

Financial news for JNJ dated on 2013-05-28: UPDATE: Jefferies Raises PT on Johnson & Johnson Following SOTP Analysis

Financial news for JNJ dated on 2013-05-28: Jefferies Maintains Hold on Johnson & Johnson, Raises PT to \$97.00

Financial news for JNJ dated on 2013-05-23: J&J's Janssen Poised to Continue Driving Growth, Outlines 10+ Potential New Product Filings by 2017

Financial news for JNJ dated on 2013-05-21: J&J's Janssen Announces Primary Efficacy, Safety Findings from Phase 3 Study of Simeprevir Once Daily

Financial news for JNJ dated on 2013-05-20: How Understanding the Investment Climate Equals Stock Market Success

Financial news for JNJ dated on 2013-05-16: Johnson & Johnson Stops Selling Metal Liners in Metal Hip Replacement Product; Says Decision Stemmed From Low Sales -Bloomberg

Financial news for JNJ dated on 2013-05-11: Short Interest in Vertex Rises, in Celgene Falls

Financial news for JNJ dated on 2013-05-10: S&P Highlights Biotech ETFs

Financial news for JNJ dated on 2013-05-09: DJ Reporting J&J Potential \$2.2B Settlement with DoJ Help Up

Financial news for JNJ dated on 2013-05-08: Stock Market Fake-Out: Where Is the Retrenchment?

Financial news for JNJ dated on 2013-05-08: Top 4 NYSE Stocks In The Drug Manufacturers-Major Industry With The Lowest PEG Ratio

Financial news for JNJ dated on 2013-05-06: Three Top Performing Healthcare Stocks to Watch

Financial news for JNJ dated on 2013-05-03: DJ Reporting J&J Recalls All Children's Tylenol in South Korea, Recall Doesn't Affect US Products

Financial news for JNJ dated on 2013-05-01: Earnings Trigger Volume Spike in Pharma ETF

Financial news for JNJ dated on 2013-05-01: Daratumumab Receives Breakthrough Therapy Designation in Double Refractory Multiple Myeloma from U.S. Food and Drug Administration

Financial news for JNJ dated on 2013-05-01: First Manhattan Responds to VIVUS Board Additions, Says Board Still Needs Overhaul

Financial news for JNJ dated on 2013-04-26: Form 8-K: J&J Holders Didn't Okay Holder Bid Related to Independent Chair

Financial news for JNJ dated on 2013-04-26: Short Sellers Move into Celgene, Regeneron

Financial news for JNJ dated on 2013-04-25: Yes, This ETF Offers Dividend Growth

Financial news for JNJ dated on 2013-04-25: Johnson & Johnson Announces Dividend Increase of 8.2% to \$0.66 per Share

Financial news for JNJ dated on 2013-04-25: J&J Raises Qtr. Dividend from \$0.61 to \$0.66/Share

Financial news for JNJ dated on 2013-04-22: Go Beyond Large-Cap ETFs For Dividends

Financial news for JNJ dated on 2013-04-19: Non-Streak Dividend ETFs Impress

Financial news for JNJ dated on 2013-04-19: UPDATE: Jefferies Raises PT on Johnson & Johnson on Unimpressive Q1'13 Earnings, But Strong Sentiment

Financial news for JNJ dated on 2013-04-19: Jefferies Maintains Hold on Johnson & Johnson, Raises PT to \$90.00

Financial news for JNJ dated on 2013-04-18: iShares Bolsters Factor ETF Lineup With 5 New Funds

Financial news for JNJ dated on 2013-04-18: UPDATE: J&J's Janssen to Get \$11.25 Per Elan Share, to Record Gain ~\$213M in Q2 from Sale

Financial news for JNJ dated on 2013-04-18: J&J Reports Sale of 82M Elan ADS Held by Janssen Pharma

Financial news for JNJ dated on 2013-04-17: Fitch Affirms J&J IDRs at AAA/F1+; Outlook Stable

Financial news for JNJ dated on 2013-04-17: Benzinga Market Primer: Wednesday, April 17

Financial news for JNJ dated on 2013-04-16: Johnson & Johnson Rises on Healthy Earnings

Financial news for JNJ dated on 2013-04-16: UPDATE: Johnson & Johnson Posts Drop In Q1 Profit

Financial news for JNJ dated on 2013-04-16: From J&J Call: Sees FY13 Sales \$70.4B-71.1B vs \$71.1B Est

Financial news for JNJ dated on 2013-04-16: Johnson & Johnson Reports Q1 EPS of \$1.44 vs \$1.40 Est; Revenue of \$17.50B vs \$17.46B Est

Financial news for JNJ dated on 2013-04-16: Benzinga Market Primer: Tuesday, April 16

Financial news for JNJ dated on 2013-04-16: US Stock Futures Signal Higher Start On Wall Street

Financial news for JNJ dated on 2013-04-16: Earnings Scheduled For April 16, 2013

Financial news for JNJ dated on 2013-04-16: Stocks To Watch For April 16, 2013

Financial news for JNJ dated on 2013-04-15: Lawyer Says J&J Jury Should Award \$5M for Defective Hip

Financial news for JNJ dated on 2013-04-14: Earnings Expectations for the Week of April 15

Financial news for JNJ dated on 2013-04-14: A Look Ahead: This Week's ETFs to Watch

Financial news for JNJ dated on 2013-04-12: Weekly Preview: Earnings Season Kicks Into High Gear

Financial news for JNJ dated on 2013-04-12: Deutsche Bank Maintains Buy on Johnson & Johnson, Raises PT to \$87.00

Financial news for JNJ dated on 2013-04-11: ETF Showdown: A Pharma Fight

Financial news for JNJ dated on 2013-04-11: S&P Bullish on an Array of Dividend ETFs

Financial news for JNJ dated on 2013-04-10: Short Sellers Move Out of Amgen, Celgene, Pharmacyclics

Financial news for JNJ dated on 2013-04-10: UPDATE: Jefferies Raises PT on Johnson & Johnson on Attractive Valuation

Financial news for JNJ dated on 2013-04-10: Jefferies Maintains Hold on Johnson & Johnson, Raises PT to \$85.00

Financial news for JNJ dated on 2013-04-08: Johnson & Johnson Receives Positive Mad Money/Jim Cramer Mention -CNBC

Financial news for JNJ dated on 2013-04-08: JNJ Finds Support AT 20 EMA \$80.29, MACD Forming a Bearish Cross, RSI Retreats Out Of Overbought Territory

Financial news for JNJ dated on 2013-04-08: Benzinga's Top Pre-Market Losers

Financial news for JNJ dated on 2013-04-08: UPDATE: J.P. Morgan Downgrades Johnson & Johnson to Neutral on Trading Premium

Financial news for JNJ dated on 2013-04-08: JP Morgan Downgrades Johnson & Johnson to Neutral, Raises PT to \$83.00

Financial news for JNJ dated on 2013-04-07: Earnings Expectations for the Week of April 8

Financial news for JNJ dated on 2013-04-04: Four Dow Components Due for a Dividend Hike (CVX, XOM, IBM, JNJ)

Financial news for JNJ dated on 2013-04-04: J&J Wins Reversal of \$482M Patent Verdict

Over Stents, Judge Says J&J Didn't Infringe Doctor's Patent

Financial news for JNJ dated on 2013-03-29: FDA Approves J&J's Invokana Tablets for Adults with Type 2 Diabetes

Financial news for JNJ dated on 2013-03-28: Short Sellers Dump Amgen, Focus on Celgene, Gilead Sciences

Financial news for JNJ dated on 2013-03-26: Embrace These 2 Mega-Cap ETFs

Financial news for JNJ dated on 2013-03-26: 13 Drugs Pending FDA Approval in 2013

Financial news for JNJ dated on 2013-03-26: Risk On Rally? These ETFs Say No

Financial news for JNJ dated on 2013-03-26: UBS Maintains Buy on Johnson & Johnson, Raises PT to \$87.00

Financial news for JNJ dated on 2013-03-25: What Type of Dividend ETFs Are Winning in 2013?

Financial news for JNJ dated on 2013-03-25: LifeScan Announces Voluntary Recall of All OneTouch Verio IQ Blood Glucose Meters

Financial news for JNJ dated on 2013-03-22: Johnson & Johnson's Quest to Knock Botox off the Pedestal

Financial news for JNJ dated on 2013-03-19: S&P Likes a Pair of Low Vol ETFs

Financial news for JNJ dated on 2013-03-18: PowerShares Low Volatility ETF Tops \$4B in AUM

Financial news for JNJ dated on 2013-03-12: Short Interest Swings in Biotech Stocks (AMGN, CELG, PCYC)

Financial news for JNJ dated on 2013-03-12: J&J's Cordis Buys Flexible Stenting Solutions, No Terms Disclosed

Financial news for JNJ dated on 2013-03-11: Are Scientists Edging Closer to a Cure for Alzheimer's?

Financial news for JNJ dated on 2013-03-08: UPDATE: J&J Did Not Fail to Warn But Must Pay \$8.3M in Damages in Hip Case

Financial news for JNJ dated on 2013-03-08: California Jury Finds J&J Defectively Designed ASR Hip Device

Financial news for JNJ dated on 2013-03-08: J&J Hip Implant Jury Has Reached Verdict in Montana Case, to Read Verdict at 9:30AM PST

Financial news for JNJ dated on 2013-03-08: J&J's Janssen Launches EXPLORER Research Program

Financial news for JNJ dated on 2013-03-06: 3 Sector ETFs Outpacing Larger Rivals

Financial news for JNJ dated on 2013-03-06: 3 International Dividend ETFs Your Broker Forgot to Mention

Financial news for JNJ dated on 2013-03-06: Hedging The Dow At Its All-Time High

Financial news for JNJ dated on 2013-03-04: An HIV Cure Is Great News For These Drug Manufacturers

Financial news for JNJ dated on 2013-02-28: If The Market Falls, Try These Low Beta ETFs

Financial news for JNJ dated on 2013-02-28: Short Interest Swings in Biotech Stocks (ALXN, AMGN, CELG)

Financial news for JNJ dated on 2013-02-28: J&J Jury Reaches Verdict on Punitive Win in First Mesh Trial

Financial news for JNJ dated on 2013-02-26: J&J Trial Expert Says Infection -- Not Defect -- Lead to Hip Failure

Financial news for JNJ dated on 2013-02-26: Bloomberg Reporting J&J Looking to Avoid Punitive Damages After Losing Mesh Trial Verdict

Financial news for JNJ dated on 2013-02-25: Bloomberg Reporting J&J Judge Rules Jury Can Weigh Punitive Damages in Mesh Case

Financial news for JNJ dated on 2013-02-25: J&J Ordered to Pay \$3.35M to South Dakota Nurse

Financial news for JNJ dated on 2013-02-25: NJ Jury Says J&J Failed to Warn of Vaginal Mesh Risks

Financial news for JNJ dated on 2013-02-25: Hearing Jury in J&J's New Jersey Case Has Verdict in First Vaginal Mesh Case

Financial news for JNJ dated on 2013-02-25: J&J Comments on Venezuelan Currency Devaluation, Sees \$0.04/Share Charge in Q4, Reaffirms FY EPS Outlook

Financial news for JNJ dated on 2013-02-22: J&J Discloses Government Investigations Related to False Claims Related to Hips, Surgical Mesh - Bloomberg

Financial news for JNJ dated on 2013-02-19: Under The Hood: A New Dividend ETF Diva

Financial news for JNJ dated on 2013-02-19: Investment Style Rankings For ETFs & Mutual Funds

Financial news for JNJ dated on 2013-02-14: Berkshire Adds Archer-Daniels, Verisign; Boosts GM Stake

Financial news for JNJ dated on 2013-02-14: AP Reporting J&J Unit DePuy Orthopaedics Recalling 'Thousands' of Adept Hip Implants

Financial news for JNJ dated on 2013-02-12: Short Interest Swings in Biotech Stocks (AMGN, CELG, ONXX)

Financial news for JNJ dated on 2013-02-07: UPDATE: Credit Suisse Downgrades Johnson & Johnson to Underperform on Valuation

Financial news for JNJ dated on 2013-02-07: Credit Suisse Downgrades Johnson & Johnson to Underperform, Raises PT to \$73.00

Financial news for JNJ dated on 2013-02-06: Johnson & Johnson Breaks Out Over \$75 Resistance

Financial news for JNJ dated on 2013-02-03: Buying What Buffett Sells? Sometimes it Works

Financial news for JNJ dated on 2013-01-27: 2 Attractively Valued Blue Chips

Financial news for JNJ dated on 2013-01-26: Short Interest Swings in Biotech Stocks (BIIB, CELG, VVUS)

Financial news for JNJ dated on 2013-01-25: California Jury Finds J&J Failed to Warn of Hip Implant's Risks

Financial news for JNJ dated on 2013-01-22: J&J Sees FY13 Sales \$70.9-71.6B vs \$72B Est

Financial news for JNJ dated on 2013-01-22: From J&J's Qtr. Conference Call: Will Explore Options for Ortho Clinical Diagnostics Unit

Financial news for JNJ dated on 2013-01-22: UPDATE: Johnson & Johnson Posts Higher Q4 Profit

Financial news for JNJ dated on 2013-01-22: J&J Reports Velcade Sales \$502M, Remicade Sales \$1.504B, Prezista Sales \$353M

Financial news for JNJ dated on 2013-01-22: Johnson & Johnson Sees FY2013 EPS \$5.35-5.45 vs \$5.49 Est

Financial news for JNJ dated on 2013-01-22: Johnson & Johnson Reports Q4 EPS of \$1.19 vs \$1.17 Est; Revenue of \$17.60B vs \$17.67B Est

Financial news for JNJ dated on 2013-01-22: Benzinga Market Primer: Tuesday, January 22

Financial news for JNJ dated on 2013-01-22: US Stock Futures Flat Ahead Of Economic Data, Earnings

Financial news for JNJ dated on 2013-01-22: Earnings Scheduled For January 22, 2013

Financial news for JNJ dated on 2013-01-22: Stocks To Watch For January 22, 2013

Financial news for JNJ dated on 2013-01-20: Earnings Expectations for the Week of

January 21

Financial news for JNJ dated on 2013-01-18: The Week Ahead: Tech Earnings in Focus

Financial news for JNJ dated on 2013-01-18: S&P Highlights 1 ETF For Lengthy Streaks of Dividend Increases

Financial news for JNJ dated on 2013-01-18: J&J Said to Have Offered to Pay More Than \$200K per Hip Case; May Total \$2B -Bloomberg

Financial news for JNJ dated on 2013-01-16: UPDATE: Jefferies & Company Reiterates Hold Rating, Raises PT on Johnson & Johnson

Financial news for JNJ dated on 2013-01-16: Jefferies Maintains Hold on Johnson & Johnson, Raises PT to \$79.00

Financial news for JNJ dated on 2013-01-11: J&J's Janssen-Cilag Drug Zytiga Approved in EU for Use in Treatment of Metastatic Cancer

Financial news for JNJ dated on 2013-01-11: UBS Maintains Buy on Johnson & Johnson, Raises PT to \$78.00

Financial news for JNJ dated on 2013-01-10: FDA Panel Backs J&J's New Type of Diabetes Drug

Financial news for JNJ dated on 2013-01-10: FDA Panel Votes 8-7 J&J's Canagliflozin Has Heart Concerns

Financial news for JNJ dated on 2013-01-08: FDA Posts Briefing Documents for J&J's Canagliflozin

Financial news for JNJ dated on 2013-01-07: 4 Health Care ETFs Your Broker Forgot to Mention

Financial news for JNJ dated on 2013-01-07: Sanofi Buys OTC Antacid Rolaid's from J&J's McNeil-PPC

Financial news for JNJ dated on 2013-01-07: A Look Ahead: This Week's ETFs to Watch

Financial news for JNJ dated on 2013-01-04: UPDATE: Deutsche Bank Upgrades Johnson & Johnson to Buy on Improving Trends

Financial news for JNJ dated on 2013-01-04: A Peek Into The Market Before The Trading Starts

Financial news for JNJ dated on 2013-01-04: Benzinga's Top Upgrades

Financial news for JNJ dated on 2013-01-04: Deutsche Bank Upgrades Johnson & Johnson to Buy, Raises PT to \$82.00

Financial news for JNJ dated on 2013-01-03: Merck, Pfizer, Abbott, J&J, Sanofi Said to Show Interest in Bausch & Lomb Bid - Bloomberg

Financial news for JNJ dated on 2013-01-02: J&J Declares \$0.61/Share Q1 Dividend

Financial news for JNJ dated on 2013-01-02: US Stock Futures Higher On Fiscal-Cliff Deal

Financial news for JNJ dated on 2013-01-02: Stocks To Watch For January 2, 2013

Financial news for JNJ dated on 2012-12-28: Short Interest Swings in Biotech Stocks (CELG, GILD, REGN)

Financial news for JNJ dated on 2012-12-26: A Growth ETF for 2013

Financial news for JNJ dated on 2012-12-21: J&J to Host Analyst Meeting at 8:30AM EST on Jan. 22nd

Financial news for JNJ dated on 2012-12-19: How To Avoid the Worst Sector ETFs

Financial news for JNJ dated on 2012-12-19: S&P Sees Better 2013 For Health Insurance Providers

Financial news for JNJ dated on 2012-12-16: These 2 Dow Laggards Could Rebound in 2013

Financial news for JNJ dated on 2012-12-15: Barron's Recap (12/15/12): Outlook for 2013



Financial news for JNJ dated on 2012-12-12: Short Interest Swings in Biotech Stocks (BIIB, CELG, VVUS)

Financial news for JNJ dated on 2012-12-12: J&J's Janssen R&D Submits NDA for Canagliflozin/Metformin Fixed-Dose Combo Therapy

Financial news for JNJ dated on 2012-12-10: FDA Expands J&J's Zytiga's Use for Late-Stage Prostate Cancer

Financial news for JNJ dated on 2012-12-10: Davenport Upgrades Johnson & Johnson to Buy

Financial news for JNJ dated on 2012-12-08: A Look at Fortune's Health Care Picks for 2013 (ALGN, FMS, GILD)

Financial news for JNJ dated on 2012-12-07: J&J's EVARREST Fibrin Sealant Patch Approved by FDA

Financial news for JNJ dated on 2012-12-06: J&J's Janssen Submits Applications Requesting Approval of STELARA in US, Europe

Financial news for JNJ dated on 2012-12-05: J&J Says New Long-Term Study Suggests Lower Morality in Alzheimer's Patients Treated with Galantamine vs Placebo

Financial news for JNJ dated on 2012-12-03: How To Find the Best Sector ETFs

Financial news for JNJ dated on 2012-12-02: BioMarin, Prestige Brands and Other Top Performing Health Care Stocks in November

Financial news for JNJ dated on 2012-12-02: Mid-Cap Dividend Stocks For 2013

Financial news for JNJ dated on 2012-11-30: J&J Wins Reversal of \$1.1M Levaquin punitive Verdict

Financial news for JNJ dated on 2012-11-30: J&J's Bill Weldon to Retire as Chairman in Q1; Names CEO Alex Gorsky Chair

Financial news for JNJ dated on 2012-11-29: J&J's Janssen Announces Intent Not to Enforce Patents for Darunavir

Financial news for JNJ dated on 2012-11-28: J&J Says FDA Panel Recommends Accelerated Approval of Bedaquiline

Financial news for JNJ dated on 2012-11-20: UPDATE: Stifel Nicolaus Initiates Johnson & Johnson at Hold; Fairly Valued

Financial news for JNJ dated on 2012-11-20: Stifel Nicolaus Initiates Coverage on Johnson & Johnson at Hold

Financial news for JNJ dated on 2012-11-19: J&J's Cordis Says INCRAFT AAA Stent-Graft System INNOVATION Study Shows Safety, Efficacy

Financial news for JNJ dated on 2012-11-19: J&J's Janssen-Cilag's ZYTIGA Receives Positive EU Recommendation

Financial news for JNJ dated on 2012-11-18: Mid-Cap Dividend Dynamos

Financial news for JNJ dated on 2012-11-16: S&P Reiterates Bullish View on Health Care ETFs

Financial news for JNJ dated on 2012-11-15: Berkshire Dumps Most of J&J and GE Stakes; Adds Deere & Co.

Financial news for JNJ dated on 2012-11-14: Buffett's Berkshire Hathaway Cuts Stakes in GE, Visa, J&J, Conoco

Financial news for JNJ dated on 2012-11-14: These ETFs Offer Solid Yield in Uncertain Times

Financial news for JNJ dated on 2012-11-12: New Phase 3 Findings Show STELARA(r) Significantly Reduced Signs and Symptoms of Active Psoriatic Arthritis

Financial news for JNJ dated on 2012-11-12: UPDATE: Jefferies Downgrades Johnson & Johnson to Hold, Lowers PT

Financial news for JNJ dated on 2012-11-12: Benzinga's Top Downgrades

Financial news for JNJ dated on 2012-11-12: Jefferies & Company Downgrades Johnson & Johnson from Buy to Hold, Lowers PT from \$78 to \$75

Financial news for JNJ dated on 2012-11-08: SMART Vascular Stent Systems Gets FDA Approval

Financial news for JNJ dated on 2012-11-08: Mylan Announces Settlement with Janssen Related to Ortho Tri-Cyclen Lo

Financial news for JNJ dated on 2012-11-07: More Pain Awaits Medical Device ETFs

Financial news for JNJ dated on 2012-11-01: J&J Settles Suits Related to Levaquin and Tendon Injuries -Bloomberg

Financial news for JNJ dated on 2012-11-01: Vertex, JNJ's Janssen Enter Agreement for Phase 2 Hepatitis C Study

Financial news for JNJ dated on 2012-10-30: More Equal-Weight ETFs Your Broker Forgot to Mention

Financial news for JNJ dated on 2012-10-30: Johnson & Johnson Postpones November 1 Medical Devices & Diagnostics Review

Financial news for JNJ dated on 2012-10-25: How To Find the Best ETFs

Financial news for JNJ dated on 2012-10-24: Sector Rankings For ETFs & Mutual Funds

Financial news for JNJ dated on 2012-10-24: Rating Breakdown: Best & Worst ETFs & Mutual Funds by Sector

Financial news for JNJ dated on 2012-10-23: Top Performing Dividend Payers in Health Care with the Most Upside Potential (TRIB, STE, CMN)

Financial news for JNJ dated on 2012-10-17: Barclays Maintains Johnson & Johnson at Overweight, Raises PT from \$75 to \$85

Financial news for JNJ dated on 2012-10-17: UPDATE: Deutsche Bank Reiterates Hold Rating, Raises PT on Johnson & Johnson

Financial news for JNJ dated on 2012-10-17: Deutsche Bank Maintains Johnson & Johnson at Hold, Raises PT from \$72 to \$75

Financial news for JNJ dated on 2012-10-16: Upbeat Earnings Reports Spark Triple Digit Gain in the Dow

Financial news for JNJ dated on 2012-10-16: Johnson & Johnson Rises 1% After Topping Estimates, Raising Guidance

Financial news for JNJ dated on 2012-10-16: Johnson & Johnson Guides FY Revenue \$67-67.6B, Had Seen \$66.7-67.3B vs \$67.22B Est

Financial news for JNJ dated on 2012-10-16: Johnson & Johnson Guides FY EPS \$5.05-5.10, Had Seen \$5.05-5.07 vs \$5.08 Est

Financial news for JNJ dated on 2012-10-16: Johnson & Johnson Reports Q3 EPS \$1.25 vs \$1.29 Est; Revenues \$17.1B vs \$16.70B Est

Financial news for JNJ dated on 2012-10-16: Benzinga Market Primer, Tuesday October 16

Financial news for JNJ dated on 2012-10-16: US Stock Futures Up Ahead Of Earnings, Economic Data

Financial news for JNJ dated on 2012-10-16: Earnings Scheduled For October 16, 2012

Financial news for JNJ dated on 2012-10-16: Stocks To Watch For October 16, 2012

Financial news for JNJ dated on 2012-10-15: The Gores Group Extends Binding Offer to Acquire Therakos

Financial news for JNJ dated on 2012-10-15: Short Interest Swings in Biotech Stocks (BIIB, CELG, GILD)

Financial news for JNJ dated on 2012-10-15: Earnings Expectations for the Week of October 15

Financial news for JNJ dated on 2012-10-12: Jefferies & Company Maintains Johnson & Johnson at Buy, Raises PT from \$76 to \$78

Financial news for JNJ dated on 2012-10-09: Part I: Must Know ETFs For Q3 Earnings

Financial news for JNJ dated on 2012-10-09: Benzinga's Top Downgrades

Financial news for JNJ dated on 2012-10-02: S&P Index and Big 10 Weekly Outlook

Financial news for JNJ dated on 2012-10-02: From Earlier: J&J Says Phase 3 Trial for Canagliflozin Met Secondary Endpoints

Financial news for JNJ dated on 2012-09-28: From Earlier: Janssen-Cilag Says Velcade Approved in EU

Financial news for JNJ dated on 2012-09-27: Amazon Could Relinquish Key Trademark to Apple

Financial news for JNJ dated on 2012-09-25: S&P Highlights Election ETFs

Financial news for JNJ dated on 2012-09-25: Knee Replacements Have Doubled -Bloomberg

Financial news for JNJ dated on 2012-09-25: Janssen Research & Development Says Will Present Latest Phase 3 Results for Canagliflozin October 1-5

Financial news for JNJ dated on 2012-09-24: Johnson & Johnson is Facing Trial Over Risperdal; Lawyer Says Company Hid Fact Caused Female Breasts in Boys

Financial news for JNJ dated on 2012-09-24: S&P 500 Index and Big 10 Weekly Outlook-Week of September 24, 2012

Financial news for JNJ dated on 2012-09-18: Johnson & Johnson Finding Support at \$68

Financial news for JNJ dated on 2012-09-18: Defensive Stocks Maintain Gains in Mixed Market

Financial news for JNJ dated on 2012-09-18: Johnson & Johnson Establishing 4 Innovation Centers

Financial news for JNJ dated on 2012-09-13: Sandra Peterson to Join Johnson & Johnson as Group Worldwide Chairman and Member of the Executive Committee

Financial news for JNJ dated on 2012-09-12: Johnson&Johnson Has Right to Buy Vascular After Phase 2

Financial news for JNJ dated on 2012-09-11: Credit Suisse Reinstates Coverage on Johnson & Johnson at Neutral, Announces PT of \$70

Financial news for JNJ dated on 2012-09-10: These 4 Companies Have Been Increasing Their Dividends for Decades

Financial news for JNJ dated on 2012-09-06: This Dividend ETF Isn't The Same Old Song

Financial news for JNJ dated on 2012-09-05: U.S. FDA Grants Priority Review to Bedaquiline for Multi-Drug Resistant Tuberculosis Treatment

Financial news for JNJ dated on 2012-09-04: Transvaginal Mesh Suit Filed Against Johnson & Johnson

Financial news for JNJ dated on 2012-08-31: Delaware Nets \$4.2 Million Settlement from Johnson & Johnson Subsidiary

Financial news for JNJ dated on 2012-08-29: U.S. FDA Grants Priority Review of Johnson & Johnson's ZYTIGA

Financial news for JNJ dated on 2012-08-29: FDA Approves Johnson and Johnson's NUCYNTA ER

Financial news for JNJ dated on 2012-08-27: Xarel Helped to Stem Heart Attack Patients; Xarel Group Had Better Survival Rate Without Another Attack

Financial news for JNJ dated on 2012-08-23: ORTHOCON Announces Uninterrupted Availability of HEMASORB Resorbable Hemostatic Bone Putty

Financial news for JNJ dated on 2012-08-17: Five Practical Books & 5 Investment Lessons

Financial news for JNJ dated on 2012-08-16: S&P Still Bullish on Health Care ETFs

Financial news for JNJ dated on 2012-08-14: Berkshire Hathaway Sells Intel; Buys National-Oilwell Varco

Financial news for JNJ dated on 2012-08-14: UPDATE: Berkshire Reduced Stake in Visa, UPS, J&J, P&G; Increased Stake in Lee Enterprises, IBM

Financial news for JNJ dated on 2012-08-06: Elan Shares Fall 11% After-Hours on Disappointing Pfizer Bapineuzumab Study

Financial news for JNJ dated on 2012-08-06: Teva Pharmaceutical Subpoenaed By SEC in Bribery Charge

Financial news for JNJ dated on 2012-08-03: Johnson & Johnson Reaches Risperdal Lawsuit Agreement

Financial news for JNJ dated on 2012-08-01: UBS Maintains Johnson & Johnson at Buy, Raises PT from \$70 to \$76

Financial news for JNJ dated on 2012-07-31: Long Term Bull in Johnson & Johnson

Financial news for JNJ dated on 2012-07-31: Option Alert: Johnson & Johnson January 2014 77.5 Call; Block Trade: 16,000 Contracts; Currently \$69.46

Financial news for JNJ dated on 2012-07-30: UPDATE: Dendreon on Call Says Provenge Should be Sequenced Upfront Before J&J's Zytiga

Financial news for JNJ dated on 2012-07-30: J&J's Synthes Sued for Wrongful Death/Fraud -Bloomberg

Financial news for JNJ dated on 2012-07-25: S&P Likes Some "Young" ETFs

Financial news for JNJ dated on 2012-07-24: What You Need in Order to Retire Before Age 60

Financial news for JNJ dated on 2012-07-19: J&J, DoJ Settlement for as Much as \$2.2 Billion -WSJ, Sources

Financial news for JNJ dated on 2012-07-18: Kapito: 'We Like ATT, VZ, MRK, JNJ for Yields''

Financial news for JNJ dated on 2012-07-18: UPDATE: Jefferies Reiterates Buy Rating, Raises PT on Johnson & Johnson

Financial news for JNJ dated on 2012-07-18: Piper Jaffray Maintains Johnson & Johnson at Neutral, Raises PT from \$68 to \$74

Financial news for JNJ dated on 2012-07-18: Johnson and Johnson's Janssen Diagnostic's AVIGA(tm) Receives Complete ONC-ATCB Certification by Drummond Group

Financial news for JNJ dated on 2012-07-18: Jefferies & Company Maintains Johnson & Johnson at Buy, Raises PT from \$75 to \$76

Financial news for JNJ dated on 2012-07-18: Deutsche Bank Maintains Johnson & Johnson at Hold, Raises PT from \$69 to \$72

Financial news for JNJ dated on 2012-07-17: Johnson & Johnson Beats on EPS but Fails to Impress

Financial news for JNJ dated on 2012-07-17: J&J CEO Expects More Consolidation Among Hospitals

Financial news for JNJ dated on 2012-07-17: UPDATE: J&J Sees Pretax Operating Margin Improving by 100-150 Basis Points

Financial news for JNJ dated on 2012-07-17: J&J Sees Year Reported Sales \$66.7-\$67.3 Billion, Says Any 2012 Guidance Will Include Forex Impact, Sees Future Earnings Affected by Forex, Sees Net Interest Expense \$500-\$550 Million

Financial news for JNJ dated on 2012-07-17: J&J Sees \$600 Million in Restructuring Charges Ahead

Financial news for JNJ dated on 2012-07-17: UPDATE: J&J CEO Says Pharma Ops Will Continue to Be Strong Driver of Sales

Financial news for JNJ dated on 2012-07-17: UPDATE: Johnson and Johnson to Report Top-Line Results on Bapineuzumab This Quarter at Meeting in September

Financial news for JNJ dated on 2012-07-17: Johnson and Johnson Plans to Resume Supply of Doxil in Q4

Financial news for JNJ dated on 2012-07-17: Johnson & Johnson Falls On Weak Guidance

Financial news for JNJ dated on 2012-07-17: UPDATE: Johnson & Johnson Posts Drop In Q2 Profit, Lowers Full-Year Forecast

Financial news for JNJ dated on 2012-07-17: Benzinga's Top Pre-Market Losers

Financial news for JNJ dated on 2012-07-17: Johnson & Johnson Guides FY EPS \$5.00-5.07 vs \$5.14 Est

Financial news for JNJ dated on 2012-07-17: Popular Drug Manufacturing Stocks Among Hedge Funds

Financial news for JNJ dated on 2012-07-17: Johnson & Johnson Reports Q2 EPS \$1.30 vs \$1.29 Est; Revenues \$16.5B vs \$16.69B Est

Financial news for JNJ dated on 2012-07-17: Benzinga Market Primer, Tuesday July 17

Financial news for JNJ dated on 2012-07-17: US Stock Futures Up; All Eyes On Bernanke

Financial news for JNJ dated on 2012-07-17: Earnings Scheduled For July 17

Financial news for JNJ dated on 2012-07-17: Stocks To Watch For July 17

Financial news for JNJ dated on 2012-07-16: Earnings Expectations for the Week of July 16

Financial news for JNJ dated on 2012-07-13: Low Volume, High Returns for These ETFs (BIB, FHC, DRW)

Financial news for JNJ dated on 2012-07-13: Jefferies & Company Maintains Johnson & Johnson at Buy, Raises PT from \$72 to \$75

Financial news for JNJ dated on 2012-07-11: J&J Agrees To Corporate Governance Changes, Drug Marketing Changes as Part of NJ Settlement - Bloomberg Headlines

Financial news for JNJ dated on 2012-07-09: Johnson & Johnson Receives Positive Mad Money/Jim Cramer Mention -CNBC

Financial news for JNJ dated on 2012-07-09: J&J Unit: Stent Thrombosis sNDA Contingent On ACS sNDA

Financial news for JNJ dated on 2012-07-09: J&J: FDA Grants Priority Review For Xarelto Supplemental NDAs

Financial news for JNJ dated on 2012-07-04: Benzinga's M&A Chatter for Tuesday July 3, 2012

Financial news for JNJ dated on 2012-07-03: Elan Spokesperson Would Not Comment on Earlier Chatter of JNJ Offer

Financial news for JNJ dated on 2012-07-03: Hearing Unconfirmed Chatter of Johnson and Johnson Offer for Elan, \$19/Share

Financial news for JNJ dated on 2012-06-29: ALPS Unveils Dogs of the Dow ETF

Financial news for JNJ dated on 2012-06-26: Leveraged ETFs for the Obamacare Ruling

Financial news for JNJ dated on 2012-06-26: The New High Frequency Trading Landscape: Man Versus Machine

Financial news for JNJ dated on 2012-06-25: Ahead of Obamacare Ruling, S&P Likes Health Care SPDR

Financial news for JNJ dated on 2012-06-25: Saving More Vs. Seeking Higher Returns for Retirement

Financial news for JNJ dated on 2012-06-22: Premarket Stock Talk: Sell the Market, Buy.. Facebook?

Financial news for JNJ dated on 2012-06-21: Premarket Stock Talk: Beyond a Best Bed and Bath Buy

Financial news for JNJ dated on 2012-06-20: Study Says J&J Vaginal Sling Cuts Incontinence Risk in Half

Financial news for JNJ dated on 2012-06-20: Arkansas Judge Who Fined J&J \$1.2 Billion Denies Request for New Trial in Risperdal Case -AP

Financial news for JNJ dated on 2012-06-15: Goldman Sachs Raises PT on Johnson & Johnson from \$65 to \$67, Maintains Neutral

Financial news for JNJ dated on 2012-06-14: Johnson & Johnson to Complete Synthes

## Acquisition

Financial news for JNJ dated on 2012-06-13: UPDATE: Jefferies Upgrades Johnson & Johnson

Financial news for JNJ dated on 2012-06-13: UPDATE: JP Morgan Upgrades Johnson & Johnson to Overweight; Discounted Valuation Compared to Peers

Financial news for JNJ dated on 2012-06-13: Financial Breakfast: Morning News Summary for June 13, 2012

Financial news for JNJ dated on 2012-06-13: Jefferies & Company Upgrades Johnson & Johnson from Hold to Buy, Raises PT from \$68 to \$72

Financial news for JNJ dated on 2012-06-13: JP Morgan Upgrades Johnson & Johnson from Neutral to Overweight, PT Raised from \$74 to \$69

Financial news for JNJ dated on 2012-06-12: Johnson & Johnson Receives US Regulatory Clearance for Synthes Acquisition

Financial news for JNJ dated on 2012-06-12: Johnson and Johnson Receives US Regulatory Approval for Synthes Acquisition, Closing Date for Acquisition Set for June 14.

Financial news for JNJ dated on 2012-06-12: Johnson and Johnson Announces \$12.9B Accelerated Buyback Plan

Financial news for JNJ dated on 2012-06-12: 5 Healthcare Stocks With The Highest Revenue

Financial news for JNJ dated on 2012-06-11: Johnson&Johnson Reports Positive Results from First Human Clinical Trials of a First-Generation Artificial Pancreas System

Financial news for JNJ dated on 2012-06-08: Johnson & Johnson to Incur Special Charge in Q2 Due to Legal Matters -8K

Financial news for JNJ dated on 2012-06-07: Elan Spokesperson Says Company is Not Involved in Actual Data of Alzheimer Treatment. Says Data is Handled by Johnson & Johnson and Pfizer

Financial news for JNJ dated on 2012-06-06: Three Keys to Finding Good Dividend Stocks

Financial news for JNJ dated on 2012-06-05: Dendreon Jumps 10%

Financial news for JNJ dated on 2012-06-04: The US Economy and the United Nations: Bold Strategies Needed - Tax Reform and Benefits Reform

Financial news for JNJ dated on 2012-06-04: UPDATE: J&J's Zytiga Slows Cancer Growth In Men With Prostate Cancer; Negative for Dendreon, Positive for Medivation

Financial news for JNJ dated on 2012-06-02: ZYTIGA Plus Prednisone Show Improvements in Asymptomatic or Mildly Symptomatic Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer

Financial news for JNJ dated on 2012-06-01: Johnson & Johnson Receives Positive Mad Money/Jim Cramer Mention -CNBC

Financial news for JNJ dated on 2012-05-31: 5 Risky Dividend Stocks (WIN, EXC, FTR, HAS, JNJ)

Financial news for JNJ dated on 2012-05-31: Goldman Sachs Comments on Breaking Up of Johnson & Johnson

Financial news for JNJ dated on 2012-05-29: FDA Issues Complete Response Letter for 800mg PREZISTA

Financial news for JNJ dated on 2012-05-29: 5 Healthcare Stocks With The Highest Cash

Financial news for JNJ dated on 2012-05-28: S&P 500 Undex And Big 10 Weekly Outlook-Week of May 28th

Financial news for JNJ dated on 2012-05-24: Three Stocks from Goldman's Hedge Fund Short List, Will They Pop or Flop?

Financial news for JNJ dated on 2012-05-23: FDA Advisory Panel Votes 6-4-1 Against the Approval of Johnson & Johnson's and Bayer's XARETO Pill

Financial news for JNJ dated on 2012-05-22: Health Care SPDR In Focus Ahead Of

## Obamacare Decision

Financial news for JNJ dated on 2012-05-22: Prostate Cancer Companies Suffer When They Ignore Urologists

Financial news for JNJ dated on 2012-05-14: S&P 500 Index and Big 10 Weekly Outlook-Week of May 14th

Financial news for JNJ dated on 2012-05-09: ETFs on the Market that will Line Your Pockets 12 Times a Year

Financial news for JNJ dated on 2012-05-09: Option Alert: Johnson & Johnson July 67.5 Calls; Block Trade: 10,000 Contracts; Currently \$64.41

Financial news for JNJ dated on 2012-05-07: Buffett's Holdings Beat the S&P 500 One Month After Meeting

Financial news for JNJ dated on 2012-05-07: S&P 500 Index and Big Ten Analysis - Week of May 7, 2012

Financial news for JNJ dated on 2012-04-30: S&P 500 Index and Big Ten Weekly Outlook - April 30th

Financial news for JNJ dated on 2012-04-26: Johnson & Johnson Announces Dividend Increase of 7.0% to \$0.61

Financial news for JNJ dated on 2012-04-25: Fitch Removes Johnson & Johnson from Watch Negative

Financial news for JNJ dated on 2012-04-25: Five Cheap Stocks Under \$15 (BAC, NAK, SD, RIMM, ELN)

Financial news for JNJ dated on 2012-04-25: Colgate-Palmolive Earnings Preview: Q1 EPS, Sales Expected to Be Higher

Financial news for JNJ dated on 2012-04-23: S&P Futures and Big 10 Weekly Analysis - Week of April 23

Financial news for JNJ dated on 2012-04-19: Street Yearning For Better Earnings?

Financial news for JNJ dated on 2012-04-19: S&P: Bullish On Pharma ETFs Long-Term

Financial news for JNJ dated on 2012-04-18: UBS Maintains Johnson & Johnson at Buy, Lowers PT from \$71 to \$70

Financial news for JNJ dated on 2012-04-18: UPDATE: Goldman Sachs Lowers Johnson & Johnson's PT

Financial news for JNJ dated on 2012-04-18: UPDATE: Citigroup Reiterates Buy Rating, Raises PT on Johnson & Johnson

Financial news for JNJ dated on 2012-04-18: Citigroup Maintains Johnson & Johnson at Buy, Raises PT from \$76 to \$77

Financial news for JNJ dated on 2012-04-18: Goldman Sachs Maintains Johnson & Johnson at Neutral, Lowers PT from \$70 to \$65

Financial news for JNJ dated on 2012-04-17: Checking In: Turn Down The "Vol" (LVOL, SPLV)

Financial news for JNJ dated on 2012-04-17: Deutsche Bank: Johnson & Johnson Beat EPS, Misses Sales

Financial news for JNJ dated on 2012-04-17: J&J Says Will File Motion to Dismiss Risperdal Ruling; Will Appeal if Dismissal Fails

Financial news for JNJ dated on 2012-04-17: Earnings Roundup

Financial news for JNJ dated on 2012-04-17: UPDATE: Johnson & Johnson Posts 12% Rise In Q1 Earnings, Lifts Forecast

Financial news for JNJ dated on 2012-04-17: Johnson & Johnson Reports Q1 EPS \$1.37 vs \$1.35 Est; Revenues \$16.1B vs \$16.26B Est

Financial news for JNJ dated on 2012-04-17: Stocks To Watch For April 17

Financial news for JNJ dated on 2012-04-17: Earnings Scheduled For April 17

Financial news for JNJ dated on 2012-04-17: US Stock Futures Up Ahead Of Earnings

Financial news for JNJ dated on 2012-04-17: US Stock Futures Up Ahead Of Earnings

Financial news for JNJ dated on 2012-04-17: Earnings Scheduled For April 17

Financial news for JNJ dated on 2012-04-17: Earnings Scheduled For April 17

Financial news for JNJ dated on 2012-04-17: Stocks To Watch For April 17

Financial news for JNJ dated on 2012-04-16: S&P Futures and Big 10 Weekly Analysis - Week of April 16

Financial news for JNJ dated on 2012-04-16: UPDATE: Citi Raises Johnson & Johnson's PT

Financial news for JNJ dated on 2012-04-16: Citigroup Maintains Johnson & Johnson at Buy, Raises PT from \$75 to \$76

Financial news for JNJ dated on 2012-04-15: Earnings Expectations for the Week of April 16 (GS, MSFT, MCD)

Financial news for JNJ dated on 2012-04-12: Volatility Is Not Risk

Financial news for JNJ dated on 2012-04-11: Judge Awards Arkansas \$1.1B Over Johnson & Johnson's Risperdal Sales

Financial news for JNJ dated on 2012-04-10: We like these proven performers in this market

Financial news for JNJ dated on 2012-04-09: S&P 500 Index and Big Ten Analysis - Week of April 9th

Financial news for JNJ dated on 2012-04-09: Avon's New CEO to Cleanse Brand Image as L'Oreal Sparks Upgrade Rumors

Financial news for JNJ dated on 2012-04-09: Morgan Stanley Comments on Johnson & Johnson's First 100 Days in 2012

Financial news for JNJ dated on 2012-04-09: Johnson & Johnson Announces Resignation of Sheri S. McCoy

Financial news for JNJ dated on 2012-04-03: Biomet in Pact to Buy J&J's Depuy Trauma Business

Financial news for JNJ dated on 2012-03-29: Is 1400 The Top For Now?

Financial news for JNJ dated on 2012-03-27: Arkansas Seeking \$1.25B in Penalties Over Marketing for J&J Antipsychotic Drug

Financial news for JNJ dated on 2012-03-27: FDA Approves INTELENCE Tablets for Treatment-Experienced Pediatric Patients with HIV-1

Financial news for JNJ dated on 2012-03-27: Brean Murray Carret: Johnson & Johnson's EINSTEIN-PE Results Overshadowed

Financial news for JNJ dated on 2012-03-26: S&P 500 Index and Big 10 Weekly Outlook - March 26th

Financial news for JNJ dated on 2012-03-26: UPDATE: Bayer's Xarelto Comparable to Standard Therapy; Blood Thinner Treats Blood Clots with Less Bleeding

Financial news for JNJ dated on 2012-03-26: Bayer's Xarelto Comparable to Standard Therapy; Blood Thinner Treats Blood Clots with Less Bleeding

Financial news for JNJ dated on 2012-03-23: Three Effective Tools For Controlling Portfolio Risk Without Relying Purely on Fixed Income

Financial news for JNJ dated on 2012-03-22: Fast Money Picks For March 23rd (FCX, CHD, JNJ)

Financial news for JNJ dated on 2012-03-21: St. Jude, Novo Nordisk and Other Health Care Stocks Worth a Look Now

Financial news for JNJ dated on 2012-03-19: S&P 500 and Big 10 Weekly Outlook - March 19, 2012

Financial news for JNJ dated on 2012-03-16: ETF Showdown: Dividend Dilemma (HDV, HDIV, JNJ)



Financial news for JNJ dated on 2012-03-16: Accenture, Covidien, Seagate and Other St. Patrick's Stock Picks

Financial news for JNJ dated on 2012-03-15: A Look At The New Russell High Yield ETF (HDIV, ABT, KFT)

Financial news for JNJ dated on 2012-03-14: Investor Alert: Xerox is a Cash Machine

Financial news for JNJ dated on 2012-03-12: Painkillers Win FDA Panel Backing to Continue Development; Pfizer, JNJ, Regeneron Pain Drugs Should Resume Halted Studies -Bloomberg

Financial news for JNJ dated on 2012-03-12: Option Alert: Johnson & Johnson July 70 Call; Block Trade, 10,000 Contracts

Financial news for JNJ dated on 2012-03-12: S&P 500 and Big 10 Weekly Outlook - March 12th

Financial news for JNJ dated on 2012-03-08: Will Johnson & Johnson Cure Cancer?

Financial news for JNJ dated on 2012-03-08: Medivation Rises 17% on Positive J&J Zytiga

Financial news for JNJ dated on 2012-03-08: Medivation Shares Rise 10% on J&J's Zytiga Data, Dendreon Falls 12%

Financial news for JNJ dated on 2012-03-08: J&J's Zytiga Study to be Unblinded on Committee Recommendation; Interim Data Could Show Clinical Benefit; Could be Positive for Medivation, Negative for Dendreon

Financial news for JNJ dated on 2012-03-05: Pfizer Sues Johnson & Johnson Over Heat Patch Patent

Financial news for JNJ dated on 2012-03-04: S&P 500 And Big 10 Weekly Outlook - March 5, 2012

Financial news for JNJ dated on 2012-02-27: U.S. FDA Grants Priority Review for XARELTO to Reduce Secondary Cardiovascular Events in Patients with Acute

Financial news for JNJ dated on 2012-02-27: S&P 500 & Big 10 Analysis - Week of February 27

Financial news for JNJ dated on 2012-02-27: Buffett On Johnson & Johnson: Still An Attractive Business At This Price, But Would Sell If He Needed Capital -CNBC

Financial news for JNJ dated on 2012-02-23: Option Alert: Johnson & Johnson January 2013 50 Call; Block Trade, 2X 12,000; 2X 10,000 Contracts

Financial news for JNJ dated on 2012-02-22: Financial Breakfast: Morning News Summary for February 22, 2012

Financial news for JNJ dated on 2012-02-21: Johnson & Johnson Says Bill Weldon Will Retire in April, Gorsky Will Succeed as CEO

Financial news for JNJ dated on 2012-02-21: Johnson & Johnson to Name Vice Chairman Gorsky CEO -WSJ

Financial news for JNJ dated on 2012-02-21: US High Court Rejects J&J's Bid To Save Patent Case Against Abbott

Financial news for JNJ dated on 2012-02-20: S&P Futures & Big 10 Analysis - Week of February 20

Financial news for JNJ dated on 2012-02-16: Johnson & Johnson Wins First Personal Injury Trial Over Risperdal Risk

Financial news for JNJ dated on 2012-02-14: Hedge Fund 13-F Updates: Berkshire, Greenlight, Paulson & Co., Appaloosa and More!

Financial news for JNJ dated on 2012-02-14: Berkshire Filing Shows Reduced JNJ Stake

Financial news for JNJ dated on 2012-02-13: S&P Futures & Big 10 Analysis - Week of February 13

Financial news for JNJ dated on 2012-02-10: Healthcare Analyst: Contraceptive Costs Are Not Issue; Birth Statistics Can be Manipulated

Financial news for JNJ dated on 2012-02-10: Grandpa's 2012 ETF Portfolio

Financial news for JNJ dated on 2012-02-06: S&P Futures & Big 10 Analysis - Week of Feb 6, 2012

Financial news for JNJ dated on 2012-02-02: Benzinga's M&A Chatter for Thursday February 2, 2012

Financial news for JNJ dated on 2012-02-02: UPDATE: First Global Downgrades Johnson & Johnson to Market Perform

Financial news for JNJ dated on 2012-02-02: First Global Downgrades Johnson & Johnson to Market Perform

Financial news for JNJ dated on 2012-01-31: S&P Futures & Big 10 Analysis - Week of Jan 30th, 2012

Financial news for JNJ dated on 2012-01-26: Benzinga's M&A Chatter for Thursday January 26, 2012

Financial news for JNJ dated on 2012-01-26: Johnson & Johnson Wins Jury Verdict Over Levaquin Warning Claim

Financial news for JNJ dated on 2012-01-26: Elan Spokesperson Will Not Comment on Rumor of Johnson & Johnson Offer

Financial news for JNJ dated on 2012-01-26: Hearing Chatter Johnson & Johnson to Bid for Elan

Financial news for JNJ dated on 2012-01-25: Johnson & Johnson Receives Positive Mad Money/Jim Cramer Mention -CNBC

Financial news for JNJ dated on 2012-01-25: Piper Jaffray Lowers PT on Johnson & Johnson to \$68

Financial news for JNJ dated on 2012-01-25: Morgan Stanley Concerned with Johnson & Johnson Sustaining a Path to Leverage

Financial news for JNJ dated on 2012-01-25: Morgan Keegan Maintains Market Perform Rating on Johnson & Johnson

Financial news for JNJ dated on 2012-01-25: Morgan Keegan Maintains Market Perform Rating on Johnson & Johnson

Financial news for JNJ dated on 2012-01-24: Benzinga's M&A Chatter for Tuesday January 24, 2012

Financial news for JNJ dated on 2012-01-24: Hearing William Blair Making Negative Comments on Mako Surgical; Johnson & Johnson Not Interested in Acquisition

Financial news for JNJ dated on 2012-01-24: JP Morgan Reiterates Neutral on Johnson & Johnson

Financial news for JNJ dated on 2012-01-24: Earnings Roundup

Financial news for JNJ dated on 2012-01-24: Achillion Pharmaceuticals Spiking Higher on Renewed Takeover Chatter

Financial news for JNJ dated on 2012-01-24: UPDATE: Johnson & Johnson Q4 Net Income Drops 89%

Financial news for JNJ dated on 2012-01-24: Johnson & Johnson Guides FY2011 EPS \$5.05-5.15 vs \$5.20 Est

Financial news for JNJ dated on 2012-01-24: Johnson & Johnson Reports Q4 EPS \$1.13 vs \$1.10 Est; Revenues \$16.30B vs \$16.28B Est

Financial news for JNJ dated on 2012-01-24: US Stock Futures Down; McDonald's, Johnson & Johnson In Focus

Financial news for JNJ dated on 2012-01-24: Earnings Scheduled For January 24

Financial news for JNJ dated on 2012-01-24: Stocks To Watch For January 24

Financial news for JNJ dated on 2012-01-24: Johnson & Johnson Earnings Preview

Financial news for JNJ dated on 2012-01-22: Earnings Expectations for the Week of January 23

Financial news for JNJ dated on 2012-01-20: Democrats Seeks Hearing on Hazardous Medical Devices; Says Studies Show Risks wit J&J, Allergan Devices

Financial news for JNJ dated on 2012-01-18: Benzinga's M&A Chatter for Wednesday January 18, 2012

Financial news for JNJ dated on 2012-01-18: Positive Rumors Circulate About Vertex Pharmaceuticals

Financial news for JNJ dated on 2012-01-18: Hearing Wedbush Says Idenix Pharmaceuticals Takeover Target of Merck, Johnson & Johnson, Abbott Labs; \$24/Share

Financial news for JNJ dated on 2012-01-10: Going Nuclear on Hepatitis C -- Is Idenix the Next Target?

Financial news for JNJ dated on 2012-01-06: Dividend Champions a Rare Undervalued Opportunity

Financial news for JNJ dated on 2012-01-05: FDA Says Johnson & Johnson Doribax Trial Was Recently Stopped Early Because of Significant Safety Concerns -Reuters

Financial news for JNJ dated on 2012-01-05: J&J Said to Agree to \$1B Accord in Risperdal Sales Probe

Financial news for JNJ dated on 2012-01-04: J&J and CR Bard Ordered to Study Injuries from Vaginal Implants

Financial news for JNJ dated on 2012-01-04: Bark At The Dow's Dogs With These ETFs

Financial news for JNJ dated on 2011-12-30: ETF Showdown: Fun With Pharma

Financial news for JNJ dated on 2011-12-30: Benzinga's Top Pre-Market Losers

Financial news for JNJ dated on 2011-12-28: Five ETFs For Fans Of Extreme Couponing

Financial news for JNJ dated on 2011-12-27: Fast Money Picks For December 28th (CP, TSM, SLB, SBUX, JNJ, ANF)

Financial news for JNJ dated on 2011-12-27: Will This Company's Drug Cure Your Allergies?

Financial news for JNJ dated on 2011-12-27: Best Biotech Stocks of 2011

Financial news for JNJ dated on 2011-12-09: FDA Advisers Vote That Current Label Adequately Reflects Risks and Benefits of Johnson & Johnson's Ortho Evra Contraceptive Patch

Financial news for JNJ dated on 2011-12-09: Mad Money Lightning Round: Cramer Likes Johnson & Johnson

Financial news for JNJ dated on 2011-12-08: Janssen Says Deal to Cut Johnson & Johnson 2011 EPS by \$0.04-\$0.05

Financial news for JNJ dated on 2011-12-08: Pharmacyclics Forms Pact to Develop and Commercialize PCI-32765 for Hematologic Cancers with Janssen Biotech

Financial news for JNJ dated on 2011-12-07: Affymax Wins FDA Panel Backing on Anemia Drug to Rival Amgen's

Financial news for JNJ dated on 2011-12-05: Biotech Stocks On the Move

Financial news for JNJ dated on 2011-12-01: Are the Samsung M&A Rumors True?

Financial news for JNJ dated on 2011-12-01: Piper Jaffray Maintains Neutral Rating and \$69 PT on Johnson & Johnson

Financial news for JNJ dated on 2011-12-01: These Stocks May Be Better Than Their Dow Equivalents

Financial news for JNJ dated on 2011-11-29: UPDATE: Citi Lowers PT to \$70 on Johnson & Johnson

Financial news for JNJ dated on 2011-11-29: Citigroup Lowers PT on Johnson & Johnson to \$70

Financial news for JNJ dated on 2011-11-16: Stocks Going Ex Dividend the Fourth Week of November

Financial news for JNJ dated on 2011-11-16: Moving Away From The Materials Sector, Toward A Growth/Momentum Style

Financial news for JNJ dated on 2011-11-15: Invest Like Buffett...With ETFs

Financial news for JNJ dated on 2011-11-14: Brean Murray Carret & Co maintain Buy, \$77 Target on Johnson & Johnson

Financial news for JNJ dated on 2011-11-14: Citi Has Buy on J&J

Financial news for JNJ dated on 2011-11-11: Maintaining Stability in My Dividends and Yield Portfolio

Financial news for JNJ dated on 2011-11-09: Four Defensive ETFs You're Not Considering, But Should

Financial news for JNJ dated on 2011-11-08: JNJ's Sterilmed Gets FDA Letter on Lack of Approval for Device

Financial news for JNJ dated on 2011-11-04: FDA Approves Bayer/J&J's Xarelto for Stroke Prevention

Financial news for JNJ dated on 2011-11-03: J&J-Synthes Deal Will Get Extend EU Antitrust Review

Financial news for JNJ dated on 2011-11-01: Mad Money Lightning Round: Cramer Advises Investors Not To Buy Microsoft

Financial news for JNJ dated on 2011-10-31: A Look at The New DRGS ETN

Financial news for JNJ dated on 2011-10-31: How We Pick Stocks: The Case of Johnson & Johnson

Financial news for JNJ dated on 2011-10-25: Merck Earnings Preview: Analysts Expect Higher EPS, Revenue

Financial news for JNJ dated on 2011-10-24: Bristol-Myers Squibb Earnings Preview: Analysts Expect Rising Revenue, Falling EPS

Financial news for JNJ dated on 2011-10-21: The Donald Trump Bottom? 2 Months Later

Financial news for JNJ dated on 2011-10-19: Earnings Preview: Analysts Expect Boston Scientific's Revenue, Earnings to Dip

Financial news for JNJ dated on 2011-10-19: JP Morgan Maintains Neutral on Johnson & Johnson's Mixed 3Q Results

Financial news for JNJ dated on 2011-10-19: Piper Jaffray Raises PT on Johnson & Johnson to \$69

Financial news for JNJ dated on 2011-10-19: Morgan Stanley Maintains Equal Weight Rating on Johnson & Johnson

Financial news for JNJ dated on 2011-10-19: Deutsche Bank Reiterates Hold Rating on Johnson & Johnson

Financial news for JNJ dated on 2011-10-18: End-of-Day Market Summary for October 18, 2011

Financial news for JNJ dated on 2011-10-18: Earnings Roundup For October 18

Financial news for JNJ dated on 2011-10-18: Johnson & Johnson Sees Net Income Climb

Financial news for JNJ dated on 2011-10-18: UPDATE: Johnson & Johnson Reports Drop In Q3 Profit

Financial news for JNJ dated on 2011-10-18: Johnson & Johnson Guides FY2011 EPS \$4.95-5.00 vs \$4.96 Est

Financial news for JNJ dated on 2011-10-18: Johnson & Johnson Guides FY2011 EPS \$4.95-5.00 vs \$4.96 Est

Financial news for JNJ dated on 2011-10-18: Johnson & Johnson Reports Q3 EPS \$1.24 vs \$1.21 Est; Revenues \$16.0B vs \$16.02B Est

Financial news for JNJ dated on 2011-10-18: US Stock Futures Mixed Ahead Of Earnings Reports; IBM Shares Down In Pre-Market

Financial news for JNJ dated on 2011-10-18: Earnings Scheduled For October 18

Financial news for JNJ dated on 2011-10-17: Brean Murray Carret & Co. Reiterates Buy Rating on J&J

Financial news for JNJ dated on 2011-10-17: UBS Lowers PT on Johnson & Johnson to \$72

Financial news for JNJ dated on 2011-10-16: Earnings Expectations for the Week of October 17

Financial news for JNJ dated on 2011-10-14: Abbott Laboratories Earnings Preview: Analysts Expect Higher EPS, Revenue

Financial news for JNJ dated on 2011-10-14: Johnson & Johnson Earnings Preview: Analysts Expect Rising Revenue, Falling EPS

Financial news for JNJ dated on 2011-10-13: Under The Hood: Emerging Markets Health Care

Financial news for JNJ dated on 2011-10-13: Piper Jaffray Neutral on Johnson & Johnson

Financial news for JNJ dated on 2011-09-29: Boston Scientific Announces Favorable Appellate Court Ruling Affirming Non-Infringement of Johnson & Johnson Patent

Financial news for JNJ dated on 2011-09-24: Remicade Receives FDA Approval as First Biologic Treatment for Pediatric Ulcerative Colitis

Financial news for JNJ dated on 2011-09-23: Charles Sizemore Quoted in Smart Money

Financial news for JNJ dated on 2011-09-23: Johnson & Johnson Recalls 200,000 Syringes of Eprex Anemia Drug

Financial news for JNJ dated on 2011-09-22: 5 Exceptional Dividend Growth Stocks - Lower Volatility and Higher Total Return

Financial news for JNJ dated on 2011-09-22: UPDATE: Goldman Sachs Downgrades Johnson & Johnson to \$63.13

Financial news for JNJ dated on 2011-09-22: Financial Breakfast: Morning News Summary for September 22, 2011

Financial news for JNJ dated on 2011-09-22: Goldman Sachs Downgrades Johnson & Johnson to Neutral, \$74 PT

Financial news for JNJ dated on 2011-09-19: Piper Jaffray Comments on Johnson & Johnson

Financial news for JNJ dated on 2011-09-16: Johnson & Johnson CEO Weldon Says Too Early to Tell on US Economy

Financial news for JNJ dated on 2011-09-14: Greece: The Questions Investors Should be Asking

Financial news for JNJ dated on 2011-09-14: Johnson & Johnson to Face Arkansas Trial Over Risperdal -Bloomberg

Financial news for JNJ dated on 2011-09-14: S&P Likes Three Health Care ETFs

Financial news for JNJ dated on 2011-09-14: UPDATE: J&J Unit To Pay \$85M Fine, Plead Guilty To Charge

Financial news for JNJ dated on 2011-09-14: J&J Unit, US In Plea Pact For Natrecor Marketing Probe - Court Filing

Financial news for JNJ dated on 2011-09-13: What If I'm Wrong?

Financial news for JNJ dated on 2011-09-12: Is Hansen Medical a Takeover Target?

Financial news for JNJ dated on 2011-09-09: Citi Has Buy On Johnson & Johnson

Financial news for JNJ dated on 2011-09-09: Benzinga's Top Pre-Market Gainers

Financial news for JNJ dated on 2011-09-08: FDA Advisory Committee Recommends Approval of Johnson & Johnson Oral Anticoagulant

Financial news for JNJ dated on 2011-09-07: S&P Endorses Two Dividend ETFs

Financial news for JNJ dated on 2011-09-07: Johnson & Johnson's Zytiga Prostate-Cancer Drug Gets European Approval

Financial news for JNJ dated on 2011-08-30: Citi Maintains Buy on Johnson & Johnson

Financial news for JNJ dated on 2011-08-26: Groupon's Andrew Mason: "I've Never Been More Confident and Excited about the Future of our Business"

Financial news for JNJ dated on 2011-08-25: 12 Most Popular Healthcare Stocks Among Hedge Funds

Financial news for JNJ dated on 2011-08-25: 12 Most Popular Healthcare Stocks Among Hedge Funds

Financial news for JNJ dated on 2011-08-23: The Greatest Risk We Face: To Again Falling Into a Recession

Financial news for JNJ dated on 2011-08-15: The Global Meltdown of Confidence

Financial news for JNJ dated on 2011-08-15: Johnson & Johnson's McNeil Healthcare Division Recalling Tylenol Cold Nighttime Gelcaps

Financial news for JNJ dated on 2011-08-15: Perrigo Earnings Preview

Financial news for JNJ dated on 2011-08-11: The Donald Trump Bottom

Financial news for JNJ dated on 2011-08-10: Warren Buffett Said Ignore Political and Economic Forecasts

Financial news for JNJ dated on 2011-08-10: Embrace Your Inner Spock: Three Questions Investors Should be Asking

Financial news for JNJ dated on 2011-08-09: UPDATE: Goldman Sachs Reiterates Buy on Johnson & Johnson, Reduces PT to \$74

Financial news for JNJ dated on 2011-08-09: Goldman Sachs Lowers PT on Johnson & Johnson To \$74

Financial news for JNJ dated on 2011-08-08: Where to Invest When the Market Crashes

Financial news for JNJ dated on 2011-08-08: S&P States that Recent US Downgrade Won't Affect Rating of these Six Top-Tier Companies: ADP, XOM, JNJ, MSFT, GE, GWW

Financial news for JNJ dated on 2011-08-02: The New World Order of Global Sovereigns

Financial news for JNJ dated on 2011-08-01: Hold These Funds Forever! Really? Forever?

Financial news for JNJ dated on 2011-08-01: Benzinga's Top Pre-Market Losers

Financial news for JNJ dated on 2011-07-29: The Best 8 Stocks in the Dow

Financial news for JNJ dated on 2011-07-29: 10 Wall Street All-Stars With Money-Making Potential

Financial news for JNJ dated on 2011-07-29: Trading Weekly Options to Extract Profit from Amazon (AMZN)

Financial news for JNJ dated on 2011-07-29: 7 'Buy Rated' Stocks Trading Under \$20

Financial news for JNJ dated on 2011-07-29: 15 Safe Dividend Kings for This Summer: Part 2

Financial news for JNJ dated on 2011-07-29: Central Bank of Colombia Raises Rate 25bps to 4.50%

Financial news for JNJ dated on 2011-07-29: 15 Safe Dividend Kings for This Summer: Part 1

Financial news for JNJ dated on 2011-07-29: 7 Fortune 500 Companies That Are Hiring: Time to Jump in and Buy?

Financial news for JNJ dated on 2011-07-29: What Investors Should Know About Apple but Often Don't

Financial news for JNJ dated on 2011-07-28: High Yield Birth Control Stocks

Financial news for JNJ dated on 2011-07-28: How to Profit from Exploding Government Healthcare Costs

Financial news for JNJ dated on 2011-07-28: Top Yield Stocks of Warren Buffett

Financial news for JNJ dated on 2011-07-27: Hearing Supreme Court Asked to Overturn Obama's Health Care Reform

Financial news for JNJ dated on 2011-07-26: Earnings Preview: Merck EPS, Revenue Expected to Rise from Previous Quarter

Financial news for JNJ dated on 2011-07-25: Ratchet Back The Risk With These ETFs

Financial news for JNJ dated on 2011-07-25: Boston Scientific Earnings Preview: Analysts Expect Rising Revenue, Falling EPS Over Previous Quarter

Financial news for JNJ dated on 2011-07-25: Bristol-Myers Squibb Earnings Preview: Analysts Expect Rising Revenue, Falling EPS Over Previous Quarter

Financial news for JNJ dated on 2011-07-25: Nothing To Sneeze At Here

Financial news for JNJ dated on 2011-07-22: No Respect: The Rodney Dangerfield of the Investment World

Financial news for JNJ dated on 2011-07-21: Johnson and Johnson: FDA Panel Backs Additional Use Of Remicade For Pediatric Patients

Financial news for JNJ dated on 2011-07-21: Fifteen Health Care ETFs Trading Near 52-Week Highs

Financial news for JNJ dated on 2011-07-21: Earnings Preview: Gilead Sciences EPS, Revenue Expected to Rise from Previous Quarter

Financial news for JNJ dated on 2011-07-20: Deutsche Bank Comments on Johnson & Johnson

Financial news for JNJ dated on 2011-07-20: Gabelli Maintains Earnings Estimates On Johnson & Johnson

Financial news for JNJ dated on 2011-07-20: JP Morgan Reiterates JNJ Neutral Rating

Financial news for JNJ dated on 2011-07-20: UPDATE: Citi Raises PT on Johnson & Johnson to \$73

Financial news for JNJ dated on 2011-07-20: Morgan Stanley Comments on Johnson & Johnson

Financial news for JNJ dated on 2011-07-20: Citigroup Raises PT On Johnson & Johnson To \$73

Financial news for JNJ dated on 2011-07-19: Is It Time To Buy Cisco?

Financial news for JNJ dated on 2011-07-19: Malus domestica Produces 07-19-2011

Financial news for JNJ dated on 2011-07-19: Will AAPL Succumb to Gravity? 07-19-2011

Financial news for JNJ dated on 2011-07-19: Dow Jones Industrial Average Companies Increase Expected Dividend Distribution by 12.66% From a Year Ago

Financial news for JNJ dated on 2011-07-19: Earnings Roundup

Financial news for JNJ dated on 2011-07-19: UPDATE: Johnson & Johnson Reports Upbeat Q2 Profit

Financial news for JNJ dated on 2011-07-19: Benzinga's Top Pre-Market Losers

Financial news for JNJ dated on 2011-07-19: FDA Posts Staff Review of Study of J&J's Remicade in Children

Financial news for JNJ dated on 2011-07-19: Johnson & Johnson Guides 2011 EPS \$4.90-5.00 vs \$4.96 Est.

Financial news for JNJ dated on 2011-07-19: Johnson & Johnson Reports Q2 EPS of \$1.28 vs. \$1.23 Est; Revenues \$16.6B vs. \$16.22B Est

Financial news for JNJ dated on 2011-07-19: US Stock Futures Up As Investors Await Earnings Reports

Financial news for JNJ dated on 2011-07-19: Earnings Scheduled For July 19

Financial news for JNJ dated on 2011-07-18: Johnson & Johnson Announces Third-Quarter 2011 Quarterly Dividend of \$0.57/Share

Financial news for JNJ dated on 2011-07-17: Earnings Expectations for the Week of July 18

Financial news for JNJ dated on 2011-07-15: Boston Scientific Earnings Preview: Revenue, Earnings Expected to Fall from Previous Quarter

Financial news for JNJ dated on 2011-07-15: Forest Laboratories Earnings Preview: Analysts Expect Rising Revenue

Financial news for JNJ dated on 2011-07-15: Earnings Preview: Johnson & Johnson EPS, Revenue Expected to Rise from Previous Quarter

Financial news for JNJ dated on 2011-07-15: Earnings Preview: Analysts Expect Abbott Laboratories Revenue, Earnings to Dip from Previous Quarter

Financial news for JNJ dated on 2011-07-15: Benzinga's Top Pre-Market Losers

Financial news for JNJ dated on 2011-07-14: 5 High Dividend Names For Sound Sleeping

Financial news for JNJ dated on 2011-07-13: Boston Scientific Earnings Preview: Revenue, Earnings Expected to Fall from Previous Quarter

Financial news for JNJ dated on 2011-07-13: Twelve Health Care ETFs Trading Near 52-Week Highs

Financial news for JNJ dated on 2011-07-12: J.P. Morgan Previews 2Q Results For JNJ

Financial news for JNJ dated on 2011-07-12: Twelve ETFs Trading Near 52-Week Highs

Financial news for JNJ dated on 2011-07-08: UPDATE: Deutsche Bank Initiates Johnson & Johnson at Hold

Financial news for JNJ dated on 2011-07-08: Deutsche Bank Initiates Johnson & Johnson At Hold, \$73 PT

Financial news for JNJ dated on 2011-07-08: Stocks to Watch for 07/8/11: Fresh 52 Week Highs and Lows

Financial news for JNJ dated on 2011-07-07: Court of Appeals Affirms \$16.56 Million Judgment Against Johnson & Johnson in Defective Fentanyl Patch Case

Financial news for JNJ dated on 2011-07-07: Johnson & Johnson Announces Global Sponsorship of the 2014 FIFA World Cup Brazil

Financial news for JNJ dated on 2011-07-06: "Can Stocks Be Safer than Bonds?"

Financial news for JNJ dated on 2011-07-05: Piper Jaffray Remains Neutral On Johnson & Johnson

Financial news for JNJ dated on 2011-07-01: UPDATE: Johnson & Johnson: FDA Approves XARELTO

Financial news for JNJ dated on 2011-07-01: Time To Look At Boston Scientific?

Financial news for JNJ dated on 2011-06-24: High Yield Big Pharmaceutical Stocks

Financial news for JNJ dated on 2011-06-23: Morgan Stanley Provides Color on Johnson & Johnson, Equal-Weight

Financial news for JNJ dated on 2011-06-20: 3 High Dividend Stocks The Smart Money Is Buying

Financial news for JNJ dated on 2011-06-17: Ortho-McNeil-Janssen Pharmaceuticals Voluntarily Recalls One Lot of RISPERDAL(r) Tablets and One Lot of Risperidone Tablets

Financial news for JNJ dated on 2011-06-16: Goldman Sachs Maintains Buy on Johnson & Johnson

Financial news for JNJ dated on 2011-06-15: Johnson & Johnson Announces Special Charge of \$500-\$600 Million Related to Restructuring Plans for Cordis Corporation Subsidiary

Financial news for JNJ dated on 2011-06-15: The 8 Most Appropriate Strategies

Financial news for JNJ dated on 2011-06-14: Hearing that J&J's Depuy has Won U.S. Approval for the First Ceramic-on-Metal Hip